Innual Keport - 2013 - 20 15-6-5



NOTICE

Notice is hereby given that the 16th Annual General Meeting of the members of Global Health Private Limited will be held at its registered office at E-18, Defence Colony, New Delhi - 110024 on Thursday, the 29th day of October, 2020 at 10.30 A.M., to transact the following business:

ORDINARY BUSINESS:

- 1. To receive, consider and adopt:
 - (a) the audited standalone financial statement of the Company for the financial year ended March 31, 2020, together with the reports of the Board of Directors and Auditors thereon; and
 - (b) the audited consolidated financial statement of the Company for the financial year ended March 31, 2020 together with the Report of Auditors thereon.
- 2. To appoint a Director in place of Mr. Ravi Kant Jaipuria (DIN-00003668), who retires by rotation and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS:

3. To consider and if thought fit, to pass with or without modification (s), the following resolution as an Ordinary Resolution

Ratification of the Remuneration of the Cost Auditors

"RESOLVED THAT pursuant to the provisions of Section 148(3) and other applicable provisions, if any, of the Companies Act,2013 and the Companies (Cost Records and Audit) Rules, 2014 (including any statutory modification (s) of re-enactment (s) thereof, for the time being in force), the Company hereby ratifies the remuneration of Rs.7,70,000/- (Rupees Seven Lakhs Seventy Thousand only) excluding GST and out of pocket expenses, payable to M/s. Ramanath Iyer & Co., who are appointed as Cost Auditors by the Board of Directors of the Company, to conduct the audit of the cost records of the Company for the financial year ending March 31, 2021.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution."

Cartified True Copy









Regd. Office: E-18, Defence Colony, New Delhi -1100024



4. To consider and if thought fit, to pass with or without modification (s), the following resolution as an Ordinary Resolution

Appointment of Mr. Udairam Thali Kottiath as Nominee Director of the Company

"RESOLVED THAT pursuant to the provisions of Sections 149, 152, 161 and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") and the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof, for the time being in force) and pursuant to the Provisions of Articles of Association of the Company, Mr. Udairam Thali Kottiath (DIN: 08703201), who was appointed as an additional – nominee director by the board of directors of the company to represent M/s Dunearn Investments (Mauritius) Pte Ltd w.e.f. 05th June, 2020 and who holds office as such up to the date of this Annual General Meeting, be and is hereby appointed as a Nominee Director of the Company representing M/s Dunearn Investments (Mauritius) Pte Ltd, liable to retire by rotation."

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do all such acts, deeds and things as may be necessary to give effect to the aforesaid resolution."

5. To consider and if thought fit, to pass with or without modification (s), the following resolution as an Ordinary Resolution

<u>Appointment of Ms. Prayeen Mahajan as Non Executive Independent Director of the Company</u>

"RESOLVED THAT pursuant to the provision of Section 149, 150, 152 read with schedule IV and other applicable provisions of the Companies Act (the Act) and the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modifications or re-enactment thereof for the time being in force) and pursuant to the provisions of Articles of Association of the Company, Ms. Praveen Mahajan (DIN: 07138514) who was appointed as an additional – non executive Director – Independent by the board of directors of the company w.e.f. 10th July, 2020 and who has submitted a declaration that she meets the criteria for independence as provided under Section 149 (6) of the Act and who holds office as such up to the date of ensuing Annual General Meeting be and is hereby, appointed as a Non - Executive Independent Director of the Company with immediate effect for a period of 5 years, not liable to retire by rotation."
















RESOLVED FURTHER THAT Ms. Praveen Mahajan be paid a sitting fee of Rs 1,00,000/- (Rs One Lac) per Board / Committee meeting attended by her as per provisions of the Companies Act, 2013 and the Rules framed thereunder and the total amount of sitting fee shall not exceed Rs 10,00,000/- P.A. (Rs Ten Lakhs) for every financial year.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do all such acts, deeds and things as may be necessary to give effect to the aforesaid resolution."

6. To consider and, if thought fit, to pass with or without modification(s), the following resolution as a Ordinary Resolution:

Approval of Remuneration of Mr. Pankaj Sahni, Chief Executive Officer of the Company for the FY 2019-20 & FY 2020-21

1. "RESOLVED THAT pursuant to the provisions of Section 188 of Companies Act, 2013 and other applicable provisions and rules thereunder, the consent of the Members of the Company be and is hereby accorded for payment of the remuneration of Rs.2,26,01,106/- (Two Crore Twenty Six Lakhs One Thousand One Hundred Six Only) plus a Car with Driver to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company) for the FY-2019-20.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do all such acts, deeds and things as may be necessary to give effect to the aforesaid resolution."

2. "RESOLVED THAT pursuant to the provisions of Section 188 of Companies Act, 2013 and other applicable provisions and rules thereunder, the consent of the Members of the Company be and is hereby accorded for payment of the remuneration of Rs.2,26,01,106/- (Two Crore Twenty Six Lakhs One Thousand One Hundred Six Only) plus a Car with Driver to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company) for the FY-2020-21.


RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do all such acts, deeds and things as may be necessary to give effect to the aforesaid resolution."













By order of the Board of Directors For Global Health Private Limited

Date: 28.09.2020

Place: Gurgaon

S K Bansal

Vice President - Head Legal &

Company Secretary (M. No. - F 4810)














Notes:

- (a) Explanatory Statement pursuant to Section 102(1) of the Companies Act, 2013 in relation to above item no.(s) 3, 4, 5 and 6 are annexed herewith and forms part of this Notice.
- (b) A member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote instead of herself/himself and the proxy need not be a member of the company.
- (c) Corporate Members intending to send their authorized representatives are requested to send a duly certified copy of the Board Resolution authorizing the representatives to attend and vote at the AGM.

















EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013 FORMING PART OF NOTICE CONVENING THE 16th ANNUAL GENERAL MEETING

Item No. 3

The Board has approved the appointment and remuneration of the Cost Auditors to conduct the audit of the cost records of the Company for the financial year ending March 31, 2021.

In accordance with the provisions of Section 148 of the Act read with the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditors, has to be ratified by the members of the Company.

Accordingly, consent of the members is sought for passing an Ordinary Resolution as set out at Item No. 3 of the Notice for ratification of the remuneration payable to the Cost Auditors for the financial year ending March 31, 2021.

The Board recommends the Ordinary Resolution set out at Item No. 3 of the Notice for approval by the members.

None of the Directors / Key Managerial Personnel of the Company / their relatives are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 3 of the Notice.

Item No. 4

Mr. Udairam Thali Koattiath was appointed as an additional - nominee director on the Board of the Company representing Dunearn Investments (Mauritius) Pte Ltd. (Dunearn) w.e.f 05th June, 2020 in terms of section 149, 152 and 161 of the Companies Act, 2013 and pursuant to the provisions of the Articles of Association of the Company, to hold office till the date of ensuing Annual General Meeting of the Company. The Board proposes to appoint Mr. Udairam Thali Kottiath as nominee director of the Company in this Annual General Meeting. The resolution is placed before the members for their consideration and approval. The Board recommends the passing of resolution as ordinary resolution.















Mr. Udairam is a graduate from University of Singapore, Bachelor of Arts in 1976 and also is a post graduate in Advanced Management Program from Harvard Business School. He is the Chief Operating Officer of Sheares Healthcare Management whose mandate is to acquire and develop hospitals and health care facilities and operations primarily in Asia, but also in the rest of the world. The mission is to create value by introducing new technology, from information technology to early adoption of new treatment modalities and systems. He has 39 years of health care experience in Singapore with substantial experience in the operation and management of hospitals (ranging from 2,500 bed psychiatric hospital to 800 bed acute care hospital). He was involved in developing and implementing the first computerised hospital administration system in Singapore in 1984 and has been Chair of various IT committees in public healthcare (from cluster steering committees to the national telehealth committee). In addition Mr. Udairam was involved in a number of national projects including the development and implementation of the national Medisave scheme (a national health care personal savings fund). He has also been involved in corporatising government hospitals, including successfully commissioning and establishing Ang Mo Kio Community Hospital. His last role in public healthcare was to establish the first integrated primary to tertiary care cluster in Singapore, which is a model the Ministry of Health has now established as a target for all clusters.

None of the Directors except Mr. Udairam Thali Kottiath (DIN: 08703201), Key Managerial Personnel of the Company/ their relatives, are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 4 of the Notice.

Item No. 5

Ms. Praveen Mahajan was appointed as Additional Non-Executive - Independent Director w.e.f. 10th July, 2020 to hold office till date of this Annual General meeting. She was also appointed as member of the Audit Committee, Remuneration Committee & CSR Committee of the Company.

Ms. Praveen Mahajan has a rich experience in the field of public administration, tax policy & tax administration in the sphere of indirect taxes, enforcement of various laws and regulations - customs, central, excise, service tax etc., international trade and economic relations - FTAs, CEPA, CMAA, WCO and WTO matters, public finance & budgeting and legal matters & quasi-judicial proceedings. She was also awarded the "Presidential Award for extraordinary devotion to duty and specially dictinguished record of service" in the year 1992. She has served as a first ever lady officer to head the Central Board of Excise and Customs (CBEC), since its inception.





The Company had received necessary declaration(s) from Ms. Praveen Mahajan confirming that she meets the criteria of Independent Director as prescribed under the Companies Act, 2013 (the Act). In the opinion of the Board, Ms. Praveen Mahajan fulfills the conditions for her appointment as a Non Executive Independent Director as specified in the Act.

The Board believes that induction of Ms. Praveen Mahajan on the Board will support in broadening the overall experience of the Board and will bring wide experience in the area of Corporate Governance. It is proposed to pay her a sitting fee of Rs 1,00,000/- (Rs One Lac) per Board / Committee meeting attended by her as per provisions of the Companies Act, 2013 and the Rules framed thereunder and the total amount of sitting fee shall not exceed Rs. 10,00,000/- P.A. (Rs Ten Lakhs) for every financial year.

The Board of Directors accordingly recommends the ordinary resolution set out at Item No. 5 of the Notice for the approval of the Members.

None of the Directors except Ms. Praveen Mahajan (DIN: 07138514), Key Managerial Personnel of the Company/ their relatives, are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 5 of the Notice.

Item No. 6

Mr. Pankaj Sahni, CEO of the Company, has played vital role in the growth of the Company in different functions and considering his achievements and contribution. He was paid remuneration of Rs. 2,40,65,992/- (Rupees Two Crores Forty Lacs Sixty Five Thousand Nine Hundred Ninety Two only) for the FY-2018-19 as under:

- a) Fixed Amount of Rs. 2,26,01,106 (Two Crores Twenty Six Lakhs One Thousand One Hundred Six Only) plus a Car with Driver and
- b) Variable Amount of Rs.14,64,886/- (Rs. Fourteen Lacs Sixty Four Thousand Eight Hundred Eighty Six only).

The Board had approved the financials & non-financial parameters for payment of variable amount for the F.Y. 2019-20 at its board meeting held on 26th September, 2019.


Mr. Pankaj Sahni has been paid a fixed remuneration of Rs.2,20,01,106/- for the F.Y. 2019-20. The variable remuneration of Mr. Pankaj Sahni for the F.Y. 2019-2020 was due for approval by the Board, based on above financial and non-financial parameters.











Further, Mr. Pankaj Sahni is being paid remuneration @ 2,26,01,106/- p.a., with applicable salary cuts due to cash flow/ financial constraints faced by the Company amid COVID 19 pandemic from April, 2020 onwards.

Mr. Pankaj Sahni has vide his letter dated 28th September, 2020 voluntarily expressed his desire to not withdraw any variable remuneration for the FY 19-20 and FY 20-21.

Accordingly, the Remuneration Committee and Board in its meeting held on 28th September, 2020 have approved the above proposals.

Based on above, the board has approved the remuneration of Rs. 2,26,01,106/- p.a. plus a Carwith Driver to Mr. Pankaj Sahni for the F.Y. 2019-20 & FY 2020-21 as stated in resolution no.(s) 1 & 2 of Item no. 6.

Educational Background and experience:

Mr. Pankaj Sahni is a graduate in Mathematics from St. Stephens College, Delhi and is also an Associate member of the Institute of Chartered Accountants of India. Mr. Sahni is also an MBA from Kellogg School of Management, with specialization in Strategy, Finance and International Business. Mr. Sahni has worked with leading International Business Consultants like Arthur Anderson & Co., Ernst & Young. Lastly, Mr. Sahni was associated with Mckinsey & Co. as Associate Partner and currently working as Chief Executive Officer of the Company.

Mr. Sahni is son in law of Dr. Naresh Trehan, CMD and accordingly this is a related party transaction as per Section 188 of the Companies Act, 2013.

None of the Directors, except Dr. Naresh Trehan (being father in law of Mr Sahni) & Mr. Pankaj Sahni, himself, and his relatives or any key managerial personnel or their relatives is interested in passing of this Ordinary Resolution.

Date: 28.09.2020

Place: Gurgaon

By order of the Board of Directors For Global Health Private Limited

S K Bansal

Vice President - Head Legal &

Company Secretary

(M. No. - F 4810)















GLOBAL HEALTH PRIVATE LIMITED

Registered Office: E-18, Defence Colony, New Delhi – 110024 CIN: U85110DL2004PTC128319


Telephone: (011) 4411 4411 * Fax: (011) 2433 1433* Website: www.medanta.org

ATTENDANCE SLIP

Members attending the Meeting in person or by Proxy are requested to complete the Attendance Slip and hand it over at the entrance of the meeting room.

I hereby record my presence at the 16th Annual General Meeting of the Company at its registered office at E-18, Defence Colony, New Delhi - 110024, on Thursday, the 29th day of October, 2020 at 10.30 A.M.

Name of the Member:		E	
			Signature
Folio No.:* DP ID No.:*		Client ID No:*	
*Applicable for Members holding shares	in electronic fo	rm	
			· · · · · · · · · · · · · · · · · · ·
Full name of the Proxy/ Authorized Representation	esentative (if ap	plicable)	Signature





GLOBAL HEALTH PRIVATE LIMITED

Registered Office: E-18, Defence Colony, New Delhi - 110024

CIN: U85110DL2004PTC128319

Telephone: (011) 4411 4411 * Fax: (011) 2433 1433 * Website: www.medanta.org

Form No. MGT - 11 PROXY FORM

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

·CIN: U85110DL2004PTC128319

Name of the Company: GLOBAL HEALTH RPIVATE LIMITED

Registered Office: E-18, Defence Colony, New Delhi - 110024

Nan	ne of the Member(s):		
da ilid	istered Address:	A Comment of the Comm	
E-m		P ID No:*	Client ID No.:*
I/We			Shares of Global Health Private
ĭ.	Name:		
	1. (4.8°)		
	Email id:	;	
	Signature:	:	, or falling him/her
2.	Name:		
		Company of the Company	
	Signature:		
	***3		a canno
















Name:	
Address:	
Email id:	
Signature:	, or falling him/her

as my / our proxy to attend and vote (on a poll) for me / us and on my / our behalf at the 16th Annual General Meeting of the Company, to be held on Thursday, the 29th day of October, 2020 at 10.30 A.M. at its registered office at E-18, Defence Colony, New Delhi - 110024 and at any adjournment thereof, in respect of the Resolutions set out in the Notice convening the Meeting, as indicated below:

S. NO.	RESOLUTIONS	FOR	AGAINST
Ordinar	y Business		
1.	To receive, consider and adopt:		<u> </u>
	a) the audited standalone financial statement of the Company for the financial year ended March 31, 2020, together with the reports of the Board of Directors and Auditors thereon; and		
	b) the audited consolidated financial statement of the Company for the financial year ended March 31, 2020 together with the Report of Auditors thereon.		
2.	To appoint a Director in place of Mr. Ravi Kant Jaipuria (DIN-00003668), who retires by rotation and being eligible, offers himself for reappointment.		
Special I	Business		
3.	To ratify the Remuneration of M/s. Ramanath Iyer & Co, Cost Auditors		
4.	Appointment of Mr. Udairam Thali Kottiath as nominee director of the Company		
5.	Appointment of Ms. Praveen Mahajan as non executive independent director of the Company	\	
6.	Approval of remuneration Mr. Pankaj Sahni, Chief Executive Officer of the Company for the FY 2019-20 & FY 2020-21		















Signed this 28th day of September, 2020

Signature of Shareholder

Affix Revenue Stamp Signature

Signature of Proxy Holder(s)

Notes:

- 1. This form should be signed across the stamp as per specimen signature registered with the Company.
- 2. The Proxy, to be effective, should be deposited at the Registered Office of the Company not less than 48 hours before the commencement of the AGM.
- 3. A proxy need not be a member of the Company.
- 4. Please put a √ in the appropriate column against the resolutions indicated in the Box. If you leave the For or Against column blank against any or all the resolutions, your proxy will be entitled to vote in the manner as he/she thinks appropriate. This is only optional.











Board's Report

Dear Members,

Your Directors are pleased to present the 16th Annual Report on business and operations together with the Audited Financial Statements for the financial year ended March 31, 2020.

FINANCIAL RESULTS

The Company's financial performance including its subsidiaries for the year ended March 31, 2020 is summarized below:

A. Standalone financial performance

The state of the s	The state of the s	(Rupees in Lakhs)
Particulars	31.3.2020	31 3 0010
Revenue from operations	1,45,657.18	1,44,113.22
Other Income	5,905.33	6468,94
Total Revenue	1,51,562.51	1,50,582.16
Total Expenditure	1,38,469.17	1,40,930.11
Profit before Taxation	13,093.34	9,652.05
Current Tax	4,971.83	5,158.47
Deferred tax expense (Income)	(2,154.15)	(1,800.21)
Profit after Taxation	10,275.66	6,293.79

B. Consolidated financial performance

	S. C.	(Rupees in Lakhs)
Particulars	31.3.2020	31.3.2019
Revenue from operations	1,48,421.58	1,44,113.22
Other Income	5,942.51	6,485.59
Total Revenue	1,54,364.09	1,50,598.81
Total Expenditure	1,47,974.94	1,41,076.62
Profit before Taxation	6,386.96	9,519.61
Current Tax	4,971.83	5,158.47
Deferred tax expense	(2,217.76)	(1,736.64)
Profit after Taxation	3,632.89	6,097.78

For the FY 2019-20, the Company recorded revenue from operations of Rs.1,45,657.18/Lakhs (previous year Rs. 1,44,113.22/- Lakhs) resulting in an increase by 1.07% and net profit of Rs.10,275.66/- Lakhs (previous year Rs. 6,293.79 Lakhs) resulting in an increase by 63.27% on standalone basis.

The consolidated financials of the company includes the financials of Medanta Duke Research Institute Private Limited (MDRI), Global Health Patliputra Private Limited (GHPPL) and Medanta Holdings Private Limited (MHPL), being the subsidiaries of the Company.

Page 1 of 36



The COVID-19 pandemic outbreak during March 20 has affected countries across the Globe resulting in material impact on the healthcare industry in India as well due to travel restrictions imposed by the State / National /International Govt.(s) and deferment of elective surgeries / preventive health check-ups by people at large.

Your Company has arisen to the situation and has taken a strong leadership in responding to the COVID-19 Management. All safety protocols / preventive / safety measures defined by regulatory bodies and the Company have been followed in providing best possible care for COVID / Non -Covid patients, clinical & non-clinical staff. Separate wards have been established for COVID patients, E-clinic facility has been provided for home consultations, home care facility / post Covid rehabilitation facility has also been provided to COVID 19 patients by partnering with various Hotels.

"Medanta - the Medicity" has been declared as the Best Private Hospital in India for the year 2020 by "Newsweek" and 2nd in all hospitals including Govt. Hospitals in India.

Further, Medanta – the Medicity has been chosen as best Covid Care Hospital in India for "Safaigiri Award" by India Today.

The financial impact of COVID 19 pandemic will be reflected during the FY 20-21.

Extract of Annual Return

Extract of Annual Return of the Company is annexed herewith as Annexure- I to this Report.

Number of Meetings of the Board

The Board met 4 times during the financial year 2019-20. The intervening gap between any two meetings was within the period prescribed by the Companies Act, 2013.

Dividend

Your directors have not recommended any dividend on its equity shares for the financial year ended March 31, 2020.

The dividend of Rs. 32.50 is accrued to be paid to M/s. Anant Investment on 4,66,954 Class A fully convertible Preference Shares held by it.

Fixed Deposit

Your company has not accepted any fixed deposits from the public and as such, no amount of principal or interest was outstanding on the date of the Balance Sheet.

Transfer to Reserve

Your company proposes to transfer Rs. 10,275.66 Lakhs (Previous Year: Rs. 6,293.79 Lakhs) to the general reserves out of amount available for appropriation.

Page 2 of 36



Directors and Key Managerial Personnel

The composition of Board of Directors is well balanced with a view to manage the affairs of the Company efficiently and professionally.

Mr. Ravi Kant Jaipuria (DIN00003668), Director of the Company is liable to retire by rotation at ensuing Annual General Meeting of the Company and being eligible, has offered himself for re-appointment and the Board recommends his appointment as Director at the ensuing Annual General Meeting.

Mr. Rohit Sipahimalani (DIN-00904065) had resigned from the directorship of the Company with effect from w.e.f. 26th September, 2019. The Board of Directors places on record its appreciation for the support and guidance provided by Mr. Rohit Sipahimalani during his tenure as Non-Executive Directors of the Company.

Dr. (Mrs.) Shayama Chona (DIN-02749576), Non-Executive Independent Director had resigned from the directorship of the Company with effect from 24th February, 2020. She was also a member of CSR and Remuneration Committee (s). The Board of Directors places on record its appreciation for the support and guidance provided by Dr. (Mrs.) Shayama Chona during her tenure as a Non-Executive Independent Director of the Company.

Mr. Udairam Thali Koattiath (DIN-08703201) has been appointed as nominee director of Dunearn Investments (Mauritius) Pte Ltd. on 5th June, 2020 and also member of the Audit Committee.

Ms. Praveen Mahajan (DIN-07138514) has been appointed as an independent Director of the Company on 10th July, 2020 and member of Audit, Remuneration and CSR Committee(s). She has submitted a declaration that she meets the criteria for independent director as laid down under Section 149(6) of the Companies Act, 2013. She has also submitted declaration that she has registered herself on the online data bank of Indian Institute of Corporate Affairs (IICA) in accordance with the Companies (Appointment and Qualification of Directors) Fifth Amendment Rules, 2019.

Employee Stock Option Plan (ESOP) 2014 and ESOP Plan 2016 of the Company

There are two ESOP Schemes in force named GHPL ESOP Plan 2014 and GHPL ESOP Plan 2016. The details of ESOP(s) available and allocated under both plans are as under:

Particulars	No. of options under ESOP Plan 2014	No. of options under ESOP Plan 2016
Number of total options	8,52,973	10,25,000
Total options granted as on 1 st April 2019	8,44,824	9,55,000
Options lapsed, forfeited and added back to the pool during the year	NIL	91,000 (options lapsed)

Page 3 of 36



Options granted during the FY 2019-20(including Options lapsed, forfeited and added back to the pool during the year)	NA	, NA
Total Options in force as on 31st March, 2020	8,09,097	8,64,000
Total options exercised as on 31st March, 2020	5,48,449	3,02,500
Total options vested but not yet exercised as on 31st March, 2020	2,15,648	2,15,250
Total option pending for allocation as on 31.3. 2020	43,876	1,61,000
The exercise price for each option	Rs.10 each	Rs.10 each
Money realized by exercise of options	54,84,490	30,25,000
Employee-wise details of options granted to: (i) Key managerial personnel	NIL	20,000
(ii) Any other employee who receives a grant of options in any one year of option amounting to 5% or more of options granted during that year; (iii) Identified employees who were granted option, during any one year, equal to or exceeding 1% of the issued capital (excluding	NIL	NIL
outstanding warrants and conversions) of the company at the time of grant	NIL	NIL

- Each option has been granted at Rs 10 each convertible into one Equity share of Rs each at par.
- The total options granted shall vest every year @ 20% / 25% / 33%, from date of grant over a period of 5/4/3 years as per terms of respective, Offer Letter(s).
- The vested options can be exercised within a period of 3 years from the date of vesting.

Page 4 of 36



The company had allotted 2,12,225 (Two Lakh Twelve Thousand Two Hundred Twenty Five) equity shares of Rs.10 each upon exercise of vested options under ESOP Scheme 2014 & 2016 during financial year 2019-20. Subsequently, 31,113 (Thirty One Thousand One Hundred Thirteen) equity shares of Rs.10 each have been issued upon exercise of vested options as per the ESOP Schemes 2014 & 2016.

The Summary detail of ESOPs as on date is as under:

SI. No.	Particulars	ESOP 2014	Scheme	ESOP 2016	Scheme
1.	ESOP vested & exercised		5,55,062		3,27,000
2.	ESOP vested but not yet exercised		2,02,422		2,34,750
3,	ESOP not yet vested	-	51,613		3,02,250
4.	ESOP pending for allocation		43,876		1,61,000
	Total		8,52,973		10,25,000

Audit Committee

During the year under review, the Audit Committee comprises of the following members:

Mr. Neeraj Bharadwaj	Member
Mr. Rohit Sipahimalani*	Member
Mr. Udairam Thali Koattiath**	Member
Ms. Praveen Mahajan ***	Member

^{*}Resigned w.e.f. 26th September, 2019
** Appointed w.e.f 5th June, 2020

The Company has voluntarily constituted the Audit Committee.

Remuneration Committee

During the year under review, the Remuneration Committee comprises of the following members:

Dr. (Mrs.) Shayama Chona*	Member
Mr. Neeraj Bharadwaj	Member
Ms. Praveen Mahajan **	Member

^{*}Resigned w.e.f. 24th February, 2020. ** Appointed w.e.f 10th July, 2020

^{***} Appointed w.e.f 10th July, 2020



The Company has voluntarily constituted the Remuneration Committee and is in the process to appoint more members in due course of time.

Corporate Social Responsibility (CSR) Committee

The Corporate Social Responsibility Committee comprises of the following members:

Dr. Naresh Trehan	Chairmar
Mr. Sunil Sachdeva	Member
Dr. (Mrs.) Shayama Chona*	Member
Ms. Praveen Mahajan * *	Member

^{*} Resigned w.e.f 24th February, 2020. ** Appointed w.e.f 10th July, 2020

Corporate Social Responsibility Initiatives

As a part of its initiatives under Corporate Social Responsibility (CSR), the Company has undertaken projects in the areas of promoting health care including "Mission – TB Free Haryana" & Preventive Health Care Program. These projects are in accordance with Schedule-VII of the Companies Act, 2013.

The report on CSR activities for the financial year 2019-20 is annexed herewith Annexure-II forming part of the Board Report pursuant to clause (o) of sub-section (3) of Section 134 of the Companies Act, 2013 read with Rule 9 of the Companies (Corporate Social Responsibility) Rules, 2014.

Risk Management Committee

The Company has developed and implemented a Risk Management Policy and a Risk Management Committee (RMC) comprising of senior executives of the Company has been constituted. The Committee assists the Audit Committee and Board in (a) Overseeing and approving the Company's enterprise wide risk management framework; and (b) Overseeing that all the risks have been identified and assessed by the organization and there is an adequate risk management infrastructure in place capable of addressing those risks.

Whistle Blower Mechanism (Vigil Mechanism)

Pursuant to the provisions of Section 177 of the Companies Act, 2013 and Rules made there under, the Company has adopted a Whistle Blower Policy and has established the necessary vigil mechanism for Directors and employees to report genuine concerns about unethical behaviour, actual or suspected fraud or violation of the Company's code of conduct or ethics policy.

Sexual Harassment Policy

A policy on Sexual Harassment of Women at Workplace had been implemented in the Company and an Internal Complaint Committee(s) had been constituted to handle / investigate the matters relating to Sexual Harassment at various locations. The Company had

Page 6 of 36



received 4 (Four) complaints under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH) & same had been disposed as per the terms of the policy of the Company. The company has complied with provisions relating to constitution of Internal Committee under POSH.

The Hon'ble High Court (Indore) order dated 16.09.2019 passed by Hon'ble Single Judge was challenged by GHPL by way of Writ Appeal bearing number 1619/2019 before Hon'ble Double Bench Indore. The Hon'ble Double Bench accepted GHPL's arguments and by way of order dated 04.10.2019 granted stay on the operation of the order dated 16.09.2019. The matter was last listed on 16.03.2020, but hearing could not take place due to Corona Pandemic.

Subsidiaries

During the year under review, the Company has three subsidiaries viz. Medanta Duke Research Institute Private Limited (MDRI), Global Health Patliputra Private Limited" (GHPPL) and Medanta Holdings Private Limited (MHPL). The Reports on the performance and financial position of MDRI, GHPPL and MHPL as per the Companies Act, 2013 are given below and also provided to the consolidated financial statement of the Company.

1. MDRI

MDRI's financial performance for the year ended March 31, 2020 is as under:

Particulars		oks In Lacs)
	2020	2019
Other Income	8.17	24.00
Total Revenue	8.17	24.00
Total Expenditure	12.04	29.16
Loss before Tax	(3.87)	(5.16)
Tax Expenses - Deferred Tax	0.49	Nil
Loss after Taxation	(4.36)	(5.16)

MDRI a subsidiary of Global Health Private Ltd. (GHPL / Company) wherein GHPL was holing 10,001 (50.01%) equity shares and Duke Medicine Asia Pte. Ltd. ("Duke") is holding 10,000 (49.99%) equity shares.

The international strategy of Duke Medicine Asia Pte. Ltd. ("Duke") had been changed and it had taken a policy decision not to undertake clinical trials internationally. MDRI at its Extra Ordinary General Meeting held on 24th September, 2019 has decided to go for voluntary liquidation and is in process of voluntary liquidation under Section 59 of the Insolvency and



Bankruptcy Code, 2016 (IBC Code 2016). Mr. Prabhakar Kumar Insolvency Professional holding Registration No. IBBI/IPA-002/IP-N00774/2018-2019/12373 had been appointed as a liquidator of the Company in terms of the applicable provisions of the IBC Code, 2016 for the purpose of voluntary liquidation of the Company.

2. MHPL

MHPL is a 100% subsidiary of the Company.

The Company has subscribed for 1,40,21,420 Equity Shares of Rs.10 each and 1,31,19,764 Compulsorily Convertible Preference Shares (CCPS) of Rs.10 each amounting to Rs.102.99 Crores during the financial year 2019-20. The Company holds 6,54,07,228 Equity shares and 63,29,113 CCPS of Rs 10/- each as on 31st March, 2020 and 63, 29,113 CCPS were converted into 63,29,113 equity shares thereafter. Total equity shares held by GHPL as on date is 7,17,36,341. The total amount invested in MHPL by the Company till date is Rs.401.50 Crores.

With the vision of providing state-of-the-art medical treatment at an affordable cost to the people of Lucknow, Uttar Pradesh and its neighboring States - Medanta Lucknow commenced its operations on 05 November 2019 and is now offering state-of-the-art Patient Care Services in Cardiology and Cardiac-surgery, Neurosciences, Nephrology, Urology, Orthopedics & Joint Replacement, Digestive and Hepatobiliary Sciences, Internal Medicine, Pulmonary Medicine, Critical Care, Anesthesiology, Transfusion Medicine and Blood Bank, Radiology and Nuclear Medicine, Pathology and Laboratory Medicine and 24X7 Emergency Medicine and Trauma Care.

Spread over 12.58 acres, MEDANTA LUCKNOW – a 1000 bedded hospital – is an excellent combination of future generation healthcare services comprising of 350 critical care beds (ICUs), more than 30 super-specialties, 37 ultra-clean operation theaters, state of the art highend Laboratory Services, 24X7 Blood Bank, Bone Densitometry, Mammography, Ultrasound, high-end MRI, CT, PET Scan, Gamma Camera, etc.

The Executive Health Check-up Center at Medanta Lucknow is also operational and is offering state-of-the-art Health Check-up services to the citizens of Lucknow, Uttar Pradesh and its neighboring States under Preventive Health.

In the coming days, MEDANTA intends to introduce the facility of Obstetrics and Gynaecology, Pediatric Intensive Care Unit (PICU), Neo-natal ICU (NICU), Pediatric, Rehabilitation Unit and Lever Transplant.

MEDANTA's mission is to provide world-class, holistic and affordable health services to the citizens of Lucknow, Uttar Pradesh, neighboring states and also to those around the globe.

In recent past, many lives in emergency situations have also been saved here at Medanta Lucknow during the course of COVID-19 lockdown across cities and states. Patients have been airlifted from across the states to Medanta Lucknow and emergency surgeries were performed by concerned doctors after taking due precautions in light of COVID-19 limitations. A dedicated 20 bedded COVID ward, which is a make shift arrangement, has also

Page 8 of 36



been established to provide round-the-clock treatment to COVID-19 positive patients — without disturbing the existing hospital facility that is already providing world-class medical treatment to Non-Covid patients.

Its financial performance for the year ended March 31, 2020 is as under:

Particulars		(Rs, In Lakhs)
	2020	2019
Revenue from operations	2,779.88	0.00
Other Income	118.28	16.23
Total Revenue	2,898.16	16.23
Total Expenditure	8,350.67	92.96
Loss before Tax	(5,452.51)	(76.73)
Tax Expenses - Deferred Tax	34.33	(34.38)
Loss after Taxation	(5,486.84)	(42.35)

3. GHPPL

GHPPL is a 100% subsidiary of the Company.

Global Health Patliputra Private Limited (GHPPL) is in process of development of 500 beds Super Specialty Hospital (in 4 Phases) in Patna (Kankarbagh) over an area of 7 acres approx through PPP mode on a design, build, finance, operate and transfer basis.

GHPPL has commenced its OPD operations with effect from 18th September, 2020 and 200 - 250 IPD beds are likely to be commenced in next 3-4 months thereafter.

The Company had subscribed an additional 4,00,00,000 Equity Shares of Rs. 10 each amounting to Rs. 40 Crores during FY-2019-20 and subsequently 1,50,00,000 Equity Shares of Rs.10 each amounting to Rs. 15 Crore. The total amount invested by the Company in GHPPL till date is Rs. 110 Crores.

GHPPL's financial performance for the year ended March 31, 2020 is as under:

Particulars Other Income	2020 2.48	(Rs, In; Lakhs), 2019 0.44
Total Revenue	2.48	0.44

Page 9 of 36



Total Expenditure	1,256.35	473.93
Loss before Tax	(1,253.87)	(473.49)
Tax Expenses - Deferred Tax	NIL	NIL
Loss after Taxation	(1,253.87)	(473.49)

Consolidated Financial Statement

In accordance with the provisions of the Companies Act, 2013 and Accounting Standard (AS) - 21, the audited consolidated financial statement is provided in the prescribed form AOC-1 as Annexure-III which forms a part of the Annual Report.

Directors' Responsibility Statement

Pursuant to the requirement of the Companies Act, 2013, the Board of Directors confirms that:

- (a) In the preparation of the annual accounts for the year ended 31st March,2020, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- (b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year 2020 and of the profit of the company for that period;
- (c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- (d) the directors had prepared the annual accounts on a going concern basis; and
- (e) the directors, had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
- (f) the directors had devised proper systems to ensure compliance with the provision of all applicable laws and that such systems were adequate and operating effectively.

Internal Financial Controls

The Company has in place adequate internal financial controls with reference to financial statements. During the year, such controls were tested and no reportable material weakness in the design or operation was observed.

Page 10 of 36



Significant and Material Orders passed by the Regulators or Courts

There are no significant material orders passed by the Regulators / Courts except the matter pending before the National Green Tribunal ("NGT") regarding 'Jharsa bundh' land.

The matter is pending before the NGT and the next date is 17.11. 2020.

Particulars of loans given, Investment made, Guarantees given and Securities provided

Your Company has made an investment for an amount aggregating to Rs. 40.00 Crores in the shares of GHPPL during the financial year 2019-20 and Rs. 15 Crore thereafter.

Further, Your Company has also made an investment for an amount aggregating to Rs.102.99 Crores in the shares of MHPL during the financial year 2019-20.

Particulars of contracts or arrangements with related parties

Contracts / arrangements / transactions entered by the Company during the financial year with related parties were in the ordinary course of business and on an arm's length basis. During the year, the Company had obtained the necessary approvals as applicable while entering into contracts or arrangements with related parties.

Particulars of contracts or arrangements with related parties referred to in Section 188 (1) of the Companies Act, 2013, in prescribed form AOC-2 is appended as Annexure-IV to the Board's report.

Your Directors draw your attention to Note No(s) 38 to the standalone financial statement which sets out related party Disclosures.

The Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

The particulars relating to conservation of energy, technology absorption, foreign exchange earnings and outgo, as required to be disclosed under the Act, are provided in Annexure-V to this Report.

Auditors and Auditors' Report

Statutory Auditors

M/s Walker Chandiok& Co. LLP, Chartered Accountants were appointed as Statutory Auditors of the Company for a period of 5 consecutive years at the Annual General Meeting held on 15th September, 2017. They have confirmed that they are not disqualified from continuing as Statutory Auditors of the Company.

M/s Walker Chandiok& Co. LLP, Statutory Auditors of the Company have submitted their report for the financial year 2019-2020. The Notes on financial statement referred to in the Auditors' Report are self- explanatory and do not call for any further comments. The Auditors' Report does not contain any qualification, reservation or adverse remark.

Page 11 of 36



Cost Auditors

The Cost Auditors have submitted their Report and it does not contain any qualification, reservation or adverse remark. M/s. Ramanath Iyer & Co., retiring Cost Auditors were eligible for re-appointment. They had confirmed their eligibility to the effect that their reappointment, if made, for the financial year 2020-21 would be within the prescribed limits under the Act and that they were not disqualified for re-appointment.

Internal Auditors

M/s Pricewaterhousecoopers, Services LLP, Chartered Accountants, (PwC) has been appointed as Internal Auditors in place of M/s Deloitte Haskins & Sells, by the Board on 19th December, 2019 for the financial year 2019-20.

Acknowledgements:

Your Directors place on record their sincere appreciation for significant contribution made by your Company's employees at all levels and look forward to their continued support.

Your directors also take this opportunity to express sincere thanks to the medical professionals / fraternity and patients for their continued co-operation, patronage and trust reposed in the Company and its services.

Your Directors also wish to place on record their appreciation and acknowledge with gratitude the support and co-operation extended by State Governments, our bankers, consultants, customers, vendors, affiliated hospitals, shareholders and other business associates for their confidence reposed in the Company and its management.

For and on behalf of the Board Global Health Private Limited

Place: Gurgaon Date: 28.09.2020

Dr. Naresh K. Trehan

Chairman and Managing Director

(DIN No.: 00012148)



Annexure-I to Directors' Report Form No. MGT-9

EXTRACT OF ANNUAL RETURN AS ON THE FINANCIAL YEAR ENDED ON MARCH 31, 2020

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

1. REGISTRATION AND OTHER DETAILS:

CIN	U85110DL2004PTC128319
Registration Date	13.08.2004
Name of the Company	Global Health Private Limited
Category/Sub-Category of the Company	Private Company/Limited by Shares
Address of the Registered office and contact Details	E-18, Defence Colony, New Delhi- 110024
Whether listed company	No
Name, Address and Contact details of Registral and Transfer Agent, if any	KFin Technologies Private Limited Selenium Tower B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad – 500 032 P: +91 40 6716 1602 M: +91 9381616972 Email: einward.ris@kfintech.com Website:www.kfintech.com

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10% or more of the total turn over of the company shall be stated:

Sr. · No.	Name and Description of main products/ services	NIC Code o Product/ sea	f the % to total turnover of the vice company
1	To establish, maintain, operate, run manage or administer hospitals, medicare healthcare, diagnostic, health aids and research centers	861	100

Page 13 of 36



III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

1.772.773.411	Name and Address of the Company	CIN/GLN	Holding/ Subsidiary /Associate	%of shares held	Applicable Section
	Medanta Duke	U73100DL201	Subsidiary	50.01	Section 2(87) (ii) of the
-	Research	0PTC211892			Companies Act, 2013
	Private Limited				
	Global Health	U74999DL201	Subsidiary	100	Section 2(87)(i) & (ii) of
	Patliputra	5PTC283932			the Companies Act, 2013
	Private Limited				
	Medanta	U74140DL201	Subsidiary	100	Section 2(87)(i) & (ii) of
	Holdings	3PTC250579	·		the Companies Act, 2013
	Private Limited				-

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i. Category-wise Shareholding

Categor y of Shareho lders	of the ye	ar	d at the beg		year				% Chang e during the year
对于是参考的			Loal Park	OI Total Share	Demä	150	00000	Totali Totali Sharei	
Promot er	10 m					Z.17. 282 (1055; 131)	23195(10)(25)		
Indian									
Individu al/ HUF	-	2,38,9 2,075	2,38,92,0 75	48.63	1,70,9 2,075	68,00,0 00	2,38,92,0 75	48.42	(0.21)*
Central Govt	-	3-1 1	=			_	•	-	with appendict to the first state or minimizer or an appendix plan about the state of the state
State Govt(s)			**	-	-	~	#-J	_	
Bodies Corp	-	LT	•	-	-			na dimension mangan da annuan d	-
Banks / Fl	•	-	-	-	-	Programme and the second of th	**		
Any	-	-		-	-	_		-	_

Page 14 of 36



Other		1	1	1	1		T	1	
spanning of the same of the sa		2,38,9	2.38,92,0	48.53	1.70.9	68,00,0	2,38,92,0	10 10	(0.01)
Sub- total(A)(1):-		2,075	75		2,075	00	75	1 90/92	(0.21)
Poreign					Ì			 	-
NRIs- Individu als	-	•	-			-	-	-	
Other- Individu als		~		-	_	- ·			-
Bodies Corp.	-	-	_	•	-		_	61	
Banks / Fl	-	_	_		_	**	-		
Any Other	_	m.	***	_	*	-	-	-	-
Sub- total(A)(2):-	•	-		~	-	••	-	-	
Public Shareho Iding			A 36			11 - 12 - 12 - 12 - 12 - 12 - 12 - 12 -			100
Instituti ons									
Mutual Funds		_	-	~	=:		<u>.</u>	-	-
Banks / FI	-	**	-	-				·	w
Central Govt	-		TAN	~	_	1	Put	-	<u></u>
State Govt(s)		_	**	-	-			-	-
Venture Capital Funds	-	-	••		5 5		n-	-	
Insuranc e Compan	-	•	-	14	#4	av .	er		**************************************
ies					V		wanteners and antique to be a free and a fre	***************************************	
FIIs			<u> </u>	~	_	-	**		-
Foreign Venture Capital Funds			-		1	~	_	-	-

Page 15 of 36



[04]	T	7	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·					and the state of t
Others (specify)	-	-	-	-	-		-	**	-
{ (sheetik)	1	1	1	1	1	!	<u> </u>	1	
Sub-		-	-		-	_		-	-
total									
(B)(1)									
2. Non								!	***************************************
Instituti									
ons									
Bodies									
Corp.			20.00.00						
(i) Indian		20,00,	20,00,00	4.07	20,00,	-	20,00,00	4.06	(0.01)
(ii)		000	0		000		0		
Oversea					1				
S									
Individu									
als									
(i)	36,448	~	36,448	0.07	48,44	-	48,448	0.09	0.02
Individu al					8				
sharchol									
ders									
holding									
nominal							٠		
share									
capital									
upto Rs.									
1 lakh									
(ii)									
Individu	6,02,27		6,02,276	1.23	8,02,5		0.00.501	3 63	A 40
al	6		0,02,570	1,23	0,02,0		8,02,501	1.63	0.40
sharehol					0.7				
ders	;								
holding									
nominal									
share									
capital									
in excess			,						
of Rs 1								A PARAMA	
lakh				·				}	
Others	86,01,9	1,40,0	2,26,01,9	46.00	86,01,	1,40,00	2,26,01,9	45.80	(0.20)
(Foreig	79	0,000	79	13,00	979	,000	79	42,00	(0.20)
n		-				,		ļ	
Compa									

Page **16** of **36**



ny)									
Sub-	92,40,7	1.60,0	2.52,40,7	51.37	1,14,5	1,40,00	2,54.52,9	51.58	0.21
total(B)(03	0,000	03		2,928	,000	28		
2)									
Total	92,40,7	1,60,0	2,52,40,7	51.37	1,14,5	1,40,00	2,54,52,9	51.58	0.21
Public	03	0,000	03		2,928	,000	28		
Shareho					·	1			
lding			1						
(B)=(B)(Parameter Control of the Control of		
1)+									
(B)(2)									
C.	**	~	~	**	-	-	-	~	-
Shares							Washington		
held by									
Custodia									
n for									
GDRs &									
ADRs				·					
Grand	92,40,7	3,98,9	4,91,32,7	100	2,85,4	2,08,00	4,93,45,0	100	
Total	03	2,075	78		5,003	,000	03		
(A+B+C)									
)									

^{*}variation in % change in share holding during the year due to allotment of 2,12,225 equity shares of Rs.10 each under ESOP Scheme 2014 & 2016 pursuant to exercise the vested options to Employees.

ii. Shareholding of Promoters

S r. N	Shareholder? s Name	Shareholdi beginning			Sharcholdin the year	g at the o	nd of	
1.	Dr. Naresh Trehan and Ms. Madhu	No. of Shares 68,92,075	total Shares s qt the comp	%of Share Pledgi ed / cricu mbe red to total shares	No. 01 Shares 10 10 10 10 10 10 10 10 10 10 10 10 10	% of lotal soft the coinp any *13.9	Mot Sharës Pledgod Jengumb Gred to total	%: cliange initiality share liolding the year (0.06)
annesse translate sa	Trehan					20 10 10 10 10 10 10 10 10 10 10 10 10 10		

Page 17 of 36



2.	Dr. Naresh Trehan	1,02,00,00	20.76		1,02,00,000	*20.6 7	_	(0.09)

3.	Mr. Sunil Sachdeva and Mrs. Suman Sachdeva**	68,00,000	13.84	-	68,00,000	*13.7 8	.=	(0.06)
	Total	2,38,92,07 5	48.63	36	2,38,92,075	48.42	NO.	

^{*}variation in % change in shareholding during the year due to allotment of 2,12,225 equity shares of Rs.10 each under ESOP Scheme 2014 & 2016 pursuant to exercise the vested options

iii. Change in Promoters 'Shareholding (please specify, if there is no change)

Sr. no	Particulars		lding at the g of the year	Cumulative Shareholding during the year		
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company	
1.	Dr. Naresh Trehan and Ms. Madhu Trehan					
	At the beginning of the year	68,92,075	14.03	68,92,075	14.03	
	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons -for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	0	0.00	0	0.00	
	At the End of the year	66,92,075	04.03	68.92,075	13.97*	
2.	Dr. Naresh Trehan		111111111111111111111111111111111111111			
	At the beginning of the year	1,02,00,00 0	20.76	1.02,00,000	20.76	
	Date wise Increase / Decrease in Promoters Share	0	0	0	0	

Page 18 of 36

^{**}Beneficial interest in these shares are held by SAS Fininvest LLP, an entity owned & controlled by Mr. Sumil Sachdeva and Mrs. Suman Sachdeva



1		·	·		
	holdingduring the year				
	specifying the reasons for				
	increase				1
	/ decrease (e.g. allotment / 👚				
	transfer / bonus/ sweat equity				
	ctc):				
	At the End of the year	1,02,00,00	20.76	1,02,00,000	20.67*
		0			
100 PM		Walley A.			
3,	Mr. Sunil Sachdeva and Mrs.	61361938	222222114		Taket Jaket Jaket A
	Suman Sachdeva				
	At the beginning of the year	68,00,000	12 00 00 00 00 00 00 00 00 00 00 00 00 00	(COCON 0000)	10.64
3,000 8,000	At the beginning of the year	30,00,000	1-1-2-06	68,00,000	13.84
	27N22N2	· · · · · · · · · · · · · · · · · · ·			
	Date wise Increase /	0	0	0	0
	Decrease in Promoters Share:	i			
	holding during the year				
	specifying the reasons -for		,		
	increase			,	
	./ decrease (c.g. allotment /				
	transfer / bonus/ sweat equity				
	etc):				
	At the End of the year	68,00,000	M 84	68,000:000	13.79
الله (۱۹۱۶) واستسانت ا	***************************************	التناوات المستوالة المائلة التناسيس	CONTROL CONTROL CONTROL	Mark Wallshall	

^{*}variation in % change in shureholding during the year due to allotnent of 2,12,225 equity shares of Rs.10 each under ESOP Scheme 2014 & 2016 pursuant to exercise the vested options to Employees.

V. <u>INDEBTEDNESS</u>

Indebtedness of the Company including interest outstanding/accrued but not due for payment

(Rs. In Lakhs) Secured Izoans Total 🦪 Unsecure Particulars ... excluding Deposits Indebtednes d Loans deposits Rs s-Rs Indebtedness at the beginning of the financial year i) Principal Amount 3,746.69 61.08 3,807.77 ii) Interest due but not paid iii) Interest accrued but not Total (i+ii+iii) 61.08 3,807.77 Change in Indebtedness during the financial year - Addition - Reduction 1,736.87 1,736.87 Net Change 1,736.87 NIL 1,736.87

Page 19 of 36



Indebtedness at the		4		
end of the financial year				
i) Principal Amount	2,009.82	61.08		2,070.90
ii) Interest due but not paid iii) Interest accrued but not due				······································
Total (i+ii+iii)	2,009.82	61.08	-	2,070.90

VI. <u>REMUNERATION OF DIRECTORS AND KEY MANAGERIAL</u> PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager

ŠI.	Particulars of Remuneration	Name of MD
No.		
		Dr. Naresh Kumar Trehan
		Chairman and Managing Director
		(DIN No.: 00012148)
		Total Amount (Rs)
The state of the	Gross salary	18,25,05,000
	·	, , ,
	(a) Salary as per provisions contained in	
	Section 17(1) of the Income-tax Act, 1961	
	(b) Value of perquisites u/s 17(2) Income-tax	
	Act, 1961	
	(c) Profits in lieu of salary under	P
	section17(3) Income- tax Act, 1961	
	Stock Option	
****	Sweat Equity	
<u> </u>	Commission	
	- as % of profit	
	- others, specify	
	Others, please specify	
	Total(A)	18,25,05,000
}	Ceiling as per the Act	N.A
ł	CONTRACTOR	N.A.

C. Remuneration to other directors:

A STATE OF THE PARTY OF THE PAR
Sl. Particulars of Remuneration Name of Directors Total
(1) 10 10 10 10 10 10 10 10 10 10 10 10 10

Page 20 of 36



No.		12 ta 13	100.34.4	Lieder (Amount
	Independent Directors	TYPERTERING AND	Transfer that is many reasonable of	Y	The state of the s	Orenzaliana may
	· Fee for attending board committee			1		
	meetings					
	·Commission					
	Others, please specify					A CATA PRINCIPLE VALUE
	Total(1)			- 10 m	 36.1.	
	Other Non-Executive Directors	-	-		_	
	· Fee for attending board committee					
	meetings		***************************************			
	Commission			Ì		
	· Others, please specify					
	Total(2)	- 2		- P		
	Total(B)≒(1+2)	ė.		-		
	Total Managerial Remuneration	-	_	-	_	- 37,7467,1437,174501.1
	Overall Ceiling as per the Act		~	-		*

C. Remuneration to Key Managerial Personnel Other Than MD /Manager /WTD

SI.	Particulars of Remuneration	Key Manageria			
		Compañy Secretary	CFO	CEO	Total
		S.K. Barisal	Sanjeev Kumar	Pankaj Sahni	
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	Rs. 76,10,257	Rs. 1,70,05,023	Rs. 2,26,01,098	Rs. 4,72,16,378
	Stock Option			Rs. 40,94,000	Rs. 40,94,000

Page 21 of 36



Sweat Equity				
Others, please specify		<i>!</i> }		
Total	Rs.	Rs.	Rs.	Rs.
•	76,10,257	1,70,05,023	2,66,95,098	5,13,10,378

VII. Neither any penalty / punishment was levied against the Company nor there was any case of compounding of Offences made against the Company during the Financial Year 2019-20.

On behalf of the Board of Directors

Dr. Naresh Kumar Trehan Chairman & Managing Director (DIN No.: 00012148)

Annexure-II to Directors' Report

Corporate Social Responsibility

1. A brief outline of the Company CSR Policy

Global Health Private Limited ("Medanta") recognizes its social responsibility as an integral part of its corporate citizenship. Driven by its value system, Medanta commits to support and nurture societies through innovative solutions to satisfy evolving needs of the society. Medanta strives to foster a socially responsible corporate culture by introducing a balanced approach to business by addressing social and environmental challenges through required investments, necessary resource allocation and stakeholder engagements.

Your Company has undertaken CSR activities during the year to create a meaningful and lasting impact on the communities through providing free health care facilitate to needy persons. Your company wishes to extend comprehensive integrated healthcare services to the Communities. Your Company is also committed to developing the skill of youth through high quality education and research in healthcare services.

Your Company continues to focus on the CSR activates and has initiated the following CSR Projects:

- Mission TB-Free
- Preventive Health Care Program

The CSR Policy as approved by the Board are available on the Company's web site at http:// medanta.org.

2. Composition of the CSR Committee

The Corporate Social Responsibility Committee has been constituted by the Board of Directors of your company comprising of the following members:

1)	Dr. Naresh Trehan	Chairman
2)	Mr. Sunil Sachdeva	Member
3)	Dr.(Mrs.) Shayama Chona*	Member
4)	Ms. Praveen Mahajan * *	Member

^{*} Resigned w.e.f 24th February,2020. ** Appointed w.e.f 10th July, 2020

- 3. Average Net profits of the Company for last three financial years: Rs.83.50 Crores
- 4. Amount required to be spent: Rs.1.67 Crores.
- 5. Overview of project/ programs undertaken / proposed to be undertaken:

The Company has initiated the following CSR Project:

Page 23 of 36



- Mission TB-Free Haryana
- Preventive Health Care Program

Mission TB-Free Haryana

"CSR Plan - "TB Free Haryana" was launched on 20th November 2015 at Medanta the Medicity, Gurgaon to end the TB in Haryana State over a period of 5 years.

Partners: GHPL, The Govt. of Haryana, the International Union Tuberculosis and Lungs Disease and the Central TB Division of the Ministry of Health & Family Welfare, Govt. of India.

The total Project Cost was Rs 11 Crores over a period of 5 years and total Cost to be incurred by GHPL was Rs 10 Crores over a period of 5 years.

The CSR Project "TB-Free Haryana" has been awarded the Gold Award on 24th August, 2017 in the Community Involvement category in the Hospital Management Asia (HMA) Award at Shangri-La at the Fort Manila, Philippines.

Preventive Health Care Program

The objective of the GHPL Preventive Health Care Program is to generate awareness and understanding regarding health issues related problems and make the health care available to all.

6. Details of CSR spend during the Financial Year:

The Company had spent Rs.224.88 Lakhs [this includes Rs.127.28 Lakhs towards Manpower & administrative overheads which were in excess of 5% of total CSR expenditure of the Company (CSR) Rules, 2014] on its all CSR projects.

7. In case the company has failed to spend the two per cent of the average net profit of the last three financial years or any part thereof, the company shall provide the reasons for not spending the amount in its Board report.

The scope of existing CSR projects has been increased and the pending amount will be spent in subsequent years.

On behalf of the Board of Directors

Dr./Naresh Kumar Trehan

Chairman & Managing Director

(DIN No.: 00012148)

Page 24 of 36



Annexure-III to Directors' Report

Form AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries/associate companies/joint ventures

Part "A": Subsidiaries

(Information in respect of each subsidiary to be presented with amounts in Rs.)

No.	Particulars	Details		
1.	Name of the subsidiary	Medanta Duke	Global Heath	Medanta
		Research Institute	Patliputra Private	Holdings Pvt.
		Private Limited	Limited	
·		(MDRI)	(GHPPL)	
	Reporting period for the	31 st March, 2020	31 st March, 2020	31 st March,
	subsidiary concerned, if			2020
	different from the holding			
	company's reporting			
	period			
	Reporting currency and	INR(Rs) in Lakh	INR(Rs) in Lakh	INR(Rs) in
	Exchange rate as on the last date of the relevant			Lakh
	Financial year in the case			
	of foreign subsidiaries			
	Share capital	2.00	9,500.00	7,173.63
	Reserves & surplus	55.75	(2,753.53)	20,278.68
	Total assets	58.80	31,917.67	
	Total Liabilities	58.80	31,917.67	78,473.58
	Investments	NIL	NIL	75,475.56 NIL
	Turnover	NIL	NIL	2,779.88
	Profit (Loss) before	(3.87)	(1,253.87)	(5,452.51)
	taxation		(-,)	(0,102.01)
	Provision for taxation -	(0.49)	NIL	34.33
	Deferred Tax	` ′		34,55
	Profit (Loss) after taxation	(4.36)	(1,253.87)	(5,486.84)
	Proposed Dividend	ŅIĹ	NIL	NIL
	% of shareholding	50,01	100	100

Notes: The following information shall be furnished at the end of the statement:

1. Names of subsidiaries which are yet to commence operations-GHPPL has commenced its OPD operations from 18th September, 2020.

Page 25 of 36



2. Names of subsidiaries which have been liquidated or sold during the year-MDRI is in process of liquidation.

Part "B": Associates and Joint Ventures

Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures:

Not Applicable

Chairman and Managing

Director

Group CFO

Company Secretary

Note: This Form is to be certified in the same manner in which the Balance Sheet is to be certified.

CEO



Annexure-IV to Directors' Report

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arms length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis:

There were no contracts or arrangements or transactions entered into during the year ended March 31, 2020, which are not on arm's length basis.

2. Details of contracts or arrangements or transactions at Arm's length basis:

related party & nature of relationship	contracts/arra ugements/tran	n of the contract	Salient terms of the contracts of arrangements of transaction including the value if any	approval	接受
Medanta Duke Research Institute Private Limited Subsidiary	Lease Deed	Months	The Company has leased a space of 150 sq. feet to MDRI at a Lease rent of Rs.2,36,308 quarterly	05.11.2018	Nil
Company			(Transaction during the year was Rs. 4.01Lakhs)	,	
			The Company has availed equipment from MDRI at a rent of Rs. 2,00,000/- (Two Lakhs) per month.		
			(Transaction during the year was Rs.8.98 Lakhs) The Company has purchased assets from MDRI for Rs.		

Page 27 of 36



	1	1	67 88 7 1 1	Ţ	
			57.51 Lakhs.		
	ì	1	vvv		
	-		5000		

			Total Andrews		
IFAN Global	Agreement for	Three	The Company has availed	22.12.2017	Nil
India Private	Human	years	Recruitment services from		
Limited	Resource		IFAN and paid a fee of		
	Services		Rs.158.06 Lakhs during the		
	(Nursing)		year.		
Mr. Naveen	(ivaising)		year.		
Trehan, CEO of			·		
IFAN is the				-	
brother of Dr.					
Naresh Trehan,		,			
CMD of the					
1					
Company.					
Law Chamber of	Retainership	One year	Retainership and Appearance	26.09.2019	NUI
Kapur and Trehan	Agreement	One year		20.09.2019	Nil
Teapar and 110mm	1 Proprieti			,	
			competent forum in India on		
Ms. Shyel			behalf of the Company in		
Trehan, Partner of			relation to legal cases and		
the firm, is the			any other cases as the case		
daughter of Dr.			may be.		
Naresh Trehan,			/CTS		
			(Transaction during the year		
			was Rs 34.35 Lakhs)		
Company					
	,				***************************************
Vidyanta Skill	Service	Three	VSIPL Identifies training	05.11,2018	NY:T
Institute Private			_	03.11,2018	Nil
Limited(VSIPL)	1 181 OCHIOIII	years	^		
Duillod (ADIT D)			Nursing Personnel of the		
			Company.		
Mr. Naveen			Imparting training to the	24.09.2015	
Trehan, director	Agreement	Five	Students/Nursing Staff of		Nil
and member of		Years	-		
VSIPL, is the			, J		
brother of			Course fee to GHPL		
			(Transaction during the year		
Dr.Naresh					

Page 28 of 36



Trehan, CMD of the Company.			was Rs. 121.30 Lakhs)	
Raksha TPA Private Limited Dr. Naresh Trehan, CMD of the Company is director in Raksha TPA Private Limited	TPA Agreement	Open- ended	Raksha avails the medical services for Raksha TPA Members at Medanta Hospital (GHPL) for IPD services. (Transaction during the year was Rs.1,844.33 Lakhs)	Nil
Sharak Healthcare Private Limited (SHPL) Dr. Naresh Trehan, CMD of the Company is director in SHPL.	Agreement for Medical Service	Two Years	SHPL avails medical services for SHPL Members at Medanta Hospital (GHPL) for Customized Preventive Health Check up packages. (Transaction during the year was Rs. 0.24 Lakh)	Nil
Mr. Pankaj Sahni Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company.	Employment	Open ended	Total amount paid to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount in Lakhs Remunerati Rs 226.01 on	Nil

Page 29 of 36



	T		1	·		
			ESOP	Rs.20.20		
,		1	Perquisites		ļ	
			-			
	************		Variable	Rs.14.65	ļ	
			pay for year			
			2018-19			
,			2010-19		and the second s	
					•	
			Total	Rs.260.86		
						-
	,		Further 4.000	equity shares		
				h were allotted	22.07.2019	***************************************
			[
			to Mr. Pankaj S	оапи Стания		
Medanta Institute	Contract for	Open	The Company	/ has given a	21.12.2012	Nil
of Education &	providing	ended	3	q. feet to MIER		
Research(MIER)	services		and provid	les Clinical		
			services to MI	ER.		
Dr. Naresh						
Trehan, CMD of	·		(Transaction d	uring the year		
the Company is			was 10.17Laki	hs)		}
trustee of MIER.						
Global Health	Offer Letters	30 days		GHPPL during		Nil
Patliputra Private				Rs. 4,200.00	10 10 0010	
Limited (GHPPL)	subscription of		Lakhs		19.12.2019	
	equity shares			:		
1000/ 6-1-11			<u> </u>			
100% Subsidiary			Re-imburseme		24.09.2015	
Company			Performance	Guarantee		
The state of the s			provided by the	e Company		
		:				
			(The C	. Y		
			_ -	has paid Bank		
				7.08 Lakhs and		
				of Rs.11.41		
				alf of GHPPL		
			during the year	-)		

Page 30 of 36



	· · · · · · · · · · · · · · · · · · ·	·			•
Devyani International Ltd (DIL)* Mr. Ravi Kant Jaipuria, Director of the Company is Director of DIL.	Agreement for serving food and beverages at Food Court of Medanta	15 years, effective from Feb 9,2013	The Company has provided space to DIL for serving food and beverages at Food Court of Medanta. The terms of the Agreement dated 9th Feb 2013 were modified on 6th January 2016 and Revenue sharing by DIL to GHPL was revised from 25% to 21%. (Transaction during the year	06.01.2016	Nil
			was Rs.258.92 Lakhs)		
Medanta Holdings Private Limited	Offer Letters for subscription of shares	30 days	The Company has made investment in MHPL during the year was Rs. 10,300.00 Lakhs. The Company has given guarantee on behalf of MHPL for Rs.818.54 Lakhs during the year. The Company has sold assets/ equipments for	22.07.2019 19.12.2019	
		and the second s	Rs.6.96 Lakhs during the year.)		
S.A.S. Infotech Private Limited ("SAS") Mr. Sunil	Re- imbursement of electricity charges	Open ended	Company has supplied electricity during the financial year 2019-20 to SAS for consumption of electricity in SAS Tower.	29.03.2019	

Page **31** of **36**



Sachdeva, Director of the Company is director of SAS		100	(Transaction during the year was Rs.311.99 Lakhs)		
Metropolis Healthcare Limited (MHL)* Mr. Neeraj Bharadwaj, Director of the Company was Director of MHL.	Agreement for conducting tests by MHL on the biological material provided by GHPL and reporting of test results of such test to GHPL	1 year	The Company shall pay Service Fees to MHL at 42% discount on the Invoice generated by MHL on the basis of the rates set out in the Agreement. (Transaction relating to the financial year 2017 for Rs.0.46 Lac was paid during the financial year 2019-20)	13.05.2017	Nil

Note: In addition to above, some relatives of directors/employees have availed medical treatment at hospital of the Company which are in ordinary course of business as mentioned at note no.37 of standalone financial statement.

*These contracts were entered when these were not related party transactions.

On behalf of the Board of Directors

Dr. Naresh Kumar Trehan Chairman & Managing Director (DIN No.: 00012148)



Annexure-V- to Directors' Report

INFORMATION AS PER SECTION 134(3)(M) READ WITH RULE 8 (3) OF THE COMPANIES (ACCOUNTS) RULES, 2014 AND FORMING PART OF THE DIRECTORS' REPORT FOR THE YEAR ENDED 31ST MARCH, 2020

CONSERVATION OF ENERGY

Steps taken or Impact on Conservation of Energy

The operations of the Company are not energy-intensive. However, significant measures have been taken to reduce the energy consumption by using energy-efficient equipments. The Company has implemented the following additional Energy Conservation Measures during the Financial Year 2019-2020.

Boiler and Kitchen fuel conversion from HSD/LPG to PNG (Piped Natural Gas)

One of the boiler burner was converted into PNG as fuel instead of HSD, which is proved to be safe and environmental friendly besides cost effective operations. There was saving of Rs: 1,48,80,257.00 (Rupees One Crore Forty Eight Lac Eighty Thousand Two Hundred Fifty Seven only) during the period (June-19 to May20).

The project cost: Rs 16,72,904.00.

Proposal

DG Set fuel conversation kit installation for HSD and PNG both in 30:70 ratio for FY-2020-21

It is proposed for converting the DG sets with duel firel kit. HSD and PNG shall be used to run DG Set in ratio of 30:70. It will result in saving of Rs. 17 Lacs - 27 Lacs per year approximately depending on load and fuel sharing.

Project cost: Rs.33 Lacs per DG

TECHNOLOGY ABSORPTION

In its continuous endeavour to serve the patients better and to bring healthcare of international standards within the reach of every individual, your company has introduced the latest technologies in its hospitals.

Endoscopy Cart for GI Surgery

ICG (Indocyanine Green) - Enhanced Fluorescence Guided Laparoscopic Surgery

Initially, Indocyanine green (ICG) was used in clinical applications to measure cardiac output, to study the anatomy of retinal vessels and to determine liver functional reserve before hepatic resection in cirrhotic livers.

Page 33 of 36.



NOTICE

Notice is hereby given that the 16th Annual General Meeting of the members of Global Health Private Limited will be held at its registered office at E-18, Defence Colony, New Delhi - 110024 on Thursday, the 29th day of October, 2020 at 10.30 A.M., to transact the following business:

ORDINARY BUSINESS:

- 1. To receive, consider and adopt:
 - (a) the audited standalone financial statement of the Company for the financial year ended March 31, 2020, together with the reports of the Board of Directors and Auditors thereon; and
 - (b) the audited consolidated financial statement of the Company for the financial year ended March 31, 2020 together with the Report of Auditors thereon.
- 2. To appoint a Director in place of Mr. Ravi Kant Jaipuria (DIN-00003668), who retires by rotation and being eligible, offers himself for re-appointment.


SPECIAL BUSINESS:

3. To consider and if thought fit, to pass with or without modification (s), the following resolution as an Ordinary Resolution

Ratification of the Remuneration of the Cost Auditors

"RESOLVED THAT pursuant to the provisions of Section 148(3) and other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Cost Records and Audit) Rules, 2014 (including any statutory modification (s) of re-enactment (s) thereof, for the time being in force), the Company hereby ratifies the remuneration of Rs.7,70,000/- (Rupees Seven Lakhs Seventy Thousand only) excluding GST and out of pocket expenses, payable to M/s. Ramanath Iyer & Co., who are appointed as Cost Auditors by the Board of Directors of the Company, to conduct the audit of the cost records of the Company for the financial year ending March 31, 2021.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution."














4. To consider and if thought fit, to pass with or without modification (s), the following resolution as an Ordinary Resolution

Appointment of Mr. Udairam Thali Kottiath as Nominee Director of the Company

"RESOLVED THAT pursuant to the provisions of Sections 149, 152, 161 and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") and the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof, for the time being in force) and pursuant to the Provisions of Articles of Association of the Company, Mr. Udairam Thali Kottiath (DIN: 08703201), who was appointed as an additional – nominee director by the board of directors of the company to represent M/s Dunearn Investments (Mauritius) Pte Ltd w.e.f. 05th June, 2020 and who holds office as such up to the date of this Annual General Meeting, be and is hereby appointed as a Nominee Director of the Company representing M/s Dunearn Investments (Mauritius) Pte Ltd, liable to retire by rotation."

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do all such acts, deeds and things as may be necessary to give effect to the aforesaid resolution."

5. To consider and if thought fit, to pass with or without modification (s), the following resolution as an Ordinary Resolution

Appointment of Ms. Praveen Mahajan as Non Executive Independent Director of the Company

"RESOLVED THAT pursuant to the provision of Section 149, 150, 152 read with schedule IV and other applicable provisions of the Companies Act (the Act) and the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modifications or re-enactment thereof for the time being in force) and pursuant to the provisions of Articles of Association of the Company, Ms. Praveen Mahajan (DIN: 07138514) who was appointed as an additional – non executive Director – Independent by the board of directors of the company w.e.f. 10th July, 2020 and who has submitted a declaration that she meets the criteria for independence as provided under Section 149 (6) of the Act and who holds office as such up to the date of ensuing Annual General Meeting be and is hereby, appointed as a Non - Executive Independent Director of the Company with immediate effect for a period of 5 years, not liable to retire by rotation."














Regd. Office: E-18, Defence Colony, New Delhi -1100024



RESOLVED FURTHER THAT Ms. Praveen Mahajan be paid a sitting fee of Rs 1,00,000/- (Rs One Lac) per Board / Committee meeting attended by her as per provisions of the Companies Act, 2013 and the Rules framed thereunder and the total amount of sitting fee shall not exceed Rs 10,00,000/- P.A. (Rs Ten Lakhs) for every financial year.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do all such acts, deeds and things as may be necessary to give effect to the aforesaid resolution."

6. To consider and, if thought fit, to pass with or without modification(s), the following resolution as a Ordinary Resolution:

Approval of Remuneration of Mr. Pankaj Sahni, Chief Executive Officer of the Company for the FY 2019-20 & FY 2020-21

1. "RESOLVED THAT pursuant to the provisions of Section 188 of Companies Act, 2013 and other applicable provisions and rules thereunder, the consent of the Members of the Company be and is hereby accorded for payment of the remuneration of Rs.2,26,01,106/- (Two Crore Twenty Six Lakhs One Thousand One Hundred Six Only) plus a Car with Driver to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company) for the FY-2019-20.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do all such acts, deeds and things as may be necessary to give effect to the aforesaid resolution."

2. "RESOLVED THAT pursuant to the provisions of Section 188 of Companies Act, 2013 and other applicable provisions and rules thereunder, the consent of the Members of the Company be and is hereby accorded for payment of the remuneration of Rs.2,26,01,106/- (Two Crore Twenty Six Lakhs One Thousand One Hundred Six Only) plus a Car with Driver to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company) for the FY-2020-21.


RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do all such acts, deeds and things as may be necessary to give effect to the aforesaid resolution."













By order of the Board of Directors For Global Health Private Limited

Date: 28.09.2020

Place: Gurgaon

S K Bansal

Vice President - Head Legal &

Company Secretary (M. No. - F 4810)
















Notes:

- (a) Explanatory Statement pursuant to Section 102(1) of the Companies Act, 2013 in relation to above item no.(s) 3, 4, 5 and 6 are annexed herewith and forms part of this Notice.
- (b) A member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote instead of herself/himself and the proxy need not be a member of the company.
- (c) Corporate Members intending to send their authorized representatives are requested to send a duly certified copy of the Board Resolution authorizing the representatives to attend and vote at the AGM.















EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013 FORMING PART OF NOTICE CONVENING THE 16th ANNUAL GENERAL MEETING

Item No. 3

The Board has approved the appointment and remuneration of the Cost Auditors to conduct the audit of the cost records of the Company for the financial year ending March 31, 2021.

In accordance with the provisions of Section 148 of the Act read with the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditors, has to be ratified by the members of the Company.

Accordingly, consent of the members is sought for passing an Ordinary Resolution as set out at Item No. 3 of the Notice for ratification of the remuneration payable to the Cost Auditors for the financial year ending March 31, 2021.

The Board recommends the Ordinary Resolution set out at Item No. 3 of the Notice for approval by the members.

None of the Directors / Key Managerial Personnel of the Company / their relatives are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 3 of the Notice.

Item No. 4

Mr. Udairam Thali Koattiath was appointed as an additional - nominee director on the Board of the Company representing Dunearn Investments (Mauritius) Pte Ltd. (Dunearn) w.e.f 05th June, 2020 in terms of section 149, 152 and 161 of the Companies Act, 2013 and pursuant to the provisions of the Articles of Association of the Company, to hold office till the date of ensuing Annual General Meeting of the Company. The Board proposes to appoint Mr. Udairam Thali Kottiath as nominee director of the Company in this Annual General Meeting. The resolution is placed before the members for their consideration and approval. The Board recommends the passing of resolution as ordinary resolution.















Mr. Udairam is a graduate from University of Singapore, Bachelor of Arts in 1976 and also is a post graduate in Advanced Management Program from Harvard Business School. He is the Chief Operating Officer of Sheares Healthcare Management whose mandate is to acquire and develop hospitals and health care facilities and operations primarily in Asia, but also in the rest of the world. The mission is to create value by introducing new technology, from information technology to early adoption of new treatment modalities and systems. He has 39 years of health care experience in Singapore with substantial experience in the operation and management of hospitals (ranging from 2,500 bed psychiatric hospital to 800 bed acute care hospital). He was involved in developing and implementing the first computerised hospital administration system in Singapore in 1984 and has been Chair of various IT committees in public healthcare (from cluster steering committees to the national telehealth committee). In addition Mr. Udairam was involved in a number of national projects including the development and implementation of the national Medisave scheme (a national health care personal savings fund). He has also been involved in corporatising government hospitals, including successfully commissioning and establishing Ang Mo Kio Community Hospital. His last role in public healthcare was to establish the first integrated primary to tertiary care cluster in Singapore, which is a model the Ministry of Health has now established as a target for all clusters.

None of the Directors except Mr. Udairam Thali Kottiath (DIN: 08703201), Key Managerial Personnel of the Company/ their relatives, are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 4 of the Notice.

Item No. 5

Ms. Praveen Mahajan was appointed as Additional Non-Executive - Independent Director w.e.f. 10th July, 2020 to hold office till date of this Annual General meeting. She was also appointed as member of the Audit Committee, Remuneration Committee & CSR Committee of the Company.

Ms. Praveen Mahajan has a rich experience in the field of public administration, tax policy & tax administration in the sphere of indirect taxes, enforcement of various laws and regulations - customs, central, excise, service tax etc., international trade and economic relations - FTAs, CEPA, CMAA, WCO and WTO matters, public finance & budgeting and legal matters & quasi-judicial proceedings. She was also awarded the "Presidential Award for extraordinary devotion to duty and specially distinguished record of service" in the year 1992. She has served as a first ever lady officer to head the Central Board of Excise and Customs (CBEC), since its inception.







Regd. Office: E-18, Defence Colony, New Delhi -1100024



The Company had received necessary declaration(s) from Ms. Praveen Mahajan confirming that she meets the criteria of Independent Director as prescribed under the Companies Act, 2013 (the Act). In the opinion of the Board, Ms. Praveen Mahajan fulfills the conditions for her appointment as a Non Executive Independent Director as specified in the Act.

The Board believes that induction of Ms. Praveen Mahajan on the Board will support in broadening the overall experience of the Board and will bring wide experience in the area of Corporate Governance. It is proposed to pay her a sitting fee of Rs 1,00,000/- (Rs One Lac) per Board / Committee meeting attended by her as per provisions of the Companies Act, 2013 and the Rules framed thereunder and the total amount of sitting fee shall not exceed Rs. 10,00,000/- P.A. (Rs Ten Lakhs) for every financial year.

The Board of Directors accordingly recommends the ordinary resolution set out at Item No. 5 of the Notice for the approval of the Members.

None of the Directors except Ms. Praveen Mahajan (DIN: 07138514), Key Managerial Personnel of the Company/ their relatives, are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 5 of the Notice.


Item No. 6

Mr. Pankaj Sahni, CEO of the Company, has played vital role in the growth of the Company in different functions and considering his achievements and contribution. He was paid remuneration of Rs. 2,40,65,992/- (Rupees Two Crores Forty Lacs Sixty Five Thousand Nine Hundred Ninety Two only) for the FY-2018-19 as under:

- a) Fixed Amount of Rs. 2,26,01,106 (Two Crores Twenty Six Lakhs One Thousand One Hundred Six Only) plus a Car with Driver and
- b) Variable Amount of Rs.14,64,886/- (Rs. Fourteen Lacs Sixty Four Thousand Eight Hundred Eighty Six only).

The Board had approved the financials & non-financial parameters for payment of variable amount for the F.Y. 2019-20 at its board meeting held on 26th September, 2019.

Mr. Pankaj Sahni has been paid a fixed remuneration of Rs.2,26,01,106/- for the F.Y. 2019-20. The variable remuneration of Mr. Pankaj Sahni for the F.Y. 2019-2020 was due for approval by the Board, based on above financial and non-financial parameters.





Further, Mr. Pankaj Sahni is being paid remuneration @ 2,26,01,106/- p.a., with applicable salary cuts due to cash flow/ financial constraints faced by the Company amid COVID 19 pandemic from April, 2020 onwards.

Mr. Pankaj Sahni has vide his letter dated 28th September, 2020 voluntarily expressed his desire to not withdraw any variable remuneration for the FY 19-20 and FY 20-21.

Accordingly, the Remuneration Committee and Board in its meeting held on 28th September, 2020 have approved the above proposals.

Based on above, the board has approved the remuneration of Rs. 2,26,01,106/- p.a. plus a Carwith Driver to Mr. Pankaj Sahni for the F.Y. 2019-20 & FY 2020-21 as stated in resolution no.(s) 1 & 2 of Item no. 6.

Educational Background and experience:

Mr. Pankaj Sahni is a graduate in Mathematics from St. Stephens College, Delhi and is also an Associate member of the Institute of Chartered Accountants of India. Mr. Sahni is also an MBA from Kellogg School of Management, with specialization in Strategy, Finance and International Business. Mr. Sahni has worked with leading International Business Consultants like Arthur Anderson & Co., Ernst & Young. Lastly, Mr. Sahni was associated with Mckinsey & Co. as Associate Partner and currently working as Chief Executive Officer of the Company.

Mr. Sahni is son in law of Dr. Naresh Trehan, CMD and accordingly this is a related party transaction as per Section 188 of the Companies Act, 2013.

None of the Directors, except Dr. Naresh Trehan (being father in law of Mr Sahni) & Mr. Pankaj Sahni, himself, and his relatives or any key managerial personnel or their relatives is interested in passing of this Ordinary Resolution.

Date: 28.09.2020

Place: Gurgaon

For Global Health Private Limited

By order of the Board of Directors

S K Bansal

Vice President - Head Legal &

Company Secretary

(M. No. - F 4810)














GLOBAL HEALTH PRIVATE LIMITED

Registered Office: E-18, Defence Colony, New Delhi – 110024 CIN: U85110DL2004PTC128319


Telephone: (011) 4411 4411 * Fax: (011) 2433 1433* Website: www.medanta.org

ATTENDANCE SLIP

Members attending the Meeting in person or by Proxy are requested to complete the Attendance Slip and hand it over at the entrance of the meeting room.

I hereby record my presence at the 16th Annual General Meeting of the Company at its registered office at E-18, Defence Colony, New Delhi - 110024, on Thursday, the 29th day of October, 2020 at 10.30 A.M.

Name of the Member:			
UNIT UNITED STATES UNITED STATES			Signature
Folio No.: DP ID No.:*		Client ID No:*	
*Applicable for Members holding share	es in electronic fo		
Full name of the Proxy/ Authorized Re	presentative (if a	pplicable)	Signature



Regd. Office: E-18, Defence Colony, New Delhi -1100024



GLOBAL HEALTH PRIVATE LIMITED

Registered Office: E-18, Defence Colony, New Delhi - 110024

CIN: U85110DL2004PTC128319

Telephone: (011) 4411 4411 * Fax: (011) 2433 1433 * Website: www.medanta.org

Form No. MGT – 11 PROXY FORM

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

·CIN: U85110DL2004PTC128319

Name of the Company: GLOBAL HEALTH RPIVATE LIMITED

Registered Office: E-18, Defence Colony, New Delhi - 110024

the first of the control of the cont	er(s):		
E-mail id:	DP ID No:*	Client ID No.:*	
*Applicable for Me	embers holding shares in electroni	c form	Marie Marie and Marie Andrews
I/We, being the Me	mber(s) of	Shares of Global Health F	rivato
Limited, hereby app	OOINT:		
1.4			
Email id:			
Signature: _			
2. Name:			
•			
		or falling him/her	alih A
SA.			\$
















Name:	,
Address:	
Email id:	
Signature:	, or falling him/her

as my / our proxy to attend and vote (on a poll) for me / us and on my / our behalf at the 16th Annual General Meeting of the Company, to be held on Thursday, the 29th day of October, 2020 at 10.30 A.M. at its registered office at E-18, Defence Colony, New Delhi - 110024 and at any adjournment thereof, in respect of the Resolutions set out in the Notice convening the Meeting, as indicated below:

S. NO.	RESOLUTIONS	FOR	AGAINST
Ordina	ry Business		1,
1.	a) the audited standalone financial statement of the Company for the financial year ended March 31, 2020, together with the reports of the Board of Directors and Auditors thereon; and b) the audited consolidated financial statement of the Company for the financial year ended March 31, 2020 together with the Report of Auditors thereon.		
2.	To appoint a Director in place of Mr. Ravi Kant Jaipuria (DIN-00003668), who retires by rotation and being eligible, offers himself for reappointment.		
Special	Business	·····	
3.	To ratify the Remuneration of M/s. Ramanath Iyer & Co, Cost Auditors		
4.	Appointment of Mr. Udairam Thali Kottiath as nominee director of the Company		
5.	Appointment of Ms. Praveen Mahajan as non executive independent director of the Company		
6.	Approval of remuneration Mr. Pankaj Sahni, Chief Executive Officer of the Company for the FY 2019-20 & FY 2020-21		















Signed this 28th day of September, 2020

Signature of Shareholder

Affix Revenue Stamp Signature

Signature of Proxy Holder(s)

Notes:

- 1. This form should be signed across the stamp as per specimen signature registered with the Company.
- 2. The Proxy, to be effective, should be deposited at the Registered Office of the Company not less than 48 hours before the commencement of the AGM.
- 3. A proxy need not be a member of the Company.
- 4. Please put a √ in the appropriate column against the resolutions indicated in the Box. If you leave the For or Against column blank against any or all the resolutions, your proxy will be entitled to vote in the manner as he/she thinks appropriate. This is only optional.













Board's Report

Dear Members,

Your Directors are pleased to present the 16th Annual Report on business and operations together with the Audited Financial Statements for the financial year ended March 31, 2020.

FINANCIAL RESULTS

The Company's financial performance including its subsidiaries for the year ended March 31, 2020 is summarized below:

A. Standalone financial performance

O DO PER MINERAL DEGRAMMENT OF THE PROPERTY OF		(Rupees in Lakhs)
The state of the s	31.3.2020	31.3.2019
Revenue from operations	1,45,657.18	1,44,113.22
Other Income	5,905.33	6468.94
Total Revenue	1,51,562.51	1,50,582.16
Total Expenditure	1,38,469.17	1,40,930.11
Profit before Taxation	13,093.34	9,652.05
Current Tax	4,971.83	5,158.47
Deferred tax expense (Income)	(2,154.15)	(1,800.21)
Profit after Taxation	10,275.66	6,293.79

B. Consolidated financial performance

	(Rupees in Lakhs)
Particulars	31.3:2020	31.3,2019
Revenue from operations	1,48,421.58	1,44,113.22
Other Income	5,942.51	6,485.59
Total Revenue	1,54,364.09	1,50,598.81
Total Expenditure	1,47,974.94	1,41,076.62
Profit before Taxation	6,386.96	9,519.61
Current Tax	4,971.83	5,158.47
Deferred tax expense	(2,217.76)	(1,736.64)
Profit after Taxation	3,632.89	6,097.78

For the FY 2019-20, the Company recorded revenue from operations of Rs.1,45,657.18/Lakhs (previous year Rs. 1,44,113.22/- Lakhs) resulting in an increase by 1.07% and net profit of Rs.10,275.66/- Lakhs (previous year Rs. 6,293.79 Lakhs) resulting in an increase by 63.27% on standalone basis.

The consolidated financials of the company includes the financials of Medanta Duke Research Institute Private Limited (MDRI), Global Health Patliputra Private Limited (GHPPL) and Medanta Holdings Private Limited (MHPL), being the subsidiaries of the Company.

Page 1 of 36



The COVID-19 pandemic outbreak during March 20 has affected countries across the Globe resulting in material impact on the healthcare industry in India as well due to travel restrictions imposed by the State / National /International Govt.(s) and deferment of elective surgeries / preventive health check-ups by people at large.

Your Company has arisen to the situation and has taken a strong leadership in responding to the COVID-19 Management. All safety protocols / preventive / safety measures defined by regulatory bodies and the Company have been followed in providing best possible care for COVID / Non -Covid patients, clinical & non-clinical staff. Separate wards have been established for COVID patients, E-clinic facility has been provided for home consultations, home care facility / post Covid rehabilitation facility has also been provided to COVID 19 patients by partnering with various Hotels.

"Medanta - the Medicity" has been declared as the Best Private Hospital in India for the year 2020 by "Newsweek" and 2nd in all hospitals including Govt. Hospitals in India.

Further, Medanta – the Medicity has been chosen as best Covid Care Hospital in India for "Safaigiri Award" by India Today.

The financial impact of COVID 19 pandemic will be reflected during the FY 20-21.

Extract of Annual Return

Extract of Annual Return of the Company is annexed herewith as Annexure- I to this Report.

Number of Meetings of the Board

The Board met 4 times during the financial year 2019-20. The intervening gap between any two meetings was within the period prescribed by the Companies Act, 2013.

Dividend

Your directors have not recommended any dividend on its equity shares for the financial year ended March 31, 2020.

The dividend of Rs. 32.50 is accrued to be paid to M/s. Anant Investment on 4,66,954 Class A fully convertible Preference Shares held by it.

Fixed Deposit

Your company has not accepted any fixed deposits from the public and as such, no amount of principal or interest was outstanding on the date of the Balance Sheet.

Transfer to Reserve

Your company proposes to transfer Rs.10,275.66 Lakhs (Previous Year: Rs. 6,293.79 Lakhs) to the general reserves out of amount available for appropriation.

Page 2 of 36



Directors and Key Managerial Personnel

The composition of Board of Directors is well balanced with a view to manage the affairs of the Company efficiently and professionally.

Mr. Ravi Kant Jaipuria (DIN00003668), Director of the Company is liable to retire by rotation at ensuing Annual General Meeting of the Company and being eligible, has offered himself for re-appointment and the Board recommends his appointment as Director at the ensuing Annual General Meeting.

Mr. Rohit Sipahimalani (DIN-00904065) had resigned from the directorship of the Company with effect from w.e.f. 26th September, 2019. The Board of Directors places on record its appreciation for the support and guidance provided by Mr. Rohit Sipahimalani during his tenure as Non-Executive Directors of the Company.

Dr. (Mrs.) Shayama Chona (DIN-02749576), Non-Executive Independent Director had resigned from the directorship of the Company with effect from 24th February, 2020. She was also a member of CSR and Remuneration Committee (s). The Board of Directors places on record its appreciation for the support and guidance provided by Dr. (Mrs.) Shayama Chona during her tenure as a Non-Executive Independent Director of the Company.

Mr. Udairam Thali Koattiath (DIN-08703201) has been appointed as nominee director of Dunearn Investments (Mauritius) Pte Ltd. on 5th June, 2020 and also member of the Audit Committee.

Ms. Praveen Mahajan (DIN-07138514) has been appointed as an independent Director of the Company on 10th July, 2020 and member of Audit, Remuneration and CSR Committee(s). She has submitted a declaration that she meets the criteria for independent director as laid down under Section 149(6) of the Companies Act, 2013. She has also submitted declaration that she has registered herself on the online data bank of Indian Institute of Corporate Affairs (IICA) in accordance with the Companies (Appointment and Qualification of Directors) Fifth Amendment Rules, 2019.

Employee Stock Option Plan (ESOP) 2014 and ESOP Plan 2016 of the Company

There are two ESOP Schemes in force named GHPL ESOP Plan 2014 and GHPL ESOP Plan 2016. The details of ESOP(s) available and allocated under both plans are as under:

Particulars	No. of options under ESOP Plan 2014	No. of options under ESOP Plan 2016
Number of total options	8,52,973	10,25,000
Total options granted as on 1 st April 2019	8,44,824	9,55,000
Options lapsed, forfeited and added back to the pool during the year	NIL	91,000 (options lapsed)

Page 3 of 36



Options granted during the FY 2019-20(including Options lapsed, forfeited and added back to the pool during the year)	NA	NA NA
Total Options in force as on 31 st March, 2020	8,09,097	8,64,000
Total options exercised as on 31 st March, 2020	5,48,449	3,02,500
Total options vested but not yet exercised as on 31st March, 2020	2,15,648	2,15,250
Total option pending for allocation as on 31.3. 2020	43,876	1,61,000
The exercise price for each option	Rs.10 each	Rs.10 each
Money realized by exercise of options	54,84,490	30,25,000
Employee-wise details of options granted to: (i) Key managerial personnel	NIL	20,000
(ii) Any other employee who receives a grant of options in any one year of option amounting to 5% or more of options granted during that year; (iii) Identified employees who were granted option, during any one year, equal to or exceeding 1% of the issued conital (granted).	NIL	NIL
of the issued capital (excluding outstanding warrants and conversions) of the company at the time of grant	NIL	NIL

- Each option has been granted at Rs 10 each convertible into one Equity share of Rs each at par.
- The total options granted shall vest every year @ 20% / 25% / 33%, from date of grant over a period of 5/4/3 years as per terms of respective, Offer Letter(s).
- The vested options can be exercised within a period of 3 years from the date of vesting.

Page 4 of 36



The company had allotted 2,12,225 (Two Lakh Twelve Thousand Two Hundred Twenty Five) equity shares of Rs.10 each upon exercise of vested options under ESOP Scheme 2014 & 2016 during financial year 2019-20. Subsequently, 31,113 (Thirty One Thousand One Hundred Thirteen) equity shares of Rs.10 each have been issued upon exercise of vested options as per the ESOP Schemes 2014 & 2016.

The Summary detail of ESOPs as on date is as under:

SI. No.	Particulars	ESOP 2014	Scheme	ESOP 2016	Scheme
1.	ESOP vested & exercised		5,55,062		3,27,000
2.	ESOP vested but not yet exercised		2,02,422		2,34,750
3.	ESOP not yet vested	,	51,613		3,02,250
4.	ESOP pending for allocation		43,876		1,61,000
	Total		8,52,973		10,25,000

Audit Committee

During the year under review, the Audit Committee comprises of the following members:

Mr. Neeraj Bharadwaj	Member
Mr. Rohit Sipahimalani*	Member
Mr. Udairam Thali Koattiath**	Member
Ms. Praveen Mahajan ***	Member

^{*}Resigned w.e.f. 26th September, 2019
** Appointed w.e.f 5th June, 2020

The Company has voluntarily constituted the Audit Committee.

Remuneration Committee

During the year under review, the Remuneration Committee comprises of the following members:

Dr. (Mrs.) Shayama Chona*	Member
Mr. Neeraj Bharadwaj	Member
Ms. Praveen Mahajan **	Member

^{*}Resigned w.e.f. 24th February, 2020.
** Appointed w.e.f 10th July, 2020

^{***} Appointed w.e.f 10th July, 2020



The Company has voluntarily constituted the Remuneration Committee and is in the process to appoint more members in due course of time.

Corporate Social Responsibility (CSR) Committee

The Corporate Social Responsibility Committee comprises of the following members:

Dr. Naresh Trehan	Chairman
Mr. Sunil Sachdeva	Member
Dr. (Mrs.) Shayama Chona*	Member
Ms. Praveen Mahajan * *	Member

^{*} Resigned w.e.f 24th February, 2020. ** Appointed w.e.f 10th July, 2020

Corporate Social Responsibility Initiatives

As a part of its initiatives under Corporate Social Responsibility (CSR), the Company has undertaken projects in the areas of promoting health care including "Mission – TB Free Haryana" & Preventive Health Care Program. These projects are in accordance with Schedule-VII of the Companies Act, 2013.

The report on CSR activities for the financial year 2019-20 is annexed herewith Annexure-II forming part of the Board Report pursuant to clause (o) of sub-section (3) of Section 134 of the Companies Act, 2013 read with Rule 9 of the Companies (Corporate Social Responsibility) Rules, 2014.

Risk Management Committee

The Company has developed and implemented a Risk Management Policy and a Risk Management Committee (RMC) comprising of senior executives of the Company has been constituted. The Committee assists the Audit Committee and Board in (a) Overseeing and approving the Company's enterprise wide risk management framework; and (b) Overseeing that all the risks have been identified and assessed by the organization and there is an adequate risk management infrastructure in place capable of addressing those risks.

Whistle Blower Mechanism (Vigil Mechanism)

Pursuant to the provisions of Section 177 of the Companies Act, 2013 and Rules made there under, the Company has adopted a Whistle Blower Policy and has established the necessary vigil mechanism for Directors and employees to report genuine concerns about unethical behaviour, actual or suspected fraud or violation of the Company's code of conduct or ethics policy.

Sexual Harassment Policy

A policy on Sexual Harassment of Women at Workplace had been implemented in the Company and an Internal Complaint Committee(s) had been constituted to handle / investigate the matters relating to Sexual Harassment at various locations. The Company had

Page 6 of 36



received 4 (Four) complaints under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH) & same had been disposed as per the terms of the policy of the Company. The company has complied with provisions relating to constitution of Internal Committee under POSH.

The Hon'ble High Court (Indore) order dated 16.09.2019 passed by Hon'ble Single Judge was challenged by GHPL by way of Writ Appeal bearing number 1619/2019 before Hon'ble Double Bench Indore. The Hon'ble Double Bench accepted GHPL's arguments and by way of order dated 04.10.2019 granted stay on the operation of the order dated 16.09.2019. The matter was last listed on 16.03.2020, but hearing could not take place due to Corona Pandemic.

Subsidiaries

During the year under review, the Company has three subsidiaries viz. Medanta Duke Research Institute Private Limited (MDRI), Global Health Patliputra Private Limited" (GHPPL) and Medanta Holdings Private Limited (MHPL). The Reports on the performance and financial position of MDRI, GHPPL and MHPL as per the Companies Act, 2013 are given below and also provided to the consolidated financial statement of the Company.

1. MDRI

MDRI's financial performance for the year ended March 31, 2020 is as under:

2020 8.17	The state of the s
8.17	The same of the sa
	24.00
8.17	24.00
12.04	29.16
(3.87)	(5.16)
0.49	Nil
(4.36)	(5.16)
	12.04 (3.87) 0.49

MDRI a subsidiary of Global Health Private Ltd. (GHPL / Company) wherein GHPL was holing 10,001 (50.01%) equity shares and Duke Medicine Asia Pte. Ltd. ("Duke") is holding 10,000 (49.99%) equity shares.

The international strategy of Duke Medicine Asia Pte. Ltd. ("Duke") had been changed and it had taken a policy decision not to undertake clinical trials internationally. MDRI at its Extra Ordinary General Meeting held on 24th September, 2019 has decided to go for voluntary liquidation and is in process of voluntary liquidation under Section 59 of the Insolvency and



Bankruptcy Code, 2016 (IBC Code 2016). Mr. Prabhakar Kumar Insolvency Professional holding Registration No. IBBI/IPA-002/IP-N00774/2018-2019/12373 had been appointed as a liquidator of the Company in terms of the applicable provisions of the IBC Code, 2016 for the purpose of voluntary liquidation of the Company.

2. MHPL

MHPL is a 100% subsidiary of the Company.

The Company has subscribed for 1,40,21,420 Equity Shares of Rs.10 each and 1,31,19,764 Compulsorily Convertible Preference Shares (CCPS) of Rs.10 each amounting to Rs.102.99 Crores during the financial year 2019-20. The Company holds 6,54,07,228 Equity shares and 63,29,113 CCPS of Rs 10/- each as on 31st March, 2020 and 63, 29,113 CCPS were converted into 63,29,113 equity shares thereafter. Total equity shares held by GHPL as on date is 7,17,36,341. The total amount invested in MHPL by the Company till date is Rs.401.50 Crores.

With the vision of providing state-of-the-art medical treatment at an affordable cost to the people of Lucknow, Uttar Pradesh and its neighboring States - Medanta Lucknow commenced its operations on 05 November 2019 and is now offering state-of-the-art Patient Care Services in Cardiology and Cardiac-surgery, Neurosciences, Nephrology, Urology, Orthopedics & Joint Replacement, Digestive and Hepatobiliary Sciences, Internal Medicine, Pulmonary Medicine, Critical Care, Anesthesiology, Transfusion Medicine and Blood Bank, Radiology and Nuclear Medicine, Pathology and Laboratory Medicine and 24X7 Emergency Medicine and Trauma Care.

Spread over 12.58 acres, MEDANTA LUCKNOW – a 1000 bedded hospital – is an excellent combination of future generation healthcare services comprising of 350 critical care beds (ICUs), more than 30 super-specialties, 37 ultra-clean operation theaters, state of the art highend Laboratory Services, 24X7 Blood Bank, Bone Densitometry, Mammography, Ultrasound, high-end MRI, CT, PET Scan, Gamma Camera, etc.

The Executive Health Check-up Center at Medanta Lucknow is also operational and is offering state-of-the-art Health Check-up services to the citizens of Lucknow, Uttar Pradesh and its neighboring States under Preventive Health.

In the coming days, MEDANTA intends to introduce the facility of Obstetrics and Gynaecology, Pediatric Intensive Care Unit (PICU), Neo-natal ICU (NICU), Pediatric, Rehabilitation Unit and Lever Transplant.

MEDANTA's mission is to provide world-class, holistic and affordable health services to the citizens of Lucknow, Uttar Pradesh, neighboring states and also to those around the globe.

In recent past, many lives in emergency situations have also been saved here at Medanta Lucknow during the course of COVID-19 lockdown across cities and states. Patients have been airlifted from across the states to Medanta Lucknow and emergency surgeries were performed by concerned doctors after taking due precautions in light of COVID-19 limitations. A dedicated 20 bedded COVID ward, which is a make shift arrangement, has also

Page 8 of 36



been established to provide round-the-clock treatment to COVID-19 positive patients — without disturbing the existing hospital facility that is already providing world-class medical treatment to Non-Covid patients.

Its financial performance for the year ended March 31, 2020 is as under:

Particulars		(Rs, lp Lakhs)
	2020	2019
Revenue from operations	2,779.88	0.00
Other Income	118.28	16.23
Total Revenue	2,898.16	16.23
Total Expenditure	8,350.67	92.96
Loss before Tax	(5,452.51)	(76.73)
Tax Expenses - Deferred Tax	34,33	(34.38)
Loss after Taxation	(5,486.84)	(42.35)

3. GHPPL

GHPPL is a 100% subsidiary of the Company.

Global Health Patliputra Private Limited (GHPPL) is in process of development of 500 beds Super Specialty Hospital (in 4 Phases) in Patna (Kankarbagh) over an area of 7 acres approx through PPP mode on a design, build, finance, operate and transfer basis.

GHPPL has commenced its OPD operations with effect from 18th September, 2020 and 200 - 250 IPD beds are likely to be commenced in next 3-4 months thereafter.

The Company had subscribed an additional 4,00,00,000 Equity Shares of Rs. 10 each amounting to Rs. 40 Crores during FY-2019-20 and subsequently 1,50,00,000 Equity Shares of Rs.10 each amounting to Rs. 15 Crore. The total amount invested by the Company in GHPPL till date is Rs. 110 Crores.

GHPPL's financial performance for the year ended March 31, 2020 is as under:

Particulars	2020	(Rs. In Lakhs) 2019
Other Income	2.48	0.44
Total Revenue	2.48	0.44

Page 9 of 36



Total Expenditure	1,256.35	473.93
Loss before Tax	(1,253.87)	(473.49)
Tax Expenses - Deferred Tax	NIL	NIL
Loss after Taxation	(1,253.87)	(473.49)

Consolidated Financial Statement

In accordance with the provisions of the Companies Act, 2013 and Accounting Standard (AS) - 21, the audited consolidated financial statement is provided in the prescribed form AOC-1 as Annexure-III which forms a part of the Annual Report.

Directors' Responsibility Statement

Pursuant to the requirement of the Companies Act, 2013, the Board of Directors confirms that:

- (a) In the preparation of the annual accounts for the year ended 31st March,2020, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- (b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year 2020 and of the profit of the company for that period;
- (c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- (d) the directors had prepared the annual accounts on a going concern basis; and
- (e) the directors, had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
- (f) the directors had devised proper systems to ensure compliance with the provision of all applicable laws and that such systems were adequate and operating effectively.

Internal Financial Controls

The Company has in place adequate internal financial controls with reference to financial statements. During the year, such controls were tested and no reportable material weakness in the design or operation was observed.

Page 10 of 36



Significant and Material Orders passed by the Regulators or Courts

There are no significant material orders passed by the Regulators / Courts except the matter pending before the National Green Tribunal ("NGT") regarding 'Jharsa bundh' land.

The matter is pending before the NGT and the next date is 17.11, 2020.

Particulars of loans given, Investment made, Guarantees given and Securities provided

Your Company has made an investment for an amount aggregating to Rs. 40.00 Crores in the shares of GHPPL during the financial year 2019-20 and Rs. 15 Crore thereafter.

Further, Your Company has also made an investment for an amount aggregating to Rs.102.99 Crores in the shares of MHPL during the financial year 2019-20.

Particulars of contracts or arrangements with related parties

Contracts / arrangements / transactions entered by the Company during the financial year with related parties were in the ordinary course of business and on an arm's length basis. During the year, the Company had obtained the necessary approvals as applicable while entering into contracts or arrangements with related parties.

Particulars of contracts or arrangements with related parties referred to in Section 188 (1) of the Companies Act, 2013, in prescribed form AOC-2 is appended as Annexure-IV to the Board's report.

Your Directors draw your attention to Note No(s) 38 to the standalone financial statement which sets out related party Disclosures.

The Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

The particulars relating to conservation of energy, technology absorption, foreign exchange earnings and outgo, as required to be disclosed under the Act, are provided in Annexure-V to this Report.

Auditors and Auditors' Report

Statutory Auditors

M/s Walker Chandiok& Co. LLP, Chartered Accountants were appointed as Statutory Auditors of the Company for a period of 5 consecutive years at the Annual General Meeting held on 15th September, 2017. They have confirmed that they are not disqualified from continuing as Statutory Auditors of the Company.

M/s Walker Chandiok& Co. LLP, Statutory Auditors of the Company have submitted their report for the financial year 2019-2020. The Notes on financial statement referred to in the Auditors' Report are self- explanatory and do not call for any further comments. The Auditors' Report does not contain any qualification, reservation or adverse remark.

Page 11 of 36



Cost Auditors

The Cost Auditors have submitted their Report and it does not contain any qualification, reservation or adverse remark. M/s. Ramanath Iyer & Co., retiring Cost Auditors were eligible for re-appointment. They had confirmed their eligibility to the effect that their reappointment, if made, for the financial year 2020-21 would be within the prescribed limits under the Act and that they were not disqualified for re-appointment.

Internal Auditors

M/s Pricewaterhousecoopers, Services LLP, Chartered Accountants, (PwC) has been appointed as Internal Auditors in place of M/s Deloitte Haskins & Sells, by the Board on 19th December, 2019 for the financial year 2019-20.

Acknowledgements:

Your Directors place on record their sincere appreciation for significant contribution made by your Company's employees at all levels and look forward to their continued support.

Your directors also take this opportunity to express sincere thanks to the medical professionals / fraternity and patients for their continued co-operation, patronage and trust reposed in the Company and its services.

Your Directors also wish to place on record their appreciation and acknowledge with gratitude the support and co-operation extended by State Governments, our bankers, consultants, customers, vendors, affiliated hospitals, shareholders and other business associates for their confidence reposed in the Company and its management.

For and on behalf of the Board GlobakHealth Private Limited.

Place: Gurgaon Date: 28.09.2020

Dr. Naresh K. Trehan

Chairman and Managing Director

(DIN No.: 00012148)



Annexure-I to Directors' Report Form No. MGT-9

EXTRACT OF ANNUAL RETURN AS ON THE FINANCIAL YEAR ENDED ON MARCH 31, 2020

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

1. REGISTRATION AND OTHER DETAILS:

CIN	U85110DL2004PTC128319
Registration Date	13.08.2004
Name of the Company	Global Health Private Limited
Calegory/Sub-Category of the Company	Private Company/Limited by Shares
Address of the Registered office and contact Details	E-18, Defence Colony, New Delhi- 110024
Whether listed company	No
Name, Address and Contact details of Registrational Transfer Agent, if any	KFin Technologies Private Limited Selenium Tower B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad – 500 032 P: +91 40 6716 1602 M: +91 9381616972 Email: einward.ris@kfintech.com Website:www.kfintech.com

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10% or more of the total turn over of the company shall be stated:

Sr. No.	Name and Description of main products/ services	NIC Code of the Product/ service	% to total turnover of the company
1	To establish, maintain, operate, run, manage or administer hospitals, medicare healthcare, diagnostic, health aids and research centers	861	100

Page 13 of 36



III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

100.000.000	Name and Address of the Company	CIN/GLN	Hölding/ Subsidiary /Associate	%of shares held	Applicable Section
	Medanta Duke	U73100DL201	Subsidiary	50.01	Section 2(87) (ii) of the
	Research	0PTC211892		·	Companies Act,2013
	Private Limited				-
	Global Health	U74999DL201	Subsidiary	100	Section 2(87)(i) & (ii) of
	Patliputra	5PTC283932			the Companies Act, 2013
	Private Limited				
	Medanta	U74140DL201	Subsidiary	100	Section 2(87)(i) & (ii) of
	Holdings	3PTC250579			the Companies Act,2013
	Private Limited	,			-

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i. Category-wise Shareholding

Categor y of Shareho Iders	No. of SI of the ye		d at the be	ginning .	No. of S year,	Shares bel	d af the en	d of the	% Chang e during the year
			ioal Postantia	Dolal Lolal Share	Dema 1	Dhyslish J		o cil Totali Share	
Promot er									
Indian 🐇									
Individu	-	2,38,9	2,38,92,0	48.63	1,70,9	68,00,0	2,38,92,0	48.42	(0.21)*
al/ HUF		2,075	75		2,075	00	75		,
Central	-	-	<u>-</u>	-			-	-	•
Govt			· · · · · · · · · · · · · · · · · · ·						
State	-	-	-	-	-	-	-	-	_
Govt(s)			energentraksus energia <mark>ksisk. His p</mark> eluna sammanasasan passasasa						
Bodies		<u>-</u>	a-a	-	-	-	-	~	
Corp									
Banks /	-	~	-	-	-	-	-	-	-
FI			***************************************			-			
Any		-	_		~	-		-	-

Page 14 of 36



Other						1		1	-
(711101		2,38,9	2.38,92,0	48.63	1.70.9	68,00,0	2,38,92,0	10.43	(0.31)
Sub-		2,075	75	[************************************	2,075	00,00,0	75	፤ የውጭል 	(0.21)
total(A)(10,000	/-3		£1,9(₹7,5)	VV	/3		
1):-									
Poreign			<u> </u>						
NRIs-	-	-	_	-	-	-	_		
Individu		ļ			-				
als									
Other-	-	-		-	-	_	~	-	-
Individu									
als									
Bodies	•	-	~	_	-	P4	-	**	<u></u>
Corp.					***				
Banks/	•	~	-	-	-	-	b4	-	-
Fl									
Any	in-	-		-	_	+	~	-	
Other									
	-		-	~	-	-		~	h-d
Sub-	•								
total(A)(·
2):-				<u> </u>	viscondestrates.		100000000000000000000000000000000000000	(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	~*J.~**********************************
Public		020				1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		Alice Control	ig Objection
Shareho						4 19	jų.		
lding Instituti	. ***********				3000				77.6
ons									
Mutual		_	·	<u> </u>	·				
Funds		_		-	-	-	-	-	**
Banks /	-		40	-					
FI	~	_	"	-	-				**
Central		-	19						
Govt	,			_	_	72	-		~
State					-	L-,		-	· · · · · · · · · · · · · · · · · · ·
Govt(s)						·		-	•
Venture	-	_	.,	_		gra.	-		
Capital							·	· •	-
Funds									
Insuranc	-		**************************************	**	radera e a franco a a franco a a a a a a a a a a a a a a a a a a a	-	_	_	
е	aboutton	-						:	
Compan	***************************************								
ies									
FIIs	*	. (************************************	and the state of t		**	_	~		
Foreign		-	44	**	-				No.
Venture									
Capital	1								
Funds	1						. 1		

Page 15 of 36



y	γ		***************************************		****				***********
Others (specify)		-	-	••		-	~	*	~
Sub- total (B)(1)		*	-	-	•	•		-	•
2. Non Instituti ous								тактору и потомого продолого под	
Bodies Corp. (i) Indian (ii) Oversea s		20,00, 000	20,00,00 0	4.07	20,00, 000	-	20,00,00 0	4.06	(0.01)
Individu als									
(i) Individu al sharchol ders holding nominal share capital upto Rs. 1 lakh	36,448		36,448	0.07	48,44 8		48,448	0.09	0.02
(ii) Individu al sharehol ders holding nominal share capital in excess of Rs 1 lakh	6,02,27		6,02,276	1.23	8,02,5		8,02,501	1.63	0.40
Others (Foreig n Compa	86,01,9 79	1,40,0 0,000	2,26,01,9 79	46.00	86,01, 979	1,40,00	2,26,01,9 79	45.80	(0.20)

Page 16 of 36



ny)								<u> </u>	T
Sub- total(B)(92,40,7 03	1.60,0	2,52,40,7 03	51.37	1,14.5	1,40,00	2,54.52,9 28	51.58	0.21
Total Public Shareho Iding (B)=(B)(1)+ (B)(2)	92,40,7	1,60,0	2,52,40,7	51.37	1,14,5 2,928	1,40,00	2,54,52,9 28	51.58	0.21
C. Shares held by Custodia n for GDRs & ADRs		wa	-		•	-	-	_	-
Grand Total (A+B+C)	92,40,7 03	3,98,9 2,075	4,91,32,7 78	100	2,85,4 5,003	2,08,00	4,93,45,0 03	100	

^{*}variation in % change in share holding during the year due to allotment of 2,12,225 equity shares of Rs.10 each under ESOP Scheme 2014 & 2016 pursuant to exercise the vested options to Employees.

ii. Shareholding of Promoters

s r.	Shareholder? s Name	Shareholdi beginning		Sharcholdii the year	ig at the	end of	
1.	Dr. Naresh Trehan and Ms. Madlju	No. of Shares 68,92,075	%of Share s Pledg ed/ eg/cu mbe red to total shares	No. of: Sharos (1) (68,92,075	ांक्षेप्रकार अ of	Voot Sharës Pledgod Sheumb Gred to total	% change in share lipiding during the year
	Trehan				* 47 200000000000000000000000000000000000		

Page 17 of 36



2.	Dr. Naresh Trehan	1,02,00,00	20.76		1,02,00,000	*20.6 7	**	(0.09)
	•					mage specifying the graph for the control of the co		
3.	Mr. Sunil Sachdeva and Mrs. Suman Sachdeva**	68,00,000	13.84	-	68,00,000	*13.7 8		(0.06)
	Total	2,38,92,07 5	48.63	***	2,38,92,075	48,42	40	

^{*}variation in % change in shareholding during the year due to allotment of 2,12,225 equity shares of Rs.10 each under ESOP Scheme 2014 & 2016 pursuant to exercise the vested options

iii. Change in Promoters 'Shareholding (please specify, if there is no change)

Sr;	Particulars		lding at the g of the year	Cumulative : during	Shareholding the year
Andrews of the control of the contro		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	Dr. Naresh Trehan and Ms. Madhu Trehan				
	At the beginning of the year:	68,92,075	14.03	68,92,075	14.03
	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons -for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	0	0.00		0.00
	At the End of the year	(6)92,075	14.03	68.92,075	13.97*
2.	Dr. Naresh Trehan			The second secon	removes and 3.35% a bridge ps as any and in his his hiller of
	At the beginning of the year	1,02,00,00 0	20.76	1.02,00,000	20.76
	Date wise Increase / Decrease in Promoters Share	0	0	0	0

Page 18 of 36

^{**}Beneficial interest in these shares are held by SAS Fininvest LLP, an entity owned & controlled by Mr. Sunil Sachdeva and Mrs. Suman Sachdeva



	holdingduring the year specifying the reasons -for		The state of the s	`	
	increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):				
	At the End of the year	1,02,00,00 0	20,76	\$1,02,00,000	20.67*
3.	Mr. Sunil Sachdeva and Mrs. Suman Sachdeva				
	At the beginning of the year	68,00,000	13.80	68,00,000	13.84
	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons -for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	0	0	()	0
	At the End of the year	68,00,000	/13.84	68,000,000	13.788

^{*}variation in % change in shareholding during the year due to allotment of 2,12,225 equity shares of Rs.10 each under ESOP Scheme 2014 & 2016 pursuant to exercise the vested options to Employees.

V. <u>INDEBTEDNESS</u>

Indebtedness of the Company including interest outstanding/accrued but not due for payment

		-	(Rs.	In Lakhs)
Particulars	Secured Loans excluding deposits Rs	Unsecure d Loans		Total Indebtednes s-Rs
Indebtedness at the beginning of the financial year	Manager and the second			
i) Principal Amount	3,746.69	61.08		3,807.77
ii) Interest due but not paid	54*	<u>~</u>		,
iii) Interest accrued but not		, , , , , , , , , , , , , , , , , , ,		
Total (i+ii+iii)		61.08	***	3,807.77
Change in Indebtedness during the financial year				
- Addition				
- Reduction	1,736.87	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,	1,736.87
Net Change	1,736.87	NIL	-	1,736.87

Page 19 of 36



Indebtedness at the	-			
end of the financial year				
i) Principal Amount	2,009.82	61.08		2,070.90
ii) Interest due but not paid iii) Interest accrued but not due				
Total (i+ii+iii)	2,009.82	61.08	-	2,070,90

VI. <u>REMUNERATION OF DIRECTORS AND KEY MANAGERIAL</u> <u>PERSONNEL</u>

A. Remuneration to Managing Director, Whole-time Directors and/or Manager

ŠI.	Particulars of Remuneration	Name of MD
No.		
		Dr. Naresh Kumar Trehan
		Chairman and Managing Director
		(DIN No.: 00012148)
		Total Amount (Rs)
		7
149-25-20	Curan colour	
	Gross salary	18,25,05,000
	(a) Salary as per provisions contained in	
	Section 17(1) of the Income-tax Act, 1961	
	tan, toly	
	(b) Value of perquisites u/s 17(2) Income-tax	
:	Act, 1961	
	(c) Profits in lieu of salary under	
	section17(3) Income- tax Act, 1961	
	Stock Option	
	Sweat Equity	
	Commission	
	- as % of profit	
	- others, specify	
	Others, please specify	
	Total(A)	18,25,05,000
1	Ceiling as per the Act	N.A

C. Remuneration to other directors:

SL. Particulars of Remuneration	Name of Directors Total
\$ THE REPORT OF THE PROPERTY O	AND THE RESIDENCE OF THE PROPERTY OF THE PROPE

Page 20 of 36



No.		N ₆ (2) (4)	A.a. 18				Amount
	Independent Directors	መራመጥ ያለም ስለመተመፈ ቀስ <u>መ</u> ራስያ <u>የ</u> ደንጀት ያስፈ የ ፈት ያስ ትል የለጉተ ትል የ	n kinden kara bana bana bana ba	TAYSTATAN LABOUR DOOR		The state of the s	
	· Fee for attending board	committee		ST THE STATE OF TH			
	meetings						
	· Commission						
	Others, please specify						33
	Total(1)			¥.()			
	Other Non-Executive Dir	rectors	-		4		-
	· Fee for attending board	committee					1
	meetings						
	·Commission						
	Others, please specify						
	Total(2)		- : i'.,		- 100 mg		in the second
	Total(B)=(1+2)				-		
	Total Managerial Remun	eration	An.	-	*	_	- 30.2M(\$1800) 1 00000
	Overall Ceiling as per the	Act			-		*

C. Remuneration to Key Managerial Personnel Other Than MD /Manager /WTD

Sl. no.	Particulars of Remuneration	Key Manageria	Key Managerial Personnes					
	, .	Compañy Secretary	CFO	CEO	Total			
		S-K. Bafisal	Sanjeev Kumar	Pankaj Sālīnī,	197			
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	Rs. 76,10,257	Rs. 1,70,05,023	Rs. 2,26,01,098	Rs. 4,72,16,378			
	Stock Option			Rs. 40,94,000	Rs. 40,94,000			

Page 21 of 36



Sweat Equity				
Others, please specify		1	A. Chinaman	
 Total	Rs.	Rs.	Rs.	Rs.
	76,10,257	1,70,05,023	2,66,95,098	5,13,10,378
	A STATE OF THE STA			

VII. Neither any penalty / punishment was levied against the Company nor there was any case of compounding of Offences made against the Company during the Financial Year 2019-20.

On behalf of the Board of Directors

Dr. Naresh Kumar Trehan Chairman & Managing Director (DIN No.: 00012148)

Page 22 of 36

Annexure-II to Directors' Report

Corporate Social Responsibility

1. A brief outline of the Company CSR Policy

Global Health Private Limited ("Medanta") recognizes its social responsibility as an integral part of its corporate citizenship. Driven by its value system, Medanta commits to support and nurture societies through innovative solutions to satisfy evolving needs of the society. Medanta strives to foster a socially responsible corporate culture by introducing a balanced approach to business by addressing social and environmental challenges through required investments, necessary resource allocation and stakeholder engagements.

Your Company has undertaken CSR activities during the year to create a meaningful and lasting impact on the communities through providing free health care facilitate to needy persons. Your company wishes to extend comprehensive integrated healthcare services to the Communities. Your Company is also committed to developing the skill of youth through high quality education and research in healthcare services.

Your Company continues to focus on the CSR activates and has initiated the following CSR Projects:

- Mission TB-Free
- Preventive Health Care Program

The CSR Policy as approved by the Board are available on the Company's web site at http://medanta.org.

2. Composition of the CSR Committee

The Corporate Social Responsibility Committee has been constituted by the Board of Directors of your company comprising of the following members:

1)	Dr. Naresh Trehan	Chairman
2)	Mr. Sunil Sachdeva	Member
3)	Dr.(Mrs.) Shayama Chona*	Member
4)	Ms. Praveen Mahajan * *	Meinber

^{*} Resigned w.e.f 24th February,2020. ** Appointed w.e.f 10th July, 2020

- 3. Average Net profits of the Company for last three financial years: Rs.83.50 Crores
- 4. Amount required to be spent: Rs.1.67 Crores.
- 5. Overview of project/ programs undertaken / proposed to be undertaken:

The Company has initiated the following CSR Project:

Page 23 of 36



- Mission TB-Free Haryana
- Preventive Health Care Program

Mission TB-Free Haryana

"CSR Plan - "TB Free Haryana" was launched on 20th November 2015 at Medanta the Medicity, Gurgaon to end the TB in Haryana State over a period of 5 years.

Partners: GHPL, The Govt. of Haryana, the International Union Tuberculosis and Lungs Disease and the Central TB Division of the Ministry of Health & Family Welfare, Govt. of India.

The total Project Cost was Rs 11 Crores over a period of 5 years and total Cost to be incurred by GHPL was Rs 10 Crores over a period of 5 years.

The CSR Project "TB-Free Haryana" has been awarded the Gold Award on 24th August, 2017 in the Community Involvement category in the Hospital Management Asia (HMA) Award at Shangri-La at the Fort Manila, Philippines.

Preventive Health Care Program

The objective of the GHPL Preventive Health Care Program is to generate awareness and understanding regarding health issues related problems and make the health care available to all.

6. Details of CSR spend during the Financial Year:

The Company had spent Rs.224.88 Lakhs [this includes Rs.127.28 Lakhs towards Manpower & administrative overheads which were in excess of 5% of total CSR expenditure of the Company (CSR) Rules, 2014] on its all CSR projects.

7. In case the company has failed to spend the two per cent of the average net profit of the last three financial years or any part thereof, the company shall provide the reasons for not spending the amount in its Board report.

The scope of existing CSR projects has been increased and the pending amount will be spent in subsequent years.

On behalf of the Board of Directors

Dr./Naresh Kumar Trehan

Chairman & Managing Director

(DIN No.: 00012148)



EN 1

Global Health Pvt. Ltd.

Annexure-III to Directors' Report

Form AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries/associate companies/joint ventures

Part "A": Subsidiaries

(Information in respect of each subsidiary to be presented with amounts in Rs.)

SEN SE	Particulars	Details		And the state of t
No.				
1.	Name of the subsidiary	Medanta Duke	Global Heath	Medanta
		Research Institute	Patliputra Private	Holdings Pvt.
ŀ	**************************************	Private Limited	Limited	Ltd(MHPL)
		(MDRI)	(GHPPL)	
	Reporting period for the	31 st March, 2020	31 st March, 2020	31 st March,
	subsidiary concerned, if			2020
	different from the holding			
	company's reporting period			
	Reporting currency and	TNID/Day in Tala	13.113.723 \ 1	
	Exchange rate as on the	INR(Rs) in Lakh	INR(Rs) in Lakh	INR(Rs) in
	last date of the relevant	Y		Lakh
	Financial year in the case			
	of foreign subsidiaries	***************************************		
	Share capital	2.00	9,500.00	7,173.63
.	Reserves & surplus	55.75	(2,753.53)	20,278.68
	Total assets	58.80	31,917.67	
	Total Liabilities	58.80	31,917.67	78,473.58
	Investments	NIL	NIL	NIL
	Turnover	NIL	NIL	2,779.88
	Profit (Loss) before	(3.87)	(1,253.87)	(5,452.51)
	taxation	. ,		(0,104,01,0
	Provision for taxation -	(0.49)	NIL	34.33
	Deferred Tax			
	Profit (Loss) after taxation	(4.36)	(1,253.87)	(5,486.84)
	Proposed Dividend	NIL	NIL	NIL
	% of shareholding	50,01	100	100

Notes: The following information shall be furnished at the end of the statement:

1. Names of subsidiaries which are yet to commence operations-GHPPL has commenced its OPD operations from 18th September, 2020.

Page 25 of 36



2. Names of subsidiaries which have been liquidated or sold during the year- MDRI is in process of liquidation.

Part "B": Associates and Joint Ventures

Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures:

Not Applicable

Chairman and Managing

Director

CEO Group CFO

Company Secretary

Note: This Form is to be certified in the same manner in which the Balance Sheet is to be certified.



Annexure-IV to Directors' Report

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arms length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis:

There were no contracts or arrangements or transactions entered into during the year ended March 31, 2020, which are not on arm's length basis.

2. Details of contracts or arrangements or transactions at Arm's length basis:

related party & nature of relationship	contracts/arra ngements/tran-	n of the contract	Salient terms of the contracts of arrangements of transaction including the value of any	approval	nt
Medanta Duke Research Institute	Lease Deed	11	The Company has leased a	05.11.2018	Nil
Private Limited		Months	space of 150 sq. feet to	·	
			MDRI at a Lease rent of Rs.2,36,308 quarterly		
Subsidiary			atom, 50,500 quartorly		
Company		į	(Transaction during the year		
			was Rs. 4.01Lakhs)		
			The Company has availed		
			equipment from MDRI at a		
			rent of Rs. 2,00,000/- (Two Lakhs) per month.		
			Dakney por month.		
			(Transaction during the year		
			was Rs.8.98 Lakhs)		
		The state of the s	The Company has purchased	į	
			assets from MDRI for Rs.		

Page 27 of 36



		57 51 Lakhs		
·		57.51 Daktis.		
	·	1 		
i				
Agreement for	Three	The Company has availed	22.12.2017	Nil
Human	years	Recruitment services from		
Resource		IFAN and paid a fee of		
Services		Rs.158.06 Lakhs during the		
(Nursing)		_		
(· · · · · · · · · · · · · · · · · · ·			Í	
Retainershin	One vear	Retainership and Appearance	26 09 2019	Nil
- 1	Jan Jour		~0.07.2019	1417
r Proprietti			W. (1975)	
	-			
		_		
		may be.		
		(Transaction desires the		
İ		_ *		
	•	was Ks 34,35 Lakhs)		
			- Control of the Cont	
Sarrica	Thes	VCIDY Identifies to the	AS 11 0010	* Y ' '
		-	V3.11.2018	Nil
Agreement	years			
		_		
		Company.		
		Townself and the second	24,09,2015	
Agreement	Five			Nil
	1			
	Loais	VSIPL and payment of		
		Course fee to GHPL		
1	I		1	
		(Transaction during the year	j	
	Resource	Human Resource Services (Nursing) Retainership Agreement Service Agreement Three Agreement years	Human Resource Resource Retainership Agreement Service Three Agreement Three Agreement Retainership Agreement Three Agre	Agreement for Human years Recruitment services from IFAN and paid a fee of Rs.158.06 Lakhs during the year. Retainership Agreement One year Retainership and Appearance fees before Courts/competent forum in India on behalf of the Company in relation to legal cases and any other cases as the case may be. (Transaction during the year was Rs 34.35 Lakhs) Service Agreement Years VSIPL Identifies training requirements/ needs of Nursing Personnel of the Company. Imparting training to the Students/Nursing Staff of VSIPL and payment of

Page 28 of 36



Tueline OME	T				-	
Trehan, CMD of			was Rs. 121.30) Lakhs)		
the Company.		1				
		1				
Raksha TPA	TPA	Open-	Rakeha availe	the medical	01 00 2010	3714
Private Limited	Agreement	ended	services for		01.09.2010	Nil
	71810011011	Cilded				
				at Medanta		
Dr. Naresh			Hospital (GH	PL) for IPD		
Trehan, CMD of			services.			
the Company is						
director in Raksha			(TD			A Comment of the Comm
TPA Private			(Transaction d			
			was Rs.1,844.3	3 Lakhs)		
Limited						
Sharak	Agreement for	Two	CTIDE	353	0.5 0.0	
Healthcare	Medical		SHPL avails m		07.09.2017	Nil
Private Limited	Service	Years	ì	Members at		
(SHPL)	Service		Medanta Hos			
(onfl)			for Customize			
,			Health Check u	p packages.		
Dr. Naresh						
Trehan, CMD of			(Transaction di	urina tha rica		
the Company is			was Rs. 0.24 La			
director in SHPL.			was 13, 0.24 L	aknj		
Ja 40102 122 5727 25,						
	:					
Mr.Pankaj Sahni	Employment	Open	Total amount	paid to Mr	26.09.2019	Nil
		ended	Pankaj Sal		20,00,2019	[[[
			Executive Offi		,	
Mr. Pankaj Sahni,			the Company of			
CEO, is the son in			was as under:	iding me year	•	
law of Dr. Naresh			was as under.			
Trehan, CMD of			Particulars	Amount in		
the Company.				Lakhs		
The state of the s						
- Indiana				and the state of t		
Annanakan	,		Remunerati	Rs 226.01		
				1/3 2/20.01		
			on	Authorason		
		•				
	ļ		İ			
			<u> </u>			

Page 29 of 36



	·		T .	,	·	
			ESOP	Rs.20.20		
		1	Perquisites			
3-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7						
		<u> </u>	Variable	Rs.14.65		
			pay for year			
			2018-19			
r						
			Total	Rs.260.86		
		[<u> </u>	I		
	,		Further 4.000	equity shares		
			1	h were allotted	22.07.2019	
			to Mr. Pankaj :			
			to wir. rankaj i	Janua		
Medanta Institute	Contract for	Open	The Company	/ has given a	21.12.2012	Nil
of Education &	providing	ended	i - '	q. feet to MIER		
Research(MIER)	services		and provid	•		
		-	services to MI			
		:				
Dr. Naresh						
Trehan, CMD of			(Transaction d	luring the year		
the Company is			was 10.17Lak	hs)		
trustee of MIER.						
<u> </u>						
Global Health	Offer Letters	30 days	Investment in	GHPPL during	26.09.2019	Nil
Patliputra Private			i ·	Rs. 4,200.00		1 411
Limited (GHPPL)	subscription of		Lakhs	.,	19.12.2019	
, _,	equity shares					
	Y 2					
100% Subsidiary			Re-imburseme	nt of	24.09.2015	
		;	Performance	Guarantee	±¬,∪≯,∠∪1,∂	
Company			provided by the	e Company		
state and the st			· ·	~ •		
and the same of th			(CD1 - C)			
			,	has paid Bank		
 			į.	7.08 Lakhs and		
			i .	of Rs.11.41		
			3	nalf of GHPPL		
,			during the year	()		

Page 30 of 36



		7			•
Devyani International Ltd (DIL)* Mr. Ravi Kant Jaipuria, Director of the Company is Director of DIL. Medanta Holdings Private	Agreement for serving food and beverages at Food Court of Medanta Offer Letters for	15 years, effective from Feb 9,2013	The Company has provided space to DIL for serving food and beverages at Food Court of Medanta. The terms of the Agreement dated 9th Feb 2013 were modified on 6th January 2016 and Revenue sharing by DIL to GHPL was revised from 25% to 21%. (Transaction during the year was Rs.258.92 Lakhs)	06.01.2016	Nil
Holdings Private Limited S.A.S. Infotech	Re- imbursement of electricity charges	Open ended	investment in MHPL during the year was Rs. 10,300.00 Lakhs. The Company has given guarantee on behalf of MHPL for Rs.818.54 Lakhs during the year. The Company has sold assets/ equipments for Rs.6.96 Lakhs during the year.) Company has supplied electricity during the financial year 2019-20 to SAS for consumption of	22.07.2019 19.12.2019	
Mr. Sunil			electricity in SAS Tower.		

Page 31 of 36



Sachdeva, Director of the Company is director of SAS	5		(Transaction during the year was Rs.311.99 Lakhs)		
Metropolis Healthcare Limited (MHL)* Mr. Neeraj Bharadwaj, Director of the Company was Director of MHL.	Agreement for conducting tests by MHL on the biological material provided by GHPL and reporting of test results of such test to GHPL	1 year	The Company shall pay Service Fees to MHL at 42% discount on the Invoice generated by MHL on the basis of the rates set out in the Agreement. (Transaction relating to the financial year 2017 for Rs.0.46 Lac was paid during the financial year 2019-20)	13.05.2017	Nil

Note: In addition to above, some relatives of directors/employees have availed medical treatment at hospital of the Company which are in ordinary course of business as mentioned at note no.37 of standalone financial statement.

*These contracts were entered when these were not related party transactions.

On behalf of the Board of Directors

Dr. Naresh Kumar Trehan Chairman & Managing Director

(DIN No.: 00012148)



Annexure-V- to Directors' Report

INFORMATION AS PER SECTION 134(3)(M) READ WITH RULE 8 (3) OF THE COMPANIES (ACCOUNTS) RULES, 2014 AND FORMING PART OF THE DIRECTORS' REPORT FOR THE YEAR ENDED 31ST MARCH, 2020

CONSERVATION OF ENERGY

Steps taken or Impact on Conservation of Energy

The operations of the Company are not energy-intensive. However, significant measures have been taken to reduce the energy consumption by using energy-efficient equipments. The Company has implemented the following additional Energy Conservation Measures during the Financial Year 2019-2020.

Boiler and Kitchen fuel conversion from HSD/LPG to PNG (Piped Natural Gas)

One of the boiler burner was converted into PNG as fuel instead of HSD, which is proved to be safe and environmental friendly besides cost effective operations. There was saving of Rs: 1,48,80,257.00 (Rupees One Crore Forty Eight Lac Eighty Thousand Two Hundred Fifty Seven only) during the period (June-19 to May20).

The project cost: Rs 16,72,904.00.

Proposal

DG Set fuel conversation kit installation for HSD and PNG both in 30:70 ratio for FY-2020-21

It is proposed for converting the DG sets with duel fuel kit. HSD and PNG shall be used to run DG Set in ratio of 30:70. It will result in saving of Rs. 17 Lacs - 27 Lacs per year approximately depending on load and fuel sharing.

Project cost: Rs.33 Lacs per DG

TECHNOLOGY ABSORPTION

In its continuous endeavour to serve the patients better and to bring healthcare of international standards within the reach of every individual, your company has introduced the latest technologies in its hospitals.

Endoscopy Cart for GI Surgery

ICG (Indocyanine Green) - Enhanced Fluorescence Guided Laparoscopic Surgery

Initially, Indocyanine green (ICG) was used in clinical applications to measure cardiac output, to study the anatomy of retinal vessels and to determine liver functional reserve before hepatic resection in cirrhotic livers.

Page 33 of 36



ICG dye can be injected into the human blood stream with practically no adverse effects. ICG becomes fluorescence once excited with light of a specific wavelength in the NIR spectrum delivered by a Xenon Light source or NIR Laser device. Fluorescence can be detected using specific scopes & cameras, then transmitted to a video screen, thus enabling the observer to visualize the areas of anatomical interest where the dye has accumulated (eg: Biliary ducts, vessels, lymph nodes.)

In the recent years, ICG-enhanced fluorescence has been introduced in laparoscopic surgery to improve visualization and provide detailed anatomical information during the surgery.

ICG- enhanced fluorescence imaging provides for improved visualization of the biliary duct system and tracing the flow of bile, intraoperative evaluation of lymphatic drainage, sentinel lymph node mapping, identification of vascular anatomy, and for perfusion control of solid organs, colon and rectum.

The video camera is connected to an ICG Laparoscope (Manufactured By KARL STORZ) equipped with a special filter for optimal reproduction during ICG- enhanced florescence and standard white light imaging. Switching from standard white light mode to near-infrared mode is simply done via foot-pedal control. Cost involved there in for endoscopy system is approx. Rs 25 lacs.

Anesthesia Machine for OT Area

The 9100c NXT is the new upgraded platform of Wipro GE's gold standard product 9100c. This is ideal solution for clinicians seeking a precise, versatile and dependable anesthesia system and has neonatal capabilities and ventilation modes that make it a versatile choice for all types of day care, low-medium acuity and multi-specialty hospitals. It is based on GE/DatexOhmeda's legacy of 100+ years of innovation and trust. This product is scalable across a wide range of patient groups and surgical procedures. The cost involved therein is approx. Rs 20 Lacs.

EECP Therapy System for Cardiology

EECP© is a Non-Invasive treatment for patients with refractory angina and heart failure. Enhanced External Counter Pulsation (EECP) is performed as a non-invasive treatment to lower the number and intensity of angina episodes. Treatment is administered through three pairs of external inflatable cuffs that are applied around the lower legs, upper legs and buttocks. These cuffs continuously inflate and deflate between the resting period of the heartbeat and increase blood returned to the heart.

The basic principle of EECP treatment involves increasing the amount of blood returning to the heart, which helps supply more oxygen to its starved areas. With more oxygen available, the heart can function much more efficiently and therefore reduce chest pain. Cost involved there in for EECP Therapy System is approx. Rs 50 lacs.

C-Arm Cios fit for Ortho Surgery

This is a smart dose management system specially designed for the Cios C-arm family. It continuously analyses each and every one of the image sensor pixels and constantly optimizes their dose efficiency. The result is an always optimized balance of image quality

Page 34 of 36



and dose as well as automatic contrast and brightness regulation. Automatic metal exclusion and optimized balance of image quality and dose. Integrated dose measuring chamber with automatic transfer of the accumulated dose into a radiation report. Cost involved there in for C-arm System is approx. Rs 21 lacs.

Vitek MS for microbiology

VITEK® MS is an automated mass spectrometry microbial identification system that uses Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) technology.

EW! After recent additions of mycobacteria, Nocardia and moulds, the VITEK® MS comprehensive CE-marked database now also includes Brucella, Candida auris and Elizabethkingiaanophelis.

In just minutes, VITEK® MS can provide single-choice identifications at the species, genus, or group level. With both VITEK® MS and the VITEK® 2, clinicians receive quick information to adjust therapy for better overall patient care and outcomes.

bioMérieux's proprietary Advanced Spectra Classifier offers robust and accurate results needed for optimal patient-care decisions. The VITEK® MS system reads each spectrum as a series of peaks that are detected and sorted by mass and intensity. With the use of the Advanced Spectra Classifier, better discrimination is provided as every peak is considered in the calculation of the identification result. Cost involved there in for Vitek MS System is approx. Rs 1.4 Cr.

Real Time PCR System for hematology

Thermo Fisher Scientific has developed high performance, superior, real-time PCR (qPCR) instruments for laboratories all over the world.

During this time, they have also committed to developing systems to meet the specific needs of clinical, diagnostic, and assay developers—with the increased security and compliance of an IVD medical device.

The Applied Biosystems Quant Studio 5 DX Real-Time PCR system is the latest additional to our CE-IVD marked quantitative PCR system portfolio. It delivers proven performance and support to help meet the needs of clinical/hospital laboratories and test developers, in a compact footprint and cost-effective package.

The Quant Studio 5 Dx Real-Time PCR instrument features:

- An enhanced user experience with the intuitive software that you have come to expect from smart devices
- Intelligent, multi-modal software that allows you to move between IVD and development modes in a single instrument
- A simplified interface that allows you to set up a run, lay out assays, control the instrument, and conduct plate analysis within a single, easy-to-use software
 - Affordability and accessibility with low cost of ownership
 - Enhanced security, including auditing and e-signature functionalities
 - A protected IVD test menu that allows only authorized IVD tests to be run through IVD mode, helping to reduce the risk of unauthorized, accidental or intentional misuse

Page 35 of 36



Cost involved there in for QuantStudio 5 Dx Real-Time PCR instrument is approx. Rs 23 lacs.

InterX unit for neuroreheb

E-LINK is a computerized modular system bringing both evaluation and exercise together in an exciting format with an extensive scope of clinical applications for the upper and lower extremities:

Precise objective measurements can be undertaken very early in hand therapy and continue throughout the full rehabilitation process, with E-LINK providing comprehensive progress reports including impairment calculations.

E-LINK sensors, using EMG, enable innovative exercise to begin from a small flicker of muscular activity, even with no visible joint movement - ideal for stroke and neuro rehabilitation.

E-LINK ForcePlates assist desensitization exercise from the touch of one finger through to full weight-bearing evaluation and exercise for standing balance.

Cost involved there in for Vitek MS System is approx. Rs 20 Lacs.

FOREIGN EXCHANGE EARNINGS AND OUTGO:

Particulars	Rs_in Grore Current year	Previous year
Foreign Exchange Earnings	118.49	145.26
Foreign Exchange outgo (remittance)	9.03	9.64

For and on behalf of the Board

Place: Gurgaon Date: 28.09.2020

Or. Naresh Kumar Trelian Chairman & Managing Director

(DIN No.: 00012148)

Watker Chandlok & Co LLP L 41, Connaught Circus, Outer Circle, New Delhi - 110.001 India

T +91 11 4278 7070 F +91 11 4278 7071

Independent Auditor's Report

To the Members of Global Health Private Limited.

Report on the Audit of the Standalone Financial Statements

Opinion

- 1. We have audited the accompanying standalone financial statements of Global Health Private Limited (the Company), which comprise the Balance Sheet as at 31 March 2020, the Statement of Profit and Loss (including Other Comprehensive Income), the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and a summary of the significant accounting policies and other explanatory information.
- 2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including Indian Accounting Standards ('Ind AS') specified under section 133 of the Act, of the state of affairs of the Company as at 31 March 2020, and its profit (including other comprehensive income), its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information other than the Pinancial Statements and Auditor's Report thereon

4. The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Director's Report but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereographics.

Chartered Accountante

Offices in Bengaluru, Chandigath, Channai, Gurugter

Kontae, Mumbel, New Delhil, Noide and Pune

Walker Chandlok & Co LLP is registered with limited isobility with Identification number AAC-2085 and its registered office at L-1 Conneaght Circus, New Dathl, 110001, India

Independent Auditor's Report to the members of Global Health Private Limited, on the standalone financial statements for the year ended 31 March 2020 (cont'd)

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

- 5. The accompanying standalone financial statements have been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Ind AS specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
- 6. In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
- 7. Those Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

- 8. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
- 9. As part of an audit in accordance with Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that
 are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for
 expressing our opinion on whether the Company has adequate internal financial controls with reference
 to financial statements in place and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;

Independent Auditor's Report to the members of Global Health Private Limited, on the standalone financial statements for the year ended 31 March 2020 (cont'd)

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- 10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on Other Legal and Regulatory Requirements

- 11. Based on our audit, we report that the provisions of section 197 read with Schedule V to the Act are not applicable to the Company since the Company is not a public company as defined under section 2(71) of the Act. Accordingly, reporting under section 197(16) is not applicable.
- 12. As required by the Companies (Auditor's Report) Order, 2016 ('the Order') issued by the Central Government of India in terms of section 143(11) of the Act, we give in the Annexure A, a statement on the matters specified in paragraphs 3 and 4 of the Order.
- 13. Further to our comments in Annexure A, as required by section 143(3) of the Act, based on our audit, we report, to the extent applicable, that:
 - a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the accompanying standalone financial statements:
 - b) in our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - c) the standalone financial statements dealt with by this report are in agreement with the books of account;
 - d) in our opinion, the aforesaid standalone financial statements comply with Ind AS specified under section 133 of the Act;
 - e) on the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2020 from being appointed as a director in terms of section 164(2) of the Act;
 - f) we have also audited the internal financial controls with reference to financial statements of the Company as on 31 March 2020 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date and our report dated 28 September 2020 as per Annexure B expressed unmodified opinion; and
 - g) with respect to the other matters to be included in the Auditor's Report in accordance with rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:
 - i. the Company, as detailed in note 40A to the standalone financial statements, has disclosed the impact of pending litigations on its financial position as at 31 March 2020;

Chartered Accountants

Independent Auditor's Report to the members of Global Health Private Limited, on the standalone financial statements for the year ended 31 March 2020 (cont'd)

- ii. the Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses as at 31 March 2020;
- iii. there were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company during the year ended 31 March 2020; and
- iv. the disclosure requirements relating to holdings as well as dealings in specified bank notes were applicable for the period from 8 November 2016 to 30 December 2016, which are not relevant to these standalone financial statements. Hence, reporting under this clause is not applicable.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rajni Mundra.

Partner

Membership No.: 058644

UDIN: 20058644AAAADW8060

Place: Gurugram

Date: 28 September 2020

Annexure A to the Independent Auditor's Report of even date to the members of Global Health Private Limited, on the standalone financial statements for the year ended 31 March 2020

Annexuge A

Based on the audit procedures performed for the purpose of reporting a true and fair view on the financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, and to the best of our knowledge and belief, we report that:

- (i) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of property, plant and equipment, capital work-in-progress, right of use assets and intangible assets.
 - (b) The Company has a regular program of physical verification of its property, plant and equipment and capital work-in-progress under which property, plant and equipment and capital work-in-progress are verified in a phased manner over a period of two years, which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. In accordance with this program, certain property, plant and equipment were verified during the year and no material discrepancies were noticed on such verification.
 - (c) The title/lease deeds of all the immovable properties (which are included under the head 'property, plant and equipment' and 'right of use assets') are held in the name of the Company.
- (ii) In our opinion, the management has conducted physical verification of inventory at reasonable intervals during the year and no material discrepancies between physical inventory and book records were noticed on physical verification.
- (iii) The Company has not granted any loan, secured or unsecured to companies, firms, Limited Liability Partnerships (LLPs) or other parties covered in the register maintained under Section 189 of the Act. Accordingly, the provisions of clauses 3(iii)(a), 3(iii)(b) and 3(iii)(c) of the Order are not applicable.
- (iv) In our opinion, the Company has complied with the provisions of Section 186 in respect of investments and guarantees. Further, in our opinion, the Company has not entered into any transaction covered under Section 185 and Section 186 of the Act in respect of loans and security.
- (v) In our opinion, the Company has not accepted any deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, the provisions of clause 3(v) of the Order are not applicable.
- (vi) We have broadly reviewed the books of account maintained by the Company pursuant to the Rules made by the Central Government for the maintenance of cost records under sub-section (1) of Section 148 of the Act in respect of Company's services and are of the opinion that, prima facie, the prescribed accounts and records have been made and maintained. However, we have not made a detailed examination of the cost records with a view to determine whether they are accurate or complete.
- (vii)(a) Undisputed statutory dues including provident fund, employees' state insurance, income-tax, sales tax, service tax, duty of customs, duty of excise, value added tax, goods and services tax, cess and other material statutory dues, as applicable, have generally been regularly deposited to the appropriate authorities, though there has been a slight delay in a few cases. Further, no undisputed amounts payable in respect thereof were outstanding at the year-end for a period of more than six months from the date they became payable.
 - (b) The dues outstanding in respect of income-tax, sales tax, service-tax, duty of customs, duty of excise, value added tax and goods and services tax on account of any dispute, are as follows:



Annexute A to the Independent Auditor's Report of even date to the members of Global Health Private Limited, on the standalone financial statements for the year ended 31 March 2020 (cont'd)

Statement of Disputed Dues

Name of the	Nature of dues	Amount (₹ in lakhs)	Amount paid under protest	Period to which the amount relates	Forum where dispute is pending
Income-tax Act, 1961	Disallowance of certain expenses	30.55	-	Assessment Year 2016-17	Commissioner of Income Tax (Appeals)
Income-tax Act, 1961	Disallowance of share based payment expense and certain other expenses	1,050.83	-	Assessment Year 2017-18	Commissioner of Income Tax (Appeals)

- (viii) The Company has not defaulted in repayment of loans or borrowings to any financial institution or bank during the year. The Company does not have any loans or borrowings payable to government and no dues payable to debenture-holders during the year.
- (ix) The Company did not raise moneys by way of initial public offer or further public offer (including debt instruments). In our opinion, the term loans were applied for the purposes for which the loans were obtained, though idle/surplus funds which were not required for immediate utilisation have been invested in liquid investments, payable on demand.
- (x) No fraud by the Company or on the Company by its officers or employees has been noticed or reported during the period covered by our audit.
- (xi) The provisions of Section 197 of the Act read with Schedule V to the Act are not applicable to the Company since the Company is not a public company as defined under Section 2(71) of the Act. Accordingly, provisions of clause 3(xi) of the Order are not applicable.
- (xii) In our opinion, the Company is not a Nidhi Company. Accordingly, provisions of clause 3(xii) of the Order are not applicable.
- (xiii) In our opinion, all transactions with the related parties are in compliance with Section 188 of the Act, where applicable, and the requisite details have been disclosed in the financial statements, as required by the applicable Ind AS. Further, in our opinion, the Company is not required to constitute audit committee under Section 177 of the Act.
- (xiv) During the year, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures.
- (xv) In our opinion, the Company has not entered into any non-cash transactions with the directors or persons connected with them covered under Section 192 of the Act.

(This space has been intentionally left blank)



Annexure A to the Independent Auditor's Report of even date to the members of Global Health Private Limited, on the standalone financial statements for the year ended 31 March 2020 (cont'd)

(xvi) The Company is not required to be registered under Section 45-LA of the Reserve Bank of India Act, 1934.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rajni Mundra

Partner

Membership No.: 058644

UDIN: 20058644AAAADW8060

Place: Gurugram

Date: 28 September 2020

Annexure B to the Independent Auditor's Report of even date to the members of Global Health Private Limited, on the standalone financial statements for the year ended 31 March 2020

Annexure B

Independent Auditor's Report on the internal financial controls with reference to the standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

 In conjunction with our audit of the standalone financial statements of Global Health Private Limited ('the Company') as at and for the year ended 31 March 2020, we have audited the internal financial controls with reference to financial statements of the Company as at that date.

Responsibilities of Management and Those Charged with Governance for Internal Financial Controls

2. The Company's Board of Directors is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the 'Guidance Note') issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of the Company's business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility for the Audit of the Internal Financial Controls with Reference to Financial Statements

- 3. Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the ICAI prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements, and the Guidance Note issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.
- 4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements includes obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
- 5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Meaning of Internal Pinancial Controls with Reference to Financial Statements

6. A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as



Annexure B to the Independent Auditor's Report of even date to the members of Global Health Private Limited on the standalone financial statements for the year ended 31 March 2020 (cont'd)

necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

7. Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

8. In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such controls were operating effectively as at 31 March 2020, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

For Walker Chandlok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rajni Mundra

Partner

Membership No.: 058644

UDIN: 20058644AAAADW8060

Place: Gurugram.

Date: 28 September 2020



Standalone balance sheet us at 31 March 2020		4	Λεατ
	Notes	As as 31 March 2020	31 March 2019
	140fcu	(7 in lokhu)	(Cin bikha)
ASSETS		(, ,,, ,,,,,,,,,,	(* 111 11111117)
Non-current assets			
Property, plant and equipment	6 A	62,653.80	86,784,37
Capital work-in-progress	6 A	347.13	520.95
Right of the Assets	6 11	29,869.50	
Intangible narete	7	363.60	137.00
Pinancial nescus			
favestments	8	50,050.00	35,550.00
Loans	9 A	596.13	548.36
Other financial agress	10 A	1,672.11	•
Income-ian arren (nei)	, 11	6,584.03	5,939.47
Other non-corrent assets	12 A	76.82	314.65
Total non-current assets		1,52,213.12	1,29,794.78
Current assets			
Inventories	13	3,225.62	2,328.96
Financial assets	3.3	A i b 185m	14 115 00
Trade receivables	14	14,842338	16,417.89
Carh and earls equivalents	15	13,155,36	3,997.62
Other bank balances	16.	8,721.39	19 ₁ 967.58
Loans	9.8	9.79	84,34
Other financial assets	10-B	2,981:83 640.77	2,389.80 808.92
Other current assets:	12.B	43,576,84	45,995.30
Total current nexcts			
Tatal assets		1,95,789.96	1,75,790.08
EQUITY AND LIABILITIES:			
Equity			
Requiry share capital	.17.A	4,934.50	4,913.28
histoments entirely equity in nature	17.B	3,250 (X)	3,250.00
Other equity	18	1,54,087.75	1,23,080.44
Total equity		1,42,272.25	1,31,193.72
, .		,	(
Linbilities			
Non-current Habilities			
Pinancial liabilities			
Bononjup	19	1,807.84	11,474,88
Leneo liabilities	20 Λ	£9,439.64	•
Provisions	21. Å.	4,211.97	2,895.09
Deferred the liabilities (net)	22	811.37	3,024.49
Other non-current liabilities	23 A	1,886.47	2,283.56
Total non-current liabilities		28,157,29	19,678,62
A (() A 18 d			
Current flabilities financial fabilities			
Longe liabilities	20 B	3,282.38	
Tode mysbles	*0 B	ار <u>ک</u> ومی _ا ن	•
t mue sayanes - total outstanding three of micro enterprises and small enterprises	24 A	1,643.35	444.56
total outstanding does of creditors wher than micro enterprises and small	24 B	10,160.23	12,185.51
entemples	21.17	10,116.6.3	12,403.21
Other funncial liabilities	25	5,506,60	7,244.10
Other current liabilities	23:13	3,899.60	4,094,19
Provisions	2())	868.26	949.98
Total current Rablilities	 .	25,360,42	24,918.34
Total liabilities		1,95,789,96	1,75,790.08
· •			HOMEON AND A STATE OF THE PARTY

The accompanying aummany of significant accounting policies and other explanatory information are an integral part of these standalune financial statements.

This is the standalone balance alrest referred to in our report of even date.

Por Walker Chandlok & Co LLP

Chartered Accountants

Pirm's Registration No.: 001076N/N500013

Rajui Rajal Munden Paruser

Partitor Membership No.: 058644

Pincer New Delhi Dater-28 September 2026 For and on behalf of the Board of Directors

Definition Trelian Chalmon and Managing Director [DIN:00012148]

Pieces Gungmin Dates 28 September 2020

Santeev Kumar Chief Pinancial Officer

Places Gurageam Dates 28 September 2020 Chief Breentlye Officer

Pankaj Sahni

Place: Gueggan Date: 28 September 2020

> Sunft Kumar Bansal Company Secretary

Pincer Gurogram Date: 28 September 2020

Global Health Private Limited

Standalone statement of profit and loss for the year ended 31 March 2020

	Note	For the year ended 31 March 2020	Por the year ended 31 March 2019
		(Cin lakhe)	(₹ in lakhs)
Income			
Revenue from operations	26	1,45,657.18	1,44,113.22
Other income	27	5,905.33	6,468,94
		1,51,562.51	1,50,582.16
Ехрепвен			
Cost of materials consumed	28	31,920.66	32,491.69
Employee benefits expense	29	52,230.13	54,071.67
Pinance costs	30	2,765.45	1,654.72
Depreciation and amortisation expense	31	9,856.82	9,068.92
Impairment losses on financial assets	32	1;141.61	1,800.22
Other expenses	33·	40,584.50	41,842.89
·		1,38,469.17	1,40,930.11
Profit before tax		13,093,34	9,652.05
Tax expenses	34		,
Current tax (including earlier years)		4,971.83	5,158.47
Deferred tax credit		(2,154,15)	(1,800.21)
Profit after tax		10,275.66	6,293.79
Other comprehensive income			
Items that will not be reclassified to profit or loss			
Re-measurement gains on defined benefit plaus:		(234:29)	49.00
Income tax relating to items that will not be reclassified to profit and loss		58.97	(17.12)
Total comprehensive income for the year		10,100,34	6,325.67
Barnings per equity share	35		
Basic (?)		20.53	12.71
Diluted (₹)		20,42	12.58
			,

The accompanying summary of significant accounting policies and other explanatory information are an integral part of these standalone financial statements.

This is the standalone statement of profit and loss referred to in our report of even date.

For Walker Chandlok & Co LLP

Chattered Accountants

Firm's Registration No.: 001076N/N500013

Rajal Mundra

Partner

Membership No. 058644

Place: New Delhi

Date: 28 September 2020

For and on behalf of the Board of Directors

Dr. Natosh Trelian

Chairman and Managing Director

[IDIN:00012148]

Place: Gurugram

Date: 28 September 2020

Sanjeey Kumar

Chief Pinancial Officer

Place: Guingram

Date: 28 September 2020

Pankaj Sahni

Chief Executive Officer

Place: Gurugium Date: 28 September 2020

> Sunil Kumar Bansal Company Secretary

Place: Gurogam Date: 28 September 2020

·

Ag.

Global Health Private Limited		
Simplatone cash flow eletement for the year ended 31 March 2020	Por the year ended 51 March 2020	For the year entied 31 March 2019
	(Cin lakhe)	(f in lakha)
A CASH PLOW'S PROM OPERATING ACTIVITIES Profit before tax	13,093.34	9,682.05
A45		
Adjustments for: Depreciation of property, plant and equipment	K,262,73	9,027,58
Depreciation of right of use assets	1,499.52	7,027130
Amortisation of intaligible deserts	94.57	41,34
Liss on sile of property, plant and equipments (iiet)	9:65	18.52
Pixers provision written back		(787,61)
Interest income on bank deposit and other financials assets measured at amortired cost	(1,887,01)	(1,842.34)
Government grants income	(1,551.44)	(1,467.03)
Impriment in the value of investments	•	904,886
Unrealised foreign exchange gain (not)	(89,04)	•
interest on bomovings	110.20	290.98
Interest on lesso liabilities	2,413.16	1,198,07
Office france costs	240,09 1,111,61	163.67
Uspected credit Juss on tente receivables Employee whire based psyment expense	956.97	1,8kX),22 2,603,07
Provision for employee benefits (net)	. 1,000.86	429,30
Operating profit before working capital changes	25,267,21	22,031,62
*Promise de la company de la c	(
Movement in working capital		
Current and non-current toans	(ch'84)	(101,60)
finentiales	(R96.65)	(56.28)
Other current funticial assets	(574.43)	516.55
Other current arrets	143.91	(218.11)
!Frade receivables	353.24	(3,937.03)
Other non current assets	23.91	4,93
Other current liabilities and current funncial Habitinies	276.64	378.68
Other non-current inbillities	973.85	401.65
Tinde payables Cash flows from operations	(626.59) 24,872.34	2,018.48
Inconic tex paid (net of refunds)	(5,616.39)	21,938.65 (6,738.74)
Net each flows from operating activities (A)	19,255.96	15,199,92
B CASH FLOWS FROM INVESTING ACTIVITIES		
Prichiste of property plant and equipments, expital work-in-progress and intaggible argus (helinding capital advances, capital	(1,750.32)	(3,947.10)
creditors and deferred payment liabilities)		
Proceeds from sale/disposal of property, plant and equipments	53.11	104.77
Movement in other hank balances (net)	11,246.18	1,323.65
Movement in Dank deposits having maturity period more than 12 months	(1,672.11)	2,31-1.05
Internat received	1,869.41	1.823.35
Investment in subsidiary companies	(14,300,00)	[12,900.00]
Net cash used in investing activities (D)	(4,533,75)	(10,581,28)
C CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from issue of equity share capital	21.22	/4 No
Répsymient of thon-coirean borrowings	(1,632.54)	63.87 (640.96)
Repayment of current burrowings (ner).	(1,032.54)	(2,540.12)
Inferent paid on horrowings	(83.10)	(272.12)
Office finance corts paid	(54.41)	(1.487.16)
Interres paid on lease Babilities	(2,4)5,16}	(1111)2-10)
Naymeni of lease liabilities	(1,400.50)	
:Not cash flow used in financing notivities (C)	(5;564.49)	(4,876,79)
Interester/(decrease) in eash and each equivatents (A+8+C)	9,157.74	(58.15)
. Cash and cash equivalents at the beginning of the year Cash and cash equivalents at the end of the year (refer note below)	3,997.02	4,055,77
	13,155,36	3,997.62
Note: Reconciliation of eash and eash equivalents as per each flow statement (refer note 15)		
Defences with tranks in current accounts	3,069.69	2,527.47
Cheques on hand	1.37	34.61
Cash on hand. Birth deposits with adjust mutually text than three months.	110.76	172.56
rican arbitatio quai reflenii mental), are men meet monus	9,973.54	1,262.98
	13,155.36	3,997.62

The accompanying automaty of significant accounting policies and other explanatory information are an integral past of these resultabore foreneed statements.

This is the standalone cash flow statement referred to in our repair of even date.

Por Walker Cliandlok & Co. LLP

Chartered Accountems
Pinn's Registration No.: 001076N/N500013

Rajai dunden Partice

Membership No.: 058644

Pigers New Delhi Date: 28 September 2020 For and on belief of the Board of Directors

De Natesh Trelenn Chairman and Managing Director [DIN:00012148]

Place: Gungran Dater 28 September 2020

Sanjecy Kumer Chief Plannelel Officer

Pince: Gungain Date: 28 September 2020

Place: Changan Date: 28 September 2020

Paukin Salusi Chief Executive Officer

Sunit Kumar Bausai Company Secretary Place: Gunggam Dates 28 September 2020

Q AND ACCOUNT

-	Bquity share capital* Particulars	Opening balance as at 1 April 2018	Changes in equity share capital during the year	Balance as at 31 March 2019	Changes in equity share capital during the year	(₹ in lakhs) Balance as at 31 March 2020
	Equity share capital	4,849.41	63.87	4,913.28	21,22	4,934.50

B Instruments entirely equity in nature** (7 in lakhe) Particulars Opening balance Balance as at Changes in equity Changes in Balance as at 31 equity share share capital during 31 March 2019 March 2020 1 April 2018 capital during the year the year Compulsorily convertible preference shares 3,250.00 3,250.00 3,250.00

Particulars		(l'in lakhs) Total			
	Securities premium	Share options outstanding account	Retained carnings	Capital reserve	;
Opening balance as at 1 April 2018	40,946.78.	7,441.00	65,693.92	20.00	1,14,101,70
Profit for the year		-	6,293.79		6,293.79
Other comprehensive income				ł.	•
Re-mensurement gains on defined benefit plans (not of tax)	-	•	31.88	-	31.88
Employee share based payment expense		2,603,07		. 1	2,603,07
Stock options lapsed during the year		(103.50)	103.50		
Issue of equity shares (on account of exercise stock options)	4,572.37	(4,572.37)	-	-	-
Balance as at 31 March 2019	45,519,15	5,368.20	72,123.09	20,00	1,23,030,44
Profit for the year	· · · · · · · · · · · · · · · · · · ·	*	10,275.66		10,275,66
Other comprehensive income			1	-	1,0,010,01
Re-measurement gains on defined benefit plans (net of tax)		•	(175.32)		(175.32)
Employee share based payment expense	_ }	956,97	l <u>.</u>		956.97
Issue of equity shares (on account of exercise stock options)	1,481.72	(1,481.72)	-	- 1	5,116,91 *
Balance as at 31 March 2020	47,000,87	4,843.45	82,223,43	20.00	1,34,087.75

^{*}Refer note 17A for details

The accompanying summary of significant accounting policies and other explanatory information are no integral part of these standalone financial statements.

This is the standalone statement of changes in equity referred to in our report of even date.

CHANDION

For Walker Chandlok & Co LLP

Chartered Accountants

Picm's Registration No.: 001076N/N500013

Rajui Raint Munora

Partner

Membership No.: 058644 Place: New Delhi

Date: 28 September 2020

Dr. Narceh Trehan

Chairman and Managing Director

[DIN:00012148] Place: Gungam

Date: 28 September 2020

Sanjeev Kumar Chief Financial Officer

Place: Gurogram Date: 28 September 2020 For and on behalf of the Board of Directors

Pankaj Sahni Chief Executive Officer

Place: Guragaun Date: 28 September 2020

S

Sunit Kumar Bansal Company Secretary

Place: Gurogean Date: 28 September 2020

^{**}Referencte 17B for details

^{***}Refer note 18 for details

Global Health Private Limited
Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

1. Background

Global Health Private Limited ('the Company') is engaged in the business of providing healthcare services. The Company is domiciled in India and its registered office is situated at B-18, Defence Colony, New Delhi-110024.

2. General information and statement of compliance with Ind AS

The standalone financial statements (financial statements') comply in all material aspects with Indian Accounting Standards (hereinafter referred to as the 'Ind AS') as notified by Ministry of Corporate Affairs under Section 133 of the Gompanies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules 2015, as amended and other relevant provisions of the Act.

The financial statements for the year ended 31 March 2020 were authorized and approved for issue by the Board of Directors on 28 September 2020. The revision to financial statements is permitted by Board of Directors after obtaining necessary approvals or at the instance of regulatory authorities as per provisions of the Act.

3. Basis of preparation

The financial statements have been prepared on going concern basis in accordance with accounting principles generally accepted in India. Further, the financial statements have been prepared on historical cost basis except for share based payments and certain financial assets and financial liabilities which are measured at fair value.

4. Recent accounting pronouncement

Amendment to Ind AS 103, Business Combinations

On 24 July 2020, Ministry of Corporate Affairs ("MCA") has issued an amendment to Ind AS 103 whereby definition of the business has been amended. Additionally, new amendments also provide new aspects to evaluate a set of activities as business. The effective date of these amendments is 1 April 2020. The Company is evaluating the requirements of the amendments and their impact on the financial statements.

Amendment to Ind AS 116, Leases

On 24 July 2020, Ministry of Corporate Affairs ("MCA") has issued an amendment to Ind AS 116 in respect of rent concessions occurring as a direct consequence of the Covid-19 pandemic. The effective date of these amendments is 1 April 2020. However, in case an entity (lessee) has not yet approved the financial statements before the issuance of this amendment, then the same may be applied for annual reporting periods beginning on or after 1 April 2019 as well. The Company is evaluating the requirements of the amendments and their impact on the financial statements.

Amendment to Ind AS 1, Presentation of Financial Statements

On 24 July 2020, Ministry of Corporate Affairs ("MCA") has issued an amendment to Ind AS 1 whereby definition of the word 'material' has been enhanced to make it more explanatory and it now covers more scenarios. The effective date of these amendments is 1 April 2020. The Company is evaluating the requirements of the amendments and their impact on the financial statements.

Amendment to Ind AS 10, Events After the Reporting Period

On 24 July 2020, Ministry of Corporate Affairs ("MCA") has issued an amendment to Ind AS 10 in respect of disclosure requirement related to non-adjusting event. This amendment requires additional information to be disclosed for material non-adjusting events. The effective date of these amendments is 1 April 2020. The Company is evaluating the requirements of the amendments and their impact on the financial statements.



d

Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

5. Summary of significant accounting policies

The financial statements have been prepared using the significant accounting policies and measurement bases summarised below. These policies have been consistently applied to all the years presented, unless otherwise stated.

5.1 Current versus non-current classification

All assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in Division II of Schedule III of the Act. Based on the nature of the operations and the time between the acquisition of assets for processing/servicing and their realisation in cash or cash equivalents, the Company has ascertained its operating cycle as twelve months for the purpose of current/non-current classification of assets and liabilities.

5.2 Property, plant and equipment

Recognition and initial measurement

Property, plant and equipment are stated at their cost of acquisition. The cost comprises purchase price, borrowing cost if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Any trade discount and rebates are deducted in arriving at the purchase price. Property, plant and equipment purchased on deferred payment basis are recorded at equivalent cash price. The difference between the cash price equivalent and the total payment is recognised as interest expense over the period until payment is made.

Subsequent costs and disposal

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is de-recognised when replaced. All other repair and maintenance costs are recognised in statement of profit and loss as incurred.

Items such as spare parts, stand-by equipment and servicing equipment are recognised as property, plant and equipment when they meet the definition of property, plant and equipment. Otherwise, such items are classified as inventory.

An item of property, plant and equipment initially recognised is de-recognised upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is recognised in statement of profit and loss when the asset is derecognised.

Capital work-in-progress excluding capital advances includes property, plant and equipment under construction and not ready for intended use as on the balance sheet date.

Subsequent measurement (depreciation and useful lives)

Freehold land is carried at historical cost. All other items of property, plant and equipment are subsequently measured at cost less accumulated depreciation and impairment losses. Depreciation on property, plant and equipment is provided on a straight-line basis, computed on the basis of useful lives (as set out below) prescribed in Schedule II to the Act.

Asset class	Useful life
Building	30 years
Medical equipment	5 to 15 years
Medical and surgical instruments	3 years
Other plant and equipment	15 years
Furniture and fixtures	10 years
IT equipment	3 to 6 years
Office equipment	5 years
Electrical installation	10 years
Vehicles CHANCION &	6 to 8 years



Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Till previous year, leasehold land was amortised over the period of the lease. In the current year, as this has been classified as right of use assets and accordingly its recognition and measurement is explained in the accounting policy 5.7 pertaining to leases.

Leasehold improvements are amortised over the lower of useful life and the lease term available to the Company.

The residual values, useful lives and method of depreciation of are reviewed at the end of each financial year.

5.3 Intangible assets

Recognition and initial measurement

Intangible assets (software) are stated at their cost of acquisition. The cost comprises purchase price, borrowing cost if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use.

Subsequent measurement

The cost of capitalized software is amortized over a period of five years from the date of its acquisition.

De-recognition

Intangible asset is de-recognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is recognized in the statement of profit and loss, when the asset is derecognised.

5.4 Inventories

Inventories are valued at cost or net realisable value, whichever is lower. Cost is calculated on weighted average basis. Cost of these inventories comprises of all cost of purchase, taxes and other costs incurred in bringing the inventories to their present location and condition. Cost of purchased inventory is determined after deducting rebates and discounts.

Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale.

5.5 Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable. Revenue is recognized upon transfer of control of promised products or services to customers/patients in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. Revenue is measured net of rebates, discounts and taxes. The Company applies the revenue recognition criteria to each component of the revenue transaction as set out below.

Healthcare services

Revenue from healthcare services is recognized as and when related services are rendered and include services for patients undergoing treatment and pending for discharge, which is shown as unbilled revenue under other current financial assets. The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for the services, excluding amounts collected on behalf of third parties (for example, indirect taxes).

A receivable is recognised by the Company when the control is transferred as this is the case of point in time recognition where consideration is unconditional because only the passage of time is required. When either party to a contract has performed, an entity shall present the contract in the balance sheet as a contract asset or a contract liability, depending on the relationship between the entity's performance and the payment.

Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Clinical research

Clinical research income is recognized over time basis percentage completion method which is determined based on achievement of milestones.

Interest income

Interest income is recorded on accrual basis using the effective interest rate (EIR) method.

Sponsorship income

Sponsorship income is recognised in the accounting year in which the services are rendered as per the agreed terms with the customers.

Other income

Revenue arising from revenue sharing agreements is recognized as per the terms of the arrangement.

Rental income is recognised on a straight-line basis over the lease term, except for contingent rental income which is recognised when it arises.

5.6 Borrowing cost

Borrowing cost includes interest expense as per effective interest rate (EIR). Borrowing costs directly attributable to the acquisition, construction or production of a qualifying asset are capitalized during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for its intended use or sale. All other borrowing costs are expensed in the period they occur.

5.7 Leases

Company as a lessee - Right of use assets and lease liabilities

Till previous year, assets acquired on leases where a significant portion of risk and rewards of ownership are retained by the lessor are classified as operating leases. Lease rental are charged to statement of profit and loss on straightline basis except where scheduled increase in rent compensate the lessor for expected inflationary costs.

For any new contracts entered into on or after 1 April 2019, the Company considers whether a contract is, or contains a lease (for existing leases, the transition approach has been explained and disclosed in Note 41). A lease is defined as 'a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration'.

Classification of leases

The Company enters into leasing arrangements for various assets. The assessment of the lease is based on several factors, including, but not limited to, transfer of ownership of leased asset at end of lease term, lessee's option to extend/purchase etc.

Recognition and initial measurement of right of use assets

At lease commencement date, the Company recognises a right-of-use asset and a lease liability on the balance sheet. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Company, an estimate of any costs to dismantle and remove the asset at the end of the lease (if any); and any lease payments made in advance of the lease commencement date (net of any incentives received).

Subsequent measurement of right of use assets

The Company depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The Company also assesses the right-of-use asset for impairment when such indicators exist.





Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Lease liabilities

At lease commencement date, the Company measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the Company's incremental borrowing rate. Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed payments) and variable payments based on an index or rate. Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is re-measured to reflect any reassessment or modification, or if there are changes in in-substance fixed payments. When the lease liability is re-measured, the corresponding adjustment is reflected in the right-of-use asset.

The Company has elected to account for short-term leases using the practical expedients. Instead of recognising a right-of-use asset and lease liability, the payments in relation to these short-term leases are recognised as an expense in statement of profit and loss on a straight-line basis over the lease term.

Company as a lessor

Leases in which the Company does not transfer substantially all the risks and rewards of ownership of an asset are classified as operating leases. The respective leased assets are included in the balance sheet based on their nature. Rental income is recognized on straight-line basis over the lease-term.

5.8 Impairment of non-financial assets

Assessment is done at each balance sheet date as to whether there is any indication that an asset may be impaired. For the purpose of assessing impairment, the smallest identifiable group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows from other assets or groups of assets, is considered as a cash generating unit. If any such indication exists, an estimate of the recoverable amount of the asset/cash generating unit is made. Assets whose carrying value exceeds their recoverable amount are written down to the recoverable amount. Recoverable amount is higher of an asset's or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. Assessment is also done at each balance sheet date as to whether there is any indication that an impairment loss recognised for an asset in prior accounting periods may no longer exist or may have decreased.

5.9 Foreign currency

Hunctional and presentation currency

Items included in the financial statement of the Company are measured using the currency of the primary economic environment in which the entity operates ('the functional currency'). The financial statements have been prepared and presented in Indian Rupees (INR), which is the Company's functional and presentation currency.

Transactions and balances

Poreign currency transactions are recorded in the functional currency, by applying to the exchange rate between the functional currency and the foreign currency at the date of the transaction.

Foreign currency monetary items outstanding at the balance sheet date are converted to functional currency using the closing rate. Non-monetary items denominated in a foreign currency which are carried at historical cost are reported using the exchange rate at the date of the transaction.

Exchange differences arising on monetary items on settlement, or restatement as at reporting date, at rates different from those at which they were initially recorded, are recognized in the statement of profit and loss in the year in which they arise.

5.10 Financial instruments

Recognition and initial measurement

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the finantiality instrument and are measured initially at fair value adjusted for transaction costs, except for those carried a Pair value A cough profit or loss which are measured initially at fair value.

Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

The classification depends on the Company's business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses will either be recorded in the statement of profit and loss or other comprehensive income. For investments in debt instruments, this will depend on the business model in which the investment is held. For investments in equity instruments, this will depend on whether the Company has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income ('FVOCI').

Non-derivative financial assets

Subsequent measurement

Pinancial assets carried at amortised cost - A 'financial asset' is measured at the amortised cost if both the following conditions are met:

- The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method.

Investments in equity instruments of subsidiaries and joint ventures - Investments in equity instruments of subsidiaries and joint ventures are measured at cost in accordance with Ind AS 27 'Separate Financial Statements'.

De-recognition of financial assets

A financial asset is de-recognised when the contractual rights to receive cash flows from the asset have expired or the Company has transferred its rights to receive cash flows from the asset.

Non-derivative financial liabilities

Subsequent measurement

Subsequent to initial recognition, all non-derivative financial liabilities are measured at amortised cost using the effective interest method.

De-recognition of financial liabilities

A financial liability is de-recognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the Company or the counterparty.

5.11 Impairment of financial assets

The Company assesses on a forward looking basis the expected credit losses associated with its financial assets and the impairment methodology depends on whether there has been a significant increase in credit risk.

Trade receivables

In respect of trade receivables, the Company applies the simplified approach of Ind AS 109, which requires measurement of loss sillowance on amount equal to lifetime expected credit losses. Lifetime expected credit

Standalone summary of significant accounting policies and other explanatory information for the year ended 31 Match 2020

losses are the expected credit losses that result from all possible default events over the expected life of a financial instrument.

Other financial assets

In respect of its other financial assets, the Company assesses if the credit risk on those financial assets has increased significantly since initial recognition. If the credit risk has not increased significantly since initial recognition, the Company measures the loss allowance at an amount equal to 12-month expected credit losses, else at an amount equal to the lifetime expected credit losses.

When making this assessment, the Company uses the change in the risk of a default occurring over the expected life of the financial asset. To make that assessment, the Company compares the risk of a default occurring on the financial asset as at the balance sheet date with the risk of a default occurring on the financial asset as at the date of initial recognition and considers reasonable and supportable information, that is available without undue cost or effort, that is indicative of significant increases in credit risk since initial recognition. The Company assumes that the credit risk on a financial asset has not increased significantly since initial recognition if the financial asset is determined to have low credit risk at the balance sheet date

5.12 Taxes

Tax expense comprises current and deferred tax. Current and deferred tax is recognised in statement of profit and loss except to the extent that it relates to items recognised directly in equity or other comprehensive income.

The current income-tax charge is calculated on the basis of the tax laws enacted at the balance sheet date. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred tax is provided in full, on temporary differences arising between the tax base of assets and liabilities and their carrying amounts in the financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realised or the deferred tax liability is settled. Deferred tax assets are recognised for all deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.

5.13 Cash and cash equivalents

Cash and cash equivalents include cash in hand, demand deposits with the banks, other short-term highly liquid investments with original maturity of three months and less.

5.14 Employee benefits

Short-term employee benefits

Liabilities for wages and salaries, including non-monetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are classified as short-term employee benefits. These benefits include salaries and wages, short-term bonus, incentives etc. These are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

Defined contribution plan

Contribution towards provident fund is made to the regulatory authorities, where the Company has no further obligations. Such principles classified as defined contribution plan as the Company does not carry any further

Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

obligations, apart from the contributions made on a monthly basis. In addition, contributions are made to employees' state insurance schemes and labour welfare fund, which are also defined contribution plans recognized and administered by the Government of India and Haryana respectively. The Company's contributions to these schemes are expensed in the statement of profit and loss.

Defined benefit plan

The Company has unfunded gratuity as defined benefit plan where the amount that an employee will receive on retirement is defined by reference to the employee's length of service and final salary. The gratuity plan provides a lump sum payment to vested employees at retirement, death, incapacitation or termination of employment, of an amount based on the respective employee's salary and the tenure of employment. The Company's liability is actuarially determined (using the Projected Unit Credit method) at the end of each year. This is based on standard rates of inflation, salary growth rate and mortality.

Discount factors are determined close to each year-end by reference to market yields on government bonds that have terms to maturity approximating the terms of the related liability. Service cost and net interest expense on the Company's defined benefit plan is included in employee benefits expense.

Actuarial gains/losses resulting from re-measurements of the defined benefit obligation are included in other comprehensive income.

Other long-term employee benefits

The Company also provides benefit of compensated absences to its employees which are in the nature of long-term employee benefit plan Liability in respect of compensated absences becoming due and expected to be availed more than one year after the balance sheet date is estimated on the basis of an actuarial valuation performed by an independent actuary using the projected unit credit method as on the reporting date. Service cost and net interest expense on the Company's other long-term employee benefits plant is included in employee benefits expense. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are also recorded in the statement of profit and loss in the year in which such gains or losses arise.

5.15 Government grants

Grants from the government are recognised at their fair value when there is reasonable assurance that the grant will be received and the Company will comply with all attached conditions. When the grant relates to a revenue item, it is recognized in statement of profit and loss on a systematic basis over the periods in which the related costs are expensed. The grant can either be presented separately or can deduct from related reported expense. Government grant relating to capital assets are recognised initially as deferred income and are credited to statement of profit and loss on a straight line basis over the expected lives of the related asset and presented within other income. Ministry of Corporate Affairs ('MCA') has inserted new provisions effective 20 September 2018 and allowed government grants related to capital assets to be to be netted off from capital asset and recognise in statement of profit and loss over the life of a depreciable asset as a reduced depreciation expense.

5.16 Share based payment expense

The fair value of options granted under Global Health Employee Stock Option Scheme 2014 and 2016 is recognized as an employee benefit expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted:

- Including any market performance conditions (e.g., the entity's share price)
- Excluding the impact of any service and non-market performance vesting conditions (e.g. profitability, sales growth targets and remaining an employee of the entity over a specified time period), and
- Including the impact of any non-vesting conditions (e.g. the requirement for employees to save or holding shares for a specified period of time).

Total expense is recognized over the vesting period, which is the period over which all the specified vesting conditions are to be satisfied of the end of each period, the entity revises its estimates of the number of options

Global Health Private Limited
Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

that are expected to vest based on the non-market vesting and service conditions. It recognizes the impact of revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.

5.17 Provisions, contingent liabilities and contingent assets

Provisions are recognized when the Company has a present (legal or constructive) obligation as a result of past events, for which it is probable that an outflow of resources will be required to settle the obligation and a reliable estimate of the amount can be made. Provisions required to settle are reviewed regularly and are adjusted where necessary to reflect the current best estimates of the obligation. Provisions are discounted to their present values, where the time value of money is material.

Contingent liability is disclosed unless the likelihood of an outflow of resources is remote and there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources.

Contingent assets are disclosed only when inflow of economic benefits therefrom is probable and recognize only when realization of income is virtually certain.

5.18 Earnings per share

Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period is adjusted for events including a bonus issue.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

5.19 Rounding of amounts

All amounts disclosed in the financial statements and notes have been rounded off to the nearest lakhs as per the requirement of Division II of Schedule III, unless otherwise stated.

5.20 Critical estimates and judgements

The preparation of financial statements requires the use of accounting estimates which, by definition, will seldom equal the actual results. Management also needs to exercise judgement in applying the Company's accounting policies. This note provides an overview of the areas that involved a higher degree of judgement or complexity, and of items which are more likely to be materially adjusted due to estimates and assumptions turning out to be different than those originally assessed. Detailed information about each of these estimates and judgements is included in relevant notes together with information about the basis of calculation for each affected line item in the financial statements.

- a) Recognition of deferred tax assets The extent to which deferred tax assets can be recognized is based on an assessment of the probability of the Company's future taxable income against which the deferred tax assets can be utilized.
- b) Evaluation of indicators for impairment of assets The evaluation of applicability of indicators of impairment of assets requires assessment of several external and internal factors which could result in deterioration of recoverable amount of the assets.
- c) Contingent liabilities At each balance sheet date basis the management judgment, changes in facts and legal aspects, the Company assesses the requirement of provisions against the outstanding contingent liabilities. However, the actual future outcome may be different from this judgement.

Global Health Private Limited Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

- d) Impairment of financial assets At each balance sheet date, based on historical default rates observed over expected life, existing market conditions as well as forward looking estimates, the management assesses the expected credit losses on outstanding receivables. Further, management also considers the factors that may influence the credit risk of its customer base, including the default risk associated with industry and country in which the customer operates.
- e) Defined benefit obligation (DBO) Management's estimate of the DBO is based on a number of underlying assumptions such as standard rates of inflation, mortality, discount rate and anticipation of future salary increases. Variation in these assumptions may significantly impact the DBO amount and the annual defined benefit expenses.
- f) Useful lives of depreciable/amortisable assets Management reviews its estimate of the useful lives of depreciable/amortisable assets at each reporting date, based on the expected utility of the assets. Uncertainties in these estimates relate to technical and economic obsolescence that may change the utilisation of assets.
- g) Leases The Company evaluates if an arrangement qualifies to be a lease as per the requirements of Ind AS 116. Identification of a lease requires significant judgment. The Company uses significant judgment in assessing the lease term (including anticipated renewals) and the applicable discount rate. The Company determines the lease term as the non-cancellable period of a lease, together with both periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option; and periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option. In assessing whether the Company is reasonably certain to exercise an option to extend a lease, or not to exercise an option to terminate a lease, it considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend the lease, or not to exercise the option to terminate the lease. The Company revises the lease term if there is a change in the non-cancellable period of a lease.
- h) Government grant Grants receivables are based on estimates for utilization of the grant as per the regulations as well as analysing actual outcomes on a regular basis and compliance with stipulated conditions. Changes in estimates or non-compliance of stipulated conditions could lead to significant changes in grant income and are accounted for prospectively over the balance life of the asset.
- 1) Pair value measurements Management applies valuation techniques to determine fair value of equity shares (where active market quotes are not available) and stock option. This involves developing estimates and assumptions around volatility, dividend yield which may affect the value of equity shares or stock options.

Estimates and judgements are continuously evaluated. They are based on historical experience and other factors including expectation of future events that may have a financial impact on the Company and that are believed to be reasonable under the circumstances.



Scarcifore summary of significant accounting policies and other explanatory information for the year coded 31 March 2020. Gobal Health Private Limited

on Frederick prant and equations are						1						-		
Parisculus	Freehold land	Berlding	Medical	Medical and surgical instruments	Other plant and equipment		II equipment	Office	Electrical installation	Leasehold	Yehicles	Lesochold Land		in-progress
Section 1			-								22	2000	11 12 12 12 1	71977
tops aroun	, ,	20 200 00	20,000,23	17 555 6	12.217.61	238862	13300	300.38	3,03,23	2,032,52	153.47	1,000 CO	770/2007	3
Balance as at 01 April 2013	6,364.03	A. 45.46	30,00		2001	X2.5X	30	33.10	12.17	199,63	333.60	i	3,292,57	20806
Additions	•	ក <u>ម្ព</u>	1,632.82	113.74		550	E .		į 1		(42.88)	í	(205.13)	(40cs
O-mosals/adhistments	y	3	(342.68)	(65.8)	(11.55)	(0.96)	(14:0)	40.000	3 000 46	2 22 78	OL 05.3	17.622.00	119.364.21	52255
Relance as at 31 March 2019	630003	31,387.63	39,582,46	1,467.26	12,604.51.	2,451.89	1,637.15	33485	0,000,00	0.01	10.73		1 190 03	13.10
4. 4. C.		15.32	626.53	\$7.65	X 28	ij T	91.96	8	3	\$ + 86	0.00		101	03217
Disposity of as parents	,	1	(9.44)	.3	(S)	(C.S.S)	٠	(k.38)	व -		(na-r)	030 553 TIV	(82,00)	
Transfer to mobile of the assets	•	•		1		Y			20.100.0	m w.c	22.000		1.05.048.02	347.13
Deliner of the Month 2000	6,007.9	31.402.95	40,299.35	1,554.90	12,808.60	2,494.95	1,729.11	393.50	5,185,76	יטיאנביז	2	+		
Accommutated depreciation						4 7557 66	90100	20,500	1.857.05	842.57	223	131.09	23,834.10	-
Balance as at 01 April 2018		3,761.65	10,149.30	746.71	\$1.575.0	90.167			8050	25 03	20.05	195.80	\$5,000	
Charge for the year	-1	1,286.51	3,913.27	274.64	***	67.55	261.87	1500	rowers .	,	(32.78)		(\$1.84)	'
Dersocats/adjustroemts		1	(3031)	(858)	(1,63)	(0.0)	ľ	06 164	X0.705 ¢	1 263 89	62.43	68,929	32,779.84	٠
Balance as at 31 March 2019	•	5,043,16	14,023.06	1211.79	4,585.41	2712.40	44777	27.00	2002	75.500	59.37		8,262,73	,
Charie for the test		1,257.10	3,936.64	180.32	122270	320.87	126.20	(87)	1000	1	WY TO	,	97.10	,
Charles for Experience		:	(5.13)	٠,	(ध्रम्	(821)	ŧ	(m)	•	•		(May Ses)	(8%)	
Strate adjustical			, '	•	•		4.	ŧ	1:				12000	
Iranster to ngat of the assets	-		44 000 44	1 205 1	28.785	2033.12	1,418.89	528.18	2,905.33	2,188.67	167.28	,	オスプス	'
Relance as at 31 Murch 2020		07.55.C0	1,000	AV-22-44	200,000									
				27.50	62 646 6	F- 857	614.46	12.23	578.40	1,027.09	387.76	16,995.11	86,781.37	520.95
Ner block as at 31 March 2019	6366.09	26,339.47	24.Y5C	19767		10.00	24.412	25	130,63	482.02	320.13	-	62,653,89	347.
34 - 21 - 12 - 12 - 13 March 2020	60,055,9	25,067,69	22 244.96	58.3	7,000,73	3	377000	****						

(f) Contractual obligations

Refer Note 40B for disclosure of contractual commitment for the requisition of property, pient and equipment

Refer Note 40B for disclosure of contractual commitment for the requisition of property, pient and equipment

(f) Property, plant and equipment pickiged as security
Höspiel project land of 23 acres and all morable property, plant and equipment. However, during the year, the Company has made the full payment against outstanding term leans bahave.

Backling Other plant Vehicles Lesebold Tands						(SEP)(T) EL 2)
9,871.63 127.59 138.34 16,995.11 127.59 138.34 16,995.11 127.59 138.34 16,995.11 127.59 138.34 16,995.11 127.59 138.34 16,995.11 127.59 5.85 75.57 175.59 12	Nexts of new mosts Particulars	Beilding	Other plant and equipment	Vehicles	Lezebold	Topy
percrit (1295.1) (125.5) (138.34 (16.955.1)	The submission of the submissi					
1256.30 1.88.34 16.995.11 18,107.98 127.39 128.34 16.995.11 19,223.0 5.85 75.57 195.80 12,223.30 5.85 75.57 195.80 12,388.67 12.133 5.87 16.799.31	GROSS BLOCK	BY 128 6		138.34	,	10,137.61
terred from propherty; plant rook equipment 4,236,30 (27.59 198.34 16.995.11 (4,107.58 177.59 198.34 16.995.11 (1,222.30 5.45 775.57 195.30 (1,222.30 5.45 775.57	Balance as at 1 April 2019 - meographe on temporom to the Astron			•	16.995.11	16.595:11
1,202.00 5.85 15.57 195.80 1,202.00 5.85 75.57 195.80 1,202.00 5.85 75.57 195.80 1,202.00 5.85 75.57 195.80 1,202.00 5.85 75.57 195.80	Balance as at 1 April 2019 - massfeared from property; plant and equipment	900	t. 3		}	4,236.30
14,107,38 127,59 138,44 10,591,11 1,222,30 5,45 75,57 105,50 1,222,30 5,45 75,57 105,50 1,2385,67 121,75 62,77 16,793,31	Additions during the vair	N-00-1+			-	10071
1,222.30 5.45 75.57 195.30 1,222.30 5.85 75.57 395.50 12,385.67 12.175 62.77 16,799.31	Balance as at 31 March 2020	14,107.98		138.34	18.595.11	31,202,24
1,222.30 5.45 75.57 195.80 1,222.30 5.83 75.57 195.80 1,238.67 22.75 62.77 16.799.31						
1,222.30 5,45 75.37 195.30 1,222.30 5,485 75.57 195.80 12,2985.67 121.75 62.77 16,799.31	Accumulated dependation				•	,
1,222.0 5.85 75.57 195.50 1,222.30 5.85 75.57 195.50 1,285.67 12.15 62.77 16,799.31	Balance as at 1 April 2019	3		· }	40° 00	1,100.53
1,223.9 5.85 75.57 395.90 12,385.67 121.75 62.77 16,799.31	Thomas for the rear	1,222,30		15.57	DO CAL	
12,895,67 121.75 62.77 16,799.31	Balance as at 31 March 2020	05.02.1	5.85	75.57	05.50	7,488.52
2,585,67 (21.75 62.77 15,775.31]						42.0/000
	Not North as at 31 March 2020	12,385.67		52.77	16,0931	22,007.2

• Till pervious year, lesschold hard and related jabilisies were recognised as 'famore lease' under Ind. AS 17 'Leases' Lesschold had was presented as part of property, plant and equipment and the liabilities as decision of the Company's bornowings. Bowere, moder ind. AS 116, there have been ransferred to right of the states and kine liabilities.

For early on adjustments recognised on adoption of 13d AS 116, there now 41.





Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

(₹ in lakhs)
Software
254.61
21.21
275.82
321.17
596.99
97,48
97,48
41,34
138.82
94.57
233,39
137.00
363.60





Standatono, summary of significant accounting policies and other expiratory information for the year ended it instead 2020	As at	An as
	31 March 2020 (7 In lakhs)	31 Morch 2019 (₹ In laktis)
	((-ID 18KDS) .	((In thrus)
Note n 8:		
Investments - non-ourrent	1	
(i) Investments in equity shares		
Subsidiary - unquoted		
Global Health Pathiputa Private Limited*	9,700,00	5,51x1.170
195,000,000 equity states (31 March 2019: 55,000,000 equity shares) of ₹ 10 exchi		
Medanta Holdinga Private Limited*	35,358.08	25,330.00
[6,54,07,228 equity shares (31 March 2019: 5,13,85,808 equity shares) of ₹ 10 each]		
folat venture - unquoted		
Medanta Duke Research Institute Private Limited#	98.100	901.80
[10,001 equity shares (31 March 2019: 10,001 equity shares) of \$ 10 each]		
	45,951.80	31,751,80
Loss : Impairment in the value of investments	(901.86)	(901.80)
Sub-total (A)	45,050.00	30,850.00
(II) Th' compulsorily convertible preference shares		
Subsidiary - vinquoted.		•
Medáník Höldlings:Pévsic LindicilS	\$ (000.00)	4,700.00
165,29,113 Flaires (31 March 2019: 7,230,769 shares) of \$ 10 each and 0.00001% componerate		
Sub-total (B)	5,000.00	4,700.00
Grand total (A+B)	50,050.00	35,550,00
Aggregate amount of unquoted investments (net)	50,050.00	35,350.00
Aggregate amount of impalment in the value of inventments	901.100	901.80
	•	

Hovesiment includes ₹ 200.00 lakhs, recognised on secount of trainfer of license obtained under Served from India Scheme.

#The Board of Directors (the Board) of Medana Duke Research Institute Private Limited (a Joint venture) in its meeting held on 19 June 2019 have resolved to commence the process of winding up of the aforementioned entity and thereafter, have initiated the process of voluntary liquidation in secondance with the provisions of the Institutery and Bankrupicy Code, 2016 read with Insolvency and Bankrupicy (Voluntary Liquidation) Regulations, 2017. This has also been affirmed by the shareholders in the Annual General Meeting (AGMT) of Medanta Duke Research Institute Private Liquida held on 2d September 2019.

SSubsequent to 31 March 2020, these lave been converted into equity shares.

Particulars of subsidiaries and joint venture as at 31 Mi	irch 2020 and 31 Mar	ch 2019.		
Particulara	Relationship	Ownership Interests	Principal place of	Accounted on
	1		business	
Medanta Duke Research Institute Private Limited	Joint venture	50,01%	Indix	Measured at cost as per Ind AS 27 Separate Pinancial
Medanta Holdings Private Lunited	Subsidiary	1(90,00%)	India	Statements'
Global Fealth Pathputer Private Limited	Subridiary	100,00%	India	orgicinano

1	4010	* ;	,	
4		٠	~~~	

Loans - non cuttent*

(Unsecured considered good) Security deposits

	1	596.13	548,36
B Loane convent			
(Unsecuted considered good)			
Security deposits		9.79	84.54
		0.70	Rd Kd

The Company does not have any loans which are other credit impaired or where there is significant increase in credit risk.

Note - 10

A Other financial assets a non-current

(Unsecured considered good)

Bank deposits with manning of more than 12 mouths

1,672,11 1,672.11



(This space but been intentionally left thank)



The second state of the second		
	Ax.nt 31 March 2020	As at 31 March 2019
	(Cin lakha)	(Cin laklıs)
B Other Anancial assets - current		
(Unsecured consistered good, unless otherwise stated) Recoverable from related parties (refer note 3b)	01040	aha//4
Unbilled revenue	250.19 598,69	222.93 1,082.11
Receivables under export benefit scheme#	1,452.03	530.20
Other receivables*	1,102.003	350,24
Considered goods	680.92	554.55
Considered doubtful	156.60	156.60
1:0ss: Allowance for expected credit loss	442.20	***
12.82 Substitute to talected escat tos	(136:60) 2,981.83	(136,60) 2;389,80
6 Other receivables are primarily on account of revenue alumny arrangements.	4/30/103	2,309,00
#Movement of receivables unider exputs benefit scheme		
Opening behance	530,30	478.22
Add: grants received during the year	530.30 1,149.68	1,050,35
Leve : grants transferred and sold during the year	(20(1,00)	(515.47)
Loss; grants expired during the year	,	(448.73)
Less: milised for purchase of property, plant and equipment/communables	(27.85)	(54.17)
	1,452.03	530,20
N	7	
Note - II Income-tax assets (set)		
Advance tax (net of provision for tax amounting to ₹ 38,087.00 lakly (31 March 2019; ₹ 53,169.19 lakly))	6.601.03	2 11411 14
Mountained from a factorial social vision mailing of all barron several 21 matter 2018, 4 32 from 18	6,584.03 6,584.03	5,939.47 5,939.47
·	0,584,03	0 ₁ 939,47
Movement in income-tax assets (net)		(T in lakhe)
Pattleulars	Å1.st	Asiat
0	31 March 2020	31 March 2019
Opening balance. Add: Taxes paid (nct)	5,939.47	4,359,18
Lest: Current lax junyable for the year	5,616.39	6,738.76
Closing balance	(4,971,83) 6,584,03	(5,158.47) 5,939.47
		2777771
Note - 12		
A Other non-correct greete		
Capital advances Advances other than capital advances:	8.10	9.38
Propaid expenses	4	
Halancea with government nothodities	68.72	212.62
	76.82	92.63
B. Other queent assats	·10102	314,63
Propaul expenses	394,61	607.06
Advance to material/service providers	227.01	183,29
Vigirance to etitipolicei	19.15	18.57
	640,77	808,92
Note • 13		
Inventories*		
Plannacy, medical and laboratory consumables		
	1 023 07	241224
General stores	3,033,07 192,55	2,212.31
	192,55	116.65
General stores « valued at equi or net realizable value, whichever is hower	192,55	116.65
General stores	192,55	116.65
General stores « valued at cult or net realizable value, whichever is lanver .Note - i4 Trade receivables.	192,55 3,225,62	116.65 2,328.96
General stores « valued at eqst or net realizable value, whichever is lawer . Note - 14.	192,55 3,225,62 16,392.47	116.65 2,328.96 18,506.81
General stores * valued at cost or net realizable value, whichever is lawer Note - 14. Trade receivables. Trade receivables - considered good, unsecured# Trade receivables - credit impaired	192,55 3,225,62	116.65 2,328.96 18,506.81 2,866.89
General stores * valued at cost or net realizable value, whichever is hower .Note = 14. Trade receivables. Trade receivables - considered good, unsecured# Trade receivables - credit impaired Logs: Allowance for expected credit loss	192,55 3,228,62 3,628,62 16,392,47 4,517,03	116.65 2,328.96 18,506.81
General stores * valued at cust or net realizable value, whichever is lancer .Note - 14. Trade receivables - considered good, unsecured# Trade receivables - credit impaired Logs Allowance for expected credit loss Trade receivables - considered good, unsecured	192,55 3,225,62 16,392,47 -4,517,03 20,909,50 (1,556,39)	116.65 2,328.96 18,506.81 2,866.89
General stores * valued at cust or net realizable value, whichever is lancer . Note = 14. Trade receivables. Trade receivables - considered good, unsecured# Trade receivables - credit impaired Logs Allowance for expected credit loss	192,55 3,225,62 16,392,47 4,517,03 20,909,50	116.65 2,328.96 18,506.81 2,866.89 21,373.76

th intermita, includes \$ 283.51 lakles (31 March 2019; \$ 247:30 lakles) receivables from related parties (refer note 38).





Star

andalone summuty of algorificant accounting policies and other explanatory information for the year enucu 31 M	Ax at 31 March 2020 (7 In Jakha)	Án at 31 March 2019 (Č la lakha)
Note - 15 Cath and cash equivalents Balance with banks in current accounts Chegues on hand Cach on hand Bank deposits with original manerity tess than three months	3,069.69 1.57 110.76 9,973.54 13,185.36	2,527.47 34.61 172.56 1,262.98 3,997.62
Note - 16 Other bank balances Back deposits with manning of more than three months and upto twelve months.	8,721.39 8,721.39	19,967.58 19,967.58

^{*}Dank deposits of \$ 775.98 lakin (31 March 2019; \$ 720.00) are pledged with bank against bank gustantees and inter of credit.

Note - 17 A	31 March 2	020:	31 Marc	
A Eguity share capital	Number	Amosint. (C-In Inkha)	Number	Amount (USn Jakha)
Chas A Biquity stares of \$ 10 each Chas B Equity shares of \$ 10 each	10,10,24,009 1,000	10,102.40 0.10 10,102.50	10,10,24,000 1,000	10,102.40 0.10 10,102.50
8 Issued, hithresibed and paid up Glass A Bijitiy blaces of \$10 each	4,93,45,003	4,934.50 4,934.50	4,93,32,778	4,913,28 4,913,28
III. Reconciliation of number of equity shares outstanding at the beginning and a Equity shares Balance at the beginning of the year	4,91,32,778	4,913,28	4,84,94,054	4,849,41
Aild: Issued during the year (on account of exercise of stack uptions). Balance at the end of the year	2,12,225 4,93,45,003	21.22 4,934.50	6,58,724 4,91,32,778	63.87 4,913.28

to Rights, preferences and restrictions attached to equity shares

The Company has two class of equity shares with face value of \$ 10 per share. In case of class A share, each holder of equity is entitled to two vote per share, in case of class B share, each holder of 650,000 share shall have voting power equivalent to one class A equity share.

The dividend proposed by the Build of Directors is subject to the approval of the shareholders in the cassing Annual General Meeting, except in case of interior dividend.

v Details of shareholder holding more than 5% of egulty share capital

Y	Tatillia of Sustanostat moinnig more itim to be of educations expense				
	Name of the early shareholder	Number	%	Number	94
	Dr. Neresh Trelmin	1,02,00,000	20.67%	1,02,00,000	20.76%
	Mr. Sunil Sachdovy foliatly with Mrs. Suman Sachdova	68,00,000	13.78%	68(00,000)	13.84%
	Dr. Naresh Trelian jointly with Mrs. Madhu Trelian	68,92,075	13.97%	68,92,075	(4.0,1%
	Dinesai Investments (Maunikus) 1913 kd.	86,01,979	17.43%	86,01,979	17.31%
	Ammi Investments	1,30,00,000	26.35%	1,50,00,000	26.46%

- vi Aggregate number and class of shares allotted as fully pold up pursuant to contract(s) without payment being received in each, by way of horus shares and shares hought back for the period of 5 years immediately preceding the balance sheet date
 - The Company-tild not itsue my shares pursuant in contract(s) without payment being received in eash. The Company did not issue bonus shares in preceding 5 years.

 - The Company has not undertaken one buy back of shares.

vil Shares reserved for lesue under options

For deally of shares reserved for issue under the Employee Stock Option Plan (ESOP) of the Company, refer note 43.





B Instruments cutledly equity in nature

		As at 31 March		As at 31 Murch:	2019
ļ	Authorized	Number	Amount (* In laklu)	Number	Amount (Tin lakhs)
	Compulsorily convertible preference shares (Class A) of \$ 694 each	4,66,954	3,250.00	4,64,954	3,250.00
		4,66,954	3,250,00	4,66,954	3,250,00
ii	Issued, subscribed and fully paid up Computernly convertible profession shares (Class A) of \$ 696 each	4,66,954	3,250.00	4,66,954	3,250.00
		4,66,954	.3,250.00	4,66,954	3,250.00

Ill lughts, preferences and restrictions attached to CCPS

These shares are consequentiative Class A computationly convertible preference shares being no equing rights and not entitled to vote together with the holders of equity shares of the Company and mandatorily equitled to thirdend @ 0.00001% of the face value per nature. The shares are non transferable except as permitted by an agreement between the Company and the holder thereof and prior written permission of the Frometers. The shares are conventible into Class A Equity Shares as per the events and conditions stated below:

	Conversion eyent*	Conversion ratio
1.	Ninetcenth anniversary of the issuance of the Class A Preference Shares	
	The date on which the Anant Investments owns fewer dish 6,650,000 Class A equity shares.	Once Class A cypicy whate for each Class A profesence shares
	The occurrence of a Qualified Initial Public Offer in the last date by which all convertible securities in the Company should be converted into equity shares in order for the Qualified Initial Poblic Offer to be permitted under Initian Law.	The same of the sa
1	The occurrence of an Initial Public Offer which is not a Qualified Initial Public Offer or the last date by which all convertible Securities in the Company should be converted into equity shares as permitted under applicable law.	Hach Class A preference share shall convert into the lower of (1) One Class A equity share; or (1) The following number of Class A equity shares = {((0.32 ° X)/Y) - X)/466,954 Where X = Torst number of equity shares owned by the hulder of the Class A preference shares immediately before conversion Y = Actual IPO Price

^{*}CCPS is classified as equity as the Company expects to have equity shares in the ratio of 1st on the occurrence of conversion event, the nature of which is controlled by the Company.

iv Reconciliation of number of CCPS outstanding at the beginning and at the end of the year

	As at 31 Morch 2020		As at: 31 March 2019	
	Vinimper	Amount (Cin inkha)	Number	Amount (€ in iakha)
listance at the beginning and at the end of the year	4,66,954	3,250.00	4,66,954	3,250,00
Details of shareholder holding more than 5% of CCPS				
Name of the equity threeholder	Number	%	Number	*/4
Anant Investments	4,66,954	100,60%	4,66,954	100.009
			As at 31 March 2020	As at 31 March 2019
Note - 18		_	(Cin likhs)	(Cin lakina)
Other equity			V	
Sociaties premium			47,000,87	45,519.15
State options outstanding account			4,843.45	5,168,20
Betained camings			82,233.43	72,123,08
Capital reserve			20.00	20.00
Nature and purpose of other reserves			1,34,087,75	1,23,030.43

Securities premium

Securities premium is used to record the premium on issue of shares. This balance can be utilised in accordance with provisions of the Companies Act, 2013.

Share options outstanding account

This account is used to recognised the grant date fair value of the options issued to employees under the Company's employee stock option plan.

Retained earnings is used to record balance of statement of profit and loss.

Capital reserve

Capital reserve represents difference between share capital of transferor entity and share capital issued to cretivide shareholders of transferor entity.





Standalone summary of algulficant accounting policies and other explanatory information for the year ended 31 Merch 2020

and allowers and the state of t	As-st 31 March 2020	An at 31 March 2019
	(₹ in lakhs)	(t in laklis)
Note + 19		
Dorrowligs - non-current		
Secured loans		
Term loans		
(From banks (refer nute (h) below)	•	1,566.19
Loss: current manufiller of long-term borrowings	·	(794.63) 771.55
•		111.00
Yehlete-lowns		
Prom insucial institution (refer note (b) below)	140.02	179.27
Less; cutrent manufiles of long-term horrowings.	(43.69)	(39,26)
	96,33	140.02
Long-term maturity of finance lease obligation (refer note (e) below)		8,574.81
Deferred payment liabilities (refer note (d) below)	1,711.51	1,988.50
interest hybridia nyminos front nose fol occurs	1,807.84	11,474,88

Repayment terms (lucinding current maturities) and security details for term loan from banks:

Repayment terms (including cuttens includines) and security details for term tone, from Danisa;

(a) (b) First charge on the hospital project land of 25 acres, current asserts, eash, raw interials, sent finished goods, stores and spares including relating to plant and strachinery (consumable stores and spaces), bills receivables, whether dictionarisacy or clean, and book debta, all bank accounts, (including the tenst and retention accounts) and all other seceivables and monables, including anapible and intengible asserts, both present and future, whether histabled or not and whether lying loss or in cases or which are lying at various sites or any of the Company's premises, warelengers, stockyonis and godowns or those of the Company's agents, affiliates, associates or representatives or places wherever the situated or any time belonging to the Company.

(ii) Reposable in 32 equal quarterly instalment beginning from 30 June 2015.

(iii) Interest will be poid monthly at an agreed rate of MCLR+0.35% with both the banks.

(iv) During the year ended 31 March 2020, the Company has made the full payment against outstanding term loan balance.

- (b) During the previous year, the Company has availed vehicle loss of \$211.75 laklis from Dainiler Financial Services India Private Limited which carries as interest at 10.75% per assumption of hypothecation on vehicle purchased. The loss is repayable in 48 monthly installments continuencing from 14 May 2018.
- (c) This represent the present value of future least liability (inclusive of fixed consideration) for the lang-term land least agreement which the Company has entered with New Okhia Industrial Development Authority (Nolds). For the fixed consideration, Nolds authority has agreed installment, payments. The fixed consideration of the finance lease obligation is payable in 16 equal liality-early installments beginning 14 November 2015 along with interest at 11% presentation compounded final yearly. In the current year, this has been classified as lease liabilities on implementation of Ind AS 116. Refer note 20.
- (d) This represents limitity for medical equipment purchased on deferred payment terms.

	niaciaci as follows:		Minney and	(Tin Inklu) Total
Particulars	Borrowing Non-current*	gs: Corrent:	Pinance coall!	10(4)
	2,367,56	2,540,12		4,907,68
L April 2018	***************************************	P ⁽ 240)42		drusten
Carla Rows:			290.98	290,98
-Interest expense	}8.56	•	(18.86)	270,71
Non-costs adjustments	(640.96)	(2,540.12)	(272.12)	(3,453.19
Payments made (not)	1,745:46	(2,030.12)	(2,2,12)	1,745.40
31 March 2019	1,745,40	•	•	1314040
Cash flows:			110.20	110.20
Interest expense	27,10	•	(27.10)	110/20
Mon-cesh adjustments		•	(83.10)	(1,715.6
- Payments made (uri) 31 March 2020	(1,632,54)		(03.10)	140.0
*This includes current maturities of non-current borrowings.				
			31 March 2020	31 March 2019
		***	(Clastaklis)	31 Match 2019 (Cla lakbs)
Note + 20				
The state of the s				
Note + 20 Legge liablitles = non-current Legge liablitles (refer note 41)				
Legge linbilities enon-current			(7 In laklis)	
Legge Habilities enon-curreint Legge Habilities (refer note 41)			(Clariaklia) 19,439.64	
Legge liabilities «non-curreint Legge liabilities (refer none 41) Legge liabilities » current			(T fa: laklie) 19;439:64 19;439:64	
Legge liabilities «non-current Legge liabilities (refer note 41)			(7 fa: fakfie) 19,439,64 19,439,64 3,282,38	
Legge liabilities «non-curreint Legge liabilities (refer none 41) Legge liabilities » current			(T fa: laklie) 19;439:64 19;439:64	
Legge liabilities «non-curreint Legge liabilities (refer none 41) Legge liabilities » current	ce can be classified as follows:		(7 fa: fakfie) 19,439,64 19,439,64 3,282,38	(Cin lakhs)
Legge Habilities «non-curreint Legge Habilities (refer note 41) Legge Habilities » current Legge Habilities (refer note 41)	es can be classified as follows:		(7 fa: fakfie) 19,439,64 19,439,64 3,282,38	(Cin lakhs)
Lease liabilities - non-current Lease liabilities (refer note 41) Lonse liabilities - current Lease liabilities (refer note 41) The changes in the Company's lease liabilities arising from financing activity	ce can he classified as follows:		(7 fa: fakfie) 19,439,64 19,439,64 3,282,38	(Cin lakhs)
Legge Habilities - mon-current Legge Habilities (refer note 41) Logge Habilities - current Legge Habilities (refer note 41) The changes in the Company's legge Habilities mixing from financing action Particulars	ce can be classified as followe:		(7 fa: fakfie) 19,439,64 19,439,64 3,282,38	(C.in lakhs) (C.in lakhs) (C.in lakhs)
Lease liabilities - mon-current Lease liabilities (refer note 41) Lease liabilities - current Lease liabilities (refer note 41) The changes in the Company's lease liabilities arising from financing activit Particulars Loase liabilities as at 1 April 2019 (current and non-corrent)	ce can he classified as follows:		(7 fa: fakfie) 19,439,64 19,439,64 3,282,38	(K.in lakhs) (K.in lakh 20,059, 4,063, 2,455.
Lease liabilities - mon-current Lease liabilities (refer note 41) Lease liabilities - current Lease liabilities (refer note 41) The changes in the Company's lease liabilities mixing from financing activit Particulars Lease liabilities as at 1 April 2019 (current and non-current) Additions	es can be classified as follows:		(7 fa: fakfie) 19,439,64 19,439,64 3,282,38	(C.in lakhs) (C.in lakhs) (C.in lakhs) (C.in lakhs)





	As at 31 March 2020	As at 31 Murch 2019
	(E in inkhe)	(t in taklis)
Note - 21		•
1. Provisions - non-current		
Praxision for employee benefits:		
Gmnúty (refer note 42)	2,240.69	1,797.8
Compensated observers	1,286.84	1,097.2
Provision for contingencies# (refer 1816-6) below)	681.14	•
	4,211.97	2,875.0
#Mavement of provision for contingencies		
Opening balance	,	
Add: provision made during the year	9K4~4	
Less: amount utilised charing the year		
	G84.44	·
Note	CT THE COUNTY OF	
The provision for contingenties pertains to the estimate of the present probable obligation of each multi- owing to the current pandemic situation and ongoing discussions with the authority, the numagement is or actilement.	ow towards delay in completion of the under const recitable of the idening and amount of the aforement	nation facility. However ioned outline required
Provisions - current		
Provision for employee benefits:		
Gratisity (refer note 42)	574.87	\$93,2
Compensaed abrences	293.39	354.7
	868.26	0.000

868.26 949.98 Note - 22 Deferred tax linbilities (net) Deferred tax liabilities arising on account of: Property, plant and equipment and intangible assets 4,793.85 7,336.40 Deferred tax samets arising on account of: Impairment in value of inverturents (210.08) (1,343.62) l'imployee benefits (1,106.33) Expected credit luss on trade and other receivables (1,561.43) (1,731.76) (816.17) Interest cost and leave payments related to leavebold land (1,146.26) (210.2H) 3,024.49 (168.46) 811.37

Movement in eleferred tax liabilities (net) As nt 1 April 2018 (n) Recognised in Recognised in other Assit profit and loss comprehensive income 31 March 2019 (c) (a+b-c) (b) Difference between written down value of property, plant and equipment and intemplific 7,971.66 (635,26) 7,336.10 assets as per books and Income tax act Aszets Impainment in value of investments (210.08) (210.08) (1,471.64) (1,139.36) (341.37) (211.69) 4,807.56 Employee bestefits 110.92 17,12 (1,343.62) Expected credit loss on trade and other receivables (592.40) (1,731.76) Interest cost and leave payments related to leaveluid land (474.80) 1.41 (1,800.21) (816.17) (310.2k) 17,12 3,024.49

Pacticulars	As at 1 April 2019 (n+b-c)	Recognised in statement of profit and loss (b)	Recognised in other comprehensive income (c)	As at 31 Minich 2020 (a+b-c)
Lighilities		, , , , , , , , , , , , , , , , , , , ,		······································
Difference between written down value of property, plant and equipment and intangible assets as per books and leacome (ax act	7,336.40	(3,542.55)	-	4,793.85
Vzecte	İ			
Impairment in value of investments	(210,08)	216.08	_	_
Panjilajee benefits	(1,343.62)	296.25	(\$8,97)	(1,106.33)
Expected credit loss on texte and other receivables	(1,731.76)	178.33		(1,561,43)
Interest cost and lease payments related to finance lease obligations	(816.17)	(330.09)		(1,146.26)
Others	(210.28)	,		(168.46)
Total	3,024.49	(2,154,15)	(58,97)	811,37

1401C - V2
Other non-current liabilities
District and property and agents

* Deferred government grant		
Opening balance		
Grants received during the year		
Less: Grams expired during the year	ar	
Less : Released to statement of pao	fit or loss CHAI	NDIOR
Classified into	(4)	10
Non-current portion	[3]	`
Correst parties	≩	

			1,886.47	2,2x3.56
			1,886,47	2,283.56
			2,685.75	3,551.15
			1,149.68	1,050.35
				(448.72)
	1010		(1,551.44)	(1,467,03)
Chhi	IDION & CO		2,283.99	2,685.75
	\ <u>F</u>		1,886.47	2,283.56
ŧ	$\{\alpha'\}$		397.52	402.19
	/ <u>\$</u> /	٨	2,283.99	2,685.75
/		()		,



Standalone summary of eignificant accounting policies and other explanatory information for the year ended 31 March 2020		
	An et 31 Merch 2020	As at 31 March 2019
•••	(Cin lakha)	(t in lakha)
B. Other current Habbittee		
Payable to anatory authorities	1,309.55	1,983,82
Advance from customers	2,091.25	1,609.61
Deferred government grants	397.52	102.19
Orler fabilities -	101:28	9R.57
	3,899.60	4,094.19
Note - 24		
Trade phyables		
A Total mitstanding diex of micro emergrises and small enterprises	1,645.35	444.56
X Controlletioning divisity includes with street division of the controlletion of the control	1,643.35	444,56
Particulars -	31 March 2020	31 March 2019
	(Cin Inkha)	(7 in inkhe)
A like principal emount and the inferest due thereon tensining papard to any supplier as at the end of each accounting year;	(C.in Inkha) 1,643.35	(7 in Inkhe) 444,56
ilite principal amount and the interest due thereon tensiting unpaid to any supplier as at the end of each accounting year; it is amount of interest paid by the buyer-in-terms of section 16, along with the amounts of the payment made to the supplier lisyonit the appointed day thoing each accounting year;		
 ilie principal amount and the interest due thereon termining unpaid to any supplier as at the end of each accounting year; ii) the amount of interest paid by the buyer in terms of section 16, along will the amounts of the payment made to the supplier lieyoust the appointed day during each accounting year; iii) the amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the 		
i) like principal amount and the interest due thereon tensining unpaid to any supplier as at the end of each accounting year; ii) the amount of interest paid by the buyer in terms of section 16, along with the amounts of the payment smale to the supplier lievent the appointed day during each accounting year; iii) the amount of interest the and payable for the present of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under this Act;	1,643.35	444.56
i) like principal amount and the interest due thereon remaining suspaid to any supplier as at the end of each accounting year; ii) the amount of interest paid by the buyer in terms of section 16, along will the amounts of the payment made to the supplier lisyonal the appointed day during each accounting year; iii) the amount of interest due and payable for she period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under this Art. iv) the amount of interest secretal and remaining unpaid at the coil of each accounting year; and	1,043.35	414,56
i) like principal amount and the interest due thereon tensining unpaid to any supplier as at the end of each accounting year; ii) the amount of interest paid by the buyer in terms of section 16, along with the amounts of the payment smale to the supplier lievent the appointed day during each accounting year; iii) the amount of interest the and payable for the present of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under this Act;	1,043.35	414,56
i) the principal amount and the interest due thereon remaining unpaid to any supplier as at the end of each accounting year; ii) the amount of interest paid by the buyer in terms of section 16, along with the amounts of the payment made to the supplier lieyond the appointed day during each accounting year; iii) the amount of interest this and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under this Art. iv) the amount of interest account and remaining unpaid at the coil of each accounting year; and	1,043.35	444.56
i) the principal amount and the interest due thereon temaining unpaid to any supplier as at the end of each accounting year; ii) the amount of interest paid by the buyer in terms of section 16, along with the amounts of the payment made to the supplier lieyond the appointed day during each accounting year; iii) the amount of interest the anid payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under this Act; iv) the amount of interest secured and remaining unpaid at the end of each accounting year; and it the amount of further interest termsining due and payable even in the succeeding years, until such date when the interest dues in above are actually paid to the small enterprise; for the purpose of disallowance as a deductible expenditure under section 25,	1,643.35	1.57 As nt
i) the amount of interest the interest due thereon tensining unpaid to any supplier as at the end of each accounting year; ii) the amount of interest paid by the buyer in terms of section 16, along with the amounts of the payment made to the supplier lies on the appointed day during each accounting year; iii) the amount of interest this and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under this continue to the payment and remaining unpaid at the end of each accounting year; and the amount of further interest termsining due and payable even in the succeeding years, until and date when the interest dues as above are acasally paid to the small enterprise; for the purpose of disallowance as a deductible expenditure under section 25. B. Total outstanding dues of exclitors other than intere enterprises and small enterprises.	1,643.35	1.57 As nt
i) the principal amount and the interest due thereon remaining unpaid to any supplier as at the end of each accounting year; ii) the amount of interest paid by the buyer in terms of section 16, along with the amounts of the payment made to the supplier lieyons the appointed day during each accounting year; iii) the amount of interest the and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under this Act; iv) the amount of further interest certaining due and payable even in the succeeding year; until such date when the interest dues in above are actually paid to the small enterprine; for the purpose of disallowance as a deductible expenditure under section 25,	1,643.35 54.41 54.41 As av 31 briarch 2020	444.56 1.57 As at 31 Merch 2019

	31 March 2020	31 Máich 2019
B Total outstanding dues of excelliors office than intern enterprises and small enterprises.		· · · · · · · · · · · · · · · · · · ·
Dire to related parties (refer unte 38)	211.00	187.00
Due to offices	9,949,23	11,998.51
Windows III	10,160.25	12,185,51
Note × 23.		
Other financial flabilities - current		
Current restrictive of from correct borrowings		794.63
Current maturities of vehicle lunus	43.69	59.26
Current materities of finance lease obligations	•	1,248.30
Interest accented	185.11	547.51
Capital conditions	1,174.55	1,105.89
Security deposit received	5,50	5,50
Brinloyee related payables	4,08\$.05	5,503.01
Amount psyable to related party (refer oute 38)	12.92	
	5,506,60	7,244.10

^{*} Till previous year, leasthold land and related Sabilities were recognised as finance leases under Ind AS 17 Leases. Leasthold land was presented as part of property, plant and equipment, and the liabilities as deferred payment inbilities as part of the Company's borrowings (being current portion presented under other financial liabilities). However, under Ind AS 116, there have been transfeired to right of use assets and lease liabilities.



	Por the year ended 31 March 2020	Portite year ended 31 Murch 2019
	(tin laklis)	(t in Jakha)
Note - 26 Revenue from operations		
Sucome from Siestificate aerosces		
In patient	1,17,078.44	1,16,817.36
Out padent	28,214.27	26,873.98
Other operating revenue		
Clinical research income	186.82	251.33
Other operating revenue	177.65	17H.55
	1,45,657.18	1,44,113.22
Note - 27		
Other Lucome		
Interest inclinic on bank deposit	1,869.41	1,823.35
Interest income on other financial assets measured at amortised cost	17,60	19.(x)
Rental income	158.33	134.61
Access provision written back	*	787.61
Porcigie exchange - gain (net) Sponsurality tatamis	85.75	
Government grante income	733.55	645.99
Revenue diane from fond court	1,551.44 258.92	1,367,03 274,11
Recense share from pharmacy	768,61	733,14
Alicedianemus income	485.72	\$81.10
	5,905.33	6,466.94
	· · · · · · · · · · · · · · · · · · ·	(272777770017727777777777777777777777777
Note - 28		
Cost of materials consumed		
Pharmacy, Medical and Lab consumables		
Opening stock Add: Purchases (includes priverament assistance of ₹ 27.85 faktor (31 March 2019; ₹ 34.17 faktor))	2,212.31	2,091.01
Then Closing stock green interference assurance of \$ 27.83 (1881) (3) Airen 2019; \$ 34.17 (1881)	52,192.73	32,915.06
Materials consumed	(3,033,07)	(2,2)2.31)
	31,511.77	31,893.76
General atores		
Opening nock	116.65	181.68
Add: Parclares	624.59	\$32.98
Less: Chuing stock	(192.55)	(116.65)
Materials consumed	548.69	597.93
•	**************************************	
	31,920,66	32,491.69
Note - 29		
Employee henefits expense		
Salarier and wages"	49,213.36	19,881.77
Contribution to provident with other funds	1,926.86	1,514,14
Sight willare expenses	132.94	69.69
Hipphayee share based payment expense	956.97	2,603,07
	52,230.13	54,071.67
"This includes ralary expense of employees muching for research and development amounting to ₹99.29 faklit (31 March	(2019: ₹ 127.77.lakha)	
Note - 10		
Planace costs		
Justiest on form Joshie	92.63	211.00
interest on vehicle loans	17.37	19.43
Interest on buyers exchit/supplier's exchit	*	30.55
Interest on leave liabilities	2,415.16	1,698.07
futerest on deferred psymeat liabilities	185.68	144.10
Cities bosserving costs	59.41	1,57
,	2,765.45	1,654.72
Note -31 Depreciation and amortisation capease	*	, ,
Depreciation of property, plant and equipment	110/504	
Debreckfing on right at new reset.	8,262.73 1,499.52	9,027.58
Amostisation of intanghile assets	94.57	41.54
	9,856.82	9,068,92
	7,000	7,000,72



(Visit speec has been tetentionally left blank)



1000

Global Health Private Limited Standalone summers of similar ding policies and other explanatory information for the year ended 31 March 2020.

tandalone summary of significant accounting policies and other explanatory. Information for the year ended 31 March 2020.	For the year ended 31 March 2020	Par the year ended 31 March 2019
	(₹ in lakfit)	((in lakita)
Note • 37	•	
Impairment losses on financial ossess		
Expected credit lux on trade receivables	1,113.61	1,800.22
•	1,111.61	1,800.22
Note - 33		
Other expenses		
Power and fuel	5,110,54	3,004.58
Losse ront i		4 44 14 4 4 11
Prendres:	88.40	1,706.86
Vehiclei	43.60	196.78
Rquipmonts	3,781,32	4,306309
Replits and insintensure:		
liquipment	3,877.35	3,255.82
Office	385.45	340.75
Dailding	218.81	296.16
Rates and faces:	152.62	180.11
Recruitment expentes	185,81	144.21
Томпансо	153.31	148.30
Travelling and conveyance	808.54°	\$K818
Cohumnication expenses	275,417	229.52
Auftren Annuar Anthre		
Statutory and is feer (including taxes)	54.26	58.94
Reinthursement of expenses (including taxes)	2.21	5'48
Padity expenses	1,522.15	1,851.35
Laundy expenses	343.04	377.13
Scauthy expenses	987.81	4,017.53
Pacility distinguishent expenses	4,144.68	4,114.98
Advertisement and rates printiple.	329.65	નહત.43
Research and development expenses	1.23	2,99
Outgoined services	963,60	939.81
Legal and professional (including facilitation fees)	16,074.32	£4,509.64
Printing and stationery	564.55	633.55
Subscription and momberable charges	110.68	30.29
Companie sucial responsibility expenses (refer note () below)	224,88	134.63
Directors' sitting fees	1.18	5.54
Bankschanger	488,29	458.60
Foreign exchange - loss (not)	-	226.23
Loss on sale of properly plan and equipment (net)	9.65	FR,52
Travel, horaling and other related expenses for conferences	SH7:49	775.38
Impalment In the value of investments		901,60
Miscellancous expenses	987.97	676.42
	40,584,50	41,842.85

[&]quot;This is professional fees incurred for research and development work.

(I) Corporate social desponsibility expenses
Gross amount required to be spirit by the Company during the year is \$.107.15 (31 Abrel) 2019; \$ 280.18 laking.
Amount spent during the year on corporate social responsibility (CSR) : \$ 224.88 (31 March 2019; \$ 124.11 laking. This includes \$.127.28 laking towards personnel core and related administrative overheads which were in excess of 5% of total CSR expenditure of the Company as permitted by the Companies (Corporate Social Responsibility Policy). Itides, 2014, as antended.

Particular s	Year	in seeh	Yet to be paid in cash	T'oini
Construction/acquisition of any stact	31 March 2020 31 March 2019		<u></u>	
On purposes other than above	31 March 2020 31 March 2019	. 224.8K		274,88 124,11



(This space best been intentionally loft bisnk)



andatone stimmary of significant accounting policies and direct explinitality still transfer for the year entire 22 policies 2200	For the year ended 51 March 2020 (Cln lakks)	For the year ended 31 Maich 2019 (K in lakhr)
Note - 34		
Tax expenses		
Current lax	4,971.83	5,158.47
Deferred par eredit.	(2,154,15)	(1,800.21)
Tax expense recognised in the statement of profit and loss	2,817.68	3,358.26

The Company has elected to exercise the option pramited under rection 115DAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognized provision for income-tax for the year ended 31 March 2020 and re-measured in deferred tax assets/liabilities basis the rate prescribed in the aforesaid

The major components of the reconciliation of expected far expense based on the domestic effective tax rate of the Company at 25,168% and the reported tax expense in the statement of profit and loss are as follows:

Accounting profit before Income tax 13,095,34	9,652.05
At statistics factorist tax rate of 25,168% (3) March 2019; 34,94%) 5.295,35	3,372.81
Tax effect of amounts which are not deductible (taxable) in calculating taxable income:	
	14.65.445
Tax impact of standing distinction allowed as per Income tax Act, 1961 under the head income from 'House Property' (89.98)	(122.81)
Tax impact of expenses which will never be illowed under tricume tax Act, 1961 242.55	73.04
Tax impact on impainment is value of investments 210.08	105.06
Tax impact un accumit of change in income tax rate (904.85)	(28.07)
This implace his everpost of endier years	(54.02)
Offices C4.55	12.25
Tax expense 2,817.68	3,358,26

Note - 35 Bandings per share (RPS)

Earnings per share (1985) is determined based on the net profit attributable to the charlestolders. Darke carnings per share is computed using the weighted average number of charce-countries and distribute common equivalent strates outstanding the year, succept where the result would be antidibuted.

	31 March 2020	31 March 2019
Profit arribumble to equity that chalders for basic and aloned HPS!	10,275.66	6,293.79
Weighted average mumber of equity shates for basic BPSP [Affect of chimion - weights sevenge mumber of potential equity shates an account of employee stack options? [Weighted average mumber of equity shates adjusted for the effect of dilution	5,00,51,022 2,60,957 5,03,11,979	4,97,97,109 :5,08,647 \$,03,05,727
Estalogs per equity shate		
Basic	20.53	12.64
4Diluted	20.42	12.51

"The Company had issued compulsorily convertible preference shares which are expected to be converted into equity disses in the ratio of 1st and considered in calculation of havic carning per

"Share options (anvested) under the ISOP Plan 2014 and ISOP Plan 2016 are considered to be potential equity shares. They have been included in the determination of distred earnings pershare to the extent to which they are diffusive.



Standalone summary of alguliteant accounting policies and other captanetory information for the year ended 31 March 2028

Pair value disclosures

The following explains the judgements and estimates made in determining the foir values of the financial instruments that neo recognised and measured at fair value. To provide an indication about the fellowing explains the inputs used in determining fife value, the Company has classified in floated finite tental into the three feech prescribed moder the accounting standard. (f) Pair Yalue hierarchy

Level is usuated prices (unadjusted) in active markets for financial instruments

Level 2: inputs other than quated prices included within Level 1 that one observable for the asset or liability, either directly or indirectly Level 3: unabservable inputs for the asset or liability.

Valuation recliniques used to determine fair value

The fair value of the financial parets and liabilities are included at the amount that would be received to sell an arret and paid to transfer a liability in an orderly transaction between market participants. The following methods were used to estimate the fair vehicus

- Praise receivabler, cash and each equivalents, onlice loack balances, loans, other current financial muces, trade payabler and other current financial liabilities Approximate their energing amounts

In part of the front form materials of these introments.

Bostowings taken by the Company are as per the Company's credit and liquidity risk assessment and shere is no comparable instrument having the similar terms and conditions with related security being pletiged and hence the corrying value of the horrowings represents the best estimate of fair value.

(ii) Pale value of arreis and liabilities which are measured at amouland cost for which fair value are disclosed

(Kin lakha)

IJ,	PAI VAINE OF SERVE FIRE COUNTY WATER SEC. STATES	A+ 21.31 A	Arch 2026	A 15.20 aA.	Arch 2019
	Particulara	Carrying value	Pair value	Carrying value	Fair value
	Pinancial nascis	1,05:93	603.93	632.98	632.90
	Trade receivables Casts and cush equivalents	14,642.08 (3,135.36	13,155.36	16,417.89 3,997.62	16,417.89 3,997.62
	Other bank halances	8,721.39 8,653.94	8,721,39 4,655,94	19,967.58. 1,859.59	19,967,58 1,859,59
	Other Anancial assets Total Anancial assets	41,978.70	41,978.70 1,851.54	42,878,58 13,357,07	42,875,58 53,557,07
	Norrowings (including covern) maturities of long-term horrowings) Leans liabilities	1,851.54 27,722.01	22,722.01	,	
	Trade papables Other financial liabilities (excluding current manuface of large corm borrowings)	11,803.58 5,462.91	11,803,58, 5,462,91	12,630,07 5,561,95	12,630.07 5,161.91
	Total fluencial italifica	41,810,04	41,840,04	31,349.05	31,349.05

Financial cisk management

(i) Pinancial instruments by entegory*#		(E in Inkhis)
(i) Principle instruments by Chegory 7	Athor	liren cost
Particulars	As at 31 March 2020	As at 31 Moreh 2019
Financial nects	603.93	63290
Lans	11:1142.08	,
Tride receivables	13,155,37	,
Cathonic cash equivalents	1	1 '' 1
Other frank Indones	8,721.35	1
Other funnicid rivers	4,653.9	
Total financial assets	41,978,70	42,875,58
Pinancial Babilitie		
Homewings (including current magazities of non-current homewings)	1,851.5	
Leave lightifries	22,722.0	1
Trade payables	11,803.50	
Other financial liabilities (excluding entrent maturities of two-current burrowings)	5,462.9	
Total financial liabilities	41,840.0	31,349.03

There are no financial orien and liabilities which are subsequently incorred at fair value.

Mineraturents in suinidiaries and joint venture is measured at cost as per Jud AS 27 Separate Parancial Statements.

(ii) Risk management

The Company's seticities expose it to market risk (foreign exchange and interest risk), liquidity risk and credit risk. The Company's board of directors has overall responsibility for the establishment and overlight at the Company's risk insurgences for risk and responsed to risk the only manager the risk and the related impact is the financial establishment.

Riek	Exposure origing from	Meanirement	Monagement
Credit rick	Logars, lende receivaldes, crob and east equivalents adher bank hadnees and other financial assets measured at amounised cost		Diversification of bank deposits and credit limits and regular monitoring and follow ups
Liquidity risk	Horrowings, trade justifies and other financial		Acadability of committed credit lines and borrowing facilities
Market risk – forelyn exchange	Future commercial insusactions, recognised financia assets and liabilities not denominated in India tupee		
Market rick - interest rate	Long-teem Isorrowings at yariable rates	Sensitivity analysis	Dirersifeation of horeowngs

(n) Ceedit riek

Oredit risk is the risk of financial loss to the Company if a continuer or counterparty to a financial asset fails to meet its contractual obligations. The Company's exposure to credit risk is influenced mainly by the individual climateristics of each funancial asset. The comping amounts of financial assets represent the maximum credit risk exposure.

A default on a fundacial over it when the counterparty fails to make contracted payment or per regreed terms. This definition of default is determined by considering the bosiness environment in which entity operates and other macro-reconomic factors.

The Company has a credit risk management policy in place to limit eredit lustes due to non-performance of counterparties. The Company monitors in exponence to credit risk on an ongoing basis.

Arrests are written off when there is no remonthly expectation of recovery. Where load and receivables are written off, the Company combines to engage in enforcement network to attempt to recover the dues.

The Company closely monitors the credit worthiness of the receivables through intensi systems that we configured to define credit limits of customers, thereby, leming the credit rat, to precalculated minimum. The Company area a simplified approach difference special credit line model) for the purpose of computation of expected credit has for inside receivables. Expected credit lines are measured on collective have for each of the formal handless.

PED ACCOUNT



or accounting policies and other explanatory information for the year ended 31 Much 2020

Caregory	Inputs for measurement of expected credit	Assumptions .
Government	Information on deductions under by government agencies in partycam	Thate excitables outstanding for more than two years are comidered kneedownlike. Altowarde for expected credit lins on receivebles outstanding for less than two years is recognised listed on expected deductions by government agencies.
Nos-poveriment		
finlmiduals	Individual customer wise trade receivables and information obtained durangle sales receivery follow ups	Trade receivables outstanding for more than two pears are considered inventorable. Other receivables say considered good that to engoing communication with continuous.
Corporates	years	Yeard of eatherting mode by the Company over a period of five years preceding halance shret date and completing default to have occurred if receivables are not collected for more than two years.
	year	Trade receivables outstanding for more than two years are considered irrecoverable. Absume, for expected credit loss on receivables emistanding for less than two years is recognised based on expected deductions by third party administrators.
Othery	Customer wise trade receivables and information admined through sales recovery follow ups	Specific allowance is made by an ensing party wise mursaiding receivables based on communication between sales team and customers.

Credit risk related to each and each equivalents and book deposits is managed by only accepting highly rated banks and financial institutions and diversifying bank deposits and accounts in different banks. Credit risk is considered low because the Campany deals with highly ested banks and financial institution.

Locus and other floated dittle

Loans and other financial actes areasured at unustical cost includes recordy deposits and other receivables. Credit tilk soluted to these financial actes is managed by monitoring the recoverability of such monitoring tile recoverability of such monitoring tile recoverability of such monitoring tile recoverability of such monitoring tile in the same time internal control system are the place squares the monitoring defined limits. Credit tilk is considered low-lecture due Company is in protection of the underlying actes (in case of according the point) or as per trade experience (in case of according to the place experience (in case of according to the place experience (in case of according to the underlying actes from some thating aroangoments). Periller, the Company creates provision by accessing individual financial asset for expectation of any credit loss that is 12 month expected credit loss model.

II) Constitution of Insk political parties in the Company's automatical parties in th

(b) Credit risk exposure.

1) Tapected credit fors for sinde receivables under simplified approach i.e. provision mairis approach using historical trends.

As at 31 Minisch 2020	iv nivor memov učilo	ozen arag zaroni	H, USINIA			(f in lakire)
Particulars	Government		Non-government			
		Individuals	Corporatee	Third party administrators of instrance companies	Others	'Cotal
Grans conging value	12,625.89	993.14	1,713.77	4,237.04	8,339.66	20,909,50
Lers: Expected credit loss (impairment)	3,067.15	641.01	794.48	777,80	786.98	6,067.42
Carrying amount (not of impairment)	9,558,74	352.13	919.29	3,459,24	352.68	14,842.08

As at 31 March 2019 Paulculate	Government			Non-government		(C in lakite)
		Individuals	Corporates	Third party, administrators of insurence companies.	Others	Foirl
Gross earrying value .	14,578.15	656,61	1,546.36	3,403.36	1,189.22	21,373.70
Lean Hapected credit loss (impairment)	3,223,35	443/17	384.73	467.69	432,87	₹,9\$5.H1
Corrige amount free of lunulement	11.354.80	213.74	3.157.63	2,935,67	756.55	16.317.89

11) Expected credit losses for other financial assets (massived at an amount equal to 12 months expected credit losses)

As at 31 March 2020	4		(ribiat ni 5)
Párticuláss	Relimeted gross corrying amount at default	Bapected credit losses	Carrying amount net of impairment junishing
losus	605.93		645.93
Corli unit ciuli escrivatrati	13,155.36		13,155.36
Other bank balances	8,721.39	••	8,721.39
Other financial arrets	4,790,54	136.60	4,653.91

As at 31 hiarch 2019			(f in lakha)
Particulars	Bulmuted gross corrying amount at default	Bupocied ciedli inssec	Cataging amount net of Impairment provision
LONG	632.90	*	632.90
Cash and cash educatems	3,997,62		1,997,62
Other bank balances	19,967.58	,	19,967,58
Other financial assets	1,996.19	136.60	1,659.59

	, , , , , , , , , , , , , , , , , , ,	·	
111)			(t in laklis)
	Reconsiliation of loss alluwance	Other fluencial	l'rade receivables
		setete	
	Loss afluwance on I April 2018	13679	3,155.59
	Allowance for expected credit loss	-	1,800.22
	Loss allowance on 31 March 2019.	136,60	4,955.83

Allowance for expected credit loss

Loss allowance on 31 March 2020

The fort allowance on grown trade receivables has changed due to increase in gross earlying amount and change in expected recovery rates.



Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

(b) Liquidity elek

Explicitly risk is the risk that the Company will encounter difficulty in meeting the obliquious associated with its financial Kabilities that are settled by delivering easts or another financial assoc. The Company's approach to annuaging logidity is to encourse as far in possible, that it will have sufficient liquidity to meet its liabilities when they are due.

The Company maintains flexibility in fourting by makedding availability under committed credit lines. Management monlines the Company's liquidity position (comprising the undersent horsewing facilities below) and costs equivalents on the basis of expected each times.

The Company takes into account the liquidity of the market in which the only operates.

The following are the remaining contractual materities of fusacial licibility at the reporting date. The amounts are gross and undirenseted, and include contractual interest payments and exclude the impact of needing agreements.

· · · · · · · · · · · · · · · · · · ·				() 40 12-31-21
4/2/ (00)	Lers than I year	1-3 years	More than 3 years	Tolal
As at 31 March 2020				
Non-derlyatives	312.00	890,52	917.32	2,149.84
Herrovings		}		
Lease liabilities	3,815.14	7,310,28	2,54,063.46	
Pride parable.	11,803.58		• 1	11,603,58
	5,462.91			5,462,91
Other financial liabilities	21,423,93		2,54,980,78	2,84,605.51
Total	46740373	0,000,00	A	

				(Z M INNOS)
As 8(3) March 2019	Less than 1 year	1 - 3 yenis	More than I years.	Total
Non-derientlyce		2 400 80	1,323,37	3,793.78
Horraning (other than finance lease obligation)	1,005.02 2,143.95	1,465.39 3,875.97	2.53,596.42	2,39,616.54
Vinance lesse obligation Trade parable	12,610.07	*		12,630.07
Other financial Kabilities	5,161.91			5,161.91
Paral	20,910.95	5,341.56	2,34,919.79	2,61,202,10

The Company also has access to the following undrawn burrowing from banks of the end of the reporting period

0	 taleter)

	Asat	Aust
Párticulats	31 Starch 2020	31 March 2019
		1
		564.82
Underson hetrenying helidies	L	

(c) Minthet rick

(i) Poreign exclininge risk

The Company has international transactions and is exposed to foreign exchange risk uniting from foreign currency transactions (imports and exports). Poreign exchange risk arress from force commercial transactions and recognised arress and liabilities denominated in a currency that is not the Company's functional currency. The Company has not hedged in foreign exchange receivables and 31 March 2020.

Foreign currency risk exposure:	As at 31 March 2020		Augt 31 March 2019	
Partleulans	Poreign currency	INI (* Inhat ni 5)	Poreign currency	IMR (* in laklus)
Assets Tende receivables (genss)	USD	686.90 686.90	บราว	597.86 597.86
Liabilities Capital receiture Trule papulies Fruie papulies Fruie papulies	Gills Fig. Gills G	12.55 17.08 232.36 268.99	USD SONO USD CHIP	20.5: 1.1 - 21.6

Sonalilyity

Sensionary The sensions of profit or loss to changes in the exchange rates orige from foreign correity denominated financial intercements. (8 in laking)					
Particulars	31 Marc		reh 2020	31 Rtarcl 2019	
	Currency	Exchange inte increase by 6%	Exchange rate decrease by 6%	Bachange rate Increase by 4%	Unchange rate decrease by 4%
Assets Trade receivables (gross)	USE	41,21	(41.21)	23.94	(23.91)
Linbilities Capital recelliors Trude payables Trude payables	USD EURO USD	1.17 1.02	(1.17) (1.02)	1	(5.82)
Triste payablas	GBP	13.94	(15.94)		

(II) Interest mie eink

The exposure of the Company's horrowings to interest rate changes at the end of reporting period sie no follows:

	(Fin Inklie)
31 March 2020	31 March 2019
	1.57.6.80

The Company's which he cate borrowing is subject to interest rate, below is the overall exposure of the normaling		(f ill inkits)
Parriculara	31 March 2020	31 March 2019
Variable rate borrowing		1,566.19
Total burmwings	٠	1,566,19

Sensitivity

Profit or loss is sentifice to higher/lower interest expense from borrowings as a result of changes in interest rates.		(t in laklis)
Particulate	31 March 2020	3t March 2019
Interest rates – locerate by 100 bash points		15.66
Injecest exics - decrease by 100 basis points		(15.66)

Phiance lease utiligation, vehicle loan and deferred payment katalitic WANDIO





Standalone summery of significant accounting policies and other explanatory informulos for the year ended 31 March 2020

Note - 38

Related party transactions

In accordance with the requirements of Ind AS 24 the names of the related party where control exists/able to exercise significant influence along with the transactions and year-end balances with them as identified and certified by the management are given below:

I) Untitles where control exists

31 March 2020

- Subsidiary companies
 () Global Health Pattiparta Private Limited
 - () Medanta Flohlings Private Limited

Joint rentuce

(i) Medanta Duke Research Institute Private Limited

31 March 2019

Subsidiary company:

- (i) Global Health Patliputra Private Limited
- (i) Medanta Holdings Private Limited

Joint venture

(i) Medanta Duke Research Institute Private Limited

il) Buddes and individuals which exercises eignificant influence over the Company

31 Mnrch 2020	31 March 2019
(i) Annu Investments	(i) Anant Investments
(ii) Dr. Natosh Trehan	(ii) Dr. Naresh Trehan

ili) Koy management personnel (KMP)

31 March 2020	:31 March 2019
(i) Dr. Naresh Trehan - Chairman and Managing Director	(i) Dr. Naresh Trehan - Chairman and Mauaging Director
(ii) Mr. Sunil Sachdeya	(ii) Mr. Sund Sachdeva
(iii) Mr. Havi Kant Jaiputia	(iii) Mr. Ravi Kant Jaipuna
(iv) Mr. Rohit Sipaliimplani (upto 26 September 2019)	(iv) Mr. Rohit Sipahimalani
(v) Mr. Neemi Bharadwaj	(v) Mr. Neeraj Blinradivaj
(vi) Mr. Shayana Chuna (upto 24 February 2020)	(vi) Mr. David Johnson (upto 16 July 2018)
(vii) Mr. Sanjeev Kumar	(vii) Mr. Shayama Chona
(viii) Me. Pankaj Sahni	(viii) Mr. Auil Virmani (upto 13 July 2018)
	(ix) Mr. Saujeev Kumar (from 14 July 2018)
1	(x) Mr. Pankaj Salmi

iv) Reintives of KMP

31 March 2020 and 31 March 2019						
Name of Relatives	Relationship with KMP					
Mr. R.L. Sachdova	Pather of Mr. Sunit Sachdeya					
Mrs. Savitti Sachilova	Mother of Mr. Sunit Sachdeva					
Mrs. Shonan Trehon:	Daughter of Dr. Narish Trehan					
Mrs. Shyel Trehau	Daughter of Dr. Nareth Trehan					
Mrs. Madhu Trohan	Wife of Dr. Namsh Trehan					
Mr. Naveen Trehan	Brother of Dr. Natesh Trelian					

v) Buterprises over which KMPs are able to exercise significant influence with whom transactions have been undertaken or whose balances are outstandings

31 March 2020	31 March 2019
(i) IFAN Clobal India Private Limited	(i)HAN Global India Private Limited
(ii)Law Chamber of Kapur & Trehan	(ii)Law Chamber of Kapur & Trehan
(iii)Rakslin TPA Private Limited	(iii)Raksha TPA Private Limited
(iv)Sharak Hoalthcare Private Limited	(iv)Sharak Hoalthcare Private Limited
(v)Language Architecture Body (LAB)	(y)Language Architecture Boxly (LAB)
(vi) Vidyanta Skill Institute Private Limited	(vi) Vidyanta Shall Institute Private Limited
(vii)bledanta Institute of Education & Research (Past)	(vii) bliedanta institute of Education & Herenich (l'tust)
(viii)Vanin Boverages Limited	(viii) Vanun Bevorages Limited
(ix)RJ Corp Limited	(ix)RJ Corp Limited:
(x)Dovyani-International Limited	(x)Devyani International Limited
(xi)Diagno Labs Private Limited	(xi)Diagno Labs Private Limited
(xii)S.A.S Infotoch Private Limited	(xii)S, A.S Inforech Private Limited
(xiii)Metropolis Healthcare Limited	(xiii)Metropolia Healthcare Limited





	B	ordinary course of business: Year	I		Related pariles			Tore!
2	Particulors	ren-	Buildes stilch exercises significant influence over the Company	Subsidiary companies	Joint veniure	Key management personnel and their relatives	Anterprise over which KMP exercise significant influence	
100	enisi income Colana Duke Receach Suntinus Private	31 March 2010			1,01			4.0
U	lmited Jedanta Institute of fiducation & Research	31 Merch 2019 31 Merch 2020			8.01		10,17 10,17	8.0 10.1 18.1
٦'n	(ross)	M March 2019 31 March 2020					258.92	258.9
j.	Second International Limited	3) http:// 2019					274.13	274.
ï	IAN Global India Private United	3) March 2020 3) Much 2019					30,111	111.0
7	leni expenses Jedania Duke Hesearch Institute l'abrate Jmited	31 March 2020 31 March 2019			£98 26.88			8.1 26.1
ji	Professional charges	31 Minds 2020					34.35	34. 31.
- 1	Serience Floblings Private Limited	31 March 2019 31 March 2021		451				
	Fraining expenses Vidyanta Shills Institute Private Limited	51 March 2019 51 March 2000					121.30	121.
	Purchase of neserie	M March 2019	4		57.51		61.32	61.
	hledanta Duko Hercacch Institute Private Linked	31 March 2020 31 March 2019			3(-31			
	Sale of nasets (excluding toxes) Medacka Hubbings Private Limited	31 Merch 2031 31 Merch 2019	***	6.96				6
_	Resembe from patients covered under the sign							
- 1	Stekelia TVA Private Limited	31 March 2020 31 March 2019			<u> </u>	ļ <u>-</u> -	1,644,33 1,450,32 (124	1,844 1,840
	Sharak Healthraic Private Limited	31 Abrah 2000 31 Abrah 2019					0.10	
٥	Renderlog of Healthcase services* LL. Szelideva	31 March 2010		·		5.1 3.1	ō	
	Mrs. Savied Sachdova	51 March 2020 M March 2019				0.3 1.0		
	NJ Cosp Limited	31 March 2028 31 March 2019					11.84	,
	Vsam Ikeenges Limited	31 Merch 2020 31 Merch 2019					0.65 0.15 0.62	
	Decyani International Limited	34 March 2010 31 March 2019 31 March 2020				01	0.53	
	Pankej Sahni SAS Inforcch Private Limited	31 March 2019 31 March 2029			-	0.0		
	Mrdenta Holdings Pilvate Limited	31 March 2019 31 March 2020		10.93				
11	Investment in ambeldiary	31 yleich 3019		1,200.0				4,70
	Global Realth Pathputes Vivate Limited Medicus Holdings Private Limited	31 March 2020 31 March 2019 31 March 2020		3,200.0 10,300.0				3,25 10,50
12	Outsourced lab services	31 March 2019		9,900.0				9,90
	Diegen Late Private Limited	31 March 2020 31 March 2019			-		327.41 316.45	3
	Mejropolis Heithbette Limited	31 March 2020 31 March 2019					()4(\
13	Purchase of consumables Vanus Herceages Limited	31 March 2020 31 Merch 2019					D.K	
11	Expenses paid on british of Clinbal Health Perspects this to Limited	31 March 2020		7,	18			
	Medanta Holdings Private Limited	31 March 2019 31 March 2020	4	-				
	S.A.S. Inforech Private Limited	31 March 2019 31 March 2020		0.	2		311.9	
15	Tax eleducted at source paid on beholf of	31 March 2019						
	Ghabal Health Pathpurea Private Lumited	3f Alarch 2020 31 Merch 2019		1	0	***************************************		
16	lauve of share capital (including securities premium)							
	Pankaj Salani	31 March 2070 31 March 2019					121	
)7	Guarantee given on teholf of aubidiary company to third parry Medants Holdings Private Limited	31 March 2020		818	50			-
il		31 Men (c 2019		1,907.		-		. 1
	Da Naresh Trebung)	31 March 2019					8.92	
	And Vincentife	31 March 2020 31 March 2019					631	
	Smjeer Kumu@	31 March 2020 31 March 2019 31 March 2019					9.65 3.99	1
	Uankaj Saliniski * Nitaj dinerat	11 March 2020		·			6.95	
	G. There are no post employment limebis, of I There we no post employment benefits we		and their price lines.		steeli Tielan, And	Virmuni and Susjeev	Kuma.	
		137)E)				11	

THU DAGOOM



Qiabol Health Private Limited

Standalone summery of significant accounting policies and other explanatory information for the year ended 31 Merch 2020

No.	Particulars	Yene	<u> </u>		Related parties			Toisi
			Entifies which exercises algorificant Influence over the Company	Subsidiery companies	Jolos venturė	Key management personnel and their relatives	Balespriss syes widch KNII exercise significant influence	
, 	Equity shore copital		<u> </u>	A			ļ	
	Antal Investments	31 March 2030	1,3000)	*****		1		1,300
- 1	111111111111111111111111111111111111111	31 March 2012	1,200.00		****			1,300
- 1	Dr. Nameli Trelini jointly with Mrs. Madiis	31 March 2020				669.21		68
	Ticker	31 March 2019				689,21		68
	De Neigele Techen	M Much 2020	-			1,026.00	***************************************	1,07
- }		31 March 2019				1,020,00	*	1,07
1	Ale Simil Serindera Jointly with Mrs. Suman	31 March 2020				03040		6
	Sichdeva	31 March 2019				610.00		6
ĺ	RJ Com Limini	31 Marte 2020			·		200.00	2
ł	• • • • • • • • • • • • • • • • • • • •	31 Macch 2019					300,00	21
-	Panke Sahoi	31 Alendi 2020				070	-	
		31 Alexh 2019						
	Compulsority convertible preference shares							
	Λοιοι Ιουνιμοκονι	31 March 2020	3,250.00			***************************************		3,2
- 1		31 kGreh 2019	3,236100					3,2
	Trade payables	The second secon			***************************************			
~~1	Dr. Navali Trehag	31 kfirch 2020	***************************************			,10,54		
ļ		31 March 2019			j	30.54	* *********	
	Starii Sachdeva	31 March 2020	·	1	·	30.5 (
1		31 Merch 2019				30.54	1	
1	IPAN Cilotal India Private Limited	31 Merch 2019 31 Merch 2019		1			(1.13)	
1		31 hlank 2019					15.67	
]	Law Chamber of Kapins & Trehan	31 March 2020					\$331	
1		31 March 2019				1	5.12	
ı	Vidyaneta Skill Institute Private Limited	31 March 2020			1	4	1259	
		31 March 2019					X.73	}
ļ	Linguige Architecture Hedy	31 March 2000				I	(1,17	}
	,	31 March 2019	1				6.17	
	Diagon Labs Private Linuted	31 Abarit 2020	7				128.00	
	manage and the state of the sta	March 2019	-				85414	
-	Mempolis Healthcare Limbed	31 Mach 2020					uss	
		31 Mach 2019					292	
	Medania Duke Research Institute Private	21 March 2020		ļ				
	Limited	31 March 2019		<u> </u>	8.27			Primaria caller
	Medicate Holdings Private Limited	33 March 2020		151		******		J
	annessant men artisekt järkkej enjekserrekkenken tidakkenkenska all menke a sensa a mas a sen a	31 March 2019						
	Other receivables			·	.		-	<u></u>
	Medanta Institute of Ilderation & Remarch	31 March 2020					7.71	ļ
	(finul) Devyson Internstional Limited	31 Merch 2019 31 Much 2020					7.71	
	15 Erlywar Internstructure a reputer	31 Atrich 2019	-	·	ļ		13002	
	Medente Dake Research Institute Pifinte	51 Minch 2020				·	121.51	
	Linked	31 klack 2019	-{		627			
	S.A.S. Inforech Private Lindard	31 March 2020		-	·	·	185.44	
	77,773	31 March 2019		·{			92.09	
	Medanta Huldinga Private Liniked	31 March 2024	· ···	6.96	·			
		M March 2019	~[**********		·}
_	Trade receivables							
	Rakiha TPA Private Goshed	31 March 2020			· ·····		231 19	* *********
		31 854651 2019	~[·		251.71	***************************************
	Sharak Healtheare Private Limited	31 March 2020		· [av3	1
		31 March 2019	·	1			1.27	
	Iti Com Limited	31 March 2020			·		13.16	· · · · · · · ·
		31-March 2019	1		1		13.16]
	Vacua Bergages Limited	34 March 2020				1	0.39]
		31 Meich 2019					18.70	
	Devyani International Limited	3) Alarch 2020		1			0.62	1
		31 Match 2019		1			1846	
	S.A.S Infotects Private Limited	31 Alerch 2020				-	5.93	
		M March 2019		1				1
	Medanta Holdings Private Lindust	31 Meach 2020		10.93		-		1
		31 Musch 2019		.]			in heavy t vous a series	1
<u>.</u>	Oiker psyables	حصييين والبرانيين						
	Global Health Padigustor Private Limited	3) March 2019		12.91				4
	1	31 Mands 2019						
_	Allowance for expected credit loss	1137. 3.42.						
	Habria TPA Private Limited	31 March 2020						
	lavertment in laber services	31 Man (2019				·	22.75	
5	Investment in Joint venture	31 March 2020						ļ
	Medania Dishe Research Institute Vrivate Limited (gross)#2	31 A)A A A014			98180			
****	I constructed by a state of the second state of the	31 March 2019	-) <u>-</u>		\$201.80			
9	Investment in subsidiary companies Global Heakit Patiputes Private Limited	31 March 2020						9,
	CONTRACTOR OF A SECOND STATE OF THE SECOND STA	31 March 2019		9,700.00	(-
	Medante Holdings Private Linded	31 March 2019		5,500.00 40,350.00	4			5,
	methode (teathers (main twings	31 March 2019		ANTERIO	-		-	₫₽,
ñ	Quarante given on behalf of subsidiers	23 713/63/2017		00,050.0	' ····· ·	-		30,
47	fcombanges in third band.	1	1	1	i	1	,	1
	Globel Heelds Pathiouter Private Limited	3t March 2020		1,500.0				
	Diffigure and a marchine to make a venture	31 March 2019	·				-{	
	Alidana Hulding Private Limited	31 March 2020		LANA		~		J <u>.</u> [6
	terremental a territorida e avende rintinfedi	31 Mach 2019	**	2,735.00				
	1	1 10 10 10 10 10 10 10 10 10 10 10 10 10		1,907.34		. 1 · . · · · · · · · · · · · · · · · ·		1/3

3.7725.99

3.1 March 2019

3.1

[&]quot;This is the gross investment habove, thousever, the Company has recorded impulment for entire habove in previous past.





Standalane summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Note - 39

Capital management

The Company's objectives when managing capital are to:

. To ensure Company's ability to continue as a going concern, and

- To maintain optimum capital structure and to reduce cost of capital

blanagement assesses the capital requirements in order to maintain an efficient overall financing structure. The Company manages the capital structure and makes adjustments management asserter the committee an invested management and control of the modelying assets. The Company is not subject to externally imposed capital requirements to it in the light of changes in economic conditions and the risk changes risk of the underlying assets. The Company is not subject to externally imposed capital requirements. The Company management is capital requirements by overseeing the genting ratio:

(Cin iskhs) As at 31 March 2020 As at 31 March 2019 3,036.65 14,104,58 Total borrowings (including interest accrued) 1,42,272.25 1,31,193.72 11%

Noto - 40

Particulars

Lord edate.

Net debt to equity ratio

Contingent liabilities and commitments		(E in lakha)
A Contingent limitities	As at 31 March 2020	As at 31 March 2019
Particulare	1,081.38	77.95
Income-tax matters Other cases (cefer note (iii) below)	132.05	79.37

- () It is only practicable for the Company to estimate the timings of each outflows, if any, in respect of the above pending resolution of the respective proceedings.
- (ii) The amounts disclosed above represent the best possible estimates arrived at on the basis of available information and do not include any penalty payable.
- (ii) The Company is contesting employee related cases in various forums. Based on the internal analysis, the Company is of the view that the likelihood of any outflow of the
- (iv) The Company is contesting various medical related legal cases in various formus. thesed on the legal opinion from external consultant and internal analysis, the Company is of the view that the likelihand of any mullow of the resources is remote,

B Commitment

á).	Capital commitment		(P in laklu)
	Pointeniles	As at 31 March 2020	As at 31 March 2019
	Property, plant and equipment	495.36	401.25

(II) Other commissions

17.	Particulars	As at 31 March 2020	As at 31 March 2019
	Hank gummatee - Export Promotion Capital Goods*	1,969.55	1,007.73
	Performance bank avarantee \$	1,500.00	1,5(X),(X)
	Corporate guarantee(i)	2,725.90	1,907.36
-	I sparafsimmet	•	•

- The Company has imported capital goods under the Export Promotion Capital Goods, of the Government of Indis, at concessional rates of duty on an undertaking to fulfill quantified exports in the next six to eight years.
- \$. The Company has issued a performance bank guarantee of \$ 1,500,00 lakks to Government of Bihar on behalf of Chobal Health Pattiputa Private Limited (a wholly owned
- @The Company has insued corporate guarantee of ₹ 2,725,90 lakks to Deputy Commissioner of Currons, New Delhi on behalf of Medania Holdings Private Limited (a wholly owned subsidiary) for imputting capital goods under the Export Promotion Capital Goods Scheme.
- # In previous year, the Company has issued letter of support to Medanta Duke Research Institute Private Limited (a joint venture) for providing operational and financial support if it fails to fulfill its obligations for a period of 12 months, During the year, the Board of Directors (the Board) of Medanta Duke Research Institute Private Limited (a joint venture) in its meeting field on 19 June 2019 has decided to commence the process of winding up.





Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Note - 41

(i) Lease related disclosures as lessee

The Company has leases for land, buildings, equipments and vehicles. With the exception of short-term leases and leases of low-value underlying assets, each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. Variable lease payments which do not depend on an index or a rate are excluded from the initial measurement of the lease liability and right of use assets. The Company has presented its right-of-use assets in the balance sheet separately from other assets.

Each lease generally imposes a restriction that, unless there is a contractual right for the Company to sublease the asset to another party, the right-of-use asset can only be used by the Company. Some leases contain an option to extend the lease for a further term. The Company is prohibited from selling or pledging the underlying leased assets as security. Por leases over buildings equipments, vehicles and land the Company must keep those properties in a good state of repair and return the properties in their original condition at the end of the lease. Purther, the Company is required to pay maintenance fees in accordance with the lease contracts.

A Lease payments not included in measurement of lease liability

The expense relating to payments not included in the measurement of the lease liability is as follows:

	(t in lakins)
Particulars	31 March 2020
Short-term leases	3,911.78
Lenses of low value assets	1.54

B Total cash outflow for leases for the year ended 31 March 2020 was \$ 3,815.66 laklus.

C Total expense recognised during the year

Particulars 31 March 2020 Interest on lease liabilities 2,415.1€
Depreciation on right of use asset 1,499.52

D Maturity of lease liabilities

The lease liabilities are secured by the related underlying assets. Poture minimum lease payments were as follows:

Win lakhe)

31 March 2020		Minimum lease payments due							
	Less than 1 year	1-2 years	2-3 yenra	More than 3 years	Total				
Lenke phyments	3,815.44	3,688.91	3,621.37	2,54,063.46	2,65,189.18				
Interest expense	.533.06	557.09	581.66	2,40,795,35.	2,42,467.16				
Net present values	3,282.38	3,131.82	3,039.71	13,268.11	22,722.02				

Bifurcation of lease liabilities at the end of the year in current and non-current

Particulars
a) Current liability (amount due within one year)
b) Non-current liability (amount due over one year)
19,439,64
Total lease liabilities at the end of the year
22,722,02

P Information about extension and termination options

Right of use assets	Number of leases	Range of semalaling term (In years)	Average remaining lease term (in years)		Number of leases with purchase option	Number of leases with termination option
Bullding premises	46	2.25 to 40.21	10.03	9		44
Other plant and equipment	1	21	21		•	1
Vehicles	10	0.35 to 2.78	1	10	10	1()
Land	1	87	87	-		,



1

Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

P Impact on transition

- 1. Effective 1 April 2019, the Company has adopted Ind AS 116 "Leases" and applied modified retrospective approach to all lease contracts existing as at 1 April 2019, On transition, the adoption of new standard resulted in recognition of lease liabilities of \$ 20,059.16 lakhs and corresponding right of use asset of ₹ 27,132.72 lakha (including leases which were earlier classified as finance lease).
- 2 For contracts in place as at 1 April 2019, Company has elected to apply the definition of a lease from Ind AS 17 and has not applied Ind AS 116 to arrangements that were previously not identified as lease under Ind AS 17.
- 3 The Company has elected not to include initial direct costs in the measurement of the right-of-use asset for operating leases in existence at the date of initial application of Ind-AS 116, being 1 April 2019.
- 4 Instead of performing an Impairment review on the right-of-use assert at the date of initial application, the Company has relied on its historic assessment as to whether leases were onerous immediately before the date of initial application of Ind AS 116.
- 5. On transition, for leases previously accounted for as operating leases with a remaining lease term of less than 12 months, the Company has applied the optional exemptions to not recognise right of use assets but to account for the lease expense on a straight-line basis over the remaining lease term.
- 6 The Company has benefitted from the use of bindsight for determining the lease term when considering options to extend and terminate leases.
- On transition to Ind AS 116 the weighted average incremental borrowing rate applied to lease liabilities recognised was 9.97%.
- The following is a reconcillation of total operating lease commitments at 31 March 2019 (as disclosed in the financial statements of the previous year) to the lease liabilities recognised at 1 April 2019:

	(Cin lakhe)
Particulars	, Amount
Total operating lease commitments disclused as at 31 March 2019	743.20
Recognition exemptions - leaves with remaining leave term of less than 12 months	44.63
Other adjustments relating to lease commitment disclosures	28,452,34
Operating lease liabilities before discounting	29,240.17
Discounting impact (using incremental borrowing rate)	(19,316,12)
Openting lease liabilities	9,924.05
Rinnace lease obligations under Ind AS 17.	10,135.11
Total lease liabilities recognised under Ind AS 116 at 1 April 2019	20,059.16

(ii) Lense related disclosures as lessor

The Company has entered in to operating leases for car parking. The leases have terms of 3 years, Pitture minimum rentals receivable under non-cancellable operating leases are as follows:

		(₹ in inklie)
Particulars	31 March 2020	31 March 2019
Within one year	(02.00)	21.00
Later than one year but not later than five years	136.00	
Later than five years		. 1

Standalone summary of algorificant accounting policies and other explanatory information for the year ended 31 March 2020

Note - 42

Employee henefits obligations

A Defined contribution plan

Posticujara	For the year ended 31 March 2020	For the year ended 31 March 2019
[timployer's contribution to provident find charged to statement of profit and loss	1,734,98	1,255.46
Contribution to Bimployee state insurance scheme charged to statement of profit and toas	169.02	247.88
Contribution to labour welfare fund charged to statement of most and loss	27 86	trien

The Company siso has certain defined contributions plans. Committations are made to provident fund in India for employees at the rate of 12% of basic salay as per orgalations. Contributions are made to registered provident fund administered by government. The obligation of the group is limited to the amount contributed and it has no further contractual or constructive obligation. Refer note 46 for other details.

B Gratulty

The Company provides for gratuity for employees in India as per the Payment of Gratuity Act, 1972. Employees who are in continuous service for a period of 5 years are eligible for gratuity. The amount of gratuity payable on retirement/remination is the employees last drawn basic safety per month computed proportionately for 15 days safety multiplied for the number of years of service

(0)	Amounts recognized in the balance sheet		(7 in faklıs)
	Particulars	As at 31 March 2020	As at 31 March 2019
	Present value of the obligation at end	2,815.56	2,391,08
	Unfunded liability/provision in balance sheet	(2,815.56)	(2:391.08)

Bilingeation of present value of obligation at the end of the year - Current and Non Current

Particulars	As at 31 March 2020	As at 31 March 2019
Current liability	574.87	593.25
Non-current liability	2,340.69	1,797.83
Tatol	2,815.56	2,391.08

(ii) Amount recognized in other comprehensive income		(E In Jakus)
Particuless	For the year ended 31 Merch 2020	Por the year ended 31 March 2019
Actuarial loss/(gain)		***************************************
-Climper in demographic examplions	(1,69)	
-Changes in financial assumptions	177.11	31.42
-Change's in experience adjustment	58.87	(73,42)
Gain recognized in other comprehensive income	234,29	(49.00)

(iii)	Expenses recognized in statement of most and loss		(Ciu lakha)
	Particulare	For the year ended 31 March 2020	Por the year ended 31 March 2019
	Charent zervice cost	440.25	376.10
	Interest cost	183.46	159,08
	Expense recognized during the year	623,41	535,18

(iv)	v) Movement in the liability recognized in the balance sheet is as under				
	Particulars	As at 31 March 2020	As at 31 March 2010		
	Present value of defined benefit obligation at the beginning of the year	2,391,08	2,039,53		
	Current signica cost	440.25	576.10		
	Interest cost	183,16	159.08		
	Actuarisi luas/(pau)	234(39)	(49.06)		
	Benefits paid	(433.22)	(134.63)		
	Present value of defined benefit obligation at the end of the year	2,815.56	2,591.08		

(v) For determination of the liability of the Company the following actuarial assumptions were used:

٧)	For determination of the hability of the Company the following achierial assumptions were used:		
	Patticulara	As at 31 March 2020	As at 31 March 2019
	Discount mte	6.87%	7,66%
	Salary circlation rate	5.00%	
	Retirement age (years)	60 years	60 years
	Vicetalle bitt netrice	3,40	3.24 years
	Visuality with	31,53 years	
	Average remaining working life	28.47 years	
	Withlywatran		Kino / Juan
	Up to 30 Years	4,00%	4,121%
	From 31 to 44 years	3,00%	
	Above 44 years	2.00%	3.00% 2.00%
		2.KN/70	2.18776)

Morrality rates inclusive of provision for disability -100% of IALAI (2012 - 14)





Standelone summary of significant accounting policies and other explanatory information for the year ended 31 March 2020.

(vi)	Manualty profile of defined benefit	obligation			(F.in Jakha)
	Year 31 March 2020	Year 31 March 2019		An at 31 March 2020	As at 31 March 2019
	April 2020 - March 2021	April 2019 - March 2020		\$74.H7	593.25
	April 2021 - March 2022	April 2020 - March 2021	1	107,46	154.72
	April 2022- March 2023	April 2021- March 2022		162.13	64.98
	April 2023 - March 2024	April 2022- March 2023		137.13	t44.08
	April 2024 - March 2025	April 2023 - March 2024		92,03	10/198
	April 2025 - March 2026	April 2024- March 2025	Ì	136,97	109,44
	April 2026 onwirds	April 2025 onwards		5,604.98	1,223,63
	Cleans (Cotal)			2.815.56	2.391.08

Sensitivity analysis for granuity		(X in faklse)
Particulare	31 March 2020	31 March 2019
n) Impact of the change in discount rate		
Present value of obligation at the end of the year	2,815.56	2,391.08
Impact due to increase of 0.50 %	(117.54)	(86.18)
Impact threat decrease of 0.50 %	127,90	93,24
ti) Impact of the change in salary increase		
Present value of obligation at the end of the year	2,815,56	2,391.08
Impact due to increase of 0.50 %	139.64	95.23
Impact due to decreave of 0.50 %	(120.09)	(86,88)

Sensitivities the to morsely and willdrawn's are not material. Hence, impact of change is not calculated above.

Seristilistics as to rate of inflation, rate of increase of pensions in payment, rate of increase of pensions before retirement and life expectancy are not applicable being a lump sum

The above constitute analysis are based on a change in an assumption while holding all other assumptions constant, in practice, this is unlikely to occur, and changes in som of the assumptions may be currelated. When calculating the scindivity of defined benefit obligation to significant actuarist assumptions the same medical (present value of defined benefit obligations calculated with the projected unit decide as the control is being period) has been applied as when calculating the defined benefit tibility. recognised in the balance elect.

(viii) Rick

/ 24,016	
Salary increases	Actual salary increases will increase the plant's liability. Increase in salary increase rate assumption in future valuations will also increase like liability.
Discount rate	Reduction in discount rate in subsequent valuations can increase the plan's liability.
Mortality and disability	Actual deaths and disability cases proving lower or higher than assumed in the valuation can impact the liabilities.
Withstrawah	Actual withdrawals proving higher or lower than assumed withdrawals and change of withdrawal rates at subsequent valuations can
Attomayar	impact Plan's Sability,

Note - 43

Share bared payments

GHPL R5OP Plan 2014

GHPL RSOP Plan 2014

The Company wide General Meeting resolution dated 25 September 2014 approved "Global Health Employee Stock Option Scheme 2014" for genuing employee stock options in the form, of equity, that we linked to the completion of a minimum period of continued employment to the eligible employees of the Company. The plan was modified on 11 hlay 2016 where in the Company increased the number of available options from 740,628 to 852,973 to eligible employees and the vesting period was changed from 5 years from the date of gmin to gmided vesting of 25% each year starting with effect from 30 April 2016. The Company had granted 740,628 options to eligible employees on 25 September 2014. The eligible employees, including directors, for the purpose of this scheme will be determined by the Reimmentian Committee from time to time. Each stock options entitle the eligible employee to avail one share at the end of the vesting period. The vested options can be exercised within a period of 5 years from the date of vesting.

Movement in number of ontions

Pardoulars	As at 31 March 2020	As at 31 Majch 2019
Opening behaves	3,54,123	8,44,824
Beerelsed during the year	93,475	4,54,974
Lapsed during the year		35,727
Closing balance:	2,60,648	3,54,123

Particulars	Grant I	Grant II:	Grant III	Grant IV
Outstanding options (unvested and vested but not exercised)	40,972	26,451	19,838	1,73,387
Grantislate:	25 September 2014	13 July 2016	9 November 2016	10 December 2016
Vesting period	Graded vesting (25%	Graded verting (25%	Oraded vesting (25% options	Graded vesting (25%
			to vest every year from the	options to vest every year
	from the date of goot)	from the date of grant)	date of grant)	from the time of grant)
		Ī		
Hxereise price	10.00	10,00	10.00	10.00
Expiry date	29 April 2022	12 July 2023	08 November 2021	09 December 2023
Pricardor of option on the date of grant*	C91.95	742.28	755.29	755.24
Remaining contractual life (weighted months)	109.30	123.93	127.90	128,93

[&]quot;The fair value of the options has been determined using the Black Scholer model, as certified by an independent values with the following assumptions:





Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Particulars	Grant I	Grent II	Grant III	Grant 3V
Weighted average share price (Rs.)	698.65	749.78	762.95	762.95
Bxercise price (flx.)	10.00	10,00	(9,00)	10.00
Depected volatility (%)	37%	37%	37%	36%
Dispected life of the option (years)	4.7	4-7	4.7	4.7
Expected divident yield	v	•		
Hisk-free interest rate	8,70%	7.18%	6.67%	6.51%
Weighted average fair value as on the grant date (Rs.)	691.95	742,28	755,29	755.24

GHPL BSOP Plan 2016

The Company vide General Meeting resolution dated 13 July 2016 approved "Global Health Employee Stock Option Scheme 2016" for graning employee stock options in the form of equity abases based to the completion of a minimum period of continued employment to the eligible employees of the Company. The eligible employees, including directors, for the purpose of this scheme will be determined by the Remomention Committee from time to pine. Back anoth option while the eligible employee to avail one share at the end of the verting period. The authorized share expital of the Company was after increased by creation of 1,025,000 Glass A equity slatter on 13 July 2016 with a view to allot the shares under the RSOP Plan 2016. The verted options can be exercised within a period of 3 years from the date of verting.

Movement in number of ontions:

recognition in founder of Options;		
Particulars	As at 31 March 2020	As at 31 Murch 2019
Opening balance	7,71,250	6,13,000
Granted during the year		3,40,000
Bacteried during the year.	1,18,750	3,83,750
Lapsed during the year	91,000	
Closing balance	5,61,500	7,71,250

Particulars	Geant I	Grant Il	Grant III	Grant IV	Grant V
Ourstanding options (unvested and vested but not exercised)	1,57,500	80,000	50,000	50,01XI	2,24,000
Grant date	10 December 2016	19 March 2018	17 April 2018	25 April 2018	13 July 2018
Vesting period	Cinded vesting (25% options to vest every year from the date of gran)	options to vest exception	options to vest every year	options to vest every year	options to yest every year
Exercise price	10.60	10.00	10,00	10.00	10.00
Bajing date	U9 December 2023	19 March 2025	15 April 2024	23 April 2024	11 fuly 2020
Pair market value of opinion on the date of grant*		633,44	626,03	626.16	11 July 2026 626.17
Remaining contractual life (weighted months)	128.93	144,47	133.20	133.47	168.43

[&]quot;The fair value of the options has been determined using the black Scholes mudel, as certified by an independent values with the following assumptions

Particulars	Grant I.	Grant II	Grant III	Grant IV	Grant V
Weighted average share price (Its.)	762.95	633,44	633.44	633,44	633,44
Exercise price (llx.)	10.00	10.0xi	10.00	10.00	(R).O1
Expected vulnitity (%)	36%	37%	37.60%	37,76%	37,33%
Expected life of the option (years)	4-7	4-7	4-4	4.6	4-8
Expected dividend yield			•		·
Risk-free interest rate	6.51%	7.44%	8.09%	7,82%	8.22%
Weighted average fale value as on the	755.24	653.44	626.03	626,16	626.17
gmit date (Rs.)]				

During the year ended on 31 March 2020 and 31 March 2019, the Company has recorded an employee arock compensation expense of \$ 956.97 takks and \$ 2,603.07 takks respectively.

During the year emied on 31 March 2020, the total number of options vested but not exercised is 392,195 (3) March 2019 a 216,667).

The weighted overage place price on the date of exercise is \$ 505.88.

Note - 44

The chief operating decision maker (CODM) (i.e. Chaimian and Managing Director and Chief Financial Officer) examines the Company's performance from a service perspective and has identified the fleathboard services as single business signment. The Company is operating in India which constitutes a single geographical segment. The CODM reviews internal management reports to assess the performance of the segment Healthcare services.

The revenues from external customers attributed to an individual is not material and there are no tenuactions with a single external customer which would amount to ten percent or more of the Company's revenues.

Note - 4!

Research and development expenditure includes consultant's and specialist honorarium anxioning to \$ 1.23 lakhr (31 March 2019; ₹ 2.99 lakhr), and salaries of employees amounting to ₹ 99.29 (At March 2019; ₹ 127.77 Lakhr).

Note - 4

Pursuant to the judgement by the Horbbe Supreme Court of India dated 28 February 2019, it was held that basic wages, for the purpose of provident fund, to include allowances which are common for all employees. However, there is uncertainty with respect to the period of applicability of the judgement. The Company has applied the said judgement on prospective basis.

Standslane summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Note - 47

Revenue related disclusions

! Disaggregation of revenue

llevenue recognised mainly comprises of healthcare services: Set out below is the disaggregation of the Company's revenue from contracts with customers:

		(čin isklis)
Description	For the year ended	For the year ended
	31 March 2020	31 March 2019
(A) Operating revenue		***************************************
Income from healthcare services	j i	
In patient	1,17,078.44	1,16,807:36
Out patient-	28,214.37	26,875,98
(B) Other operating revenue		·
Clinical research income	186.82	251.33
Other opening revenue	177.65	178.55
Total sevenue	1,45,657.18	1,44,113,22

		(f in loklis)
Description	For the year ended	Por ilse year ended
(A) Operating revenue	31 March 2020	31 March 2019
1.7.	,	
Income from healthcare services		
Government	16,677.25	18,327.09
Non-government	1,28,615.46	1,25,356.26
Total operating sevenue:	1,45,292,71	1,43,683.35

It Contract balances

The following table provides information about receivables and contract liabilities from contract with customers:

		(8 in laklis)
Particulare	As at 31 March 2020	As at 31 March 2019
Contract liabilities		
Advance from customers	2,091,25	1,609,61
Total contract liabilities		1,609,61
		2,502,111
Contract assets		
Unbified revenue	598.69	1,082,11
Total content seeds	598.69	1,082.11

Contract saset is the right to consideration in exchange for goods or services transferred to the contoner. Contract liability is the entity's obligation to transfer goods or services to a customer for which the entity has received consideration from the customer in advance, Contract assets (unbilled receivables) are transferred to ecceivables when the rights become unconditional and contract liabilities are recognised as and when the performance obligation is satisfied.

Ħ	Significant changes in the contract liabilities balances during the year are as follows:		(\$\frac{1}{2} in fakhs)
	Contract lightlitles - Advance from customors	As at 31 March 2020	As at 31 March 2019
	Opening Infance of Contract Habilities - Advance from customers	1,609,61	2,045,23
	Less: Amount of revenue recognised during the year	(1,45,292.71)	(1,43,683,35)
	Add: Addition during the year Closing balance of Contract Habilities - Advance from customers	1,45,774.35	1,43,247,73
	I SOMME CONTRACT OF CONTRACT RECORDED = MEVANCE FROM PHILIPINGIA	0.001.03	

IV of the aggregate amount of marketlon price allocated to the performance obligations (yet to complete) as at 31 March 2020 is ₹ 2,091.25 lakhs (31 March 2019 ; ₹ 1,609.61 lakhs). This balance represents the advance received from entoners (gross) against healthcare services. The management expects to further bill and collect the remaining balance of total consideration in the coming periods. These balances will be accognised as revenue in subsequent period as per the policy of the Company.

y Reconciliation of revenue;

Petilculare		(7 In lakhx)
A KITICIDALD	For the year ended 31 March 2020	Por die year ended
Revenue		,11 March 2019
Adjustment for:	1,50,894.05	1,49,032.11
- Direcountered relates	15 101 10	
Income from healthense services	(5,601.34)	(5,348.76)
Theorie Holl Metales Brities	1,45,292.71	1,43,683.35

Note • 48

Previous period/year numbers have been regenized/reclassified who rever considered accessors

Inlance sheet Linbilistes	31 Merch 2019 (Reported)	Adjustments	31 Merch 2019 (Reclassified)
Non-current provisions Current provisions Assets	1,797.83 2,047.24	.1,097.26 (1,097.26)	2,89 5 ,09 949,98
Other current financial assets Other current assets	1,859,59 1,339,12	550.20 (550.20)	2,389.80 808.92

(Vids spore has been intentionally left Islank)





Standations summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Note - 49

Note: 49

The outbreak of 'COVID-19' has severely impacted the businesses and economic activities around the world including India. Governments, both Central and State, have imposed lock down and other emergency restrictions which has led to the disruption of all regular business operations. The Company has made a detailed assessment and considered possible effects, if any on its liquidity position, including recoverability of its assert as at the balance sheet date. Further, due to the temporary restrictions of overseas patients, business operations of the Company were lower in advergence that the year-end and see further expected to be forewer in the short-term, though the same is not likely to have a continuing injust on the business of the Company. Further, the management before that in the long-term, there may not be material impact of COVID-19 pandemic on the financial position and performance of the Company. However, the impact assessment of COVID-19 pandemic is a continuing process given the uncertainties associated with its nature and direction and accordingly, the impact may be different from that estimated as at the date of approval of these financial statements. The Company will continue to munitor any reactial changes to future economic conditions.

Note - 50

The tode receivables as at 31 March 2020 inter-alia include receivables in foreign currency which have been outstanding aggregating to 3 686,90 laklus beyond the timeline stipulated by the applicable provisions of Reserve Bank of India read with foreign exchange management regulations. The Company has filed necessary applications with the appropriate authority in this regard as per regulations. The management does not envisage any additional financial impact of the same at this stage and hence, no additional provision has been made.

"This is the standalone summary of significant accounting policies and other explanatory information referred to in our report of even date.

Par Walker Chandlok & Co LLP

Chartered Accountants

Firm's Registration No.: BRID76N/NSUBIL

Rajni Rajni Alundra

Partner Membership No.: 058614

Piece: New Delhi Date: 28 September 2020 De Narcen Trchan

Chairman and Managing Director

(B112100012148)

Placei Gungmu Date: 28 September 2020

Chief Pinancial Officer

Placei Gungaini Date: 28 September 2020 For and on behalf of the Board of Director

Chilef Executive Officer

Placet Gungmen Date: 28 September 2020

> innir Banasi Company Secretary

Placet Gungmin Date: 28 September 2020

Walker Chandlok & Co LLP L 41, Connaught Circus, Outer Circle, New Delhi - 110 001 India

T +91 11 4278 7070 F +91 11 4278 7071

Independent Auditor's Report

To the Members of Global Health Private Limited

Report on the Audit of the Consolidated Financial Statements

Opinion

- 1. We have audited the accompanying consolidated financial statements of Global Health Private Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its joint venture, as listed in Annexure I, which comprise the Consolidated Balance Sheet as at 31 March 2020, the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Consolidated Cash Flow Statement and the Consolidated Statement of Changes in Equity for the year then ended, and a summary of the significant accounting policies and other explanatory information.
- 2. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the report of the other auditor on separate financial statements and on the other financial information of the subsidiary, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including Indian Accounting Standards ('Ind AS') specified under section 133 of the Act, of the consolidated state of affairs of the Group and its joint venture, as at 31 March 2020, and their consolidated profit (including other comprehensive income), consolidated cash flows and the consolidated changes in equity for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditor in terms of their report referred to in paragraph 11 of the Other Matter section below, is sufficient and appropriate to provide a basis for our opinion.



Independent Auditor's Report to the members of Global Health Private Limited on the consolidated financial statements for the year ended 31 March 2020 (cont'd)

Information other than the Consolidated Financial Statements and Auditor's Report thereon

4. The Holding Company's Board of Directors are responsible for the other information. The other information comprises the information included in the Director's Report but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

- The accompanying consolidated financial statements have been approved by the Holding Company's Board of Directors. The Holding Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance including other comprehensive income, consolidated changes in equity and consolidated cash flows of the Group including its joint venture in accordance with the accounting principles generally accepted in India, including the Ind AS specified under section 133 of the Act. The respective Board of Directors/management of the companies included in the Group and its joint venture are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.
- 6. In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group and of its joint venture are responsible for assessing the ability of the Group and of its joint venture to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
- 7. Those Board of Directors are also responsible for overseeing the financial reporting process of the companies included in the Group and of its joint venture.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

8. Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

9. As part of an audit in accordance with Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Independent Auditor's Report to the members of Global Health Private Limited on the consolidated financial statements for the year ended 31 March 2020 (cont'd)

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures
 that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for
 expressing our opinion on whether the Holding Company has adequate internal financial controls with
 reference to financial statements in place and the operating effectiveness of such controls;
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its joint venture to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its joint venture to cease to continue as a going concern;
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation; and
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group and its joint venture, to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of consolidated financial statements of such entities included in the financial statements, of which we are the independent auditors. For the other entity included in the consolidated financial statements, which has been audited by the other auditor, such other auditor remains responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.
- 10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Other Matter

11. We did not audit the financial statements of one subsidiary, whose financial statements reflects total assets of ₹ 31,162.44 lakhs and net assets of ₹ 6,746.45 lakhs as at 31 March 2020, total revenues of ₹ 2.48 lakhs and net cash inflows amounting to ₹ 561.20 lakhs for the year ended on that date, as considered in the consolidated financial statements. This financial statement has been audited by other auditor whose report has been furnished to us by the management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, and our report in terms of sub-section (3) of Section 143 of the Act, in so far as it relates to the aforesaid subsidiary, is based solely on the report of the other auditor.

Our opinion above on the consolidated financial statements, and our report on other legal and regulatory requirements below, are not modified in respect of the above matter with respect to our reliance on the work done by and the report of the other auditor.

Independent Auditor's Report to the members of Global Health Private Limited on the consolidated financial statements for the year ended 31 March 2020 (cont'd)

Report on Other Legal and Regulatory Requirements

- 12. Based on our audit and on the consideration of the report of the other auditor, referred to in paragraph 11, on separate financial statements of the subsidiary, we report that the provisions of section 197 read with Schedule V to the Act are not applicable to the Holding Company, its subsidiary companies and joint venture company, since none of such companies is a public company as defined under section 2(71) of the Act. Accordingly, reporting under section 197(16) is not applicable.
- 13. As required by Section 143 (3) of the Act, based on our audit and on the consideration of the report of the other auditor on separate financial statements and other financial information of the subsidiary, we report, to the extent applicable, that:
 - a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the aforesaid consolidated financial statements;
 - in our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books and the report of the other auditor;
 - c) the consolidated financial statements dealt with by this report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements;
 - d) in our opinion, the aforesaid consolidated financial statements comply with Ind AS specified under section 133 of the Act;
 - e) on the basis of the written representations received from the directors of the Holding Company and taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary companies and joint venture company, none of the directors of the Group companies and its joint venture company, are disqualified as on 31 March 2020 from being appointed as a director in terms of Section 164(2) of the Act;
 - f) with respect to the adequacy of the internal financial controls with reference to financial statements of the Holding Company, and its subsidiary companies and joint venture company, and the operating effectiveness of such controls, refer to our separate report in 'Annexure II'; and
 - g) with respect to the other matters to be included in the Auditor's Report in accordance with rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the report of the other auditor on separate financial statements as also the other financial information of the subsidiary:
 - i. the consolidated financial statements disclose the impact of pending litigations on the consolidated financial position of the Group and its joint venture as detailed in Note 40A to the consolidated financial statements;
 - ii. the Group and its joint venture did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses as at 31 March 2020;
 - iii. there were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Holding Company, and its subsidiary companies and joint venture company, during the year ended 31 March 2020; and



Independent Auditor's Report to the members of Global Health Private Limited on the consolidated financial statements for the year ended 31 March 2020 (cont'd)

iv. the disclosure requirements relating to holdings as well as dealings in specified bank notes were applicable for the period from 8 November 2016 to 30 December 2016, which are not relevant to these consolidated financial statements. Hence, reporting under this clause is not applicable.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rajni Mundra

Partner

Membership No.: 058644

UDIN: 20058644AAAAADX2583

Place: Gurugram

Date: 28 September 2020

Independent Auditor's Report to the members of Global Health Private Limited on the consolidated financial statements for the year ended 31 March 2020 (cont'd)

Annexure I

Subsidiary companies -

- 1. Mcdanta Holdings Private Limited
- 2. Global Health Patliputra Private Limited

Joint venture -

1. Medanta Duke Research Institute Private Limited



Annexure II

Independent Auditor's Report on the internal financial controls with reference to the consolidated financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

1. In conjunction with our audit of the consolidated financial statements of Global Health Private Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its joint venture as at and for the year ended 31 March 2020, we have audited the internal financial controls with reference to financial statements of the Holding Company and its subsidiary companies which are companies covered under the Act, as at that date.

Responsibilities of Management and Those Charged with Governance for Internal Financial Controls

2. The respective Board of Directors of the Holding Company, its subsidiary companies and its joint venture company, which are companies covered under the Act, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the 'Guidance Note') issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of the Company's business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility for the Audit of the Internal Financial Controls with Reference to Financial Statements

- 3. The audit of internal financial controls with reference to financial statements of the aforementioned joint venture, which is a company covered under the Act, and reporting under Section 143(3)(i) is exempted vide MCA notification no. G.S.R. 583(E) dated 13 June 2017 read with corrigendum dated 14 July 2017. Consequently, our responsibility is to express an opinion on the internal financial controls with reference to financial statements of the Holding Company and its subsidiary companies, as aforesaid, based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the ICAI prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements, and the Guidance Note issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.
- 4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements includes obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
- 5. We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditor in terms of their report referred to in the Other Matter paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to financial statements of the Holding Company and its subsidiary companies as aforesaid.

Meaning of Internal Financial Controls with Reference to Financial Statements

6. A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable accurately and fairly reflect the transactions and dispositions of the assets of the company (2) provide transaction assurance that transactions are recorded as

Annexure II to the Independent Auditor's Report of even date to the members of Global Health Private Limited on the consolidated financial statements for the year ended 31 March 2020

necessary t o permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

7. Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

8. In our opinion and based on the consideration of the report of the other auditor on internal financial controls with reference to financial statements of the subsidiary company, the Holding Company and its subsidiary companies, which are companies covered under the Act, have in all material respects, adequate internal financial controls with reference to financial statements and such controls were operating effectively as at 31 March 2020, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

Other Matter

9. We did not audit the internal financial controls with reference to financial statement insofar as it relates to one subsidiary company, which is a company covered under the Act, whose financial statements reflect total assets of ₹ 31,162.44 lakhs and net assets of ₹ 6,746.45 lakhs as at 31 March 2020, total revenues of ₹ 2.48 lakhs and net cash inflows amounting to ₹ 561.20 lakhs for the year ended on that date, as considered in the consolidated financial statements. The internal financial controls with reference to financial statements in so far as it relates to such subsidiary company has been audited by other auditor whose report has been furnished to us by the management and our report on the adequacy and operating effectiveness of the internal financial controls with reference to financial statements for the Holding Company and its subsidiary companies, as aforesaid, under Section 143(3)(i) of the Act in so far as it relates to such subsidiary company is based solely on the reports of the auditor of such a company. Our opinion is not modified in respect of this matter with respect to our reliance on the work done by and on the report of the other auditor.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rajni Mundra

Partner

Membership No.: 058644

UDIN: 20058644AAAADX2583

Place: Gurugram

Date: 28 September 2020

SSETS Name All modes (as least) TORSETS (1 miles) (2 mil			As at	As at
Control bases	·	Notes	31 March 2020	31 March 2019
ASSETS Property plotts and equipment Property plotts and equipment ASSETS Property plotts and equipment ASSETS Right of ear marks ASSETS Right of ear ma			(₹ in lakhs)	
Paper to plant and equipment				. ,
Capital work-in-progrees				
Right of use answert 6.8 37,488.4 170.0 Intentingulae cases: 7 484.1 78.0 Investinated accounted for using the equity method 8 8 78.0 Incancial assess 10 A 2,944.50 179.40 Other financial assess 10 A 2,945.50 159.40 Officer and search (real) 12 A 6,585.75 5,969.50 Other financial assess 13 A 5,158.20 1,601.25 Other connecture assests 12 A 5,858.75 5,991.50 Other connecture assests 13 A 5,158.20 1,601.25 Current asserts 18 3,851.00 2,202.00 Current asserts 18 3,851.00 2,202.00 Total concerned assets 16 149.15.00 16,417.20 Other control assets 16 149.15.18 16,417.20 Other control assets 19 9,00 2,618.30 Other control assets 10 3,350.10 2,501.70 Other control assets 10 3,450.00<		6 A	1,30,053,73	1,02,856.18
International accounted for using the equity method 18		6 A	38,172.91	65,595.57
Personantal seconstrated for using the equity method Personantal secons	-	6 B	37,408.86	
Part Part	•	7	848.14	137.00
Content Cont		8	•	,
Deferender seases (any)	Loans	9 A	789 81	731 IVI
Defende the same foul (1) (2) (3,505,75) (5,951,100) 5,951,100 (1) (2) (3,100,20) 5,951,100 (1) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2	Other funnicial assets			
100 100	Deferred tax assets (net)		· · · · · · · · · · · · · · · · · · ·	
Obter non-current assets 13 A 15.8¢ 1.64.05 7.67.02.3c Current assets 1 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 1,000.00	Income-tax assets (net)			
Part Part	Other non-current assets			
Inventorias	Total non-current assets			
Primarcial assets			4,231,022	1,70,723,34
Paner Pane	Current assets			
Pinnatic assets 15 14,915.09 16,417.81 Cash and cash cepivalents 16 14,915.18 6,571.43 Other bails balances 17 10,097.11 20,073.02 Chen francial assets 10 B 3,366.13 2,561.87 Other current assets 10 B 3,366.13 2,561.87 Other current assets 1 B 3,366.13 2,507.80 Total assets 2,646.628.90 22,597.18 Total assets 8 4,785.57 450.663.33 Total assets 8 4,934.50 4,910.28 EQUITY AND LIABILITIES 8 3,250.00 3,250.00 Equity 8 3,250.00 3,250.00 Chier capity 19 1,26,760.20 1,22,557.00 Chier capity 19 1,26,760.20 1,23,551.00 Chier capity 19 1,26,760.20 1,28,551.00 Chier capity 2 2 2 2,501.36 Financial Isbilities 2 4 4,67.97 3,072.19	Inventories	14	3.851.90	2.328.96
Cate and each equivalents	Pinancial assets		,	
Adam and each equivalents 16 4,915,18 6,571,48 Other bank balancers 17 110,997,11 20,075,22 Loans 9 B 9,79 84,56 Other courtent assets 13 B 684,57 10,077,7 Total courtent assets 13 B 684,57 49,046,35 Total assets 2,46628.93 25,971,80 EQUITY AND LIABILITIES 3 4,904,53 4,912,22 Equity 18 B 3,250,00 3,250,00 Instruments entirely equity in nature 18 B 3,250,00 3,250,00 Other equity 19 1,26,769,20 1,22,553,70 Total equity 19 1,26,769,20 1,22,553,70 Total equity 20 60,551,55 58,897,13 Liabilities 21 20 60,551,55 58,897,13 Pianceial liabilities 21 4,623,97 3,072,19 Portical ext liabilities (seet) 21 8,133 3,172,19 Other one-current liabilities 21 8,681,13 2,510,28 </td <td>Trade receivables</td> <td>15</td> <td>14,915,09</td> <td>16.417.89</td>	Trade receivables	15	14,915,09	16.417.89
Charle bada balances	Cash and cash equivalents	16		
Page Page	Other bank balances	17		
Content framerical assets 10 10 10 10 10 10 10 1	Lonns	9 B		
Other current assets 13 lb 684,79 1,007,20 Total current assets 47,850,71 49,040,35 Total assets 2,64,628,89 2,25,97,880 EQUITY AND LIABILITIES S 2,25,07,880 Equity 88 N 4,904,50 4,912,880 Biquity share capital 18 B 3,250,00 3,250,00 Civer equity 19 1,24,700,20 1,20,553,70 Total equity 19 1,24,700,20 1,20,553,70 Total equity 20 60,551,55 58,871,81 Non-current liabilities 21 N 27,108,62 3,072,10 Borrowings 21 N 4,623,97 3,072,10 Lease Babilities 22 N 4,623,97 3,072,10 Deferred tax liabilities (net) 21 N 8,11,37 3,122,41 Obter one-current liabilities 21 N 8,13,40 3,122,41 Obter one-current liabilities 21 N 3,681,5 2,57,593,60 Total outstanding dues of micro enterprises and small enterprises 24 N 1,794,58 44,50	Other financial assets	10 13		
	Other current assets	13 D	· ·	
Trade passes 18	Total current assets			
EQUITY AND LIABILITIES Equity 18 A 4,934,50 4,913,28 liagity share capital 18 B 3,250,00 3,250,00 Other equity 19 1,26,769,20 1,22,353,70 Total equity 19 1,26,769,20 1,230,516,08 Liabilities 8 8 8,50,50,00 1,30,516,08 Elabilities 8 8 8,50,51,55 58,897,13 Borrowings 20 60,551,55 58,897,13 Lease liabilities 21 A 27,028,62 27,028,62 Provisions 22 A 4,623,97 3,072,19 Deferred tax liabilities (net) 11 B 811,33 3,122,41 Other con-current liabilities 23 A 2,092,49 2,503,28 Total non-current liabilities 21 B 3,668,13 5,753,28 Current liabilities 21 B 3,668,13 5,753,28 Primarical liabilities 21 B 3,668,13 5,753,28 Primarical liabilities 21 B 3,668,13 1,794,58	Total assets		***************************************	
Equity Equity share capital 18 A 4,904.50 4,913.28 18 B 3,250.00 3,280.00 18 B 3,250.00 3,280.00 19 1,267,602.00 1,30,516.98 1	TOT WELL AND THANK COLOO			
Requiry share capital 18 A 4,934.50 3,250.00				
18 B 3,250.00 3,250.00 3,250.00 19 1,26,769.20 1,22,353.70 1,20,769.20 1,20,759.20 1,20,759.20 1,20,769.20 1,20,759.20 1,20,759.20 1,20,759.20 1,20,759.20 1,20,759.20 1,20,759.20 1,20,759.20 1,20,759.20 1,20,759.20 1,20,769.20 1,20,759.20 1,20,759.20 1,20,759.20 1,20,769.20 1,20,759.20	• •			
Trade equity 19 1,26,769.20 1,22,353.70 1,30,516.98 1,22,353.70 1,30,516.98 1,22,353.70 1,30,516.98 1,30,516			4,934.50	4,913.28
Total equity	· · ·		3,250.00	3,250,00
Description Provisions Pr		19		
Non-current liabilities Financial liabilities Fi	t otal edulik		1,34,953.70	1,30,516.98
Non-current liabilities Financial liabilities Fi	Linkilitina			
Provisions 20 60,551.55 58,877.13 Lease liabilities 21 A 27,028.62 Provisions 22 A 4,623.97 3,072.19 Deferred tax liabilities (net) 11 B 811.37 3,122.41 Other non-current liabilities (net) 23 A 2,092.49 2,503.28 Total non-current liabilities Current liabilities Current liabilities Current liabilities Lease liabilities Lease liabilities Lease liabilities Lease liabilities Lease liabilities Current				
Borrowings			•	
Lease liabilities		24		
Provisions 22 A 4,623.97 3,072.19 Deferred tax liabilities (net) 11 B 811.37 3,122.41 Other non-current liabilities 23 A 2,092.49 2,503.28 Total non-current liabilities 95,108.00 67,595.01 Current liabilities Current liabilities Financial liabilities Lease liabilities Trade payables - total outstanding dues of micro enterprises and small enterprises 24 A 1,794.58 444.56 - total outstanding dues of creditors other than micro enterprises and small enterprises 24 B 11,279.46 12,201.44 Other current liabilities 25 12,806.06 10,002.11 Other current liabilities 23 B 4,144.49 4,258.25 Provisions 22 B 877.47 953.55 Total current liabilities 34,567.19 27,859.90	v.			58,897.13
Deferred tax liabilities (ret)				
Other non-current liabilities 23 Å 2,092.49 2,503.28 Total non-current liabilities 95,108.00 67,595.01 Current liabilities 8 8 Financial liabilities 21 B 3,668.13 Trade payables 8 1,794.58 444.56 - total outstanding dues of micro enterprises and small enterprises 24 Å 1,794.58 444.56 - total outstanding dues of creditors other than micro enterprises and small enterprises 24 Å 11,279.46 12,201.44 Other financial liabilities 25 12,806.06 10,002.11 Other current liabilities 23 B 4,141.49 4,258.25 Provisions 22 B 877.47 953.55 Total current liabilities 34,567.19 27,859.90				
Total non-current liabilities 95,108.00 67,595.01				
Current liabilities 3,668.13 Financial liabilities 21 B 3,668.13 Trade payables 3,668.13 444.56 total outstanding dues of micro enterprises and small enterprises 24 A 1,794.58 444.56 total outstanding dues of creditors other than micro enterprises and small enterprises 24 B 11,279.46 12,201.44 Other financial liabilities 25 12,806.06 10,002.11 Other current liabilities 23 B 4,141.49 4,258.25 Provisions 22 B 877.47 953.55 Total current liabilities 34,567.19 27,859.90		23 A		
Primancial liabilities	Lotal top Called manages		95,108.00	67,595.01
Primancial liabilities	Cuccant Nabilitian			
Lense liabilities 21 B 3,668.13 Trade payables 1,794.58 444.56 - total outstanding dues of micro enterprises and small enterprises 24 A 1,794.58 444.56 - total outstanding dues of creditors other than micro enterprises and small enterprises 24 B 11,279.46 12,201.44 Other financial liabilities 25 12,806.06 10,002.11 Other current liabilities 23 B 4,141.49 4,258.25 Provisions 22 B 877.47 953.55 Total current liabilities 34,567.19 27,859.90				
Trade payables 24 A 1,794.58 444.56 - total outstanding dues of micro enterprises and small enterprises 24 B 11,279.46 12,201.44 Other financial liabilities 25 12,806.06 10,002.11 Other current liabilities 23 B 4,141.49 4,258.25 Provisions 22 B 877.47 953.55 Total current liabilities 34,567.19 27,859.99		0(1)		
- total outstanding dues of micro enterprises and small enterprises 24 \ 1,794.58 444.56 - total outstanding dues of creditors other than micro enterprises and small enterprises 24 \ 11,279.46 12,201.44 12,		21 B	3,668.13	
- total outstanding dues of creditors other than micro enterprises and small enterprises 24 B 11,279.46 12,201.44 Other financial liabilities 25 12,806.06 10,002.11 Other current liabilities 23 B 4,141.49 4,258.25 Provisions 22 B 877.47 955.55 Total current liabilities 34,567.19 27,859.99		2		
Other financial liabilities 25 12,806.06 10,002.11 Other current liabilities 23 B 4,141.49 4,258.25 Provisions 22 B 877.47 953.55 Total current liabilities 34,567.19 27,859.90	- total outstanding thus of condition other than miss successful and small and the			
Other current liabilities 23 B 4,141.49 4,258.25 Provisions 22 B 877.47 953.55 Total current liabilities 34,867.19 27,859.90			·	
Provisions 22 B 877.47 953.55 Total current liabilities 34,867.19 27,859.90			and the second s	
Total current liabilities 34,567,19 27,859,99				
Teal 9-6-10-1		22 B		
2,64,628.89 2,25,971.89				
	AMAI PAMRUCS		2,64,628,89	2,25,971.89

The accompanying summary of significant accounting policies and other explanatory information are an integral part of these consolidated financial statements.

This is the consolidated balance sheet referred to in our report of even date.

CHANDION

CRED ACCO

For Walker Chandiok & Co LLP

Chartered Accountants

Birm's Registration No.: 001076N/N500013

Rajni Mundra

Parmer

Membership No.: 058644

Place: New Delhi

Date: 28 September 2020

Por and on behalf of the Board of Directors,

Dr. Naresh Trehan

Chairman and Managing Director

[DIN:00012148]

Pince: Gurugram

Date: 28 September 2020

Sanjeev Kumar

Chief Financial Officer

Place: Gurugram Date: 28 September 2020 Chief Executive Officer Place: Gurugram

Pankaj Sahai

Date: 28 September 2020

Sunil Kumar Bansal Company Secretary

Place: Gurugram Date: 28 September 2020

Consolidated statement of profit and loss for the year ended 31 March 2020

	Note	For the year ended 31 March 2020	For the year ended 31 March 2019
Income		(₹ in lakhs)	(₹ in laklıs)
Revenue from operations			·
Other income	26	1,48,421.58	1,44,113.22
	27	5,942.51	6,485.59
to.		1,54,364.09	1,50,598.81
Expenses			······································
Cost of materials consumed	28	32,482.74	32,491,69
Employee benefits expense	29	53,878.05	-
Finance costs	30	5,154.75	54,107.92
Depreciation and amortisation expense	31	11,441.36	1,655.80
Impairment losses on financial assets	32		9,071.03
Other expenses	33	1,111.61	1,800,21
	3,7	43,906.43	41,949.97
Profit before the and chara of the interior		1,47,974,94	1,41,076.62
Profit before tax and shate of loss in joint venture Shate of loss in joint venture		6,389.14	9,522.19
Profit before tax		(2.18)	(2.58)
		6,386.96	9,519,61
Tax expenses	34		
Current tax (including earlier years)		4,971.83	5,158.47
Deferred mx credit		(2,217.76)	(1,736.64)
Profit after tax		3,632.89	6,097.78
		P-11-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-	03071170
Other comprehensive income			
Items that will not be reclassified to profit or loss			
Re-measurement gains on defined benefit plans		(233,02)	44.61
Income tax relating to items that will not be reclassified to profit and loss		58.68	49.21
Other comprehensive income for the year		(174,34)	(17.17)
·		(1/4,34)	32.04
Total comprehensive income for the year		2 500 70	
,		3,458.55	6,129.82
Net profit attributable to:			
Owners of the Holding Company			
Non-controlling interests		3,632.89	6,097.78
- In to its only		-	
Other comprehensive income attributable to:		3,632.89	6,097.78
Owners of the Holding Company			
Non-controlling interests		(174.35)	32,04
Mon-controlling interests			
Maria de la companya della companya		(174.35)	32,04
Total comprehensive income attributable to:			
Owners of the Holding Company		3,458.55	6,129.82
Non-controlling interests			
		3,458.55	6,129.82
Earnings per equity share	35		7,507,000
Basic (₹)		7.26	12.25
Diluted (₹)		7.22	12.12
		,	12.12

The accompanying summary of significant accounting policies and other explanatory information are an integral part of these consolidated financial statements.

This is the consolidated statement of profit and loss referred to in our report of even date.

HANDIOR

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rajni Mundra

Partner

Membership No.: 058644

Place: New Delhi

Date: 28 September 2020

For and on behalf of the Board of Directors

Dr. Naresh Trchan

Chairman and Managing Director

[DIN:00012148]

Piace: Gurogram

Date: 28 September 2020

Sanjeev Rumar

Chief Financial Officer

Place: Gurugram Date: 28 September 2020

Pankai Sahai Chief Executive Officer

Place: Gurugram

Date: 28 September 2020

Sunii Kumar Bansal Company Secretary

Place: Gurugram Date: 28 September 2020

A CASH PLOWS FROM OPERATING ACTIVITIES	Por the year ended 31 March 2020	Por the year ended 31 March 2019
	(₹ in taktis)	(₹ in laklır)
Profit before tax and share of loss in joint venture	6,389.14	9,522.19
Adjustments for:		
Depreciation of property, plant and equipment	9,506.65	9,029.69
Depreciation of right of use of assets	1,799.49	
Amortization of intangible assets	135.22	41.34
Loss on sale of property, plant and equipments (net)	9.65	18.52
Excess provision written back	21 11 21 11 11	(787.61)
Interest income on bank deposit and financials assets measured at amortised cost. Government grants income	(94,169,1) (20,872,1)	(1,858.96) (1,467.03)
(Reversit)/impairment in the value of investments	(2.18)	481.43
Unrealised foreign exchange - loss (net)	135.61	10163
Interest on borrowings	1,396.80	299.98
Interest on loase liabilities	3,138.48	1,198.97
Other finance costs	619.46	166.75
Expected credit loss on made receivables	1,1(1.6)	1,800.21
Employee share based payment expense	956.97	2,603.07
Provision for employee benefits (net)	1,242.69	435.62
Operating profit before working capital changes	22,917.08	21,474.27
Movement in working capital		
Current and non-current loans	(79.88)	(284.44)
Inventories	(1,522.94)	(56.28)
Other current financial assets	(806.66)	\$16.53
Other current assets	299.13	(388.62)
Trade receivables	480.23	(3,036.98)
Other non-current assets	(143.76)	5.61
Other current liabilities and current financial liabilities	586.53	685.71
Other non-current liabilities Trade payables	966.72 428.84	821.35 2,020.10
Cash Rows from operations	23,124,49	21,757.26
Income-tax paid (net of refunds)	(5,617.61)	(6,749.79)
Net cash flows from operating activities (A)	17,506.88	15,007.47
	E	
B CASH PLOWS PROM INVESTING ACTIVITIES		
Purchase of property plant and equipments, capital work-in-progress and intangible assem (including capital advances,	(18,826.73)	(29,969.32)
capital creditors and deferred payment liabilities)		
Proceeds from sale/disposal of property, plant and equipments	53.11	104.77
Movement in other bank halances (net)	9,976.81	1,284.32
Movement in bank deposits having maturity period more than 12 months (net) Interest received	(2,224.87) 1,946.89	2,390,41 1,839,96
Net cash used in investing activities (B)	(9,074.79)	(24,349.86)
Net cast user at integral servates (a)	(7)074,737	(21,517.00)
C CASH PLOWS FROM FINANCING ACTIVITIES		
Proceeds from issue of share capital	21.22	63.87
Proceeds from non-current borrowings	11,230.00	22,725.01
Repayment of non-current borrowings	(1,832,42)	(640.97)
Repayment of/proceeds from current horrowings (net)	-	(6,740.12)
Interest paid on borrowings	(5,198.41)	(4,156,49)
Other finance costs poid	(56.25)	=
Interest paid on lease liabilities	(2,447.44) (1,805.04)	-
Payment of lease liabilities Net east: flows from flouncing activities (C)	(88,34)	11,251.30
Telecon police and minimum (o)	and the second second	
forcease in east and east equivalents (A+B+C)	8,343.75	1,908.90
Cash and cash equivalents at the beginning of the year	6,571.43	4,662.53
Cash and cash equivalents at the end of the year (refer note no. 16)	14,915,18	6,571.43
Reconciliation of cash and cash equivalents as per cash flow statement	(, ()) ***	
Balances with banks in current accounts	4,619.79	1,573.81
Cheques on hand Cash no hand	1.37 162.42	34.61 173.97
Cash on hand Bank deposits with original manurity loss than three months	10,131.69	1,789.04
Some superior and original residency are come over the control	[4,915,18	6,571.43

The accompanying summary of significant accounting policies and other explanatory information are an integral part of these consolidated financial statements.

This is the consolidated cash flow statement referred to in our report of even date,

NOICHAN

Por Walker Chandlok & Co LLP

Chartered Accountants

Pinn's Registration No.: 001076N/N500013

Rojut Mundra

Monbership No.: 058644

Place: New Delhi Date: 28 September 2020 Dr. Nacesh Trebon Chatman and Managing Director [DIN:000121-18]

Place: Goraguan Date: 28 September 2028

Saujeev Kilmar

Chief Financial Officer Placet Gaugnam Date: 28 September 2020 Por and on behalf of the Buard of Directors

Pankaj Salori Chief Executive Officer

Placer Guruguen

Date: 28 September 2020
Sunit Komar Bansal Company Secretary

Place: Guiogean Date: 28 September 2020

Consolidated statement of changes in equity for the year ended 31 March 2020

_	quity share enpital ^s articulars	Opening balance as at I April 2018	Changes in equity share eapital during the year	Balance as at 31 March 2019	Changes in equity share capital during the year	(₹ in lakhs) Balance as at 3i March 2020
13.	sprity share capital	4,849.41	63.87	4,913.28	21.22	4,934.50

Instruments entirely equity in nature** Particulats	Opening balance as at 1 April 2018	Changes in equity share capital during the year	Balance as at 31 March 2019	Changes in equity share capital during the year	(₹ in lakhs) Balance as at 31 March 2020	
Compulsarily convertible preference shares	3,250.00		3,250.00	-	3,250.60	

Particulars		Reserves and	surplus reserve		(8 in iakhs) Total
	Securities premium	Share options outstanding account	Retained earnings	Capital reserve	x Otto
Opening balance as at 1 April 2018	40,946.78	7,441.00	64,040.28	1,192.74	1,13,620,81
Profit for the year Other comprehensive income	-		6,097.78		6,097.78
Re-measurement gains on defined benefit plans (net of tax)		-	32.04		32.04
Employee share based payment expense Stock options lapsed during the year	-	2,603.07 (103.50)	102 50		
Issue of equity shares (on account of exercise of stock options)	4,572.37	(4,572.37)	1	-	-
Balance as at 31 March 2019	45,519.15	5,368.20	70,273.60	1,192.74	1,22,353,69
Profit for the year Other comprehensive income	-	*	3,632.89	- 1,172.74	3,632.89
Re-measurement gains on defined benefit plans (net of tax)			(174.35)	~	(174.35)
Employee share based payment expense Issue of equity shares (on account of exercise of stock	- 1,481.72	956.97 (1,481.72)	-	-	956.97
options)	.,101.72	(1,461.72)	-	-	-
Balance as at 31 March 2020 *Refer note 18A for details	47,000.87	4,843.45	73,732.14	1,192,74	1,26,769.20

^{*}Refer note 18A for details

The accompanying summary of significant accounting policies and other explanatory information are an integral part of these consolidated financial statements.

This is the consolidated statement of changes in equity referred to in our report of even date.

TERED ACC

For Walker Chandlok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rajni Mundra Pattner

Membership No.: 058644

Piace: New Delhi

Date: 28 September 2020

Dr. Natesh Trehan Chairman and Managing Director

[DIN:00012148]

Place: Gurugram Date: 28 September 2020

Sanjeev Kunar Chief Financial Officer

Place: Gurugram Date: 28 September 2020 For and on behalf of the Board of Directors

Pankaj Sahni Chief Executive Officer

Piace: Gurugram Date: 28 September 2020

> Sunit Kuniar Bansal Company Secretary

Place: Gurugram Date: 28 September 2020

^{**}Refer note 18B for details

^{***}Refer note 19 for details

Global Health Private Limited Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

1. Background

Global Health Private Limited ('Holding Company'), its subsidiaries and joint venture (together referred as "the Group" in following notes) are engaged in the business of providing healthcare services. The Holding Company is domiciled in India and its registered office is situated at E – 18, Defence Colony, New Delhi – 110024.

2. General information and statement of compliance with Ind AS

The consolidated financial statements comply in all material aspects with Indian Accounting Standards (hereinafter referred to as the 'Ind AS') as notified by Ministry of Corporate Affairs under Section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules 2015, as amended and other relevant provisions of the Act.

The consolidated financial statements for the year ended 31 March 2020 were authorized and approved for issue by the Board of Directors on 28 September 2020. The revision to consolidated financial statements is permitted by Board of Directors of the Holding Company after obtaining necessary approvals or at the instance of regulatory authorities as per provisions of the Act.

3. Basis of preparation

The consolidated financial statements have been prepared on going concern basis in accordance with accounting principles generally accepted in India. Further, the consolidated financial statements have been prepared on historical cost basis except for share based payments and certain financial assets and financial liabilities which are measured at fair value.

4. Recent accounting pronouncement

Amendment to Ind AS 103, Business Combinations

On 24 July 2020, Ministry of Corporate Affairs ("MCA") has issued an amendment to Ind AS 103 whereby definition of the business has been amended. Additionally, new amendments also provide new aspects to evaluate a set of activities as business. The effective date of these amendments is 1 April 2020. The Group is evaluating the requirements of the amendments and their impact on these consolidated financial statements.

Amendment to Ind AS 116, Leases

On 24 July 2020, Ministry of Corporate Affairs ("MCA") has issued an amendment to Ind AS 116 in respect of rent concessions occurring as a direct consequence of the Covid-19 pandemic. The effective date of these amendments is 1 April 2020. However, in case an entity (lessee) has not yet approved the financial statements before the issuance of this amendment, then the same may be applied for annual reporting periods beginning on or after 1 April 2019 as well. The Holding Company is evaluating the requirements of the amendments and their impact on the financial statements.

Amendment to Ind AS 1, Presentation of Financial Statements

On 24 July 2020, Ministry of Corporate Affairs ("MCA") has issued an amendment to Ind AS 1 whereby definition of the word 'material' has been enhanced to make it more explanatory and it now covers more scenarios. The effective date of these amendments is 1 April 2020. The Group is evaluating the requirements of the amendments and their impact on these consolidated financial statements.

Amendment to Ind AS 10, Events After the Reporting Period

HOLDINA

On 24 July 2020, Ministry of Corporate Affairs ("MCA") has issued an amendment to Ind AS 10 in respect of disclosure requirement related to non-adjusting event. This amendment requires additional information to be disclosed for material non-adjusting events. The effective date of these amendments is 1 April 2020. The Group is evaluating the requirements of the amendments and their impact on these consolidated financial statements.

Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

5. Summary of significant accounting policies

The consolidated financial statements have been prepared using the significant accounting policies and measurement bases summarised below. These policies have been consistently applied to all the years presented, unless otherwise stated.

5.1 Principles of consolidation

Subsidiaries

Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the relevant activities of the entity. The Group has power over the investee even if it owns less than majority voting rights i.e. rights arising from other contractual arrangements. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases. Statement of profit and loss (including other comprehensive income ('OCI')) of subsidiaries acquired or disposed of during the period are recognised from the effective date of acquisition, or up to the effective date of disposal, as applicable. All the consolidated subsidiaries have a consistent reporting date of 31 March 2020. The Group combines the financial statements of the Holding Company and its subsidiaries line by line adding together like items of assets, liabilities, equity, income and expenses. Inter group transactions, balances and unrealised gains on transactions between group companies are eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

Non-controlling interests, presented as part of equity, represent the portion of a subsidiary's statement of profit and loss and net assets that is not held by the Group. Statement of profit and loss balance (including other comprehensive income ('OCI')) is attributed to the equity holders of the Holding Company and to the non-controlling interests, basis the respective ownership interests and such balance is attributed even if this results in controlling interests having a deficit balance.

The Group treats transactions with non-controlling interests that do not result in a loss of control as transactions with equity owners of the Group. Such a change in ownership interest results in an adjustment between the carrying amounts of the controlling and non-controlling interests to reflect their relative interests in the subsidiary. Any difference between the amount of the adjustment to non-controlling interests and any consideration paid or received is recognized within equity.

Joint ventures

Investments in joint arrangements are classified as either Joint operations or Joint ventures. The classification depends on the contractual rights and obligations of each investor, rather than the legal structure of the Joint arrangement. The Group has classified its investment in joint arrangement as joint ventures.

Interest in joint venture is accounted for using the equity method, after initially being recognised at cost. The carrying amount of the investment is adjusted thereafter for the post acquisition change in the share of net assets of the investee or impairment, if any, adjusted where necessary to ensure consistency with the accounting policies of the Group. The consolidated statement of profit and loss (including the other comprehensive income) includes the Group's share of the results of the operations of the investee. Dividends received or receivable from joint ventures are recognised as a reduction in the carrying amount of the investment.

5.2 Business combinations

The Group applies the acquisition method in accounting for business combinations. The consideration transferred by the Group to obtain control of a subsidiary is calculated as the sum of the acquisition-date fair values of assets transferred and liabilities incurred. Acquisition costs are expensed as incurred.

Identifiable assets acquired and limbilities and contingent liabilities assumed in a business combination are measured initially at their acquisition pace fair value.



Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Goodwill is measured as excess of the aggregate of the fair value of the consideration transferred, the amount recognized for non-controlling interests and fair value of any previous interest held, over the fair value of the net of identifiable assets acquired and liabilities assumed. If the fair value of the net of identifiable assets acquired and liabilities assumed is in excess of the aggregate mentioned above, the resulting gain on bargain purchase is recognized in other comprehensive income and accumulated in equity as capital reserve. However, if there is no clear evidence of bargain purchase, the entity recognizes the gain directly in equity as capital reserve, without routing the same through other comprehensive income.

5.3 Current versus non-current classification

All assets and liabilities have been classified as current or non-current as per the Group's operating cycle and other criteria set out in Division II of Schedule III of the Act. Based on the nature of the operations and the time between the acquisition of assets for processing/servicing and their realisation in cash or cash equivalents, the Group has ascertained its operating cycle as twelve months for the purpose of current/non-current classification of assets and liabilities.

5.4 Property, plant and equipment

Recognition and initial measurement

Property, plant and equipment are stated at their cost of acquisition. The cost comprises purchase price, borrowing cost if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Any trade discount and rebates are deducted in arriving at the purchase price. Property, plant and equipment purchased on deferred payment basis are recorded at equivalent cash price. The difference between the cash price equivalent and the total payment is recognised as interest expense over the period until payment is made.

Subsequent vosts and disposal

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repair and maintenance costs are recognised in statement of profit and loss as incurred.

Items such as spare parts, stand-by equipment and servicing equipment are recognised as property, plant and equipment when they meet the definition of property, plant and equipment. Otherwise, such items are classified as inventory.

An item of property, plant and equipment initially recognised is de-recognised upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is recognised in statement of profit and loss when the asset is derecognised.

Capital work-in-progress excluding capital advances includes property, plant and equipment under construction and not ready for intended use as on the balance sheet date.

Subsequent measurement (depreciation and useful lives)

Freehold land is carried at historical cost. All other items of property, plant and equipment are subsequently measured at cost less accumulated depreciation and impairment losses. Depreciation on property, plant and equipment is provided on a straight-line basis, computed on the basis of useful lives (as set out below) prescribed in Schedule II to the Act.





Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Asset class	Useful life
Building	30 years
Medical equipment	5 to 15 years
Medical and surgical instruments	3 years
Other plant and equipment	15 years
Furniture and fixtures	10 years
IT équipment	3 to 6 years
Office equipment	5 years
Electrical installation	10 years
Vehicles	6 to 8 years

Till previous year, leasehold land is amortised over the period of the lease. In the current year, as this has been classified as right of use assets and accordingly its recognition and measurement are explained in the accounting policy 5.9 pertaining to leases.

Leasehold improvements are amortised over the lower of useful life and the lease term.

The residual values, useful lives and method of depreciation of are reviewed at the end of each financial year.

5.5 Intangible assets

Recognition and initial measurement

Intangible assets (software) are stated at their cost of acquisition. The cost comprises purchase price, borrowing cost if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use.

Subsequent measurement

The cost of capitalized software is amortized over a period of five years from the date of its acquisition.

De-recognition

Intangible asset is de-recognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is recognized in the statement of profit and loss, when the asset is derecognised.

5.6 Inventories

Inventories are valued at cost or net realisable value, whichever is lower. Cost is calculated on weighted average basis. Cost of these inventories comprises of all cost of purchase, taxes and other costs incurred in bringing the inventories to their present location and condition. Cost of purchased inventory is determined after deducting rebates and discounts.

Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale.

5.7 Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable. Revenue is recognized upon transfer of control of promised products or services to customers/patients in an amount that reflects the consideration the Group expects to receive in exchange for those products or services. Revenue is measured net of rebates, discounts and taxes. The Group applies the revenue recognition criteria to each component of the revenue transaction as set out below.



Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Healthcare services

Revenue from healthcare services is recognized as and when related services are rendered and include services for patients undergoing treatment and pending for discharge, which is shown as unbilled revenue under other current financial assets. The Group considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Group expects to be entitled in exchange for the services, excluding amounts collected on behalf of third parties (for example, indirect taxes).

A receivable is recognised by the Group when the control is transferred as this is the case of point in time recognition where consideration is unconditional because only the passage of time is required. When either party to a contract has performed, an entity shall present the contract in the balance sheet as a contract asset or a contract liability, depending on the relationship between the entity's performance and the payment.

Clinical research

Clinical research income is recognized over time basis percentage completion method which is determined based on achievement of milestones.

Interest income

Interest income is recorded on accrual basis using the effective interest rate (EIR) method.

Sponsorship income

Sponsorship income is recognised in the accounting year in which the services are rendered as per the agreed terms with the customers.

Other income

Revenue arising from revenue sharing agreements is recognized as per the terms of the arrangement.

Rental income is recognised on a straight-line basis over the lease term, except for contingent rental income which is recognised when it arises.

5.8 Borrowing cost

Borrowing cost includes interest expense as per effective interest rate (EIR). Borrowing costs directly attributable to the acquisition, construction or production of a qualifying asset are capitalized during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for its intended use or sale. All other borrowing costs are expensed in the period they occur.

5.9 Leases

Group as a lessee - Right of use assets and lease liabilities

Till previous year, assets acquired on leases where a significant portion of risk and rewards of ownership are retained by the lessor are classified as operating leases. Lease rental are charged to statement of profit and loss on straightline basis except where scheduled increase in rent compensate the lessor for expected inflationary costs.

For any new contracts entered into on or after 1 April 2019, the Group considers whether a contract is, or contains a lease (for existing leases, the transition approach has been explained and disclosed in Note 41). A lease is defined as 'a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration'.

Classification of leases

The Group enters into leasing arrangements for various assets. The assessment of the lease is based on several factors, including, but not limited to, transfer of ownership of leased asset at end of lease term, lessee's option to extend/purchase etc.



Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Recognition and initial measurement of right of use assets

At lease commencement date, the Group recognises a right-of-use asset and a lease liability on the balance sheet. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease (if any), and any lease payments made in advance of the lease commencement date (net of any incentives received).

Subsequent measurement of right of use assets

The Group depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist.

Lease liabilities

At lease commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the Group's incremental borrowing rate. Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed payments) and variable payments based on an index or rate. Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is re-measured to reflect any reassessment or modification, or if there are changes in in-substance fixed payments. When the lease liability is re-measured, the corresponding adjustment is reflected in the right-of-use asset.

The Group has elected to account for short-term leases using the practical expedients. Instead of recognising a right-of-use asset and lease liability, the payments in relation to these short-term leases are recognised as an expense in statement of profit and loss on a straight-line basis over the lease term.

Group as a lessor

Leases in which the Group does not transfer substantially all the risks and rewards of ownership of an asset are classified as operating leases. The respective leased assets are included in the balance sheet based on their nature. Rental income is recognized on straight-line basis over the lease-term.

5.10 Impairment of non-financial assets

Assessment is done at each balance sheet date as to whether there is any indication that an asset may be impaired. For the purpose of assessing impairment, the smallest identifiable group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows from other assets or groups of assets, is considered as a cash generating unit. If any such indication exists, an estimate of the recoverable amount of the asset/cash generating unit is made. Assets whose carrying value exceeds their recoverable amount are written down to the recoverable amount. Recoverable amount is higher of an asset's or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. Assessment is also done at each balance sheet date as to whether there is any indication that an impairment loss recognised for an asset in prior accounting periods may no longer exist or may have decreased.

5.11 Foreign currency

Functional and presentation currency

The consolidated financial statements have been prepared and presented in Indian Rupees (INR), which is the Holding Company's functional and presentation currency.

Transactions and balances

Foreign currency transactions are recorded in the functional currency, by applying to the exchange rate between the functional currency and the foreign currency at the date of the transaction.

Foreign currency monetary items outstanding at the balance sheet date are converted to functional currency using the closing rate. Non-monetary items denominated in a foreign currency which are carried at historical cost are reported using the exchange rate at the date of the transaction.

Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Exchange differences arising on monetary items on settlement, or restatement as at reporting date, at rates different from those at which they were initially recorded, are recognized in the statement of profit and loss in the year in which they arise.

5.12 Financial instruments

Recognition and initial measurement

Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted for transaction costs, except for those carried at fair value through profit or loss which are measured initially at fair value.

The classification depends on the Group's business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses will either be recorded in the statement of profit and loss or other comprehensive income. For investments in debt instruments, this will depend on the business model in which the investment is held. For investments in equity instruments, this will depend on whether the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income ('FVOCI').

Non-derivative financial assets

Subsequent measurement

Financial assets carried at amortised cost – A 'financial asset' is measured at the amortised cost if both the following conditions are met:

- The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows,
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method.

De-recognition of financial assets

A financial asset is de-recognised when the contractual rights to receive cash flows from the asset have expired or the Group has transferred its rights to receive cash flows from the asset.

Non-derivative financial liabilities

Subsequent measurement

Subsequent to initial recognition, all non-derivative financial liabilities are measured at amortised cost using the effective interest method.

De-recognition of financial liabilities

A financial liability is de-recognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the Group or the Market party.



Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

5.13 Impairment of financial assets

The Group assesses on a forward looking basis the expected credit losses associated with its financial assets and the impairment methodology depends on whether there has been a significant increase in credit risk.

Trade receivables

In respect of trade receivables, the Group applies the simplified approach of Ind AS 109, which requires measurement of loss allowance at an amount equal to lifetime expected credit losses. Lifetime expected credit losses are the expected credit losses that result from all possible default events over the expected life of a financial instrument.

Other financial assets

In respect of its other financial assets, the Group assesses if the credit risk on those financial assets has increased significantly since initial recognition. If the credit risk has not increased significantly since initial recognition, the Group measures the loss allowance at an amount equal to 12-month expected credit losses, else at an amount equal to the lifetime expected credit losses.

When making this assessment, the Group uses the change in the risk of a default occurring over the expected life of the financial asset. To make that assessment, the Group compares the risk of a default occurring on the financial asset as at the balance sheet date with the risk of a default occurring on the financial asset as at the date of initial recognition and considers reasonable and supportable information, that is available without undue cost or effort, that is indicative of significant increases in credit risk since initial recognition. The Group assumes that the credit risk on a financial asset has not increased significantly since initial recognition if the financial asset is determined to have low credit risk at the balance sheet date.

5.14 Taxes

Tax expense comprises current and deferred tax. Current and deferred tax is recognised in statement of profit and loss except to the extent that it relates to items recognised directly in equity or other comprehensive income.

The current income-tax charge is calculated on the basis of the tax laws enacted at the balance sheet date. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred tax is provided in full, on temporary differences arising between the tax base of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred tax asset is realised or the deferred tax liability is settled. Deferred tax assets are recognised for all deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.

5.15 Cash and cash equivalents

Cash and cash equivalents include cash in hand, demand deposits with the banks, other short-term highly liquid investments with original maturity of three months and less.





Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

5.16 Employee benefits

Short-term employee benefits

Liabilities for wages and salaries, including non-monetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are classified as short-term employee benefits. These benefits include salaries and wages, short-term bonus, incentives etc. These are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

Defined contribution plan

Contribution towards provident fund is made to the regulatory authorities, where the Group has no further obligations. Such benefits are classified as defined contribution plan as the Group does not carry any further obligations, apart from the contributions made on a monthly basis. In addition, contributions are made to employees' state insurance schemes and labour welfare fund, which are also defined contribution plans recognized and administered by the Government of India and Haryana respectively. The Group's contributions to these schemes are expensed in the statement of profit and loss.

Defined benefit plan

The Group has unfunded gratuity as defined benefit plan where the amount that an employee will receive on retirement is defined by reference to the employee's length of service and final salary. The gratuity plan provides a lump sum payment to vested employees at retirement, death, incapacitation or termination of employment, of an amount based on the respective employee's salary and the tenure of employment. The Group's liability is actuarially determined (using the Projected Unit Credit method) at the end of each year. This is based on standard rates of inflation, salary growth rate and mortality.

Discount factors are determined close to each year-end by reference to market yields on government bonds that have terms to maturity approximating the terms of the related liability. Service cost and net interest expense on the Group's defined benefit plan is included in employee benefits expense.

Actuarial gains/losses resulting from re-measurements of the defined benefit obligation are included in other comprehensive income.

Other long-term employee benefits

The Group also provides benefit of compensated absences to its employees which are in the nature of long-term employee benefit plan. Liability in respect of compensated absences becoming due and expected to be availed more than one year after the balance sheet date is estimated on the basis of an actuarial valuation performed by an independent actuary using the projected unit credit method as on the reporting date. Service cost and net interest expense on the Group's other long-term employee benefits plan is included in employee benefits expense. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are recorded in the statement of profit and loss in the year in which such gains or losses arise.

5.17 Government grants

Grants from the government are recognised at their fair value when there is reasonable assurance that the grant will be received and the Group will comply with all attached conditions. When the grant relates to a revenue item, it is recognized in statement of profit and loss on a systematic basis over the periods in which the related costs are expensed. The grant can either be presented separately or can deduct from related reported expense. Government grant relating to capital assets are recognised initially as deferred income and are credited to statement of profit and loss on a straight line basis over the expected lives of the related asset and presented within other income. Ministry of Corporate Affairs ('MCA') has inserted new provisions effective 20 September 2018 and allowed government grants related to capital assets to be to be netted off from capital asset and recognise in statement of profit and loss over the life of a depreciable asset as a reduced depreciation expense.

5.18 Share based payment expense

The fair value of options granted under Global Health Employee Stock Option Scheme 2014 and 2016 is recognized as an employee benefit expense with a corresponding increase in equity. The total amount to be expensed is determined by reference fair value of the options granted:

Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

- Including any market performance conditions (e.g., the entity's share price)
- Excluding the impact of any service and non-market performance vesting conditions (e.g. profitability, sales growth targets and remaining an employee of the entity over a specified time period), and
- Including the impact of any non-vesting conditions (e.g. the requirement for employees to save or holding shares for a specified period of time).

Total expense is recognized over the vesting period, which is the period over which all the specified vesting conditions are to be satisfied. At the end of each period, the entity revises its estimates of the number of options that are expected to be vest based on the non-market vesting and service conditions. It recognizes the impact of revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.

5.19 Provisions, contingent liabilities and contingent assets

Provisions are recognized when the Group has a present (legal or constructive) obligation as a result of past events, for which it is probable that an outflow of resources will be required to settle the obligation and a reliable estimate of the amount can be made. Provisions required to settle are reviewed regularly and are adjusted where necessary to reflect the current best estimates of the obligation. Provisions are discounted to their present values, where the time value of money is material.

Contingent liability is disclosed unless the likelihood of an outflow of resources is remote and there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources.

Contingent assets are disclosed only when inflow of economic benefits therefrom is probable and recognized only when realization of income is virtually certain.

5.20 Earnings per share

Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting attributable taxes) by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period is adjusted for events including a bonus issue.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

5.21 Rounding of amounts

All amounts disclosed in the consolidated financial statements and notes have been rounded off to the nearest lakhs as per the requirement of Division II of Schedule III, unless otherwise stated.

5.22 Critical estimates and judgements

The preparation of consolidated financial statements requires the use of accounting estimates which, by definition, will seldom equal the actual results. Management also needs to exercise judgement in applying the Group's accounting policies. This note provides an overview of the areas that involved a higher degree of judgement or complexity, and of items which are more likely to be materially adjusted due to estimates and assumptions turning out to be different than those originally assessed. Detailed information about each of these estimates and judgements is included in relevant notes together with information about the basis of calculation for each affected line item in the consolidated financial statements.

a) Recognition of deferred tax assets – The extent to which deferred tax assets can be recognized is based on an assessment of the granting of the Group's future taxable income against which the deferred tax assets can be utilized.



Global Health Private Limited Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

- b) Evaluation of indicators for impairment of assets The evaluation of applicability of indicators of impairment of assets requires assessment of several external and internal factors which could result in deterioration of recoverable amount of the assets.
- c) Contingent liabilities At each balance sheet date basis the management judgment, changes in facts and legal aspects, the Group assesses the requirement of provisions against the outstanding contingent liabilities. However, the actual future outcome may be different from this judgement.
- d) Impairment of financial assets At each balance sheet date, based on historical default rates observed over expected life, existing market conditions as well as forward looking estimates, the management assesses the expected credit losses on outstanding receivables. Further, management also considers the factors that may influence the credit risk of its customer base, including the default risk associated with industry and country in which the customer operates.
- e) Defined benefit obligation (DBO) Management's estimate of the DBO is based on a number of underlying assumptions such as standard rates of inflation, mortality, discount rate and anticipation of future salary increases. Variation in these assumptions may significantly impact the DBO amount and the annual defined benefit expenses.
- f) Useful lives of depreciable/amortisable assets Management reviews its estimate of the useful lives of depreciable/amortisable assets at each reporting date, based on the expected utility of the assets. Uncertainties in these estimates relate to technical and economic obsolescence that may change the utilisation of assets.
- g) Leases The Group evaluates if an arrangement qualifies to be a lease as per the requirements of Ind AS 116. Identification of a lease requires significant judgment. The Group uses significant judgment in assessing the lease term (including anticipated renewals) and the applicable discount rate. The Group determines the lease term as the non-cancellable period of a lease, together with both periods covered by an option to extend the lease if the Group is reasonably certain to exercise that option; and periods covered by an option to terminate the lease if the Group is reasonably certain not to exercise that option. In assessing whether the Group is reasonably certain to exercise an option to extend a lease, or not to exercise an option to terminate a lease, it considers all relevant facts and circumstances that create an economic incentive for the Group to exercise the option to extend the lease, or not to exercise the option to terminate the lease. The Group revises the lease term if there is a change in the non-cancellable period of a lease.
- h) Government grant Grants receivables are based on estimates for utilization of the grant as per the regulations as well as analysing actual outcomes on a regular basis and compliance with stipulated conditions. Changes in estimates or non-compliance of stipulated conditions could lead to significant changes in grant income and are accounted for prospectively over the balance life of the asset.
- i) Fair value measurements Management applies valuation techniques to determine fair value of equity shares (where active market quotes are not available) and stock option. This involves developing estimates and assumptions around volatility, dividend yield which may affect the value of equity shares or stock options.

Estimates and judgements are continuously evaluated. They are based on historical experience and other factors including expectation of future events that may have a financial impact on the Group and that are believed to be reasonable under the circumstances.



(This space has been intentionally left blank)



Obbal Health Private Limited Consolidated summany of significant accounting politics and other explanatory information for the year caded 31 March 2020

	*
ž.	
n-pro	
A.D.Y	
anita	
bac t	_
Daca	
16 594	
נמטן אנ	
1	1
•	i
Front	ć

Particulars				***************************************										(₹ in Jakhs)
	E				- 1	Unned assers	***************************************					Leased assets	Total	Capital work-
	rrenois Lind	Suciong	Medical	Medical and entmical	Other plant and	Furniture and	II equipment	Office	Electrical	Leasehold	Vehicles	Leasehold land		in-progress*
				instruments	i dub	9		edurbment	mstaltation	mprovements				
Gross block														
Balance as at 1 April 2015	22,427.01	31,254.40	38,092.32	1,355,41	12.217.61	2,390,17	1 535 12	36135	2,073.70	2 020 53	100 47	2000	20 623 62	1
Additions	,	133.23	1.632.82		708 JS	62.52	130	9.35	1000	2000	107.00	0077001	C0.055,254	37,702.78
Disposals/adjustments		,	69 740		(71.55)	989	76	(3.47)	177	20,874	203.60	•	3,205,42	97,299,59
Batance as at 51 March 2019	22,427.01	31 387 63	30 C92 46	4	10 60 61	3 450 15	(14.0)			,	(42.88)	-	(205,13)	(406.50)
Additions		21 000 01	20.202	1	AC-ACA-24	C1-70-67	80.78	לבינוני ה	5,085.46	2,532,20	450.19 /	17,622.00	1,35,640,95	65,595.37
Psonesis/artinemen		CATTON CO	Concording to	907/19	5,162.26	646.53	1,902.09	110.77	3,721.85	58.49	133.08		53.762.07	25,614.46
Transfer to right of use assets	•	•	1	•	(6.2%)	(65.0)		(1.38)			(72.60)	•	(51.23)	(53,037.12)
			_	4		***************************************					,	(00.528.77)	(17,622.00)	•
Balance as at 31 March 2020	22,427.01	62,409.66	50,098.31	1,944.93	17,766.52	3,098.73	3,546.05	494.93	6,807.31	2,590.69	522.67	,	L71,696.RI	38,172,91
Accumulated depreciation														
Balance as at 1 April 2018	,	3,761.65	10,149.70	246.71	3,378.14	1,258,10	\$63.27	206.42	1 853 05	62 GF3	20.00	00.00	22.02.00	T
Charge for the year	,	1,286.51	3,913.27	27464	1.205.90	455.63	25.5%	53 59	50.053	15(3)	2000	60.00	77.000.07	
Disposals/adjustments	,	•	(59.91)	(6.56)	(1.63)	690)	6.50	e e	TO THE PERSON NAMED IN	65.50	867.6	195.84	67'620'6	,
Salance as at 3t March 2019		5.048.16	14.023.06	1 214 70	V 585 41	1 112 00	* ***	20 0000	20.20	,	(0170)	,	(%: &-1)	
Champ for the range	-	0 / / / /		4	44.00	4775.00	*******	C7-717	/870577	UE-200-7	62.45	626.39	22,784.73	,
Newson's factors	•	AC.017.	\$0.10°	F + 5	1,355.52	345.52	¥.38	62.06	552.81	603.57	7,3		9.306.65	
Transfer to right of me access	•		(5.11)	ı	(K)	(ਜੂਰ)	•	(R)		*	(14.60)	,	3,46	,
CONTRACT OF THE PARTY OF THE PA	,		-	,					,	,	-	(636.89)	(626.87)	
Balmete as at 31 March 2020	•	6,764.66	18,269.08	1,428.99	5,940.68	2,058.39	1,567,54	333,02	3,059.88	2,208.67	112.17	,	41,643.08	,
Ner block as at 31 March 2019	22,427.01	26,339.47	25,559,40	252.47	8,019.10	739,66	417.42	113.23	578.39	3,027.30	387.76	11.2%2,31	1,02,856.18	65,595.57
Ner block as at 31 March 2020	22,427.01	55,645.00	31,829.23	515.94	11,825.54	1,040,34	1,978.51	161.91	3,747,43	482.02	60.50	,	1 TA DES 72	10 577 05
	***************************************	-									?		-	200 to 100

[.] During the year ended 31 March 2020 and 31 March 2019, following expenses has been expiralised as part of capital work-in-progents.

,		(₹ in lakhs)	
Particulars	31 March 2020	31 March 2019	
Borrowing costs	5.838.72	3,396,30	
Employee bonefits expense	762.66	85025	
Other expenses	204.08	872.23	
Total	4.795.46	4.628.82	

(6) Contractual obligations
Acfer note 40B for disclassure of contractual commitments for the acquisition of property, plant and equipment.

(ii) Property, plant and equipment pledged as security
Hospital project and of 25 security and equipment However, during the year, the Holding Company has made the full payment against outstanding turn leans balance.
The schaidsing companies have provided exclusives pash passu change on property, plant and equipment for horrowings. Refer note 20(2)(2), 20(4)(2) and 20(4)(4) for details.



(This space has been intunionally left blank)



Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

6B Right of use assets* (7 in lakhs)

				(m sakns)
Building premiecs	Other plant and equipment	Vehicle lease	Leasehold land	'Fotal
9,871.68	127.59	138.34	7,429.73	17,567.34
-		-	16,995.11	16,295.11
4,623.29	22,61	-		4,645,90
14,494.97	150,20	138.34	24,424.84	39,208.35
			j	
1,258.20	7.71	75.57	458.00	1,799.49
1,258.20	7,71	75,57	458.00	1,799.49
13,236.77	142,49	62.77	23,966.84	37,408.86
	9,871.68 - 4,623.29 14,494.97 1,258.20	9,871.68 (27.59 4,623.29 22.61 14,494.97 150.20 1,258.20 7.71 1,258.20 7.71	premiecs equipment 9,871.68 127.59 138.34 4,623.29 22.61 - 14,494.97 150.20 336.34 1,258.20 7.71 75.57 1,258.20 7.71 75.57	premiees equipment land 9,871.68 127.59 138.34 7,429.73 - - 16,995.11 4,623.29 22.61 - - 14,494.97 150.20 138.34 24,424.84 1,258.20 7.71 75.57 458.00 1,258.20 7.71 75.57 458.00

^{*} Till previous year, leasehold land and related liabilities were recognised as 'finance leases' under Ind AS 17 Leases'. Leasehold land was presented as part of property, plant and equipment and the liabilities as deferred payment liabilities as part of the Holding Company's borrowings. However, under Ind AS 116, these have been transferred to right of use assets and lease liabilities.

#For details on adjustments recognised on adoption of Ind AS 116, refer note 41.



(This space has been intentionally left blank)



Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Intangible assets	(₹ in lakhs)
•	Software
Balance as at 01 April 2018	254.61
Additions	21.21
Balance as at 31 March 2019	275.82
Additions	846.36
Balance as at 31 March 2020	1,122.18
Accumulated amortisation	
Balance as at 01 April 2018	97.48
Charge for the year	41.34
Balance as at 31 March 2019	138,82
Charge for the year	135.22
Balance as at 31 March 2020	274.04
Net block as at 31 March 2019	137.00
Net block as at 31 March 2020	848.14

(This space has been intentionally left blank)





	As at	As at
	31 March 2020 (V in fakhs)	31 March 2019 (* in lakhs)
Note - 8	(,	(
Investments accounted for using the equity method		
Joint venture - unquoted		
Medanta Duke Research Institute Private Limited# {10,001 equity shares (31 March 2019: 10,001 equity shares) of ₹ 10 each}	479,25	481.43
	479,25	481,43
Less: Impainment in the value of investments	(479.35)	(481.43)
Aggregate book value of unquoted investments		_
Aggregate amount of impairment in value of investments	479.25	481.43
#The Board of Directors ('the Board') of Medanta Duke Research Institute Private Limited (a joint venture) is process of winding up of the aforementioned entity and thereafter, have initiated the process of voluntary I Bankruptcy Code, 2016 read with Insolvency and Bankruptcy (Voluntary Liquidation) Regulations, 2017. Thi Meeting ('AGM') of Medanta Duke Research Institute Private Limited held on 24 September 2019.	liquidation in accordance with the provision	s of the Insolvency and
Note - 9		
A Loans - non current*		
(Unsecured considered good)		
Security deposits	789.81 789,81	731,00
	/37,61	731.00
B Loans - current*		
(Unseenred considered good)		
Security deposits	9.79	84.54
	9.79	84,54
Note - 10 A Other financial assets - non-current (Unsecured considered good) Bank deposits with maturity of more than 12 months (refer note below)	2,384.30	159.44
	2,384.30	159,44
Notes:		
(i) Bank deposits (excluding interest accrued) of ₹ 48.39 lakhs (31 March 2019) ₹ 45.88 lakhs) have been lien market (ii) Bank deposits (excluding interest accrued) of ₹ 594.56 lakhs (31 March 2019) ₹ 48.58 lakhs) are kept under lien w (iii) Bank deposits (excluding interest accrued) of ₹ 51.45 lakhs (31 March 2019) ₹ 48.90 lakhs) have been pledged wi (iv) Bank deposits (excluding interest accrued) of ₹ 6.44 lakhs (31 March 2019) ₹ 5.99 lakhs) have been pledged in fav	vith bank as margin money against the letter o ith banks against guamntees.	
B Other financial assets - current		
(Unsecured considered good, unless otherwise stated)		
Recoverable from related parties (refer note 38)	249.84	221,37
Oubilled revenue	618.41	1,082.11
Receivables under export benefit scheme# Other receivables*	1,824.12	702.28
Considered good	693.76	556,11
Considered doubtful	136.60	136.60
Less: Allowance for expected credit loss	(136.60)	(136.60)
	3,386,13	2,561.87
* Other receivables are primarily on account of revenue sharing arrangements.		
#Movement of receivables under export benefit setteme		
Opening balance	702.28	486.60
Add; grants received during the year	1,149.68	1,280.35
Less: grants transferred and sold during the year Less: grants expired during the year	•	(\$23.85)
Less: utilised for purchase of property, plant and equipment/consumables	(27.85)	(448.73)
	1,824.11	702,28
	·	



1

	b hoseles and only explanatoly thiorination for the year ended 31 March 2020		
		As at	Ås at
		31 March 2020	31 March 2019
		(Cin lakhs)	(č in lakhe)
	Note - 1i		
١	Doletted ian appets (net)		
	Defessed tax assets prising on account of:		
	Unalisorited business tosses and depreciation		
	Emplayee benefits	653.30	31.13
	Others	2/1.72	3.74
	·		0.48
	Deferred tax Habilities arising on account of:	674.02	54.35
	Property, plant and equipment and hypoglife exects		
	77	(674.02)	(0.1%)
		(674.02)	(0.06)
	Minimum alternate tax credit entitlement		
	The state of the s		6.33
1	One of the coloridary consequence of the Late of the L		34.62
,	One of the subsidiary company has unabsorbed business losses (including unchrocked depreciation) of \$7.828.58 likks as at 31 March 2020. Deferred was as unabnothed depreciation) are recognised to the extent that it is qualished that it will be unliked against fining temple income. Such adiability promotions	seta un unabsorbed husis	ers losser (including
	represent the residence to the extent that it is probable that it was he while prints from the period from the control of the prints of the pr	or have recognized defeat	at some significant of "

maniforment deprecusion) are recognised to the extent that it is jumbable that it will be utilised against future taxable income. Such subsidiary company has recognised deferred ax sforcementioned losses only to the extent of deferred ax liabilities. Further, the unabsorded husiness losses are available for otherwise for a maximum period of eight years.

l'articular	Deferred tax page (a a a) I April 2018	Recognised in statement of profit and loss	Recognised in other comprehensive income	Deferred tox Unbilities as at 31 March 2019	Recognised in statement of profit and loss	Recognised in other comprehensive	Deferred tax liabilities as at 31 March 2020
Assett				*****			
Unabsorbed humans a kester and depreciation		31.13		31.13	622.17		683.30
Employee bracits		279	(0.05)	2.74	18.27	(0.29)	26.73
Others Liabilities		0.48	, 1	0.48	(0.48)	. "	
Property, plant and equipment and intragible assets	(0.04)	(0.02)		(0.06)	(673.96)		(674.03
Sub-total	(0.04)	34.38	(0.05)	34.29	(34.60)		
Minimum alternate tax credit entitlement	0.33	3130	(0.03)	0.33	` ";	(0.29)	-
Total	0.29	34.38	(0,05)	34.62	(0.33)	(0.25)	

(111)			
	Expliy Annacial year		
	1 April 2031 - 31 March 2032		0.33
В	Defetted tox liabilities (net)		
	Deferred for Habilities origing on account of:		
	Property, plant and equipment and intangible ascers	4,793.84	7,336,39
	Deferred tax assets arising an account of:		
	Impairment in value of investments	•	((12.(5)
	Entployee benefits	(1,106.33)	(1,343.62)
	Expected credit tous on trade and other receivables	(1,561.43)	(1,731.76)
	Interest cost kuil lesse payments related to leasehold build Others	(1,146.26)	(816.17)
	Offices	(16%.4S)	(210.27)

Particulais	Defetted tax neects ne at 1 April 2018	Recognised in statement of profit and loss	Recognised in other comprehensive income	Deferred tou assess as at 11 hiarch 2019	Recognised in statement of profit and loss	Recognised in other comprehensive income	Deferred tax Habilities as at 31 Morch 2020
Liabilitiee	-,				~~~~~		
Property, plant and equipment and intengible assets	7,971.65	(635-26)		7,336.39	(2,512.55)		4,793.84
Assets							
Inspainment in value of investments	-	(112.15)	. 1	(112.15)	1(2.15	_	
Employee henefits	(1,471.66)	110.92	17.12	(1,343.62)		(58.97)	(1,106.33)
Expected credit loss on trade and other receivables	(1,139.36)	(592.40)		(1,731.76)			(1,56).43)
Interest cost and lesso payments related to lessehold land	(341,37)	(474.50)		(816.17)	(330.09)		(1,146.26)
Others	(211.70)	1.43		(210.27)	41.82	. 1	(168.45)
Total	4.507.56	(1.702.25)	12 12	1 102 42	(20,020,00)	/FG 684	

Note - 12		
Income-tax assets (net)		
Advance tax (net of provision for tax comming to ₹ 38,087,004.kla (31 March 2019; ₹ 33,109.19 laklas))	6,595.75	5,950,50
	6,595.75	5,950.50
Movement in income tax seets (net)		(č (n lakla)
a defection.		As at 31 Morch 2019
	Λ± αξ	
Opening balance	31 March 2020	
Add: There paid (not)	5,950.50	4,359,18
Less: Current tax papable for the year	5,617.08	6,749.79
	(4,971.83)	(5,158.47)
Closing balance	6 595 75	5 040 40





Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

		As at 31 March 2020	An nt 31 Mintch 2019
		(E in laklus)	(E in laklus)
	lote - 13		
	ther non-current assets		
	apinal advances	447.12	1,155.98
Λ	dvances other than capital advances:		
	Propaid expenses	68.70	212.62
	Balances with government authorities		92,63
		515.82	1,461.23
	ther current needs		
	repaid expenses	428.74	605.53
	dvance to material/service providers	235.99	183.29
Λ	dvance to employees	19.64	18.92
		684.37	1,007.74
Α.	inte - 14		
	tycntories*		
		* ***	
	harmacy, medical and laboratory consumables General stores	3,614,40	2,212.31
U	Guent Mores	237.50	116.65
	and the first and a second and Particle and the second field the second and the s	3,851.90	2,328.96
•	valued at cost or net calisable value, whichever is lower		
N	Note - 15		
T	rade receivables		
T	inde receivables - considered good, unsecured#	16,465.48	18,506.81
·i	ando receivables credit impaired	4,517.03	2,866.69
		20,982.51	21,373.70
1.	ess: Allowance for expected credit loss		
	Trade receivables - considered good, unsecured	(1,550.39)	(2,088,92)
	Trade receivables credit impaired	(4,517.03)	(2,866.89)
		14,915.09	16,417.89
#	inter-offer, includes ₹ 275.35 laklis (\$1 March 2019; ₹ 247.30 laklis) receivables from related parties (refer note 38).		<u> </u>
ħ	Vote - 16		
	Cash and cash equivalents		
	blances with banks in current accounts	4,619,79	4,573.81
C	Theques on hand	1.37	34.61
C	ash on band	162.42	173.97
13	bank deposits with original maturity less than three months (refer note below)	(0,131.60	1,789.04
		14,915.18	6,571.43
1	intes;		(*************************************
(i) P	kank deposits of ₹ 158.06 lakhs (31 March 2019: ₹ 526.06 lakhs) are kept under lien with bank as margin money against the lette	er of credit issued.	
7	Vote - 17		
	Other bank balances		
	hask deposits with maturity of more than three mouths and upto twelve mouths (refer note below)	10,097.11	20,073.92
		10,097,33	20,073.92
,	Notes:	>	***************************************

- (i) Bank deposits of ₹ 107.87 Jakhs (31 March 2019; ₹ 106.34 Jakhs) are kept under lien with bank as margin money against the letter of credit issued.
- (ii) Bank deposits of ₹ 775.98 laklis (3) March 2019: ₹ 720.00) are pledged with bank against bank guarantees and letter of credit.

(This space has been intentionally left blank)





Note - 18 A

A Equity share capital

As at 31 March 2020 As at 31 March 2019

i Authorised	Number	Amount (₹ in takits)	Number	Amount (* in laklis)
Class A Equity shares of ₹ 10 each	10,10,24,000	10,102.40	10,10,24,000	10,102.40
Class B Equity shares of ₹ 10 each	1,000	0.10	000,1	0.10
	** **	10,102,50		10,102.50
ii Issued, subscribed and paid up				
Class A Hapity shaces of ₹ 10 each	4,93,45,003	4,934.50 4,934.50	4,91,32,778	4,913.28 4,913.28
iii Reconciliation of number of equity shares outstanding at the l	rear of the bne oil in had grinnings			
Equity shares				
Balance at the beginning of the year	4,91,32,778	4,913.28	4,84,94,054	4,849
Add: Issued during the year (on account of exercise of stock option	2,12,225	21.22	6,38,724	63,87
Balance at the end of the year	4,93,45,003	4,934.50	4,91,32,778	4,913.28

iv Rights, preferences and restrictions attached to equity shares

The Holding Company has two class of equity shares with face value of ₹ 10 per share. In case of class A equity share, each holder of equity is entitled to one vote per share. In case of class B shares, every \$50,000 class B shares shall have voting rights equivalent to one class A shares.

The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Amoust General Meeting, except in case of interim dividend.

v Details of shareholder holding more than 5% of equity share capital

Name of the equity shareholder	Number	%	Number	Number
Dr. Natesit Trehan	1,02,00,000	20.67%	1,02,00,000	20.76%
Mr. Smil Sachdeva jointly with Mrs. Suman Sachdeva	68,00,000	13.78%	68,08,000	13.84%
Dr. Naresh Trehan jointly with Mrs. Madhn Trehan	68,92,675	13.97%	68,92,075	14.03%
Dunezen Investments (Maurinus) PTE ltd.	86,01,979	17.43%	86,01,979	17.53%
Anant Investments	1,30,00,000	26.35%	1,30,00,000	26.46%

vi Aggregate number and class of shares allotted as fully paid up pursuant to contract(s) without payment being received in cash, by way of bonus shares and shares bought back for the period of 5 years immediately preceding the balance sheet date

The Holding Company did not issue any shares pursuant to contract(s) without payment being received in early

The Holding Company did not issue bonus shares in preceding 5 years

The Holding Company has not undertaken any buy back of shaces.

vii Simres reserved for Issue under options

For details of shares reserved for issue under the Employee Stock Option Plan (ESOP) of the Hukling Company, refer note 43.

CHANDION & COUNTY

(This space has been intentionally left blank)

Consolidated running of significant accounting policies and other explanatory information for the year ended 31 March 2020

B Instruments entirely equity in nature

		As at 31 March	2020	As at 31 March	
í	Authorised	Number	Amount (f in lakhs)	Number	Amount (* in lakhe)
	Compulsorily convertible preference shares (Class A) of ₹ 696 each	4,66,954	3,250.00	4,66,954	3,250,03
		4,66,954	3,250.00	4,66,954	3,250.00
ii	Issued, subscribed and fully paid up				
	Compulsorily convertible preference shares (Class A) of ₹ 696 each	4,66,954	3,250.00	4,66,954	3,250,00
		4,66,954	3,250.00	4,66,954	3,250,00

ili Rights, preferences and restrictions attached to CCPS

These shares are non-complainted Class A compulsorily convertible preference shares having no voting rights and not entitled to vote together with the holders of empity shares of the Holding Company and mandatorily entitled to dividend @ 0.00001% of the face value per annum. The shares are non-transferable except as permuted by an agreement between the Holding Company and the holder thereof and prior written permission of the Promoters. The shares are conventible into Class A Equity Shares as per the events and conditions stated below:

	Conversion event*	Conversion ratio
ī	Nineteenth anniversary of the issuance of the Class A Preference Share	One Class A equity share for each Class A preference shares
2	The date on which the Anant Investments owns fewer than 6,630,000 Class A	
	The occurrence of a Qualified Initial Public offer ("IPO") or the last date by which all convertible Securities in the Group should be converted into equity shares in order for the Qualified IPO to be permitted under Indian Law.	
	Offer or the last date by which all convertible securities in the Holding Company	Each Class A preference share shall convert into the lower of (1) One Class A equity share; or (11) The following number of Class A equity shares = {\{(932 * X)/Y - X\}/466,954\} Where X = Total number of equity shares owned by the holder of the Class A preference shares inunediately before conversion Y = Actual IPO Price

*CCPS is classified as equity as the Holding Company expects to issue equity shares in the ratio of 1:1 on the occurrence of conversion event, the nature of which is controlled by the Holding Company.

iv Reconciliation of number of CCPS outstanding at the beginning and at the end of the year

	As at 31 March 2020		As at 31 March 2019	
	Number	Amount (l'in lakhs)	Number	Amount (₹ in laklıs)
Balance at the beginning and at the end of the year	4,66,954	3,250.00	4,66,954	3,250.00
v Details of shareholder holding more than 5% of CCPS				
Name of the equity shareholder	Number	5%	Number	4/4
Anant Investments	4,66,954	100.00%	4,66,954	100.487/
			Ás at 31 March 2020	As at 31 March 2019
Note - 19		-	(f in inkhe)	(₹ În laklıs)
Other equity				
Destionless				

Nature and purpose of other reserves

Share options outstanding account

Securities premium

Securities premium

Retained eatnings

Capital reserve

Securifies premium is used to record the premium on usue of shares. This balance can be utilised in accordance with provisions of the Companies Act, 2013.

Share options outstanding account

This account is used to recognised the grant date fair value of the options issued to employees under the Hulding Company's employee stock uption plan.

Retained earnings

Retained earnings is used to record balance of statement of profit and loss.

Capital reserve

Capital reserve represents difference between share capital of transferor entity and share capital issued to erstwhile shareholders of transferor entity.





47,000.87

4,843,45

73,732.14

1,26,769.20

1,192.74

45,519.15

5,368,20

70,273.60

1,192.74

1,22,353.69

Consultilated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Note - 20	As ni 31 March 2020	As at 31 March 2019
Burowings non-current Secured loans	(f in lakis)	(₹ in takhs)
Term loans		
From banks (refer note (a) below)	55,045.79	45,581.85
Less: current manufiles of long-term borrowings	(1,068.13)	(819.63)
	53,977.66	44,762.22
Vehicle lanns		
From funncial institution (refer note (b) below)	140.02	179.27
Less: current maturities of long-term borsowings	(43.69)	(39.26)
	96,33	140.02
Long-term maturity of finance lease obligation (refer note (c) below)		
Deferred payment liabilities (refer note (d) below)	•	8,574.81
	6,477.55	5,420.0R
	60,551.55	58,897.13

- (a) Repayment terms (including cuttent maturities) and security details for term loan from banks:
- (1) (i) First charge on the hospital project land of 25 acres, current assets, cash, raw materials, semi finished and finished goods, stores and spares including relating to plant and machinery (consumable stores and spaces), bills receivables, whether documentary or clean, and hook delty all bank accounts, funding the tenst and retention accounts) and all other receivables and movables, including tangible and intangible assets, both present and future, whether installed or not and whother lying loose or in cases or which are lying at various sites or any of the Holding Company's premises, warehouses, stockyards and godowns or those of the Holding Company's agents, affiliates, associates or representatives or places whether else situated or any time belonging to the Holding Company.

 (ii) Repayable in 32 equal quarterly instalment beginning from 30 June 2013.

 - (ii) Interest will be paid monthly at an agreed rate of MCLR+0.35% with both the banks.
 (iv) During the year ended 31 March 2020, the Holding Company has made the full payment against outstanding term loan balance.
- (2) One of the subsidiary company has availed a loan facility from Yes Bank Limited (YBL) amounting to ₹ 50,000.00 takins out of which YBL has novated ₹ 5,000 takins to State Bank of bulla (formerly known as State Bank of Hyderabad). The loan is repayable in 12 structured quarterly instalments after moratorium period of 48 months from the date of first disbursement. The rate of interest as on 31 March 2020 is 9,90% p.a. and interest is payable monthly. The outstanding balance 2s at 31 March 2020 is ₹ 34,144,08 isklu (31 March 2019): ₹ 28,015.66 laklır).

The loan is secured by way of exclusive charge on -

- equitable mortgage on project (Medanta Hospital in Eucknow) land admeasuring 12.50 acres and building:
- all current assets and movable property, plant and equipment of the project;
- project's book debts, operating cash flows, receivables, commission and intangible assets (excluding goodwill) pertaining to the project; and all project's bank accounts.
- (3) One of the subsidiary company has availed a loan facility from State Bank of Hyderabad (SBH) amounting to § 5,080.00 lakks. The loan is repayable in 32 structured quarterly instalments after mutatorium period of 33 months from the date of first disbursement. The rate of interest as on 31 March 2020 is 9,90 % p.a. and interest is payable monthly. The ourstanding balance as at 31 March 2020 is ₹ 4,971.71 takins (31 March 2019; ₹ 5,000.00 takins).

The loan is seemed by way of first parsi-passu charge on -

- equitable mortgage on project (Medanta Hospital in Lucknow) land admeasuring 12.50 acres and building
- all current assets and movable property, plant and equipment of the project;
 project's book debts, operating cash flows, exceivables, commission and intangible assets (excluding goodwill) penaining to the project; and
- all project's bank accounts

The horrower shall maintain a debts service reserve account (DSRA) for one quarter's principal repayment and one manth's interest payment and principal DSRA to be maintained one quarter prior to commencement of epayment. Interest DSRA to be excited upfront at the time of each disbursement.

- (4) (i) One of the Subsidiary company has availed a loan facility from Ratnakar Bank Limited (RBL) amounting to ₹ 36,500.00 lakks.
 - (ii) The loan is secured by way of by way of hypothecation of property, where hyphotecated property means all present and future current and movable property, plant and equipment of the bottower, including without limitation, the stocks, book debts, plant and machinery, receivables, bills of exchange, movable fittings, equipments, computer hardware, computer software, machinery spares, tools and accessories and other movables, both present and finure whether now lying loose, or in cases or which are now lying or stored in or about or shall thereafter from time to time during the continuance of the security of the loan be brought into or upon be stored or be in or all the borrower's premises, warehouses, stockyards, gadowns, but not limited to those movable assets of the horrower.
 - (iii) The loan is repsyable in quarterly installments starting from June 2022, Interest is charged at the rate of bank's three month MCLR+0.05% per annum payable monthly.
 - (iv) The amount outstanding as at 31 March 2020 is ₹ 15,930.00 lakins (31 March 2019; ₹ 11,000.00 lakins).
- (b) During the previous year, the Holding Company had availed vehicle four of 7 211.75 takks from Daimler Financial Services India Private Limited which carries an interest at 10.75% per annum, secured by way of hypothecation on vehicle purchased. The loan is reparable in 48 monthly installments commencing from 14 May 2018.
- (c) This represents the precent value of finance leave liability (inclusive of fixed consideration) for the long-term land leave agreement which the Holding Company has entered with New Okhla Industrial Development Authority (Noida). For the fixed consideration, Noida authority has agreed installment payments. The fixed consideration of the finance leave obligation is payable in 16 equal half yearly installments beginning 14 November 2015 along with interest at 11% per annum compounded half yearly. In the current year, this has been classified as lease liabilities on implementation of Ind AS 116. Refer note 21,
- (d) This represents liability for medical equipment parchased on deferred payment terms.





Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

The changes in the entities liabilities arising from financing activities are summarised as fol Particulars	Bottowing	· · · · · · · · · · · · · · · · · · ·	Pinance cost#	(₹ in lakine) Total
	norrowinge Non-current*	Current	THUMBY CORPU	7 0441
			*,	44.340.35
1 April 2018	23,658.23	6,740.12	•	30,398.35
Cash flows:	22,725.01			22,725,01
Proceeds from non-current borrowings Repayment of non-current borrowings	(640.97)	•		(640.9)
Proceeds from current borrowings (net)	(0.1.071)	(6,740.12)		(6,740.1)
Non-cash adjustments	18.86	(14,7 (0.12)	(18,86)	(0,111611
•	,		(241.57)	(241.5)
- Finance cost paid - Finance cost expense	•		260.43	260.43
31 March 2019	45,761.13		Kinean	45,761.1;
	45/101113			12,70111
Cash flows:	11.44			44.000
- Proceeds from min-carrent borrowings	11,230.00	-	-	11,230.0
- Repayment of non-convent borrowings	(1,832.42)	*	*	(1,832.4
- Non-cash adjustments	27.10	*	(27.10)	
- Finance cost paid	-		(5,198.41)	(5,198.4
- Interest expense (including interest capitalised)		_	5,225.51	5,225.5
31 March 2020	55,185.81			\$5,185.8
			<u></u>	•
This includes current maturities of non-current borrowings.				
# Opening and closing balances represent interest accord (excluding interest occured on	deterred payment habili	ics) outstanding at	the respective year-end	
			Λε nt	As at
			31 March 2020	31 March 2019
			(l'in lakirs)	(₹ in lakhs)
Note - 21				
Lease Habilitles - non-current				
Lease liabilities (refer note 41)			27,028.62	_
Exare monutes been usee 11)		****	27,028.62	
		-	27,020.02.	-
Lease liabilities - current				
Lease habilities (refer note 41)			3,668.13	-
			3,668.13	-
man and the second seco	- Lan fullamen			(ť in lakh
The changes in the Group's lesse liabilities arising from financing activities can be classifi-	(41.32.1030MS;			
Particulars				Amount
Lease Habilities as at 1 April 2019 (current and non-current)				27,321,
				4,489.6
Additions				
Additions Interest on lease liabilities				3,138.
Additions Interest on lease liabilities Payment of lease liabilities				3,138 (4,252
Additions Interest on lease liabilities				4,489.6 3,138.4 (4,252.4 30,696.2
Additions Interest on lease liabilities Payment of lease liabilities				3,138.4 (4,252.4
Additions Interest on lease liabilities Payment of lease liabilities				3,138,- (4,252,4
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22				3,138 (4,252
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provisions - non-current			· · · · · · · · · · · · · · · · · · ·	3,138 (4,252
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Pravisions - non-current Provision for employee benefits:			2272 84	3,138- (4,252- 30,696?
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provisions - non-current Provision for employee beachts: Gratuity (tefer ante 42)			2,272.86	3,138- (4,252- 30,696- 1,803-
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provisions - non-current Provision for employee benefits: Gratuity (refer unte 42) Compensated absences			1,336.03	3,138- (4,252- 30,696.7 1,603.1 1,099.1
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provisions - non-current Provision for employee beachts: Gratuity (tefer ante 42)			1,336.03 1,015.08	3,138- (4,252-4 30,696-2 1,803-1 1,099-1 176-3
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provisions - non-current Provision for employee benefits: Gratuity (refer unte 42) Compensated absences			1,336.03	3,138- (4,252- 30,696.7 1,603.1 1,099.1
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provisions - non-current Provision for employee benefits: Gratuity (refer note 42) Compensated absences Provision for contingencies# (refer note (i) below)			1,336.03 1,015.08	3,138- (4,252- 30,6967 1,803- 1,099- 170-
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provisions - non-current Provision for employee benefits: Gratuity (refer note 42) Compensated absences Provision for contingencies# (refer note (i) below)			1,336.03 1,015.08 4,623.97	3,138- (4,252- 30,696/ 1,803- 1,099- 170- 3,072-
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provisions - non-current Provision for employee benefits: Gratuity (refer note 42) Compensated absences Provision for contingencies# (refer note (t) below)			1,336.03 1,015.08 4,623.97	3,138- (4,252- 30,696/ 1,803- 1,099- 170- 3,072-
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provisions - non-current Provision for employee benefits: Gratuity (refer note 42) Compensated absences Provision for contingencies# (refer note (i) below)			1,336.03 1,015.08 4,623.97	3,138- (4,252- 30,696/ 1,803- 1,099- 170- 3,072-
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provision - non-current Provision for employee benefits: Gratuity (refer note 42) Compensated absences Provision for contingencies# (refer note (i) below) #Movement of provision for contingencies Opening balance Add: additional provision made during the year			1,336.03 1,015.08 4,623.97	3,138- (4,252- 30,6967 1,803- 1,099- 176- 3,072-
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provisions for employee benefits: Gratuity (refer unte 42) Compensated absences Provision for contingencies# (refer note (t) below) #Movement of provision for contingencies Opening balance			1,336,03 1,015,08 4,623,97 170,69 844,99	3,138- (4,252- 30,696/ 1,803) 1,099- 176: 5,072-
Additions Interest on lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provision for employee benefits: Gratuity (refer unte 42) Compensated absences Provision for contingencies# (refer note (i) below) #Movement of provision for contingencies Opening balance Add: additional provision made during the year Lease: amount utilised during the year			1,336.03 1,015.08 4,623.97	3,138- (4,252- 30,696: 1,803- 1,009- 170. 5,072-
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provisions - non-current Provision for employee benefits: Gratuity (refer note 42) Compensated absences Provision for contingencies# (refer note (i) below) #Movement of provision for contingencies Opening balance Add: additional provision matte during the year Lease: aurount utilised during the year	obligation of easts on the respective authorit	flow towsals dela	1,336.03 1,015.08 4,623.97 170.09 844.99 1,015.08 y in completion of the unit	3,138. (4,252. 30,696. 1,803. 1,099. 170 5,072 170 170 170 1cr construction facili
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provisions or employee benefits: Gratuity (refer unte 42) Compensated absences Provision for contingencies# (refer note (i) below) #Movement of provision native during the year Leas: amount utilised during the year Leas: amount utilised during the year Note The provision for contingencies, inter alia, includes estimate of the present probable However, owing to the current pandenic situation and ongoing discussions with aforementioned outflow required in settlement.	obligation of easts on the respective authorit	flow towards dela	1,336.03 1,015.08 4,623.97 170.09 844.99 1,015.08 y in completion of the unit	3,138- (4,252- 30,696: 1,803- 1,099- 170- 5,072- 170- 170- 170- 170- 1cr construction facilit
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provisions - non-current Provision for employee benefits: Gratuity (refer note 42) Compensated absences Provision for contingencies# (refer note (i) below) #Movement of provision for contingencies Opening balance Add: additional provision made during the year Leas: amount utilised during the year However, owing to the current pandemic situation and ongoing discussions with aforementioned outflow required in settlement. Provisions - enterent Provisions for comployee benefits:	obligation of cash on the respective authorit	flow towards dela	1,336.03 1,015.08 4,623.97 170.09 844.99 1,015.08 y in completion of the unit	3,138- (4,252- 30,696: 1,803- 1,009- 170. 170. 170. 170. 170. 170. 170. 170. 170. 170. 170. 170. 170.
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provision or employee benefits: Gratuity (refer unte 42) Compensated absences Provision for contingencies# (refer note (i) below) #Movement of provision for contingencies# Opening balance Add: additional provision made during the year Less: amount utilised during the year Note The provision for contingencies, inter alia, includes estimate of the present probable However, owing to the current pandemic situation and ongoing discussions with aforementioned outflow required in settlement. Provisions - entrem Provision for employee benefits: Gratuity (refer note 42)	obligation of eash on the respective authorit	flow towards dela	1,336.03 1,015.08 4,623.97 170.09 844.99 1,015.08 y in completion of the unit	3,138- (4,252- 30,696./ 1,803./ 1,099., 170. 3,072. 170. 170. 170. 170. 170. 595
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provision for employee benefits: Gratuity (refer unte 42) Compensated absences Provision for contingencies# (refer note (i) below) #Movement of provision for contingencies Opening balance Add: additional provision made during the year Lets: amount utilised during the year Note The provision for contingencies, inter alia, includes estimate of the present probable However, owing to the current pandemic situation and ongoing discussions with aforementioned outflow required in settlement.	abligation of cash on the respective authorit	flow towards dela	1,336.03 1,015.08 4,623.97 170.09 844.99 1,015.08 y in completion of the united is uncertain on the time 575.10 302.37	3,138- (4,252- 30,696.) 1,803.1 1,099.1 176.1 3,072.1 170.1 170.1 170.1 170.2 170.3 595.357.357.357.357.357.357.357.357.357.35
Additions Interest on lease liabilities Payment of lease liabilities Lease liabilities as at 31 March 2020 (current and non-current) Note - 22 Provisions - non-current Provision for employee benefits: Gratuity (refer note 42) Compensated absences Provision for contingencies# (refer note (i) below) #Movement of provision for contingencies# Opening balance Add: additional provision made during the year Leas: amount utilised during the year Note The provision for contingencies, inter ulia, includes estimate of the present probable However, owing to the current pandemic situation and ongoing discussions with aforementioned outflow required in settlement. Provisions - entrem Provisions - entrem Provision for employee benefits: Gratuity (refer note 42)	obligation of cash on the respective authorit	flow towards dela	1,336.03 1,015.08 4,623.97 170.09 844.99 1,015.08 y in completion of the unit	3,138- (4,252-5 30,696.2 1,803.1 1,099.1 176.1 5,072.1 170.1 1rc construction facilit

Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

	Au ai 31 March 2020	As at 31 March 2019
	(€ in laklır)	(₹ in lakhs)
Note - 23		
A Other non-current liabilities		
Deferred government grants*	2,892.49	2,503.28
	2,092.49	2,503,28
* Deferred government grant	*FF	***************************************
Opening balance	2,914.26	3,551.15
Grants received during the year	1,149.68	228.51
Less : Grants expited during the year		(448.73)
Less: Released to statement of profit or loss	(1,558.02)	(416.67)
	2,505,92	2,914,26
Classified into		V-1
Non current partion	2,092.49	2,503.28
Current partion	413.43	410.98
	2,505.92	2,914.26
D Other current liabilities	•	
Payable to statutory authorities	1,516,17	2,139.69
Advance from customers	2.110,61	1,609.61
Defend government grants	4{3.43	410.98
Other liabilities	101,28	98.57
The include	4,141.49	4,258.25
	43747.43	41230.63
Note - 24		
Trade payables - current		
A Total outstanding dues of micro enterprises and small enterprises	1,794.58	444.56
	1,794.58	444.56

Disclosure under the Micro, Small and Medium Enterprises Development Act, 2016 ("MSMED Act, 2006") as at 31 March 2020 and 31 March 2019

	Particulars	31 March 2020 (₹ in lakhe)	31 March 2019 (₹ in lakhs)
	the principal amount and the interest the thereon remaining unpaid to any supplier as at the end of each accounting year; the amount of interest paid by the boyer in teems of section 16, along with the amounts of the payment made to the supplier	1,794.58	4-(4.56
	beyond the appointed day during each accounting year;		-
}	the amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under this Act;	·	-
	the amount of interest accused and remaining unpoid at the end of each accounting year; and	56,25	1.57
١٠)	the amount of further interest remaining this and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance as a deductible expenditure under section 23.	·	

	As nt 31 March 2020	As at 31 March 2019
	(₹ in laklıs)	(₹ în laklu)
Total outstanding dues of creditors other than micro enterprises and small enterprises		
Due to related parties (refer note 30)	222,64	178.72
Due to others	11,056,82	12,022.72
	11,279.46	12,201.44
Note - 25		
Other financial liabilities - current		
Current maturities of non-current borrowings	1,068.}3	819.63
Current maturities of vehicle toan	43.69	39.26
Consent maturities of finance lease obligations!	-	1,248.30
Interest account	472.94	K25.62
Capital creditors	7,106.47	3,560,79
Security deposit received	5.50	5.50
Employee related payables	4,115.33	3,503.01
	12,806.06	10,002.11

[•] Till previous year, learchold land and related kabilities were recognised as 'finance leaves' under Ind AS 17 'Leases'. Leasehold land was presented as part of property, plant and equipment, and the liabilities as deferred payment liabilities as part of the Hulding Company's borrowings (being current portion presented under other financial liabilities). However, under Ind AS 116, these have been transferred to right of use assets and leave liabilities.





Consolidated summary of algulificant accounting policies and other explanatory information for the year ended 31 March 2020

	For the year ended 31 March 2020	Por the year ended 31 March 2019
	(f in lakhs)	(₹ in laldıs)
Note - 26		
Revenue from operations		
Income from healthcare services		
In patient	1,19,412.03	1,16,807.36
Out patient	28,645.08	26,875.98
Other operating revenue:		
Clinical research income	186.82	251.33
Other operating revenue	177.65	178.55
	1,48,421,58	1,44,113.22
Note - 27		
Other income		
Interest income on bank deposit	1,946.89	1,839.96
futerest income on other funncial assets measured at amortised cost	17.60	19.06
Reutal income	138.33	134.61
Excess provision written back		787.61
Sponsorship income	733.55	645.99
Reversal of impairment in the value of investments	2.18	,
Government grants income	1,558.02	1,467.03
Revenue share from food court	265.04	274.11
Revenue share from planmacy	778.38	733.14
Miscellaneous income	502.52	584.14
	5,942.51	6,485.59
Ngie · 28		
Cost of materials consumed		
Pharmacy, Medical and Laboratory consumables		
Opening stock	2,212.31	2,091.01
Add: Purchases (includes government assistance of ₹ 27.85 lakhs (31 March 2019; ₹ 34.17 lakhs))	33,302.33	32,015.00
Less: Clusing stock	(3,614.40)	(2,212.31
Materials consumed	31,900.24	31,893.70
Will Gallia Equatore		
General stores		
Opening stock	116.65	181.68
Add: Purchases	703.35	532,90
Less: Closing stack	(237.50)	(116.65
Materials consumed	582,50	597.93
	32,482.74	. 32,491.6
Note - 29		
Employee benefits expense	••	,,
Salaries and wages*#	50,758.60	49,920.3
Contribution to provident fund and other funds	2,029.06	1,514.8
Staff welface expenses	133.48	69.6
Employee share based payment expense (refer note 43)	956.97	2,603.0
	53,878.05	54,107.9

^{*} During the year ended 31 March 2020, employee benefit expenses of ₹ 762.66 lakhs (31 March 2019; ₹ 360.29 lakhs) has been capitalised as a part of capital work in-progress. # This includes salary expense of employees working for research and development amounting to ₹ 99.29 lakhs (31 March 2019; ₹ 127.77 lakhs).

Note - 30		
Pinance costs*		
Interest on term loans	1,379.43	241.00
Interest on vehicle Ioan	17.37	19.43
Interest on buyers credit/supplier's credit	•	3(1.55
Interest on lease liabilities	3,138.48	1,198.07
Interest on deferred payment liabilities	563.22	164.10
Other borrowing costs	56.25	2,65
	5,854.75	1,655.80

^{*} During the year ended 31 March 2020, borcowing cost of ₹ 3,828.72 laklus (31 March 2019; ₹ 3,396.30 laklus) has been capitalised as part of capital work-in-progress.

Note - 31
Depreciation and amortisation expense
Depreciation of property, plant and equipment
Depreciation on right of use assets
Amortisation of intangible assets



9,029.69	9,506.65
	1,799.49
41.34	135.22
9,071.03	11,441,36



	For the year ended 31 March 2020	For the year ended 31 March 2019
	(₹ In laklis)	(₹ in lakhs)
Note - 32	,	, ,
Impairment losses on financial assets		
Expected credit loss on trade receivables	1,111.61	1,800.21
	1,111.61	1,800,21
Note - 33		
Other expenses#		
Power and fuel	3,459.79	3,064.58
Lease tent:		
Land	•	387.17
Premises	135.33	1,715.88
Vehicles	43.60	196.78
Equipments	3,865.26	4,306.69
Repairs and maintenance:		
Equipment	3,931.17	3,255.82
Office	387.09	340.75
Building	227.06	296.16
Rates and taxes	754.19	263.59
Recruitment expenses	341.98	144.21
Insumice	172.35	148.36
Travelling and conveyance	731.95	812.43
Communication expenses	286.59	229.52
Auditor's commembion		
Statutory audit fees (including taxes)	76.70	47.02
Reimbursement of expenses (including taxes)	2.70	2.48
Pantry expenses	1,585.39	1,851.05
Laundry expenses	401.03	377.13
Security expenses	1,107.51	1,017.33
Facility management expenses	4,531.87	4,114.90
Advertisement and sales promotion	405.24	466.43
Research and development expense*	1.23	2.99
Outsourced services	963,60	939.81
Legal and professional (including facilitation fees)	17,247.65	14,545.36
Printing and stationery	\$98.38	633,55
Subscription and membership charges	116.68	30.29
Corporate social responsibility expenses	224.88	124.11
Directors' sitting fees	1.18	3,54
Bank charges	500.97	458.60
Unrealised foreign exchange - loss (net)	135.61	226.23
Loss on sale of property plant and equipment (net)	9.65	18.52
Travel, boarding and other related expenses for conferences	587,49	775.38
Impairment in the value of investments	*	481.43
Miscellaneous expenses	1,082.31	672,48
· · · · · · · · · · · · · · · · · · ·	43,906.43	41,949.97
ABULT 1	40120040	725747777

(This space has been intentionally left blank)





⁴ This is professional fees incurred for research and development work.

During the year ended 31 March 2020, other expenses of ₹ 204.08 lakhs (31 March 2019; ₹ 872.23 lakhs) has been capitalised as a part of capital work-in-progress.

Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

	For the year ended 31 March 2020 (3 in lakhs)	Por the year ended 31 March 2019 (₹ in lakhs)
Note - 34 "		
Тох схреняев		
Current tax	4,971,83	5,158.47
Deferred tax credit	(2217.76)	(1736.64)
Tax expense recognised in the statement of profit and loss	2,754,07	3,421.83

The Group has elected to exercise the option permitted under section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Group has recognised provision for income-tax for the year ended 31 March 2020 and re-measured its deferred tax assets/liabilities basis the rate prescribed in the aforesaid section.

The major components of income tax expense and the reconciliation of expected tax expense based on the domestic effective tax rate of the Group at 25.168% and the reported tax expense in profit or loss are as follows:

Accounting profit hefore income tax	6,386.96	9,519.61
Add: Losses incurred by subsidiaries and joint venture on which no deferred tax asset is created	6,708.56	476.06
Accounting profit before income tax (gross)	13,095.52	9,995.68
At India's statutory income tax rate of 25,168% (31 March 2019; 34,944%)	3,295.88	3,492.89
Tax effect of amounts which are not deductible (taxable) in calculating taxable income:		
Tax impact of statutory deduction allowed as per Income tax Act, 1961 under the head income from 'House Property'	(89.98)	(122.81)
Tax impact of deferred tax on impairment in value of investments	112.15	56.08
Tax impact of expenses which will never be allowed under Income-tax Act, 1961	327.42	73.614
Tax impact on account of change in income tax rate	(909.29)	(28.07)
Tax impact of unabsorbed husiness losses		(15.01)
Tax impact in respect of eatlier years	•	(\$4.02)
Others	17.90	19.73
Тэх схроняев	2,754.08	3,421.83

Note - 35

Eatnings per share (EPS)

Barnings per share (BPS) is determined based on the net profit attributable to the shareholders. Basic earnings per share is computed using the weighted average number of shares outstanding during the year. Diluted earnings per share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the year, except where the result would be anti-dilutive.

Profit attributable to equity shareholders for basic and diluted EPS*	3,632.89	6,097.78
Weighted average number of equity shares for basic EPS* Effect of dilution - weightage average number of potential equity shares on account of employee stock options^ Weighted average number of equity shares adjusted for the effect of dilution	5,00,51,022 2,60,957	4,97,97,109 5,08,617
Weighted average number of equity shares solusted for the effect of dilution Earnings per equity share	5,03,11,979	5,03,05,727
Basic	7.26	12.25
Diluted	7.22	12.12

^{*}The Holding Company had issued compulsory convertible preference shares which are expected to be converted into equity shares in the ratio of 1:1 and considered in calculation of basic earning per share.





[&]quot;Ashare options (unvested) under the ESOP Plan 2014 and ESOP Plan 2016 are considered to be potential equity shares. They have been included in the determination of diluted earnings per share to the extent to which they are dilutive.

Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Note - 36

Pair value disclosures

(i) Fair value iderarchy

The following explains the judgements and estimates made in determining the Lir values of the financial instruments that are recognised and measured at fair value. To provide an indication about the reliability of the inputs used in determining fair value, the Group has classified its financial instruments into the three levels prescribed under the accounting standard.

Level it quoted prices (unadjusted) in active markets for financial introments.

Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3: unobservable inputs for the asset or liability.

Valuation techniques used to determine fair value

The fair value of the financial assets and liabilities are included at the amount that would be received to sell as usset and paid to transfer a liability in an indeely transaction between market participants. The following methods were used to estimate the fair values:

- Teade acreerables, eath and each equivalents, other bank halances, loans, other current financial assets, trade payables and other current financial habilities: Approximate their currying annumbs largely due to the thorsterm maturities of these instruments.

- Burrowargs taken by the Group are as per the Group's credit and liquidity ork assessment and there is no comparable instrument luving the similar terms and conditions with related security being pledged and hence the exerging value of the borrowings represent the best extensite of fair value.

(ii) Fair value of assets and Habilities which are measured at amortised cost for which fair value are disclosed

				(4 114 14 11 1)	
Particulars	As at 31 h	As at 31 March 2020		As at 31 March 2019	
	Carrying value	Fair value	Catrying value	Fair value	
Pinancial assets					
Lones	799.61	799.61	815.54	815.54	
Trade receivables	14,915,89	14,915.09	16,417.89	16,417.89	
Cash and easin equivalents	14,915.18	14,915.18	6,571.43	6,571,43	
Other bank balances	10,097.11	10,097.11	20,073.92	20,073.92	
Other financial nesets	5,770.44	5,770.44	2,721.31	2,721.31	
Total financial assets	46,497.43	46,497.43	46,600.10	46,600,10	
Descrivings (including current managines of long-term barrawings)	61,663.36	61,663.36	41,001.52	61,004.32	
Leans liabilities	30,696.75	30,696.75	•		
Trade payables	13,07-1.0-1	13,074.04	12,646.00	12,646.00	
Other financial liabilities (excluding correct maturities of long-term borrowings)	11,694.24	11,694.24	7,894.92	7,894.92	
Total financial liabilities	i,17,128.39	1,17,128.39	81,545.24	81,545,24	

Pinancial tisk management

(i) Financial instruments by category

(F in table)

7 - Third and the state of the gold		(Cin takin)		
	Amartico	d cost		
Pariferlars	As at 31 March 2020	As at 31 March 2019		
Pinancial assets		·		
leans	. 799.61	815.54		
Tende receivables	14,915.89	16,417.89		
Greli stud carli equivalents	14,915.18	6,571.43		
Other bank balances	10,697.11	20,073.92		
Other floorical assers	5,770.44	2,721.31		
Total financial assets	46,497.43	46,600.10		
Pinancial liabilities				
Borrowings (including current maturities of non-current borrowings)	61,663.36	61,008.32		
Leuse Habilities	30,696.75			
Trade psyables	13,074.04	12,646.00		
Other financial Sabilities (excluding current maturities of non-current borrowings)	11,694.24	7,894.92		
Total financial liabilities	1,17,128.39	85,545.24		
There are no foreneral states and habilities which are subsequently meanined at this value		~~~~~~~~~~		

(ii) Risk management

The Group's activities expose it to market risk (foreign exchange and interest risk), liquidity risk and credit risk. The Holding Company's bound of directors has overall responsibility for the establishment and oversight of the risk management framework. This note explains the sources of risk which the entity is exposed to and how the entity manages the risk and the related impact in the financial statements

Risk	Exposure arising from Measurement	Management
Gredit risk	Leasus, trade receivables, cush and cash equivalents, Ageing analysis other bank halsness and other farancial assets measured at amortised cost	Diversification of hank deposits and credit limits and regular monitoring and follow ups
Liquality civit	Hotrowings, trade payables and other financial Cash flow forecasts fiabilities	Availability of communed credit lister and borrowing facilities
Market risk – foreign exchange	Future commercial transactions, recognised Cash flow forecasting sens financial assets and liabilities not denominated in analysis Indian super	divity Forward foreign exchange contracts
Market risk – interest rate	Long-teint bottowings at variable rates Sensitivity analysis	Diversification of horrowings





Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

(n) Credit elsk

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a funancial asset fails to meet its contractual obligations. The Group's exposure to credit risk is influenced mainly by the individual characteristics of each financial asset. The carrying amounts of financial assets represent the maximum credit risk exposure.

A default on a financial mast is when the examenparty fails in make contractual payments as per agreed terms. This definition of default is determined by considering the haviness environment in which entity operates and other macro-economic factors.

The Group lus a ceedlit risk management policy in place to limit credit lusses due to non-performance of counterparties. The Group monitors its exposure to credit risk on an ongoing basis. Assets are written off when there is no reasonable expectation of recovery. Where loans and receivables are written off, the Group continues to engage in enforcement activity to attempt to recover the dues.

Trade meinables

The Group closely monitors the credit-worthiness of the receivables through internal systems that are configured to define credit limits of customers, thereby, limiting the credit sisk to preexhabilited amounts. The Group uses a simplified approach (lifetime expected credit loss model) for the purpose of computation of expected credit loss for trade receivables. Expected credit losses are measured on collective basis for each of the following categories:

Category	Imputs for measurement of expected credit	Assumptions
Government	agencies in past years	Trade receivables outstanding for affice than two years are considered irrecoverable. Allowance for expected gredit loss on receivables outstanding for fees than two years is recognised bared on expected deductions by government agencies.
Non-доченянені		
Individuals	information obtained through sales recovery follow	Trade receivables outstanding for more than two years are considered irrecoverable. Other receivables are considered good due to origing communication with customers.
Соероганск	years	Trend of collections made by the Group over a period of five years preceding balance sheet date and considering default to have occurred if receivables are not collected for more than two years.
Third pany administrators of insurance companies	YEATS.	Trade receivables outstanding for more than two years are considered irrecoverable. Altowance for expected credit loss on receivables outstanding for less than two years is recognised based on expected deductions by that party administrators.
Others	Customer wise trade receivables and information obtained through sales recovery follow ups	Specific allowance is made by assessing party wise extissabling receivables based on continuous ation between sales team and customers.

Cosh and cash contrologis and other bank halances

Credit risk related to eath and easth equivalents and bank deposits is managed by only accepting highly rated banks and futureial institutions and diversifying hank deposits and accounts in different banks. Credit risk is considered low because the Group deals with highly rated banks and financial institution.

Losin and other financial assets measured at amortized cost includes records deposits and other receivables. Credit risk related to these financial assets is managed by maniforming the recoverability of such amounts continuously, while at the same time internal control system are in place ensure the amounts are within defined limits. Credit risk is considered low because the Group is in possession of the underlying asset (in case of security deposit) or as per reade experience (in case of unbilled revenue from patient and other receivables from revenue shading arrangements). Further, the Group creates provision by massing individual financial asset for expectation of any credit loss basis 12 month expected credit loss model.

The Group's rotatanding Indiance net of expected loss from parties net of expected credit loss of similar economic characteristics i.e. Central Government Health Science (CGHS') amisons to \$3,496.24 lables (31 March 2019; \$4,862.43 lables) and Reserviceman Contributory Health Science (ECHS') amisons to \$2,461.15 lables (31 March 2019; \$2,868.99 lables).

(This space has been intentionally left blank)

ANDION ERED ACCO

(b) Credit risk exposure

i) Expected credit lors for trade receivables under simplified approach i.e. provinon many approach using historical trends.

As at 31 March 2020		.			***************************************	(₹ in iakha)
Particulare	Government			Non-governme	111	
		Individuals	Corporates	Third party	Others	Total
				administrators of		l
		i		Insusance		1
		į		companier	į	ĺ
Gross carrying value	12,625.89	993.99	1,714.37	4,319.51	1,338.75	20,982.51
Loss: Expected credit loss (impairment)	3,067.15	641.01	794.48	777.89	786.98	6,067.42
Carrying amount (net of impairment)	9,558.74	152,98	919.89	3,541.71	541.77	14,915.09]

ts of 31 March 2019 (₹ in taklis)						
Particulats	Government , Non-government					
		Individuati	Corporates	Third party	Others	Total
	l i		,	administrators of		
	Į į			insurance		i
1				companies		
Gress castying value	14,578.15	656.61	1,546.36	3,403.34	1,189.22	21,373.71
Less: Expected credit lors (impairment)	3,221.35	(43.17	388.73	467.69	432.67	₹,955.80
Carrying amount (net of impairment)	11,354.80	213.44	1,157.63	2,935.67	756.15	16,417.90

ii) Expected credit losses for other financial assets (measured at an amount equal to 12 months expected credit losses)

(* (n.lakha) As at 31 March 2020 Particulars Estimated gross Expected credit Cauying amount net of impairment carrying amount at default 01161 provision 799.61 799.61 14,915.18 14,915.18 Cush and eash equivalents 10,097.11 10.097.13 Other bank balances 5,770.44 136.60 Other financial assets 5,507.04

As at 31 March 2019				(7 ja laklis)
Particulars		Batimated gross	Expected ciedlit	Carrying amount net of impairment
	1	carrying amount at default	losace	provision
Loans		815.54		815.54
Cash and cash equivalents	•	6,571.43	•	6,571.43
Other bank halances	as .	20,073.92		20,073.92
Other familial arrets		2,019.03	136.60	1,882.43

iii	Reconciliation of expected credit loss for wher financials asset and trade seccivables		(F in laklis)
,	Recappiliation of loss allowance	Other financial assets	Trade
			receivables
	Loss allowance on LApril 2018	136.60	3,155.60
	Allowance for expected creckit loss		1,800.21
	Loss allowance on 3i March 2019	136,60	4,955.81
	Allowance for expected credit loss		1,111,61
	Loss allowance on 31 March 2026	136,68	6,867.42

The loss allowance in respect of trade receivables has changed due to increase in gross carrying amount and change in expected recovery rates.

(b) Edquidity risk

Edquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial labilities that are settled by delivering each or another financial asset. The Group's approach to managing liquidity is to ensure, that it will have sufficient liquidity to meet its liabilities when they are due

The Group manusius flexibility in funding by manuscring availability under committed credit lines. Management monitors the Group's laquidity position (comprising the underwa bostoming facilities below) and cash equivalents on the traits of expected cash flows.

The Group takes into account the liquidity of the market in which the entity operates

Maturities of financial liabilities

The following are the remaining contractual maturalies of futureral hisbalities at the reporting date. The atmospits are gross and undiscrement, and include contractual interest payments and exchade the impact of neiting agreements. (F in table)

				(C (n saidia)
As at 31 March 2020	Less than I year	1 - 3 years	More than 3 years	'3'otal
Non-derivatives			46,845,86	62,576.05
Borowage	1,410.13	14,320.06		
Lensy listribucs	4,289.14	8,346.81	2,83,639.11	2,96,315.06
Trade payable	12,646.00			12,646.381
Other for notist liabilities	11,694.24	,		11,694.24
Total	30,039.51	22,666.87	3,30,524.97	3,83,231.35
LOIN				

				(Cin lakiis)
As at 31 March 2019	Less than I year	1 - 3 years	More than I years	Total
Non-derivatives			24 400 44	41,379,75
(Herranings (other than finance lease obligation)	1,030.02	12/450104	26,929.69	1
Finance lease addigation	2,143.95	3,875.97	2,33,596.42	2,39,616.34
Trade payable	12,635.62			12,635.62
Other fusuacid liabilities	7,905.36			7,905.30
Tetal	23,711.89	17,296.01	2,60,526.11	3,01,537.01





Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

The Group also has access to the following underwar horrowing from banks at the end of the reporting period.

		(t in lakhr)
i Particulare	As at	As nt
	31 March 2020	31 March 2019
Unifower borrowing facilities	716.32	

(c) Market rick

(i) Poreign exchange risk

The Group has internations and a exposed to foreign exchange risk arising from foreign currency transactions (imports and exposts). Foreign exchange risk auses from future commercial transactions and recognised assets and habitates denominated in a currency that is not the Group's functional currency. The Group has not hedged its fureign exchange receivables and payables as at 34 March 2020.

Poreign currency risk exposure: As at 31 March 2020 As at 31 March 2019 Poreign INR INR Partloulars Poreign currency (t in taklıs) currency (P in lakiu) Assets USD 686.90 USD 597.86 Trade receivables (grass) 686.90 597.86 Liabilities Capital creditors USD USD 20.52 EURO 19.55 EURO 1.13 Trade payables Trade payables USD 17.08 USD GHP GBP Trade payables 232.36 380.68 USD 15.13 Defened payment liabilities Deferred payment liabilities BURO EURO 5,035.03 3,468.36

Sensitivity				*	
The constivity of profit or loss to changes in the exchange rates arises from for	reign currentey demanutated fina	neal instruments.			(₹ In lakhs)
Pacifedam			ch 2020	31 March 2019	
	Custency	Exchange mie increase by 6%	Exchange rate decrease by 6%	Exclinage rate increase by 4%	Exchange inte decrease by 4%
Aesete					
Trade receivables (gross)	USD	41.21	(41.21)	23.91	(23.91)
Linbibiles		 			
Capital creditors	USD		0.00	0.82	(0.82)
Trade payables	EURO	1.17	(1.17)	0.05	(0.05)
Trade payables	USD	1.02	(1.02)		1 .
Trade payables	GBP	13.94	(13.94)	,	
Deferred payment liabilities	USD	22,84	(22.84)	16,8	(0.61)
Deferred payment listributer	P:UNO	263,12	(263.12)	137.26	(137.26)

(ii) Interest mic elsk

The exposure of the Group's horrowings to interest rate changes at the end of reporting period are as follows:

The Group's variable care borrowing is subject to interest rate. Below is the overall exposure of the borrowing		(₹ in lakha)
PostCeulars	31 March 2020	31 March 2019
Variable rate borrowing	55,845.79	45,761.13
Total borrowings	55,045.79	45,761,13

Sensitivity

Profit or loss is sensitive to higher/lower interest expense from borrowings as a result of changes in interest cates.		(₹ In iakbs)
Particulars	31 March 2020	31 March 2019
Interest rates – increase by 100 basis points	550/16	457.61
Innerest rates - decrease by 100 basis points	(550.44)	(457.61)

Finance lease obligation, vehicle loan and deferred payment liabilities are at fixed rate.





Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Note - 38

Related party transactions

In accordance with the requirements of Ind AS 24 the names of the related party where control exists/able to exercise significant influence along with the transactions and year-end balances with them as identified and certified by the management are given below:

i) Entities where joint control exists

Joint rentue

(i) Medania Duke Research Institute Private Limited

il) Entities and individuals which exercises significant influence over the Holding Company

31 March 2020	31 March 2019
	(i) Auant Investments
(ii) Dr. Naresh Trehan	(ii) Dr. Naresh Trehan

iii) Key management personnel (KMP)

31 March 2020	31 Murch 2019
i) Dr. Naresh Trehan – Chairman and Managing Director	(i) Dr. Naresh Trehan - Chairman and Managing Director
ii) Mr. Sunil Sachdeva	(ii) Mr. Sunil Sachdeva
ii) Mr. Ravi Kaut Jaipuria	(iii) Mr. Ravi Kant Jaiputia
iv) Mr. Rohit Sipahimalani (upto 26 September 2019)	(iv) Mr. Robit Sipahimalani
v) Mr. Neemj Bharadwaj	(v) Mr. Neoraj Bharachwaj
vi) Ms. Shayama Chona (upto 24 February 2020)	(vi) Mr. David Johnson (upto 16 July 2018)
vii) Mr. Sanjeev Kumar	(vii) Ms. Shayama Chona
yii) Mr. Pankaj Salmi	(viii) Mr. Anil Vitmani (utpo 13 July 2018)
ix) Mr. Pranab Bal (from 26 September 2019)	(ix) Mr. Sanjeev Kumar (from 14 July 2018)
	(x) Mr. Pankaj Sahni

iv) Relatives of IMP

31 March 2020 and 31 March 2019

Name of Relatives	Relationship with KMP
Mr. R.L. Sachdova	Father of Mr. Sunil Sachdeva
Mrs. Savitri Sachdeva	Mother of Mr. Sunit Sachdeva
Mes. Shonan Techan	Daughter of Dr. Naresh Trehan
Mes. Shyel Techan	Daughter of Dr. Natesh Trehan
Mes, Madhu Trehan	Wife of Dr. Naresh Trehan
Mr. Naveen Trehan	Brother of De. Naresh Trehan

v) Enterprises over which KMPs are able to exercise significant influence with whom transactions have been undertaken or where balances are outstanding:

31 March 2020	31 March 2019
(i) IFAN Global India Private Limited	(i)IFAN Global India Private Limited
(ii)Law Chamber of Kapur & Trehan	(ii)Law Chamber of Kapur & Trehan
iii)Raksha TPA Private Limited	(iii)Raksha TPA Private Limited
(iv)Sharik Healthcare Private Limited	(iv)Sharak Healthcare Private Limited
(v)Language Architecture Body (LAB)	(v)Language Architecture Hody (LAB)
(vi) Vidyanta Skill Institute Private Limited	(vi) Vidyanta Skill Institute Private Limited
(vii)Medanta Institute of Education & Research (Trust)	(vii)Medanta Institute of Education & Research (Trust)
viii)Varun Beverages Limited	(viii) Varun Bevernges Limited
(ix)RJ Corp Limited	(ix)R) Corp Limited
(x)Devyani International Limited	(x)Davyani International Limited
(xi)Diagno Labs Private Limited	(xi)Diagno Labs Private Limited
(xii)S.A.S Infotech Private Limited	(xii)S.A.S Infotech Private Limited
(siii)Mutropolis Healthcare Limited	(siii)Metropolis Healthcare Limited





1 Timisecin	ons with related parties extried out in the ordinary course of bus	inces	Related parties				
8 No.	Poetkeulars	Year	Enrishes which exercises significant influence over the Holding Company	Joint venture	Key management personnel and shelr relatives	Buterprise over which KhIP exercise aignificant influence	Total
	Rentel income	31 March 2020		4.01			4.0
	Medanta Duke Research Institute Private Limited	31 March 2019		8,01			8.6
	Medanta Institute of Education & Research (Trust)	31 March 2020				10.17	10.1
2		M March 2019			<u>:</u>	10.17	10.1
	Heremit thate from food court	31 March 2020			1777 007 7011-111-1-1	265.53	265.5
	Devyani futurnational Limited	31 March 2019	***************************************			274.11	274.0
3	Recruliment expenses						292,0
	IPAN Global India Private Limited	31 March 2020 31 March 2019			.,	292.02 111.06	292.0
4	Rentespentes						
	Aleilusta Diske Research Institute Private Limited	31 March 2020		8.98			, A
	1	31 March 2019	, , , , , , , , , , , , , , , , , , ,	26.85			26.
5	Professional charges	31 March 2020				34.35	34.
	Law Charriser of Kapaor and Treban	31 March 2019				31.20	31.
	Language Architecture Budy	31 Minsch 2020				· · · · · · · · · · · · · · · · · · ·	
6	Training expenses	31 Maich 2019			ļ	140,04	140.
·	Vidyana Shills Institute Private Limited	31 March 2020				121.30	121.
		31 March 2019	***************************************			61.32	61,
7	Pittchese of assests	31 March 2020		57.51	·		57
	Medzatz Duke Research fastitute Private Limited	31 March 2019			<u> </u>		
6	Revenue from patients covered under the ups						
	Rakalia 3PA Private Limited	31 March 2021 31 March 2019	ļ		-	1,850.76 1,850.33	1,850
		31 March 2026	<u> </u>			1124	
	Sharek Healtheare Private Limited	31 March 2019				Li, ki	
3	Rendering of Sealthcare acerices*	31 March 2020					
	ICE, Sactidova	31 March 2019			3,16 3,19		
		31 March 2020			0.30		è
	Mes Savitti Sachdevs	31 March 2019			1.09		
	R) Corp Einsted	31 March 2020 31 Merch 2019		ļ	ļ	11.88	
		31 March 2020				(1.05	
	Vocan Beverages Limited	31 March 2019				0.15	
	Deryani International Limited	31 March 2020				7.2	
		31 March 2019 31 March 2020	•	<u> </u>	(012	11.5.	
	Pariksį Saturi	31 March 2019	*		0.06		
	S.A.S Inforech Private Limited	31 March 2020				5.9	
		31 ålarch 2019				***************	
10	Outsourced lab services	31 March 2020		ļ		327.4	32
	Diogna Laba Private Limited	31 Merch 2019		·		316.4	
	Metropolis Healthcare Limited	38 March 2020				(14)	
		31 March 2019					
11	Purchase of consumables	31 Atarch 2020	<u></u>	-	1	·	
	Verus Bryecages Limited	31 March 2019	-		1	(L#	5
12	Expenses peld on beholf of]		
	S.A.S Inforech Private Christed	31 March 2020 31 March 2019		 		92.0	
13	Issue of share conite! (including securities premium)	31 AIMER 2019	-	 	- ···	72.0	2 2
	***************************************	31 March 2020			30.2	3	3
	Panicoj Saluti	M March 2019			ļ	4	
14	Salaries and other benefits	31 March 2020			1,825.0	5	1,82
	Dr. Naresh Techan@	31 March 2019	· · · · · · · · · · · · · · · · · · ·		1,828.9		1,62
	1.35	31 March 2000					1
	Anil Yimsan@	M March 2019		1	76.3		
	Prints Bath	31 March 2020 31 March 2019				<u>" :</u>	
		31 March 2020	[·	170.0	3	1
	Sanjeev Kuntar@	31 March 2019			83.9	9	8
	Pankej Sahni#	21 March 2020			2608		. 20
	1	31 March 2019	1		266.9		





^{*} New Journal

* New Journal

* New Journal

* New Journal

* One Links

* New Journal

* One Links

* One of the Company of the Company

* One of the Company of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

* One of the Company

*

		iiclased partice					
No.	Norticulara	Year	Emilies which exercises significant influence over the Holding Company	Joint venture	Key management personnel and their relatives	Enterpilse över which KMU exercise significant influence	Total
}	Equity share capital						
	Anant Inventories	34 March 2020	1,10000			-	1,300
		31 March 2019 31 March 2020	1,300.00		689.21		1,300
	Dr. North Techni jointly with Mrs. Madha Tichan	31 klarch 2019			6E9.31		689
	No. 3. Company of the control of the	31 March 2620			1,020.00		1,020
	Dr. Nireah Teeban	31 March 2019			1,020.00		1,02
	Mr. Sund Sachdeva Jointly with Mrs. Suman Sachdeva	31 March 2020			680.00		68
	Prokaj Salusi	31 Afarch 2019 31 Afarch 2020			680.50 0.40		- 68
	ranaj kunt	M March 2019					
	The state of the s	31 March 2020				20(10)	20
	RJ Corp Limited	31 March 2019				200,00	20
2	Compulsorily convertible preference shares					ļ	
	Attent Investments	31 March 2020 31 March 2019	3,250.00 3,250.00			<u></u>	3,2
3	Trade psychks	31 ylatest 2013	3,230.03			<u> </u>	
	Dr. Nsresh Trelum	31 March 2020			30.54		
		31 March 2019	*		30.54		
	Sunit Sachdeva	31 March 2020			30.54		
	AMERICA CONT. COMPANIENCE CONT. CONT	31 March 2019			30.54		
	IPAN Global India Private Limited	31 March 2020	ļ			15.06	ļ
		31 March 2019 31 March 2020				15.67 5.01	
	Line Chamber of Kapur & Trebus	31 March 2019				5.12	
	The property of the state of th	31 Afarch 2020				1259	-
	Vidyanata Slok Institute Private Limited	31 March 2019				8.73	
	Language Architecture Body	31 March 2020				8.17	
	The same of the same services and the same services are same services and the same services and the same services are same services and the same services are same services and the same services are same services and the same services are same services and the same services are same services and the same services are same services and the same services are same services and the same services are same services and the same services are same services and the same services are same services and the same services are same services and the same services are same services and the same services are same services and the same services are same ser	31 Merch 2019		rythornormonas vasa vasa vasa vasa vasa vasa vasa v	<u> </u>	0.17	
	Diagno Latu Private Limited	31 March 2029 31 March 2019			·	128.09 85.04	
	The state of the second section of the section of the second section of the section o	31 March 2020			 	1,66	-
	Metropolis Healthese Limited	31 Slarch 2019		***************************************		2.92	
	The second secon	31 Alarch 2020				,	
	Aledana Duke Research Institute Private Limited	31 March 2019		8.27			
4	Other receivables			*********			
	Medania Institute of Education & Research (Prist)	31 Alsrch 2020			ļ	7.77	
	.,	31 March 2019 31 March 2020			+ -	136.63	
	Desystil International Limited	31 March 2019				121.51	
	The same of the sa	31 March 2020					
	Medania Duke Research Institute Private Lunited	31 March 2019		8.27			
	S.A.S. Inforceds (Vrivare Limited)	31 March 2020				105.4	
		31 March 2019			4	92(0)	
	Trade receivables	31 March 2020				254.30	<u> </u>
	Ratoha TPA Urivate Limited	31 Alarch 2019		· · · · · · · · · · · · · · · · · · ·		231.7	
	And the second s	31 March 2026	-	-		1500	
	Sherak Heelthease Private Limited	31 March 2019				1.23	
	RJ Cop Limited	31 March 2020				33.10	
	and the control of th	31 Marei 2019				12.10	
	Varin Beverages Limited	31 March 2000 31 March 2019				(1.3)	
	The same states and a control of the same states and the same states are same and the same states and the same states are same states and the same states are same states and the same states are same states and the same states are same states and the same states are same states and the same states are same states and the same states are same states are same states and the same states are same states and the same states are same	31 March 2020		·	······	6.63	
	Devyani International Limited	31 March 2019		1	-	0.40	
		31 March 2020				5.9	
	S.A.S Infatech Private Limited	31 Alarch 2019					
1;	Allowance for expected credit fors			<u> </u>			
	Reksha TPA Private Limitest	31 March 2020		·		22.73	<u>.</u>
		31 Alarela 2019				1	"- · · ·
	Investment in foint venture	31 Alarch 2020		479.2	5		
	Medanta Dake Research Institute Private Limited (gross)#"	31 March 2019		481.4			1

WHe Board of Directors (the Bostel) of Mediana Dake Research Institute Private Limited (a joint venture) in its meeting held on 19 June 2019 here resolved to commence the powers of valuatory Equidation in accordance with the provisions of the Insolvency and Bankauptey Code, 2016 and with Insolvency and Bankauptey (Voluntary Equidation) Regulation, 2017. This has also been uffirmed by the shareholders in the Annual General Meeting (AGM) of Mediana Dake Research Institute Private Limited Edition 24 September 2019.





 $^{^{\}circ}$ This is the escrying value of investment balance.

Note - 39

Capital management

The Group's objectives when managing capital are to:

- To ensure Group's ability to continue as a going concern, and
- To maintain optimum capital structure and to reduce cost of capital

Management assesses the capital requirements in order to maintain an efficient overall financing structure. The Group manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets. The Group is not subject to externally imposed capital requirements. The Group has compiled with debt covenants as per the terms of the borrowing facility arrangements. The Group manages its capital requirements by overseeing the gearing ratio:

(f in lakits)

Particulars	As at 31 March 2020	
Total borrowings (including interest accrued)	62,136.30	61,829.94
Total equity	1,34,953.70	1,30,516.98
Net debt to equity ratio	46%	

Note - 40

Contingent liabilities and commitments

٨	Contingent liabilities		(₹ in lakhs)
	Particulars	As at 31 March 2020	As at 31 March 2019
	bicome tax matters	1,081.38	77.95
	Other cases (refer note (iv) below)	132.05	79.37

- (i) It is not practicable for the Group to estimate the timings of cash outflows, if any, in respect of the above pending resolution of the respective proceedings.
- (ii) The amounts disclosed above represent the best possible estimates arrived at on the basis of available information and do not include any penalty payable.
- (iii) The Holding Company is contesting employee related cases in various forums. Based on the internal analysis, the Holding Company is of the view that the likelihood of any outflow of the resources is remote.
- (iv) The Holding Company is contesting various medical related legal cases in various forums. Based on the legal opinion from external consultant and internal analysis, the Holding Company is of the view that the likelihood of any outflow of the resources is remote.

B Commitment

<i>(</i> a)	Capital commitment		(* in Inldis)
(-)	Particulars	As at 31 March 2020	As at 31 March 2019
	December clost and autisment	11.015.71	27,179.87
	r raperty, plant unit equipment	·····	L

(il) Other commitment

γ,	Particulars	As at 31 Morch 2020	As at 31 March 2019
Ì	Bank guarantee - Export Promotion Capital Goods*	1,969.53	1,007.73
-	Rental charges@		30,938.56
	Letter of support#		

"The Group has imported capital goods under the Export Promotion Capital Goods, of the Government of India, at concessional rates of duty on an undertaking to fulfill quantified exports in the next six to eight years.

@On implementation of Ind AS 116, the Group has recorded related present value impact as lease liabilities. For details, refer note 41.

In previous year, the Flolding Company has issued letter of support to Medanta Duke Research Institute Private Limited (a joint venture) for providing operational and financial support if it fails to fulfill its obligations for a period of 12 months. During the year, the Board of Directors ('the Board') of Medanta Duke Research Institute Private Limited (a joint venture) in its meeting held on 19 June 2019 has decided to commence the process of winding up.





Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Note - 4i

Lease related disclosures as per Ind AS 116

The Group has leases for buildings, equipments, vehicles and land. With the exception of short-term leases and leases of low-value underlying assets, each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. Variable lease payments which do not depend on an index or a rate are excluded from the initial measurement of the lease liability and right of use assets. The Group has presented its right-of-use assets in the balance sheet separately from other assets.

Each lease generally imposes a restriction that, unless there is a contractual right for the Group to sublease the asset to another party, the right-of-use asset can only be used by the Group. Some leases contain an option to extend the lease for a further term. The Group is prohibited from selling or pledging the underlying leased assets as security. For leases over buildings equipments, vehicles and land, the Group must keep those properties in a good state of repair and return the properties in their original condition at the end of the lease. Further, the Group is required to pay maintenance fees in accordance with the lease contracts.

A Lease payments not included in measurement of lease liability

The expense relating to payments not included in the measurement of the lease liability is as follows:

(₹ in takhs)

Particulars	31 March 2020
Short-term leases	4,042.66
Leases of low value assets	1,54

B Total cash outflow for leases for the year ended 31 March 2020 was ₹ 4,252.48 lakhs.

C Total expense recognised during the year

(₹ in lakhs)

Particulars	31 March 2020
Interest on lease liabilities	3,138.48
Depreciation on right of use asset	1,799.49

D Maturity of lease liabilities

The lease liabilities are secured by the related underlying assets. Puture minimum lease payments were as follows:

(₹ in lakhs)

31 March 2020		Minimum lease payments due			
	Less than I year	1-2 years	2-3 years	More than 3 years	Total
Lease payments	4,289.14	4,189.61	4,157.20	2,83,679.11	2,96,315.06
Interest expense	621.01	644,35	705.91	2,63,647.04	2,65,618.31
Net present values	3,668.13	3,545,26	3,451.29	20,032.07	30,696.75

Bifurcation of lease liabilities at the end of the year in current and non-current Particulars a) Current liability (amount due within one year) b) Non-current liability (amount due over one year) Total lease liabilities at the end of the year 30,696.75

P Information about extension and termination options

Information about extension a Right of use assets	Number of leases	Range of remaining term (in years)	Average remaining lease term (in years)	Number of leases with extension option	Number of leases with purchase option	Number of leases with termination option
Building premises	47	2.25 to 40.21	9.02	10	-	45
Other plant and equipment	2	25	25	1	-	2
Vehicles	10	0.35 to 2.78	1	10	10	10
Land	2	28 to 87	57.50	-	-	





Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

G Impact on transition

- 1 Effective 1 April 2019, the Group has adopted Ind AS 116 "Leases" and applied modified retrospective approach to all lease contracts existing as at 1 April 2019. On transition, the adoption of new standard resulted in recognition of lease liabilities of ₹ 27,321.10 lakhs and corresponding right of use asset of ₹ 34,562.45 lakhs (including leases which were earlier classified as finance lease).
- 2 For contracts in place as at 1 April 2019, the Group has elected to apply the definition of a lease from Ind AS 17 and has not applied Ind AS 116 to arrangements that were previously not identified as lease under Ind AS 17.
- 3 The Group has elected not to include initial direct costs in the measurement of the right-of-use asset for operating leases in existence at the date of initial application of Ind A8 116, being 1 April 2019.
- 4 Instead of performing an impairment review on the right-of-use assets at the date of initial application, the Group has relied on its historic assessment as to whether leaves were onerous immediately before the date of initial application of Ind AS 116.
- 5 On transition, for leases previously accounted for as operating leases with a remaining lease term of less than 12 months, the Group has applied the optional exemptions to not recognise right-of-use assets but to account for the lease expense on a straight-line basis over the remaining lease term.
- 6 The Group has benefitted from the use of hindsight for determining the lease term when considering options to extend and terminate leases.
- 7 On transition to Ind AS 116 the weighted average incremental borrowing rate applied to lease liabilities recognised in the range of 9.80% to 9.97%.
- 8 The following is a reconciliation of total operating lease commitments at 31 March 2019 (as disclosed in the financial statements for the year ended 31 March 2019) to the lease liabilities recognised at 1 April 2019:

	(₹ in laids)
Particulars	Amount
Total operating lease commitments disclosed as at 31 March 2019	31,681.76
Recognition exemptions - leases with remaining lease term of less than 12 months	44.63
Other adjustments relating to lease commitment disclosures	28,452.34
Operating lease liabilities before discounting	60,178.73
Discounting impact (using incremental borrowing mte)	(42,992.74)
Operating lease liabilities	17,185.99
Pinance lease obligations under Ind AS 17	10,135.11
Total lease liabilities recognised under Ind AS 116 at 1 April 2019	27,321.10

(li) Lease related disclosures as lessor

The Group has entered in to operating leases for car packing. The leases have terms of 3 years. Future minimum rentals receivable under non-cancellable operating leases are as follows:

(₹ in lakhs)

Particulars	31 March 2020	31 March 2019
Within one year	102.00	21.00
Later than one year but not later than five years	136.00	
Later than five years	<u> </u>	





Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Note - 42

Employee benefits obligations

A. Defined contribution plan

	Particulars	Por the year ended 31 March 2020	For the year ended 31 March 2019
ļ	Employer's contribution to provident fund charged to statement of profit and loss	1,821.37	1,256.18
1	Contribution to employee state insurance scheme charged to statement of profit and loss	184.77	247.88
1	Contribution to labour welfare fund charged to statement of profit and loss	22.86	10.80
Ì	Total	2,029.60	1,514,6

The Group also has certain defined contributions plans. Contributions are made to provident fund in India for employees at the rate of 12% of basic salary as per regulations. Contributions are made to registered provident fund administered by government. The obligation of the Group is limited to the amount contributed and it has no further contractual or constructive obligation. Refer note 50.

B Gratulty

The Group provides for grantity for employees in India as per the Payment of Gratuity Act, 1972. Employees who are in continuous service for a period of 5 years are eligible for gratuity. The amount of gratuity payable on retirement/termination is the employees last drawn basic salary per month computed proportionately for 15 days salary multiplied for the number of years of service

 Amounts recognized in the balance sheet
 (§ in lakks)

 Particulars
 As at 31 March 2020
 As at 31 March 2019

 Present value of the obligation at end
 2,847.96
 2,399.04

 Unfunded liability/provision in Balance Sheet
 (2,847.96)
 (2,399.04)

Bifurcation of present value of obligation at the end of the year - Current and Non Current

Distriction of present value of thingstrone at the end of the fext - Outstan kind from Obstent		
Particulars	As at 31 March 2020	As at 31 March 2019
Current liability	575.10	
Non-current liability	2,272.86	1,803.07
Total	2,847.96	2,399.05

(₹ în lakhs) (ii) Expenses recognized in other comprehensive income As nt 31 March 2020 Particulars As at 31 March 2019 Actuarial loss/(gains) (1.71)-Changes in demographic assumptions 177.38 ·Changes in financial assumptions 24.42 -Changes in experience adjustment \$7,35 (73.63)Expenses recognized in other comprehensive income 233.02 (49.21)

 Expenses recognized in statement of profit and loss
 (₹ in lakks)

 Current service cost
 467.07
 379.47

 Interest cost
 183.74
 159.43

 Cost recognized during the year
 550.81
 538.90

(₹ in lakhs) (iv) Movement in the liability recognized in the balance sheet is as under As at 31 March 2020 As at 31 March 2019 Particulars Present value of defined benefit obligation at the beginning of the year 2,399.05 2,013.99 467.67 379.47 Current service cost 183.74 159,43 Interest cost (49.21)233,02 Actuarial loss/(gain) (134.63) (434.91) Benefits paid Present value of defined benefit obligation at the end of the year 2,847.97 2,399.05

(v) For determination of the liability, the following actuarial assumptions were used:

Porticulars	As at 31 March 2020	As at 31 March 2019
Discount rate	6.76% to 6.87%	7.75% to 7.66%
Salary escalation rate	5.00%	5.00%
Retitement age (years)	60 years	GD years
Average tast service	0.45 to 3.40 years	1.60 to 3.21 years
Аустаре аде	28.43 to 31.53 years	31.43 to 39.80 years
Average remaining working life	28.47 to 31.57 years	20.20 to 28.57 years
Withdrawal sate	1	
Up to 30 Years	4.00%	4.00%
From 31 to 44 years	3.(NY%	3.00%
Above 44 years	2,00%	2.00%

Mortality rates inclusive of provision for disability -100% of IALM (2012 -- 14)





Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

d)	Maturity profile of defined bea	efit obligation		(₹ in lakits)
•	Year 31 March 2020	Year 31 March 2019	As at 31 March 2020	As at 31 March 2019
	April 2020- March 2021	April 2019- March 2020	575.10	\$95.9K
	April 2021 - March 2022	April 2020- March 2021	107.63	154.8B
	April 2022- March 2023	April 2021 - March 2022	162.29	65.15
	April 2023 - March 2024	April 2022- March 2023	139.12	1-14-29
	April 2024- Morch 2025	April 2023 - March 2024	93.53	101.21
	April 2025 - March 2026	April 2024 - March 2025	136.97	109.44
	Anril 2026 onwards	April 2025 onwards	1,633,33	1,228.09
	Gross Total		2,847.97	2,399.05

dit	Sensitivity analysis for gratuity		(f in lakhe)
٠٠,	Particulars	31 March 2020	31 March 2019
	a) Impact of the change in discount rate		
	Present value of obligation at the end of the year	2,847.97	2,399.05
	Impact due to increase of 0.50 %	(19.78)	(86.12)
	Impact due to decrease of 0.50 %	J 30.42	93.49
	b) Impact of the change in salary increase		1
	Present value of obligation at the end of the year	2,847.97	2,399.05
	Impact due to increase of 0.50 %	132.19	95.49
	Impact due to decrease of 0.50 %	(122.38)	(88.93)

Sensitivities due to mortality and withdrawals are not material. Hence impact of change is not calculated above.

Sensitivities as to rate of inflation, rate of increase of pensions in payment, rate of increase of pensions before retirement and life expectancy are not applicable being a hump sum benefit on retirement

The above sensitivity analysis are based on a change in an assumption while holding all other assumptions constant. In practice, this is unlikely to occur, and changes in sum of the assumptions may be correlated. When calculating the sensitivity of defined benefit obligation to significant actuarial assumptions the same method (present value of defined benefit obligations calculated with the projected unit credit method at the end of the reporting period.) has been applied as when calculating the defined benefit liability recognized in the balance sheet.

(vill) Rick

(vi

Iŧ)	106K				
Salary increases Actual salary increases will increases liability.		Actual salary increases will increase the plan's liability. Increase in salary increase rate assumption in future valuations will also increase the liability.			
		Reduction in discount exte in subsequent valuations can increase the plan's liability.			
		Actual deaths and disability cases proving lower or higher than assumed in the valuation can impact the liabilities.			
		Actual withdrawals proving higher or lower than assumed withdrawals and change of withdrawal rates at subsequent valuations can impact plan's liability.			

Note - 43 Share based payments GHPL ESOP Plan 2014

The Holding Company vide General Meeting resulution dated 25 September 2014 approved "Global Health Employee Stock Option Scheme 2014" for granting employee stock options in the form of equity shares linked to the completion of a minimum period of continued employment to the eligible employees of the Holding Company. The plan was modified on 11 May 2016 where in the Holding Company increased the number of available options from 740,628 to 852,973 to eligible employees and the vesting period was changed from 5 years from the date of grant to graded vesting of 25% each year starting with effect from 30 April 2016. The Holding Company had granted 740,628 options to eligible employees on 25 September 2014. The eligible employees, including directors, for the purpose of this scheme will be determined by the Remunteration Committee from time to time. Each stock options entitle the eligible employee to avail one share at the end of the vesting period. The vested options can be exercised within a period of 3 years from the date of vesting.

Movement in number of options:

Movement in number of options:		
Particulars	As at 31 Murch 2020	As at 31 March 2019
Opening balance	3,54,123	8,14,624
Exercised during the year	93,475	4,54,974
Lansed during the year		35,727
Closing balance	2,60,648	3,54,123

Particulars	Grant I	Grant II	Grant III	Grant IV
Outstanding options (unvested and vested but not exercised)	40,972	26,451	19,838	1,73,387
Grant date	25 September 2014	13 July 2016	9 November 2016	10 December 2016
Vesting period	Graded vesting (25%		Graded vesting (25%	
	options to vest every year	options to vest every year	options to vest every year	options to vest every year
	from the date of grant)			
Exercise price	10.00	10.00	10.00	19,00
Expiry date	29 April 2022	12 July 2023	08 November 2023	09 December 2023
Pair value of option on the date	691.95	742.28	755.29	755.24
Remaining contractual life (weighted months)	109.30	123.93	127.90	128.93





Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

"The fair value of the options has been determined using the Black Scholes model, as certified by an independent valuer with the following assumptions:

Particulars	Grant 1	Grant II	Grant III	Grant IV
Weighted average share price (Rs.)	698.65	749.78	762.95	762 ₁ 95
Exercise price (Rs.)	10,00	}(),(XI	10.00	(K).{})
Expected volatility (%)	37%	.17%	37%	36%
Expected life of the option (years)	44,016.00	44,016.00	44,016.60	44,016.00
Expected dividend yield			·	
The risk-free interest cate	8.70%	7.18%	6.67%	6.51%
Weighted average fair value as on the grant date (Ns.)	691.95	742.28	755.29	755.24

GHPL ESOP Plan 2016

The Holding Company vide General Meeting resolution dated 13 July 2016 approved "Global Health Employee Stock Option Scheme 2016" for granting employee stock options in the form of equity shares linked to the completion of a minimum period of continued employment to the eligible employees of the Holding Company. The eligible employees, including directors, for the purpose of this scheme will be determined by the Remuneration Committee from time to time. Each stock option entitle the eligible employee to avail one share at the end of the vesting period. The authorized share capital of the Company was also increased by creation of 1,025,000 Class A equity shares on 13 July 2016 with a view to allot the shares under the ESOP Plan 2016. The vested options can be exercised within a period of 3 years from the date of vesting.

Movement in sumber of onlines:

Wovement in Admocr of Opnous:		
l'articulars	As at 31 March 2020	As at 31 March 2019
Opening balance	7,71,250	6,15,000
Granted during the year		3,40,000
Exercised during the year	1,18,750	1,83,750
Lapsed during the year	91,000	
Closing balance	5,61,500	7,71,250
L.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		

Particulars	Grant I	Grant II	Grant III	Grant IV	Grant V
Outstanding options (unvested and vested but not exercised)	1,57,500	80,008	50,IX40	50,080	2,24,030
Grant date	10 December 2016	19 March 2018	17 April 2018	25 April 2018	13 July 2018
Vesting period	Graded vesting (25% options to vest every year from the date of grant)	options to vest every year	Graded vesting (33.33% options to vest every year from the date of grant)	options to vest every year	options to vest every year
Exercise price	16.00	10,00	10.00	(0),(0)	10.4%
Expiry date	09 December 2023	19 March 2025	15 April 2024	23 April 2024	14 July 2020
Fair market value of option on the date of grant*	755.24	633.44	626.03	626.16	626.17
Remaining contractual life (weighted months)	128,93	144.47	133.20	133.47	160.43

The fair value of the options has been determined using the black Scholes model, as certified by an independent valuer with the following assumptions

Particulars	Grant I	Grant H	Grant III	Grant IV	Grant V
Weighted average share price	762.95	633.44	633.44	633.44	633,44
(Rs.)	i		<u> </u>		
Exercise price (Rs.)	10.(8)	10,00	10.00	10,80	10.00
Expected volatility (%)	36%	37%	37.60%	37.76%	37.33%
Expected life of the option	4-7	4.7	4-6	4-6	4-8
(years)					
Expected dividend yield					
The risk-free interest rate	6.51%	7.44%	8,09%	7.82%	8.22%
Weighted average fair value as on	755.24	633.44	626,03	626.16	626.17
the grant date (Its.)					

During the year ended on 31 March 2020 and 31 March 2019, the Holding Company has recorded an employee stock compensation expense of ₹ 956.97 lakhs and ₹ 2,668.07 lakhs respectively.

During the year ended on 31 March 2020, the total number of options vested but not exercised is 392,195 (31 March 2019 : 216,667).

The weighted average share price on the date of exercise is ₹ 505.88.

Note - 44
Previous period/year numbers have been regrouped/reclassified wherever considered necessary.

Balance sheet	31 March 2019 (Reported)	Adjustments	31 March 2019 (Reclassified)
Liabilities			
Non-current provisions	1,973.16	1,099.03	3,072.19
Current provisions	2,052.57	(1,099.02)	953.55
Trade payables	12,635.62	10.38	12,646.00
Other current financial liabilities	10,012.49	(10,38)	10,002.11
Assets	1		
Other current financial assets	1,859.59	702.28	2,561.87
Other current assets	1,710.02	(702.28)	1,(8)7.74





Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Interest in subsidiaries and joint venture

(a) Subsidiaries

",	OROSAUMITES		Ownership Interest	held by the Group	Ownership intere	,	Principal activities
	Name of entity	Place of business	As at 31 March 2020	As at 31 March 2019	As at 31 March 2020	As nt 31 March 2019	
	Global Health Patliputer Private Limited	India	100	100	-		Healthcare services
	Medanta Holdings Private Limited	India	(00)	100		,	Healthcare services

(f in laktis) (b) Joint venture (equity method) Catrying amount (net of impairement) % of ownership Name of entity Place of business Accounting method interest As at As at 31 March 2020 31 March 2019 Medanta Duke Research Institute Private 50.01% Equity method

(i) There were no commitments and contingent liabilities in joint venture company.

(₹ In Jaklis)

Summarised financial information for joint venture	(₹ In Jaklis)			
Summarised balance sheet	Medanta Duke Research Insti	tute Private Limited		
	As at 31 March 2020	As nt 31 March 2019		
Current neects				
Cash and cash equivalents	58.80	1.28		
Other assets		7,57		
Total current assets (A)	58.80	8.85		
Total non-current assets (B)		1,31		
Assets held for sale (C)	<u> </u>	54.75		
Total assets (D = A+B+C)	58.80	64.91		
Corrent liabilities				
Financial liabilities (excluding trade payables)	1.05	- :		
Other liabilities (meluding trade payables)	4	2.79		
Tutal current liabilities (E)	1.05	2.79		
Non-current liabilities				
Pinancial liabilities	.			
Other liabilities	<u> </u>			
Total non-current liabilities (P)		-		
Total liabilities (G = E+P)	1.05	2,79		
Net assets (D-G)	57.75	62,12		

Summarised balance sheet	Medanta Duke Research Institute Private Limited			
	As at 31 March 2020	As at 31 March 2019		
Opening retained earnings	(840.61)	(835,45)		
Loss for the year	(4.36)	(5.16)		
Other comprehensive income +	·			
Closing net assets	(844.97)	(840.61)		
Group's share in %	50.01%	50.01%		
Group's share in ₹	(422.55)	(420.39)		
Gross value of investment	901.80	901.80		
Carrying value of investment	479.25	481,43		
Less 1 Impairment in the value of investment	(479.25)	(481.43)		
Net carrying value of investment	-	-		





Limited * Joint venture company is engaged in the business to undertake clinical research and trial, including controlled medical studies of novel therapeutic interventions.

Global Heshh Private Limited
Contolldated summary of significant accounting policies and other explanatory information for the year ended J. March 2020

Note + 86 Additional disclosure required under Schedale III of the Companies Act 2013 of the emittee consolidated as subsidiaries and joint recours -

Name of the entity		otal assets minus abilities	Share In statem		Share in other comprehensive Income		Share in total comprehensive income	
	As % of Consolitated net assess	Ameuni (₹ in lekiss)	As % of Consolidated profit	Amount (E in takha)	As % of Consolidated other comprehensive income	Amount (f in lakhe)	As % of Contolidated total comprehensive income	Amount (₹ in lakbr)
Holding Company								
Global Health Paivate Limited	106,00%	1,43,175.82	285.61%	10,375.78	100.5754	(175.32)	294.93%	10,200.46
Subsidiatica								
Indian								
Global Health Pathputra Private Limited	-219%	(2,953,55)	-3451%	(1,253.88)	0.(X)%	<u> </u>	-36.25%	(1,251 68)
Medera Holdings Private Limited	-4 26%	(5,747.62)	-151.03%	(5,3K(J.B3)	-0.56%	(1.5)	-158.62%-	(5,485.85)
Joint venture (investment accounted for using the equity method)				<u> </u>				
Indian				Ĭ				
Medenta Oube Research Justique Private Limited	0.35%	479.25	0.05%	(2.18)	0.00%	<u> </u>	-0,00%	(2.18
Total	100%	1,34,953.70	100%	3,632.89	106%	(174.34)	100%	3,458.51



(This space has less retentionally life block)



Note - 47

Revenue related disclosures

Disaggregation of revenue

Description

Revenue recognised mainly comprises of healthcare vervices. Set out below is the disaggregation of the Group's revenue from contracts with customers:

_	(C in lakkis)
	For the year ended
	31 March 2019
_	
	1,16,897.36
	26,875.98
	1,43,683.34
	1

Por the year ended

31 March 2020

(A) Operating revenue Income from healthcare services 1.39.412.03 In patient 28,645,08 Out patient 1,48,057.11 (B) Other operating revenue 251.33 186.82 Clinical research income 178.55 177.65 Other operating revenue 1,48,421.58 1,44,113,22 Total revenue

IT in labelies

Description	Por the year ended 31 March 2020	For the year ended 31 March 2019
(A) Operating revenue		
income from healthcare services	•	1
Government	16,677.25	18,327.08
Non-poverantest	1,31,379.86	1,25,356.26
Total operating revenue	1,48,057,11	1,43,683.34

If Contract balances

The following table provides information about receivables and contract liabilities from contract with customers:

(f in lakhs)

Particulars	As at 31 March 2020	As at 31 March 2019
Contract liabilities		
Advance from customers	2,110,61	1,609.61
Total contract liabilities	2,110.61	1,609.61
Contract assets		
Unbilled revenue	618.41	1,082.11
Total contract assets	618,41	1,082,11

Contract asset is the right to consideration in exchange for goods or services transferred to the customer. Contract liability is the entity's obligation to straisfer goods or services to a customer for which the entity has received consideration from the customer in advance. Contract assets (unbilled receivables) are transferred to receivables when the rights become unconditional and conteact liabilities are recognised as and when the performance obligation is satisfied

III Significant changes in the contract liabilities balances during the year are as follows:

C is takish

20 Billingain camples in the contract unputnes munices annual use les inc us tonous.		
Contract liabilities - Advance from customers	As at 31 March 2020	As at 31 March 2019
Opening balance of Contract liabilities - Advance from customers	1,609.61	2,045.23
Less Amount of revenue recognised during the year	(1,48,057.11)	(1,43,683.34)
Add: Addition during the year	1,48,558.11	1,43,247.72
Closing balance of Contract liabilities - Advance from customers	2,110.61	1,609,61
Closing Statistics of the Control of	***************************************	····-

The aggregate amount of transaction price allocated to the performance obligations (yet to complete) as at 31 March 2020 is 🔻 2,110.61 lakhs (31 March 2019 : ₹ 1,609.61 lakhs). This balance represents the advance received from customers (gross) against healthcare services. The management expects to further bill and collect the remaining balance of total consideration in the coming period. These balances will be recognised as revenue in subsequent period as per the policy of the Group.

V Reconciliation of revenue:

(₹ in takha)

		(z in tourse)
Porticulars	Por the year ended	For the year ended
	31 March 2020	31 March 2019
Revenue	1,53,679.40	1,49,032.11
Adjustment for:		1
Discounts and rebates	(5,622.28)	(5,348.76)
Income from healthcare services	1,48,057.12	1,43,683.35





Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2020

Note - 48

The chief operating decision maker (CODM) (i.e. Chairman and Managing Dicetor and Chief Finance Officer) examines the Group's performance from a service perspective and has identified the Healthcare services as single business segment. The Group is operating in India which constitutes a single geographical segment. The CODM reviews internal management reports to assers the performance of the segment 'Healthcare services'.

management reports to assess the performance of the segment 'Healthcare services'.

The revenues from external customers attributed to an individual is not material and there are no transactions with a single external customer which would amount to ten percent or more of the Group's revenues.

Note - 49

Research and development expenditure includes consultant's and specialist honorarism amounting to ₹ 4.23 hkbs (34 March 2019; ₹ 2.99 hkbs) and salaries of employees amounting to ₹ 99.29 (34 March 2019; ₹ 127.77 Laklis).

Note - 50

Pursuant to the judgement by the Hon'ble Supreme Cours of India dated 28 February 2019, it was held that basic wages, for the purpose of provident fand, to include allowances which are common for all employees. However, there is nucertainty with respect to the period of applicability of the judgement. The Group has applied the said judgment on prospective basis.

Note - 51

The outbreak of 'COVID-19' has severely impacted the businesses and economic activities around the world including India. Governments, both Central and State, have imposed lock down and other emergency restrictions which has led to the disruption of all regular business operations. The Group has made a detailed assessment and considered possible effects, if any on its liquidity position, including recoverability of its assets as at the balance sheet date. Purther, due to the temporary restriction/suspension of services of elective suggeties and travel restrictions of overseas patients, business operations of the Group were lower in subsequent months after the peas-end and are further expected to be lower in the short-term, though the same is not likely to have a continuing impact on the business of the Group. Further, the management believes that in the long-term, there may not be material impact of COVID-19 pandemic on the financial position and performance of the Group. However, the impact assessment of COVID-19 pandemic is a continuing process given the uncertainties associated with its nature and duration and accordingly, the impact may be different from that estimated as at the date of approval of these financial statements. The Group will continue to monitor any material changes to future committee conditions.

Note - 52

The teade receivables as at 31 March 2020 interalia include receivables in foreign currency which have been outstanding aggregating to ₹ 686.90 lakks beyond the timeline stipulated by the applicable provisions of Reserve Bank of India read with foreign exchange management regulations. The Holding Company has filed necessary applications with the appropriate authority in this segard as per regulations. The management does not envisage any additional financial impact of the same at this stage and hence no additional provision has been made.

This is the consolidated summary of significant accounting policies and other explanatory information referred to in our report of even date.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Munde

Rajni Mundea

Partner

Membership No.: 058644

Place: New Delhi Date: 28 September 2020

Place: New Dollis

Dr. Nacesh Treban

Chairman and Managing Director

(DIN:00012148)

Place: Gungeon

Date: 38 September 2020

Sanjec | Kumar

Chief Financial Officer

Place! Gurugram

Date: 28 September 2020

Por and on behalf of the Board of Director

Pankaj Salmi Chief Executive Officer

Place: Gumgram Date: 28 <u>September</u> 2020

> Sunit Marar Bansal Company Secretary

Place: Garageam Date: 28 September 2020

Certified True Copy

